Neil Alan Shneider

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$5,151,818

FY 2026

Project Title

Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS

Grant Number:

5U01NS134684-03

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2024

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ALS is a progressive neurodegenerative disease that affects tens of thousands of Americans. Therapeutic options for ALS patients remain severely limited, but for the ~15% of ALS patients with a disease-causing mutation, gene-based therapeutics, including antisense oligonucleotides (ASOs), provide a ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Roland W. Herzog

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$2,492,072

FY 2026

Project Title

Toward Safer Gene Therapy for Hemophilia A

Grant Number:

5P01HL160472-05

Activity Code:

P01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/5/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY ABSTRACT Gene therapy for the X-linked bleeding disorder hemophilia holds much promise to accomplish a lasting cure. Four clinical trials utilizing adeno-associated viral (AAV) gene transfer to the livers of males with severe hemophilia are currently being investigated in multiple Ph...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

YONG-HUI JIANG

YALE UNIVERSITY, NEW HAVEN, CT

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,379,599

FY 2026

Project Title

MAPT-targeting genome editing therapy for Alzheimer's Disease

Grant Number:

1U01NS145214-01

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Alzheimer’s disease (AD) is a devastating condition without effective treatment. Novel approaches to improving treatment are greatly needed. Accumulating evidence suggests tau as a viable target for AD therapy. Recent preclinical studies have shown promise in tau-targeting molecular therapy through ...

Research Terms

<21+ years old><AD dementia><AD pathology><AD patients><AD therapy><AD treatment><AD3-like protein><AD3LP><Ablation><Achievement><Achievement Attainment><Adult><Adult Human><Affect><Alleles><Allelomorphs><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Disease><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's disease therapy><Alzheimer's pathology><Alzheimer's patient><Alzheimer's precursor protein><Alzheimer's therapy><Alzheimers Dementia><Amentia><Amyloid A4 Protein Precursor><Amyloid Protein Precursor><Amyloid beta-Protein Precursor><Amyloid β-Protein Precursor><Angelman Syndrome><Antisense Agent><Antisense Oligonucleotides><Behavioral><Biodistribution><Biological Markers><Brain><Brain Nervous System><Brain Ventricle><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cells><Cerebellomedullary Cistern><Cerebral Dominance><Cerebral Ventricles><Clinic><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><DNA mutation><Dementia><Development><Disease><Disease Management><Disorder><Disorder Management><Encephalon><Engineering><Exons><FTD dementia><Formulation><Frontal Temporal Dementia><Frontotemporal Dementia><Generations><Genes><Genetic><Genetic Change><Genetic Induction><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic defect><Genetic mutation><Genetic propensity><Genomics><Guide RNA><Happy Puppet Syndrome><Human><Inherited Predisposition><Inherited Susceptibility><KI mice><Knock-in Mouse><Knock-out><Knockout><Late Onset Alzheimer Disease><Late onset AD><Lead><Link><M mulatta><M. mulatta><MAPT gene><MAPT protein><MT-bound tau><MTBT1><Macaca mulatta><Macaca rhesus><Mediating><Mice><Mice Mammals><Modern Man><Monitor><Murine><Mus><Mutation><NIH><National Institutes of Health><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neural Stem Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neuron Degeneration><Neurons><Onset of illness><PET><PET Scan><PET imaging><PETSCAN><PETT><PSEN1><PSEN2><Pathogenesis><Patients><Pb element><Persons><Phase><Population><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Preventative therapy><Preventive therapy><Primary Senile Degenerative Dementia><Public Health><Puppet Children><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Splicing><Rad.-PET><Regimen><Reporting><Research Grants><Research Project Grants><Research Projects><Rhesus Macaque><Rhesus Monkey><Ribonucleoproteins><S182 protein><Safety><Severities><Splicing><Stimulus><Syndrome><System><Tauopathies><Technology><Testing><Therapeutic><Therapeutic Effect><Therapeutic Gene Editing><Toxicology><Treatment Efficacy><United States National Institutes of Health><Validation><Work><aberrant tau><aberrant tau protein><abeta deposition><abnormal tau><abnormal tau protein><adulthood><amyloid beta deposition><amyloid precursor protein><amyloid β deposition><antisense oligo><aβ deposition><bio-markers><biologic marker><biomarker><brain laterality><causal allele><causal gene><causal mutation><causal variant><causative mutation><causative variant><cerebral lateralization><cisterna magna><clinical applicability><clinical application><clinical translation><clinically translatable><customized therapy><customized treatment><design><designing><developmental><disease onset><disorder onset><effective therapy><effective treatment><familial AD><familial Alzheimer><familial Alzheimer disease><front temporal dementia><frontal lobe dementia><frontotemporal lobar degeneration dementia><frontotemporal lobar dementia><frontotemporal lobe degeneration associated with dementia><gRNA><gene-editing therapy><genetic vulnerability><genetically predisposed><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic editing><heavy metal Pb><heavy metal lead><hemispheric specialization><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><intervention efficacy><knockin mice><late onset alzheimer><microtubule associated protein tau><microtubule associated protein tau mutation><microtubule bound tau><microtubule-associated protein tau><microtubule-associated protein tau mutation><microtubule-bound tau><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><murine model><mutant tau><mutant tau protein><mutation in microtubule associated protein tau><mutation in microtubule-associated protein tau><neonate><nerve stem cell><neural degeneration><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodegeneration><neurodegenerative><neurodevelopmental disease><neurogenic progenitors><neurogenic stem cell><neurological degeneration><neuron progenitors><neuronal><neuronal degeneration><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuropathologic tau><neuropathological tau><neuroprogenitor><new approaches><next generation><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><pathogenic tau><pathogenic tau gene mutation><pathogenic tau protein><pathological change in tau><pathological tau><pathological tau protein><patient living with Alzheimer's disease><patient specific therapies><patient specific treatment><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical study><preclinical study><presenilin 1 protein><presenilin 2 protein><presenilin-1><presenilin-2><preservation><primary degenerative dementia><progenitor and neural stem cells><programs><puppetlike syndrome><senile dementia of the Alzheimer type><somatic cell gene editing><somatic cell genome editing><somatic gene editing><somatic genome editing><success><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau Proteins><tau abnormality><tau associated neurodegeneration><tau associated neurodegenerative process><tau driven neurodegeneration><tau factor><tau induced degeneration><tau induced neurodegeneration><tau intronic mutation><tau mediated neurodegeneration><tau mutation><tau neurodegenerative disease><tau neuropathology><tau pathological change><tau pathology><tau pathophysiology><tau proteinopathy><tau related neurodegeneration><tau-induced pathology><tauopathic neurodegenerative disorder><tauopathy><technology platform><technology system><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapeutic target><therapy efficacy><treatment effect><treatment strategy><unique treatment><validations><τ Proteins><τ mutation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

STEPHEN M STRITTMATTER

YALE UNIVERSITY, NEW HAVEN, CT

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,379,599

FY 2026

Project Title

MAPT-targeting genome editing therapy for Alzheimer's Disease

Grant Number:

1U01NS145214-01

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Alzheimer’s disease (AD) is a devastating condition without effective treatment. Novel approaches to improving treatment are greatly needed. Accumulating evidence suggests tau as a viable target for AD therapy. Recent preclinical studies have shown promise in tau-targeting molecular therapy through ...

Research Terms

<21+ years old><AD dementia><AD pathology><AD patients><AD therapy><AD treatment><AD3-like protein><AD3LP><Ablation><Achievement><Achievement Attainment><Adult><Adult Human><Affect><Alleles><Allelomorphs><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Disease><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's disease therapy><Alzheimer's pathology><Alzheimer's patient><Alzheimer's precursor protein><Alzheimer's therapy><Alzheimers Dementia><Amentia><Amyloid A4 Protein Precursor><Amyloid Protein Precursor><Amyloid beta-Protein Precursor><Amyloid β-Protein Precursor><Angelman Syndrome><Antisense Agent><Antisense Oligonucleotides><Behavioral><Biodistribution><Biological Markers><Brain><Brain Nervous System><Brain Ventricle><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cells><Cerebellomedullary Cistern><Cerebral Dominance><Cerebral Ventricles><Clinic><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><DNA mutation><Dementia><Development><Disease><Disease Management><Disorder><Disorder Management><Encephalon><Engineering><Exons><FTD dementia><Formulation><Frontal Temporal Dementia><Frontotemporal Dementia><Generations><Genes><Genetic><Genetic Change><Genetic Induction><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic defect><Genetic mutation><Genetic propensity><Genomics><Guide RNA><Happy Puppet Syndrome><Human><Inherited Predisposition><Inherited Susceptibility><KI mice><Knock-in Mouse><Knock-out><Knockout><Late Onset Alzheimer Disease><Late onset AD><Lead><Link><M mulatta><M. mulatta><MAPT gene><MAPT protein><MT-bound tau><MTBT1><Macaca mulatta><Macaca rhesus><Mediating><Mice><Mice Mammals><Modern Man><Monitor><Murine><Mus><Mutation><NIH><National Institutes of Health><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neural Stem Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neuron Degeneration><Neurons><Onset of illness><PET><PET Scan><PET imaging><PETSCAN><PETT><PSEN1><PSEN2><Pathogenesis><Patients><Pb element><Persons><Phase><Population><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Preventative therapy><Preventive therapy><Primary Senile Degenerative Dementia><Public Health><Puppet Children><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Splicing><Rad.-PET><Regimen><Reporting><Research Grants><Research Project Grants><Research Projects><Rhesus Macaque><Rhesus Monkey><Ribonucleoproteins><S182 protein><Safety><Severities><Splicing><Stimulus><Syndrome><System><Tauopathies><Technology><Testing><Therapeutic><Therapeutic Effect><Therapeutic Gene Editing><Toxicology><Treatment Efficacy><United States National Institutes of Health><Validation><Work><aberrant tau><aberrant tau protein><abeta deposition><abnormal tau><abnormal tau protein><adulthood><amyloid beta deposition><amyloid precursor protein><amyloid β deposition><antisense oligo><aβ deposition><bio-markers><biologic marker><biomarker><brain laterality><causal allele><causal gene><causal mutation><causal variant><causative mutation><causative variant><cerebral lateralization><cisterna magna><clinical applicability><clinical application><clinical translation><clinically translatable><customized therapy><customized treatment><design><designing><developmental><disease onset><disorder onset><effective therapy><effective treatment><familial AD><familial Alzheimer><familial Alzheimer disease><front temporal dementia><frontal lobe dementia><frontotemporal lobar degeneration dementia><frontotemporal lobar dementia><frontotemporal lobe degeneration associated with dementia><gRNA><gene-editing therapy><genetic vulnerability><genetically predisposed><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic editing><heavy metal Pb><heavy metal lead><hemispheric specialization><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><intervention efficacy><knockin mice><late onset alzheimer><microtubule associated protein tau><microtubule associated protein tau mutation><microtubule bound tau><microtubule-associated protein tau><microtubule-associated protein tau mutation><microtubule-bound tau><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><murine model><mutant tau><mutant tau protein><mutation in microtubule associated protein tau><mutation in microtubule-associated protein tau><neonate><nerve stem cell><neural degeneration><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodegeneration><neurodegenerative><neurodevelopmental disease><neurogenic progenitors><neurogenic stem cell><neurological degeneration><neuron progenitors><neuronal><neuronal degeneration><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuropathologic tau><neuropathological tau><neuroprogenitor><new approaches><next generation><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><pathogenic tau><pathogenic tau gene mutation><pathogenic tau protein><pathological change in tau><pathological tau><pathological tau protein><patient living with Alzheimer's disease><patient specific therapies><patient specific treatment><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical study><preclinical study><presenilin 1 protein><presenilin 2 protein><presenilin-1><presenilin-2><preservation><primary degenerative dementia><progenitor and neural stem cells><programs><puppetlike syndrome><senile dementia of the Alzheimer type><somatic cell gene editing><somatic cell genome editing><somatic gene editing><somatic genome editing><success><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau Proteins><tau abnormality><tau associated neurodegeneration><tau associated neurodegenerative process><tau driven neurodegeneration><tau factor><tau induced degeneration><tau induced neurodegeneration><tau intronic mutation><tau mediated neurodegeneration><tau mutation><tau neurodegenerative disease><tau neuropathology><tau pathological change><tau pathology><tau pathophysiology><tau proteinopathy><tau related neurodegeneration><tau-induced pathology><tauopathic neurodegenerative disorder><tauopathy><technology platform><technology system><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapeutic target><therapy efficacy><treatment effect><treatment strategy><unique treatment><validations><τ Proteins><τ mutation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kevin Navin Sheth

YALE UNIVERSITY, NEW HAVEN, CT

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,379,599

FY 2026

Project Title

MAPT-targeting genome editing therapy for Alzheimer's Disease

Grant Number:

1U01NS145214-01

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Alzheimer’s disease (AD) is a devastating condition without effective treatment. Novel approaches to improving treatment are greatly needed. Accumulating evidence suggests tau as a viable target for AD therapy. Recent preclinical studies have shown promise in tau-targeting molecular therapy through ...

Research Terms

<21+ years old><AD dementia><AD pathology><AD patients><AD therapy><AD treatment><AD3-like protein><AD3LP><Ablation><Achievement><Achievement Attainment><Adult><Adult Human><Affect><Alleles><Allelomorphs><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Disease><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's disease therapy><Alzheimer's pathology><Alzheimer's patient><Alzheimer's precursor protein><Alzheimer's therapy><Alzheimers Dementia><Amentia><Amyloid A4 Protein Precursor><Amyloid Protein Precursor><Amyloid beta-Protein Precursor><Amyloid β-Protein Precursor><Angelman Syndrome><Antisense Agent><Antisense Oligonucleotides><Behavioral><Biodistribution><Biological Markers><Brain><Brain Nervous System><Brain Ventricle><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cells><Cerebellomedullary Cistern><Cerebral Dominance><Cerebral Ventricles><Clinic><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><DNA mutation><Dementia><Development><Disease><Disease Management><Disorder><Disorder Management><Encephalon><Engineering><Exons><FTD dementia><Formulation><Frontal Temporal Dementia><Frontotemporal Dementia><Generations><Genes><Genetic><Genetic Change><Genetic Induction><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic defect><Genetic mutation><Genetic propensity><Genomics><Guide RNA><Happy Puppet Syndrome><Human><Inherited Predisposition><Inherited Susceptibility><KI mice><Knock-in Mouse><Knock-out><Knockout><Late Onset Alzheimer Disease><Late onset AD><Lead><Link><M mulatta><M. mulatta><MAPT gene><MAPT protein><MT-bound tau><MTBT1><Macaca mulatta><Macaca rhesus><Mediating><Mice><Mice Mammals><Modern Man><Monitor><Murine><Mus><Mutation><NIH><National Institutes of Health><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neural Stem Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neuron Degeneration><Neurons><Onset of illness><PET><PET Scan><PET imaging><PETSCAN><PETT><PSEN1><PSEN2><Pathogenesis><Patients><Pb element><Persons><Phase><Population><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Preventative therapy><Preventive therapy><Primary Senile Degenerative Dementia><Public Health><Puppet Children><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Splicing><Rad.-PET><Regimen><Reporting><Research Grants><Research Project Grants><Research Projects><Rhesus Macaque><Rhesus Monkey><Ribonucleoproteins><S182 protein><Safety><Severities><Splicing><Stimulus><Syndrome><System><Tauopathies><Technology><Testing><Therapeutic><Therapeutic Effect><Therapeutic Gene Editing><Toxicology><Treatment Efficacy><United States National Institutes of Health><Validation><Work><aberrant tau><aberrant tau protein><abeta deposition><abnormal tau><abnormal tau protein><adulthood><amyloid beta deposition><amyloid precursor protein><amyloid β deposition><antisense oligo><aβ deposition><bio-markers><biologic marker><biomarker><brain laterality><causal allele><causal gene><causal mutation><causal variant><causative mutation><causative variant><cerebral lateralization><cisterna magna><clinical applicability><clinical application><clinical translation><clinically translatable><customized therapy><customized treatment><design><designing><developmental><disease onset><disorder onset><effective therapy><effective treatment><familial AD><familial Alzheimer><familial Alzheimer disease><front temporal dementia><frontal lobe dementia><frontotemporal lobar degeneration dementia><frontotemporal lobar dementia><frontotemporal lobe degeneration associated with dementia><gRNA><gene-editing therapy><genetic vulnerability><genetically predisposed><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic editing><heavy metal Pb><heavy metal lead><hemispheric specialization><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><intervention efficacy><knockin mice><late onset alzheimer><microtubule associated protein tau><microtubule associated protein tau mutation><microtubule bound tau><microtubule-associated protein tau><microtubule-associated protein tau mutation><microtubule-bound tau><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><murine model><mutant tau><mutant tau protein><mutation in microtubule associated protein tau><mutation in microtubule-associated protein tau><neonate><nerve stem cell><neural degeneration><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodegeneration><neurodegenerative><neurodevelopmental disease><neurogenic progenitors><neurogenic stem cell><neurological degeneration><neuron progenitors><neuronal><neuronal degeneration><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuropathologic tau><neuropathological tau><neuroprogenitor><new approaches><next generation><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><pathogenic tau><pathogenic tau gene mutation><pathogenic tau protein><pathological change in tau><pathological tau><pathological tau protein><patient living with Alzheimer's disease><patient specific therapies><patient specific treatment><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical study><preclinical study><presenilin 1 protein><presenilin 2 protein><presenilin-1><presenilin-2><preservation><primary degenerative dementia><progenitor and neural stem cells><programs><puppetlike syndrome><senile dementia of the Alzheimer type><somatic cell gene editing><somatic cell genome editing><somatic gene editing><somatic genome editing><success><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau Proteins><tau abnormality><tau associated neurodegeneration><tau associated neurodegenerative process><tau driven neurodegeneration><tau factor><tau induced degeneration><tau induced neurodegeneration><tau intronic mutation><tau mediated neurodegeneration><tau mutation><tau neurodegenerative disease><tau neuropathology><tau pathological change><tau pathology><tau pathophysiology><tau proteinopathy><tau related neurodegeneration><tau-induced pathology><tauopathic neurodegenerative disorder><tauopathy><technology platform><technology system><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapeutic target><therapy efficacy><treatment effect><treatment strategy><unique treatment><validations><τ Proteins><τ mutation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jiangbing Zhou

YALE UNIVERSITY, NEW HAVEN, CT

High-opportunity lead · 88/100

Likely hiring

Large award

Very recent

Active award

$1,379,599

FY 2026

Project Title

MAPT-targeting genome editing therapy for Alzheimer's Disease

Grant Number:

1U01NS145214-01

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Alzheimer’s disease (AD) is a devastating condition without effective treatment. Novel approaches to improving treatment are greatly needed. Accumulating evidence suggests tau as a viable target for AD therapy. Recent preclinical studies have shown promise in tau-targeting molecular therapy through ...

Research Terms

<21+ years old><AD dementia><AD pathology><AD patients><AD therapy><AD treatment><AD3-like protein><AD3LP><Ablation><Achievement><Achievement Attainment><Adult><Adult Human><Affect><Alleles><Allelomorphs><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Disease><Alzheimer's disease pathology><Alzheimer's disease patient><Alzheimer's disease therapy><Alzheimer's pathology><Alzheimer's patient><Alzheimer's precursor protein><Alzheimer's therapy><Alzheimers Dementia><Amentia><Amyloid A4 Protein Precursor><Amyloid Protein Precursor><Amyloid beta-Protein Precursor><Amyloid β-Protein Precursor><Angelman Syndrome><Antisense Agent><Antisense Oligonucleotides><Behavioral><Biodistribution><Biological Markers><Brain><Brain Nervous System><Brain Ventricle><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cells><Cerebellomedullary Cistern><Cerebral Dominance><Cerebral Ventricles><Clinic><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Code><Coding System><DNA mutation><Dementia><Development><Disease><Disease Management><Disorder><Disorder Management><Encephalon><Engineering><Exons><FTD dementia><Formulation><Frontal Temporal Dementia><Frontotemporal Dementia><Generations><Genes><Genetic><Genetic Change><Genetic Induction><Genetic Predisposition><Genetic Predisposition to Disease><Genetic Susceptibility><Genetic defect><Genetic mutation><Genetic propensity><Genomics><Guide RNA><Happy Puppet Syndrome><Human><Inherited Predisposition><Inherited Susceptibility><KI mice><Knock-in Mouse><Knock-out><Knockout><Late Onset Alzheimer Disease><Late onset AD><Lead><Link><M mulatta><M. mulatta><MAPT gene><MAPT protein><MT-bound tau><MTBT1><Macaca mulatta><Macaca rhesus><Mediating><Mice><Mice Mammals><Modern Man><Monitor><Murine><Mus><Mutation><NIH><National Institutes of Health><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neural Stem Cell><Neuranatomies><Neuranatomy><Neuroanatomies><Neuroanatomy><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neuron Degeneration><Neurons><Onset of illness><PET><PET Scan><PET imaging><PETSCAN><PETT><PSEN1><PSEN2><Pathogenesis><Patients><Pb element><Persons><Phase><Population><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Preventative therapy><Preventive therapy><Primary Senile Degenerative Dementia><Public Health><Puppet Children><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Splicing><Rad.-PET><Regimen><Reporting><Research Grants><Research Project Grants><Research Projects><Rhesus Macaque><Rhesus Monkey><Ribonucleoproteins><S182 protein><Safety><Severities><Splicing><Stimulus><Syndrome><System><Tauopathies><Technology><Testing><Therapeutic><Therapeutic Effect><Therapeutic Gene Editing><Toxicology><Treatment Efficacy><United States National Institutes of Health><Validation><Work><aberrant tau><aberrant tau protein><abeta deposition><abnormal tau><abnormal tau protein><adulthood><amyloid beta deposition><amyloid precursor protein><amyloid β deposition><antisense oligo><aβ deposition><bio-markers><biologic marker><biomarker><brain laterality><causal allele><causal gene><causal mutation><causal variant><causative mutation><causative variant><cerebral lateralization><cisterna magna><clinical applicability><clinical application><clinical translation><clinically translatable><customized therapy><customized treatment><design><designing><developmental><disease onset><disorder onset><effective therapy><effective treatment><familial AD><familial Alzheimer><familial Alzheimer disease><front temporal dementia><frontal lobe dementia><frontotemporal lobar degeneration dementia><frontotemporal lobar dementia><frontotemporal lobe degeneration associated with dementia><gRNA><gene-editing therapy><genetic vulnerability><genetically predisposed><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic editing><heavy metal Pb><heavy metal lead><hemispheric specialization><improved><individualized medicine><individualized patient treatment><individualized therapeutic strategy><individualized therapy><individualized treatment><intervention efficacy><knockin mice><late onset alzheimer><microtubule associated protein tau><microtubule associated protein tau mutation><microtubule bound tau><microtubule-associated protein tau><microtubule-associated protein tau mutation><microtubule-bound tau><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><murine model><mutant tau><mutant tau protein><mutation in microtubule associated protein tau><mutation in microtubule-associated protein tau><neonate><nerve stem cell><neural degeneration><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodegeneration><neurodegenerative><neurodevelopmental disease><neurogenic progenitors><neurogenic stem cell><neurological degeneration><neuron progenitors><neuronal><neuronal degeneration><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuropathologic tau><neuropathological tau><neuroprogenitor><new approaches><next generation><non-human primate><nonhuman primate><novel><novel approaches><novel strategies><novel strategy><pathogenic tau><pathogenic tau gene mutation><pathogenic tau protein><pathological change in tau><pathological tau><pathological tau protein><patient living with Alzheimer's disease><patient specific therapies><patient specific treatment><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical study><preclinical study><presenilin 1 protein><presenilin 2 protein><presenilin-1><presenilin-2><preservation><primary degenerative dementia><progenitor and neural stem cells><programs><puppetlike syndrome><senile dementia of the Alzheimer type><somatic cell gene editing><somatic cell genome editing><somatic gene editing><somatic genome editing><success><tailored medical treatment><tailored therapy><tailored treatment><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tau><tau Proteins><tau abnormality><tau associated neurodegeneration><tau associated neurodegenerative process><tau driven neurodegeneration><tau factor><tau induced degeneration><tau induced neurodegeneration><tau intronic mutation><tau mediated neurodegeneration><tau mutation><tau neurodegenerative disease><tau neuropathology><tau pathological change><tau pathology><tau pathophysiology><tau proteinopathy><tau related neurodegeneration><tau-induced pathology><tauopathic neurodegenerative disorder><tauopathy><technology platform><technology system><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapeutic target><therapy efficacy><treatment effect><treatment strategy><unique treatment><validations><τ Proteins><τ mutation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Tippi Mackenzie

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

High-opportunity lead · 82/100

Likely hiring

Above-average budget

Very recent

Active award

$649,600

FY 2026

Project Title

Prenatal AAV9 gene replacement therapy for patients with severe infantile GM1 gangliosidosis

Grant Number:

1U01NS146166-01

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT: Prenatal surgeries to treat anatomic malformations have been life-changing for thousands of patients and their availability continues to expand. The field now includes molecular therapies to treat patients with severe, early-onset genetic conditions such as in utero enzyme replacement ther...

Research Terms

<0-11 years old><AAV vector><AAV-based vector><Address><Advocate><Affect><Alleles><Allelomorphs><Amniotic Fluid><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Aqua Amnii><Aran-Duchenne disease><Assay><Attitude><Benefits and Risks><Bioassay><Biological Assay><Biological Markers><Birth><Blindness><Blood Chemical Analyses><Blood Chemical Analysis><Blood Sample><Blood Serum><Blood specimen><Caffey pseudo-Hurler syndrome><Caffey syndrome><Caring><Chemistry><Child><Child Youth><Childhood><Children (0-21)><Chronologic Fetal Maturity><Climacteric><Clinical><Clinical Protocols><Clinical Trials><Clinical Trials Data Monitoring Committees><Communities><Cord Blood><Cruveilhier disease><DNA Therapy><DNA mutation><Data><Data Monitoring Committees><Data and Safety Monitoring Boards><Development><Diagnosis><Disease><Disorder><Dose><Early treatment><Early-Stage Clinical Trials><Enrollment><Ethicists><Ethics Consultants><Family><Fetal Age><Fetal Therapies><Fetus><Funding><Future><G(A(2)) Ganglioside><G(M1) Ganglioside><G(M1) Gangliosidosis><GA(2) Ganglioside><GLB1><GLB1 gene><Galactosidase><Ganglioside GM1><Gangliosidosis GM1><Gene Transfer Clinical><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Gestation><Gestational Age><Goals><Grant><Hurler variant><Hurler-like syndrome><IND Filing><IND application><IND package><IND submission><IRB><IRBs><Infant><Infantile Gangliosidosis GM1><Infusion><Infusion procedures><Institutional Review Boards><International><Intervention><Intravenous><Investigational New Drug Application><Landing syndrome><Life><Liquor Amnii><Medical><Methods><Molecular><Monitor><Monosialosyl Tetraglycosyl Ceramide><Mothers><Mutation><Nerve Degeneration><Neurologic><Neurological><Neuron Degeneration><Norman-Landing syndrome><Onset of illness><Parturition><Patients><Pharmacology and Toxicology><Phase 1 Clinical Trials><Phase 1/2 Clinical Trial><Phase I Clinical Trials><Phase I/II Clinical Trial><Population><Pre IND FDA meeting><Pre-IND mtg><Preclinical data><Pregnancy><Prevalence><Protein Replacement Therapy><Protocol><Protocols documentation><Route><Safety><Safety Monitoring Boards><Scientist><Seizures><Serum><Somatic Gene Therapy><Spinal Muscular Atrophy><Survey Instrument><Surveys><Tay-Sachs disease with visceral involvement><Techniques><Testing><Therapy trial><Treatment Protocols><Treatment Regimen><Treatment Schedule><Type 1 Gangliosidosis GM1><Umbilical Cord Blood><Umbilical vein><Work><adeno-associated viral vector><adeno-associated virus vector><assay development><beta galactosidase deficiency><beta-galactosidase-1 (GLB1) deficiency><beta-galactosidase-1 deficiency><bio-markers><biologic marker><biomarker><blood chemistry><carrier status><cerebral GM1 gangliosidosis><curative intervention><curative therapeutic><curative therapy><curative treatments><deafness><developmental><disease causing variant><disease onset><disease-causing allele><disease-causing mutation><disorder onset><early onset><early therapy><embryo surgery><enroll><enzyme replacement therapy><enzyme replacement treatment><familial neurovisceral lipidosis><fetal cord blood><fetus therapy><first in man><first-in-human><gene repair therapy><gene replacement therapy><gene therapy><gene-based therapy><generalized infantile gangliosidosis><generalized infantile gangliosidosis with bony involvement><genetic condition><genetic diagnosis><genetic disorder><genetic disorder diagnosis><genetic therapy><genome mutation><genomic therapy><improved outcome><in utero><in utero surgery><in utero therapy><infancy><infantile><inflammation marker><inflammatory marker><infusions><intra-uterine inflammation><intrauterine inflammation><kids><lamb model><life change><malformation><model of animal><neural degeneration><neurodegeneration><neurodegenerative><neurological degeneration><neuronal Gm(1) gangliosidosis><neuronal degeneration><neurovisceral lipidosis><open label><open label study><participant engagement><pathogenic allele><pathogenic variant><patient engagement><pediatric><phase 1 trial><phase I protocol><phase I trial><postnatal><pre-IND consultation><pre-IND discussion><pre-IND meeting><pre-Investigational New Drug meeting><pre-clinical><preclinical><preclinical findings><preclinical information><prenatal><prenatal intervention><prenatal surgery><prenatal therapy><progressive neurodegeneration><prospective><pseudo-Hurler disease><safety and feasibility><safety assessment><safety study><safety testing><seropositive><somatic cell gene therapy><somatic gene transfer><spasticity><specific biomarkers><type I gagliosidosis GM1><type I generalized gangliosidosis GM1><unborn><vector><vector biodistribution><vision loss><visual loss><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Venigalla B. Rao

CATHOLIC UNIVERSITY OF AMERICA, WASHINGTON, DC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$964,530

FY 2026

Project Title

Engineering Bacteriophage T4 as a Targeted Gene Therapy Drug for in vivo HIV Cure

Grant Number:

5DP1DA060580-03

Activity Code:

DP1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

This proposal aims to establish a new category of safe and affordable in vivo HIV cure “drugs” that would transform the health of substance users who are disproportionately affected by HIV-1 (HIV) disease. Substance users suffer from high rates of HIV acquisition and transmission, poor adherence to ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patrick Hogan

LA JOLLA INSTITUTE FOR IMMUNOLOGY, LA JOLLA, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$929,885

FY 2026

Project Title

NFAT, bZIP proteins, and transcriptional programs in lymphocytes

Grant Number:

2R01AI109842-37A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2014

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Modern immunotherapies have had a broad impact in clinical oncology. CAR T cell therapy has been dramatically successful against certain hematologic malignancies, and ‘immune checkpoint blockade’ targeting the PD-1/PD- L1 pathway or other T cell inhibitory pathways has proven to be an effec...

Research Terms

<AP-1><AP-1 Enhancer-Binding Protein><AP1><AP1 protein><Activator Protein-1><Address><Affinity><Aldesleukin Gene><Antigens><Basal Transcription Factor><Basal transcription factor genes><Binding><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD152><CD152 Antigen><CD152 Gene><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Calcineurin><Calcium><Calcium Channel><Calcium Channel Antagonist Receptor><Calcium Channel Blocker Receptors><Calcium Ion Channels><Cancer Control><Cancer Control Science><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Receptors><Cell-Mediated Lympholytic Cells><Cells><Chromatin><Chronic><Clinic><Clinical Oncology><Collaborations><Complex><Consensus><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic T-Lymphocytes><DNA><Data><Deoxyribonucleic Acid><Development><Engineering><Enhancer-Binding Protein AP1><Environment><Exhibits><Exposure to><Extremities><FOS-Like Antigen 2><FOSL2><FOSL2 gene><FRA2><Family><Fos-Like Antigen 2 Gene><Fostering><Fra-2 protein><Funding><GBF bZIP protein><GBF protein><Gene Expression><Gene Targeting><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Transcription><Grant><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Human><IL-2 Gene><IL2><IL2 gene><Immune><Immune mediated therapy><Immune response><Immunes><Immunologically Directed Therapy><Immunotherapy><Individual><Interleukin 2 Precursor Gene><Interleukin-2 Gene><Intracellular Communication and Signaling><LYT3><Limb structure><Limbs><Link><Lymphatic cell><Lymphocyte><Lymphocytic><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Memory><Mice><Mice Mammals><Modern Man><Modernization><Molecular><Molecular Interaction><Murine><Mus><NF-AT><NF-AT proteins><NFAT proteins><NFAT-1><NFATC proteins><NIH><National Institutes of Health><Non-Trunk><Nuclear Receptors><PD 1><PD-1><PD-1/PD-L1><PD-1/PDL1><PD-L1 pathway><PD1><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL1 pathway><PP2B><Paper><Pathway interactions><Patients><Physiologic><Physiological><Play><Progress Reports><Protein Family><Protein Phosphatase-2B><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Expression><Recommendation><Recurrence><Recurrent><Recurrent Neoplasm><Recurrent tumor><Research Grants><Research Project Grants><Research Projects><Role><STAT3><STAT3 gene><STAT4><STAT4 gene><Signal Transduction><Signal Transduction Systems><Signaling><Site><Solid Neoplasm><Solid Tumor><T cell response><T cells for CAR><T-Cell Antigen Receptors><T-Cell Growth Factor Gene><T-Cell Receptor><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><TCGF Gene><Teff cell><Transcription><Transcription Factor AP-1><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tumor-Infiltrating Lymphocytes><United States National Institutes of Health><Upregulation><VDCC><Viral Diseases><Virus Diseases><Voltage-Dependent Calcium Channels><Work><bZIP Protein><biological signal transduction><cancer infiltrating T cells><check point blockade><checkpoint blockade><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cytokine><cytoplasmic nuclear factor of activated T-cells><cytotoxic T-lymphocyte antigen 4><developmental><effective therapy><effective treatment><effector T cell><engineered T cells><exhaust><exhaustion><expectation><experience><experiment><experimental research><experimental study><experiments><fos-related antigen-2><gene locus><genetic locus><genetically engineered T-cells><genomic location><genomic locus><host response><immune check point blockade><immune checkpoint blockade><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunoresponse><in vivo><insight><intervention design><killer T cell><lymph cell><malignancy><member><mouse model><murine model><neoplasm recurrence><neoplasm/cancer><neoplastic cell><nuclear factors of activated T-cells><pathway><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><prevent><preventing><programmed cell death 1><programmed cell death ligand 1 pathway><programmed cell death protein 1><programmed cell death protein ligand 1 pathway><programmed death 1><programs><response><sle2><social role><success><systemic lupus erythematosus susceptibility 2><therapy design><thymus derived lymphocyte><transcription factor><transcription factor NF-AT><transgenic T- cells><treatment design><tumor><tumor infiltrating T cells><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anjana Rao

LA JOLLA INSTITUTE FOR IMMUNOLOGY, LA JOLLA, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$929,885

FY 2026

Project Title

NFAT, bZIP proteins, and transcriptional programs in lymphocytes

Grant Number:

2R01AI109842-37A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2014

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Modern immunotherapies have had a broad impact in clinical oncology. CAR T cell therapy has been dramatically successful against certain hematologic malignancies, and ‘immune checkpoint blockade’ targeting the PD-1/PD- L1 pathway or other T cell inhibitory pathways has proven to be an effec...

Research Terms

<AP-1><AP-1 Enhancer-Binding Protein><AP1><AP1 protein><Activator Protein-1><Address><Affinity><Aldesleukin Gene><Antigens><Basal Transcription Factor><Basal transcription factor genes><Binding><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD152><CD152 Antigen><CD152 Gene><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Calcineurin><Calcium><Calcium Channel><Calcium Channel Antagonist Receptor><Calcium Channel Blocker Receptors><Calcium Ion Channels><Cancer Control><Cancer Control Science><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Surface Receptors><Cell-Mediated Lympholytic Cells><Cells><Chromatin><Chronic><Clinic><Clinical Oncology><Collaborations><Complex><Consensus><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><Cytotoxic T-Lymphocytes><DNA><Data><Deoxyribonucleic Acid><Development><Engineering><Enhancer-Binding Protein AP1><Environment><Exhibits><Exposure to><Extremities><FOS-Like Antigen 2><FOSL2><FOSL2 gene><FRA2><Family><Fos-Like Antigen 2 Gene><Fostering><Fra-2 protein><Funding><GBF bZIP protein><GBF protein><Gene Expression><Gene Targeting><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Transcription><Grant><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Human><IL-2 Gene><IL2><IL2 gene><Immune><Immune mediated therapy><Immune response><Immunes><Immunologically Directed Therapy><Immunotherapy><Individual><Interleukin 2 Precursor Gene><Interleukin-2 Gene><Intracellular Communication and Signaling><LYT3><Limb structure><Limbs><Link><Lymphatic cell><Lymphocyte><Lymphocytic><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Memory><Mice><Mice Mammals><Modern Man><Modernization><Molecular><Molecular Interaction><Murine><Mus><NF-AT><NF-AT proteins><NFAT proteins><NFAT-1><NFATC proteins><NIH><National Institutes of Health><Non-Trunk><Nuclear Receptors><PD 1><PD-1><PD-1/PD-L1><PD-1/PDL1><PD-L1 pathway><PD1><PD1-PD-L1><PD1/PD-L1><PD1/PDL1><PDL1 pathway><PP2B><Paper><Pathway interactions><Patients><Physiologic><Physiological><Play><Progress Reports><Protein Family><Protein Phosphatase-2B><Proteins><R-Series Research Projects><R01 Mechanism><R01 Program><RNA Expression><Recommendation><Recurrence><Recurrent><Recurrent Neoplasm><Recurrent tumor><Research Grants><Research Project Grants><Research Projects><Role><STAT3><STAT3 gene><STAT4><STAT4 gene><Signal Transduction><Signal Transduction Systems><Signaling><Site><Solid Neoplasm><Solid Tumor><T cell response><T cells for CAR><T-Cell Antigen Receptors><T-Cell Growth Factor Gene><T-Cell Receptor><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><TCGF Gene><Teff cell><Transcription><Transcription Factor AP-1><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tumor-Infiltrating Lymphocytes><United States National Institutes of Health><Upregulation><VDCC><Viral Diseases><Virus Diseases><Voltage-Dependent Calcium Channels><Work><bZIP Protein><biological signal transduction><cancer infiltrating T cells><check point blockade><checkpoint blockade><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cytokine><cytoplasmic nuclear factor of activated T-cells><cytotoxic T-lymphocyte antigen 4><developmental><effective therapy><effective treatment><effector T cell><engineered T cells><exhaust><exhaustion><expectation><experience><experiment><experimental research><experimental study><experiments><fos-related antigen-2><gene locus><genetic locus><genetically engineered T-cells><genomic location><genomic locus><host response><immune check point blockade><immune checkpoint blockade><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunoresponse><in vivo><insight><intervention design><killer T cell><lymph cell><malignancy><member><mouse model><murine model><neoplasm recurrence><neoplasm/cancer><neoplastic cell><nuclear factors of activated T-cells><pathway><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><prevent><preventing><programmed cell death 1><programmed cell death ligand 1 pathway><programmed cell death protein 1><programmed cell death protein ligand 1 pathway><programmed death 1><programs><response><sle2><social role><success><systemic lupus erythematosus susceptibility 2><therapy design><thymus derived lymphocyte><transcription factor><transcription factor NF-AT><transgenic T- cells><treatment design><tumor><tumor infiltrating T cells><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Douglas Gould

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$821,991

FY 2026

Project Title

Gene therapy for disorders of the extracellular matrix

Grant Number:

4R01NS128217-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY COL4A1 and COL4A2 mutations cause Gould syndrome (GS) – a multisystem disorder for which clinically heterogeneous cerebrovascular disease is the major consequence. Cerebrovascular disease in individuals with GS can range from porencephaly caused by germinal matrix hemorrhages in uter...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patricia L Musolino

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$821,991

FY 2026

Project Title

Gene therapy for disorders of the extracellular matrix

Grant Number:

4R01NS128217-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY COL4A1 and COL4A2 mutations cause Gould syndrome (GS) – a multisystem disorder for which clinically heterogeneous cerebrovascular disease is the major consequence. Cerebrovascular disease in individuals with GS can range from porencephaly caused by germinal matrix hemorrhages in uter...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David Andrew Brown

DUKE UNIVERSITY, DURHAM, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$804,998

FY 2026

Project Title

Gene therapy methods for enhancing limb regeneration based on conserved transcriptional programs

Grant Number:

5R01HD115266-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/12/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract: Adult teleost fish and urodele amphibians can regenerate entire amputated appendages, whereas this ability is restricted to the tip of the distal phalanx in humans and mice. Though modest in comparison to its zebrafish and salamander counterparts, mouse digit tip (MDT) regeneration exhibit...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><AAV vector><AAV-based vector><Adeno-Associated Viruses><Adult><Adult Human><Amphibia><Amphibians><Amputation><Anatomic Sites><Anatomic structures><Anatomy><Assay><Basal Transcription Factor><Basal transcription factor genes><Bioassay><Biological Assay><Body Tissues><Bone Regeneration><Brachydanio rerio><Capsid><Caring><Catalogs><Cell Body><Cells><Chromatin><Chromosomes><Comparative Study><Complex><DNA Therapy><DNA-Protein Interaction><Danio rerio><Dependoparvovirus><Dependovirus><Digit><Digit structure><Directed Molecular Evolution><Distal><Elements><Engineering><Enhancer Elements><Epidermis><Event><Exhibits><Extremities><Family><Gene Expression><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic Enhancer Element><Genetic Intervention><Genetic Transcription><Goals><Growth><Hand><Human><Immune Precipitation><Immunoprecipitation><Impairment><In vivo analysis><Injury><KO mice><Knock-out Mice><Knockout Mice><Limb structure><Limbs><Maps><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Methodology><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Genetics><Murine><Mus><Names><Natural regeneration><Non-Trunk><Null Mouse><Organism><Pathway interactions><Patients><Phalanx><RNA Expression><Regeneration><Regenerative capacity><Regulatory Element><Reporter><Reporting><Salamander><Sampling><Serotyping><Site><Specificity><Testing><Tissue Growth><Tissues><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transcriptional Control><Transcriptional Regulation><Variant><Variation><Viral><Viral Genes><Visual><Work><Zebra Danio><Zebra Fish><Zebrafish><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><adulthood><appendage><blastema><bone><catalog><cofactor><conditional knock-out><conditional knockout><digit regeneration><directed evolution><enhancer sequence><gene repair therapy><gene therapy><gene-based therapy><genetic enhancer sequence><genetic therapy><genomic therapy><global gene expression><global transcription profile><hands><healing><human tissue><improved><in vivo evaluation><in vivo testing><injuries><insight><intramembranous bone><limb loss><limb regeneration><living system><lost limb><member><name><named><naming><novel><ontogeny><pathway><programs><promoter><promotor><regenerate><regenerate bone><regenerate new tissue><regenerate tissue><regenerating damaged tissue><regenerating tissue><regeneration ability><regeneration capacity><regeneration potential><regenerative><regenerative potential><selective expression><selectively expressed><spatial and temporal><spatial temporal><spatiotemporal><teleost fish><teleostean fish><teleostfish><three dimensional><tissue regeneration><tissue regrowth><tissue renewal><tissue repair><tissue specific regeneration><transcription factor><transcriptome><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KENNETH D POSS

DUKE UNIVERSITY, DURHAM, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$804,998

FY 2026

Project Title

Gene therapy methods for enhancing limb regeneration based on conserved transcriptional programs

Grant Number:

5R01HD115266-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/12/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract: Adult teleost fish and urodele amphibians can regenerate entire amputated appendages, whereas this ability is restricted to the tip of the distal phalanx in humans and mice. Though modest in comparison to its zebrafish and salamander counterparts, mouse digit tip (MDT) regeneration exhibit...

Research Terms

<21+ years old><3-D><3-Dimensional><3D><AAV vector><AAV-based vector><Adeno-Associated Viruses><Adult><Adult Human><Amphibia><Amphibians><Amputation><Anatomic Sites><Anatomic structures><Anatomy><Assay><Basal Transcription Factor><Basal transcription factor genes><Bioassay><Biological Assay><Body Tissues><Bone Regeneration><Brachydanio rerio><Capsid><Caring><Catalogs><Cell Body><Cells><Chromatin><Chromosomes><Comparative Study><Complex><DNA Therapy><DNA-Protein Interaction><Danio rerio><Dependoparvovirus><Dependovirus><Digit><Digit structure><Directed Molecular Evolution><Distal><Elements><Engineering><Enhancer Elements><Epidermis><Event><Exhibits><Extremities><Family><Gene Expression><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic Enhancer Element><Genetic Intervention><Genetic Transcription><Goals><Growth><Hand><Human><Immune Precipitation><Immunoprecipitation><Impairment><In vivo analysis><Injury><KO mice><Knock-out Mice><Knockout Mice><Limb structure><Limbs><Maps><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Methodology><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Genetics><Murine><Mus><Names><Natural regeneration><Non-Trunk><Null Mouse><Organism><Pathway interactions><Patients><Phalanx><RNA Expression><Regeneration><Regenerative capacity><Regulatory Element><Reporter><Reporting><Salamander><Sampling><Serotyping><Site><Specificity><Testing><Tissue Growth><Tissues><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transcriptional Control><Transcriptional Regulation><Variant><Variation><Viral><Viral Genes><Visual><Work><Zebra Danio><Zebra Fish><Zebrafish><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><adulthood><appendage><blastema><bone><catalog><cofactor><conditional knock-out><conditional knockout><digit regeneration><directed evolution><enhancer sequence><gene repair therapy><gene therapy><gene-based therapy><genetic enhancer sequence><genetic therapy><genomic therapy><global gene expression><global transcription profile><hands><healing><human tissue><improved><in vivo evaluation><in vivo testing><injuries><insight><intramembranous bone><limb loss><limb regeneration><living system><lost limb><member><name><named><naming><novel><ontogeny><pathway><programs><promoter><promotor><regenerate><regenerate bone><regenerate new tissue><regenerate tissue><regenerating damaged tissue><regenerating tissue><regeneration ability><regeneration capacity><regeneration potential><regenerative><regenerative potential><selective expression><selectively expressed><spatial and temporal><spatial temporal><spatiotemporal><teleost fish><teleostean fish><teleostfish><three dimensional><tissue regeneration><tissue regrowth><tissue renewal><tissue repair><tissue specific regeneration><transcription factor><transcriptome><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

J Kevin Donahue

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$780,600

FY 2026

Project Title

Translating post-infarct ventricular tachycardia mechanisms into a therapy

Grant Number:

5R01HL167527-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/9/2023

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT In the United States, several hundred thousand people experience cardiac arrest each year, with the vast majority dying from this condition. Approximately two-thirds of cardiac arrest victims have previously suffered a myocardial infarction (MI), and death results from maladaptive response...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HANS-PETER KIEM

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$756,008

FY 2026

Project Title

CD90-targeted nanoparticles for in vivo hematopoietic stem cell gene therapy

Grant Number:

5R01HL173365-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2025

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Patients with genetic blood diseases and disorders are commonly treated with blood (hematopoietic) stem cell (HSC) transplants from healthy, human leukocyte antigen (HLA)-matched sibling donors. Unfortunately, for most patients, there is no HLA-identical sibling donor availa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wenhui Hu

TEXAS BIOMEDICAL RESEARCH INSTITUTE, SAN ANTONIO, TX

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$754,354

FY 2026

Project Title

Brain myeloid cell-targeted multiplexed gene editing for SIV/HIV eradication

Grant Number:

5R01MH130193-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/5/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary The long-lived myeloid cells such as perivascular macrophages and microglia in the central nervous system (CNS) persistently harbor HIV. These infected cells could contribute to the source of residual viremia during long-term antiretroviral therapy (ART) or to rebounding virus upon ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Binhua Julie Ling

TEXAS BIOMEDICAL RESEARCH INSTITUTE, SAN ANTONIO, TX

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$754,354

FY 2026

Project Title

Brain myeloid cell-targeted multiplexed gene editing for SIV/HIV eradication

Grant Number:

5R01MH130193-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/5/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary The long-lived myeloid cells such as perivascular macrophages and microglia in the central nervous system (CNS) persistently harbor HIV. These infected cells could contribute to the source of residual viremia during long-term antiretroviral therapy (ART) or to rebounding virus upon ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexander Bick

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$752,202

FY 2026

Project Title

Clonal hematopoiesis and inherited genetic variation in sickle cell disease

Grant Number:

5R01HL168179-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Sickle cell disease (SCD) is associated with chronic hemolysis, systemic endothelial dysfunction, inflammation and vascular occlusion. This complex pathophysiology leads to severe pain, progressive multi-organ damage and premature death with a median lifespan of 48 years in high- inc...

Research Terms

<0-11 years old><21+ years old><AML - Acute Myeloid Leukemia><APOL-I><APOL1><APOL1 gene><Acceleration><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><Adult><Adult Human><Affect><Age><Allogenic><American><Antioncogene Protein p53><Assay><Autologous><Benefits and Risks><Bioassay><Biological Assay><Blood><Blood Cells><Blood Diseases><Blood Precursor Cell><Blood Pressure><Blood Reticuloendothelial System><Blood Vessels><Cardiac Diseases><Cardiac Disorders><Cell division><Cellular Tumor Antigen P53><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Chronic><Clinical><Clonal Hematopoietic Stem Cell><Clonal expansion of hematopoietic cells><Clonal expansion of hematopoietic stem cells><Clonal hematopoietic expansion><Complex><Country><DNA><DNA Therapy><DNA mutation><DNMT3a><Data><Death><Deoxyribonucleic Acid><Development><Diathesis><Disease><Disease Outcome><Disease susceptibility><Disorder><Dysfunction><Early Intervention><Economic Income><Economical Income><FEV1><FEV1%VC><Forced Expiratory Volume 1 Test><Forced Expiratory Volume in 1 Second><Functional disorder><Future><Gene Transfer Clinical><Gene variant><General Population><General Public><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Diversity><Genetic Intervention><Genetic Variation><Genetic defect><Genetic mutation><Genetic study><Genomics><Genotype><Germ Lines><Germ-Line Mutation><Goals><Granulocytic Leukemia><Growth><HSC aging><HSC transplantation><Hb SS disease><HbSS disease><Heart><Heart Diseases><Hematologic Diseases><Hematological Disease><Hematological Disorder><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hemoglobin><Hemoglobin H Disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemolysis><Hereditary><Hereditary Mutation><Incidence><Income><Individual><Inflammation><Inherited><JAK-2><JAK2><JAK2 gene><JAK2 protein><Janus kinase 2><Kidney><Kidney Diseases><Kidney Urinary System><Life><Link><Lung><Lung Diseases><Lung Respiratory System><Lung damage><MOF syndrome><Malignant Hematopoietic Neoplasm><Measurement><Morbidity><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Mutation><Myelocytic Leukemia><Myelogenous Leukemia><Myeloid Disease><Myeloid Leukemia><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><NHLBI><NIH><National Heart, Lung, and Blood Institute><National Institutes of Health><Nephropathy><Non-Lymphoblastic Leukemia><Non-Lymphocytic Leukemia><Nonlymphoblastic Leukemia><Nonlymphocytic Leukemia><Oncoprotein p53><Organ><Outcome><P53><PFT/FEV1><Pain><Painful><Patient Selection><Patients><Peripheral Blood Cell><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Physiopathology><Predisposition><Premature Mortality><Prevalence><Probabilistic Models><Probability><Probability Models><Protein TP53><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Function Test/Forced Expiratory Volume 1><Pulmonary Hypertension><Renal Disease><Renal function><Risk><Risk Factors><Sampling><Severities><Sickle Cell Anemia><Somatic Mutation><Statistical Models><Susceptibility><Symptoms><System><TOPMed><TP53><TP53 gene><TRP53><Technology><Testing><Therapeutic><Tissue Growth><Trans-Omics for Precision Medicine><Tumor Protein p53><Tumor Protein p53 Gene><Tyrosine-Protein Kinase JAK2><United States National Institutes of Health><Variant><Variation><Work><acute granulocytic leukemia><acute myeloid leukemia><adult youth><adulthood><adverse consequence><adverse outcome><ages><allelic variant><alpha-Thalassemia><blood cancer><blood cell progenitor><blood disorder><blood progenitor><blood stem cell><blood stem cell transplantation><blood-forming stem cell><cancer of blood><cancer of the blood><cardiac damage><clonal expansions in the blood><clonal hematopoiesis><clone hematopoietic stem cell><clones in hematopoietic cells><co-morbid><co-morbidity><cohort><comorbidity><cost effective><curative intervention><curative therapeutic><curative therapy><curative treatments><customized therapy><customized treatment><damage to kidney><design><designing><developmental><disease of the lung><disorder of the lung><driver lesion><driver mutation><early adulthood><emerging adult><endothelial dysfunction><entire genome><erythrolysis><exome sequencing><exome-seq><full genome><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic variant><genome mutation><genome sequencing><genomic therapy><genomic variant><germ-line defect><germline variant><hDNA methyltransferase 3a><heart damage><heart disorder><hematopoietic cell clones><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor><hematopoietic progenitor cell transplantation><hematopoietic stem cell aging><hematopoietic stem cell clonality><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><incomes><individualized medicine><individualized patient treatment><individualized strategies><individualized therapeutic strategy><individualized therapy><individualized treatment><innovate><innovation><innovative><insight><investigate prevalence><kidney damage><kidney disorder><kidney function><kids><liability to disease><life span><lifespan><lung disorder><lung injury><mortality><multiorgan damage><multiorgan failure><multiple organ system failure><myeloid granulocytic leukemia><myeloproliferative neoplasm><myelosis><novel><ontogeny><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathophysiology><patient specific therapies><patient specific treatment><pediatric><personalized strategies><precancer><precancerous><premalignant><premature><prematurity><prevalence investigation><prevalence research><programs><prospective><protein p53><public health relevance><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><renal><renal damage><renal disorder><sex><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><somatic variant><statistical linear mixed models><statistical linear models><stem cell gene therapy><study prevalence><survey prevalence><tailored medical treatment><tailored therapy><tailored treatment><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment><treatment risk><unique treatment><vascular><whole genome><young adult><young adult age><young adulthood><youngster><α-thalassemia>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael R. DeBaun

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$752,202

FY 2026

Project Title

Clonal hematopoiesis and inherited genetic variation in sickle cell disease

Grant Number:

5R01HL168179-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Sickle cell disease (SCD) is associated with chronic hemolysis, systemic endothelial dysfunction, inflammation and vascular occlusion. This complex pathophysiology leads to severe pain, progressive multi-organ damage and premature death with a median lifespan of 48 years in high- inc...

Research Terms

<0-11 years old><21+ years old><AML - Acute Myeloid Leukemia><APOL-I><APOL1><APOL1 gene><Acceleration><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><Adult><Adult Human><Affect><Age><Allogenic><American><Antioncogene Protein p53><Assay><Autologous><Benefits and Risks><Bioassay><Biological Assay><Blood><Blood Cells><Blood Diseases><Blood Precursor Cell><Blood Pressure><Blood Reticuloendothelial System><Blood Vessels><Cardiac Diseases><Cardiac Disorders><Cell division><Cellular Tumor Antigen P53><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Chronic><Clinical><Clonal Hematopoietic Stem Cell><Clonal expansion of hematopoietic cells><Clonal expansion of hematopoietic stem cells><Clonal hematopoietic expansion><Complex><Country><DNA><DNA Therapy><DNA mutation><DNMT3a><Data><Death><Deoxyribonucleic Acid><Development><Diathesis><Disease><Disease Outcome><Disease susceptibility><Disorder><Dysfunction><Early Intervention><Economic Income><Economical Income><FEV1><FEV1%VC><Forced Expiratory Volume 1 Test><Forced Expiratory Volume in 1 Second><Functional disorder><Future><Gene Transfer Clinical><Gene variant><General Population><General Public><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Diversity><Genetic Intervention><Genetic Variation><Genetic defect><Genetic mutation><Genetic study><Genomics><Genotype><Germ Lines><Germ-Line Mutation><Goals><Granulocytic Leukemia><Growth><HSC aging><HSC transplantation><Hb SS disease><HbSS disease><Heart><Heart Diseases><Hematologic Diseases><Hematological Disease><Hematological Disorder><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hemoglobin><Hemoglobin H Disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemolysis><Hereditary><Hereditary Mutation><Incidence><Income><Individual><Inflammation><Inherited><JAK-2><JAK2><JAK2 gene><JAK2 protein><Janus kinase 2><Kidney><Kidney Diseases><Kidney Urinary System><Life><Link><Lung><Lung Diseases><Lung Respiratory System><Lung damage><MOF syndrome><Malignant Hematopoietic Neoplasm><Measurement><Morbidity><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Mutation><Myelocytic Leukemia><Myelogenous Leukemia><Myeloid Disease><Myeloid Leukemia><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><NHLBI><NIH><National Heart, Lung, and Blood Institute><National Institutes of Health><Nephropathy><Non-Lymphoblastic Leukemia><Non-Lymphocytic Leukemia><Nonlymphoblastic Leukemia><Nonlymphocytic Leukemia><Oncoprotein p53><Organ><Outcome><P53><PFT/FEV1><Pain><Painful><Patient Selection><Patients><Peripheral Blood Cell><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Physiopathology><Predisposition><Premature Mortality><Prevalence><Probabilistic Models><Probability><Probability Models><Protein TP53><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Function Test/Forced Expiratory Volume 1><Pulmonary Hypertension><Renal Disease><Renal function><Risk><Risk Factors><Sampling><Severities><Sickle Cell Anemia><Somatic Mutation><Statistical Models><Susceptibility><Symptoms><System><TOPMed><TP53><TP53 gene><TRP53><Technology><Testing><Therapeutic><Tissue Growth><Trans-Omics for Precision Medicine><Tumor Protein p53><Tumor Protein p53 Gene><Tyrosine-Protein Kinase JAK2><United States National Institutes of Health><Variant><Variation><Work><acute granulocytic leukemia><acute myeloid leukemia><adult youth><adulthood><adverse consequence><adverse outcome><ages><allelic variant><alpha-Thalassemia><blood cancer><blood cell progenitor><blood disorder><blood progenitor><blood stem cell><blood stem cell transplantation><blood-forming stem cell><cancer of blood><cancer of the blood><cardiac damage><clonal expansions in the blood><clonal hematopoiesis><clone hematopoietic stem cell><clones in hematopoietic cells><co-morbid><co-morbidity><cohort><comorbidity><cost effective><curative intervention><curative therapeutic><curative therapy><curative treatments><customized therapy><customized treatment><damage to kidney><design><designing><developmental><disease of the lung><disorder of the lung><driver lesion><driver mutation><early adulthood><emerging adult><endothelial dysfunction><entire genome><erythrolysis><exome sequencing><exome-seq><full genome><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic variant><genome mutation><genome sequencing><genomic therapy><genomic variant><germ-line defect><germline variant><hDNA methyltransferase 3a><heart damage><heart disorder><hematopoietic cell clones><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor><hematopoietic progenitor cell transplantation><hematopoietic stem cell aging><hematopoietic stem cell clonality><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><incomes><individualized medicine><individualized patient treatment><individualized strategies><individualized therapeutic strategy><individualized therapy><individualized treatment><innovate><innovation><innovative><insight><investigate prevalence><kidney damage><kidney disorder><kidney function><kids><liability to disease><life span><lifespan><lung disorder><lung injury><mortality><multiorgan damage><multiorgan failure><multiple organ system failure><myeloid granulocytic leukemia><myeloproliferative neoplasm><myelosis><novel><ontogeny><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathophysiology><patient specific therapies><patient specific treatment><pediatric><personalized strategies><precancer><precancerous><premalignant><premature><prematurity><prevalence investigation><prevalence research><programs><prospective><protein p53><public health relevance><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><renal><renal damage><renal disorder><sex><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><somatic variant><statistical linear mixed models><statistical linear models><stem cell gene therapy><study prevalence><survey prevalence><tailored medical treatment><tailored therapy><tailored treatment><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment><treatment risk><unique treatment><vascular><whole genome><young adult><young adult age><young adulthood><youngster><α-thalassemia>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Santosh Saraf

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$752,202

FY 2026

Project Title

Clonal hematopoiesis and inherited genetic variation in sickle cell disease

Grant Number:

5R01HL168179-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Sickle cell disease (SCD) is associated with chronic hemolysis, systemic endothelial dysfunction, inflammation and vascular occlusion. This complex pathophysiology leads to severe pain, progressive multi-organ damage and premature death with a median lifespan of 48 years in high- inc...

Research Terms

<0-11 years old><21+ years old><AML - Acute Myeloid Leukemia><APOL-I><APOL1><APOL1 gene><Acceleration><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><Adult><Adult Human><Affect><Age><Allogenic><American><Antioncogene Protein p53><Assay><Autologous><Benefits and Risks><Bioassay><Biological Assay><Blood><Blood Cells><Blood Diseases><Blood Precursor Cell><Blood Pressure><Blood Reticuloendothelial System><Blood Vessels><Cardiac Diseases><Cardiac Disorders><Cell division><Cellular Tumor Antigen P53><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Chronic><Clinical><Clonal Hematopoietic Stem Cell><Clonal expansion of hematopoietic cells><Clonal expansion of hematopoietic stem cells><Clonal hematopoietic expansion><Complex><Country><DNA><DNA Therapy><DNA mutation><DNMT3a><Data><Death><Deoxyribonucleic Acid><Development><Diathesis><Disease><Disease Outcome><Disease susceptibility><Disorder><Dysfunction><Early Intervention><Economic Income><Economical Income><FEV1><FEV1%VC><Forced Expiratory Volume 1 Test><Forced Expiratory Volume in 1 Second><Functional disorder><Future><Gene Transfer Clinical><Gene variant><General Population><General Public><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Diversity><Genetic Intervention><Genetic Variation><Genetic defect><Genetic mutation><Genetic study><Genomics><Genotype><Germ Lines><Germ-Line Mutation><Goals><Granulocytic Leukemia><Growth><HSC aging><HSC transplantation><Hb SS disease><HbSS disease><Heart><Heart Diseases><Hematologic Diseases><Hematological Disease><Hematological Disorder><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hemoglobin><Hemoglobin H Disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemolysis><Hereditary><Hereditary Mutation><Incidence><Income><Individual><Inflammation><Inherited><JAK-2><JAK2><JAK2 gene><JAK2 protein><Janus kinase 2><Kidney><Kidney Diseases><Kidney Urinary System><Life><Link><Lung><Lung Diseases><Lung Respiratory System><Lung damage><MOF syndrome><Malignant Hematopoietic Neoplasm><Measurement><Morbidity><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Mutation><Myelocytic Leukemia><Myelogenous Leukemia><Myeloid Disease><Myeloid Leukemia><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><NHLBI><NIH><National Heart, Lung, and Blood Institute><National Institutes of Health><Nephropathy><Non-Lymphoblastic Leukemia><Non-Lymphocytic Leukemia><Nonlymphoblastic Leukemia><Nonlymphocytic Leukemia><Oncoprotein p53><Organ><Outcome><P53><PFT/FEV1><Pain><Painful><Patient Selection><Patients><Peripheral Blood Cell><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Physiopathology><Predisposition><Premature Mortality><Prevalence><Probabilistic Models><Probability><Probability Models><Protein TP53><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Function Test/Forced Expiratory Volume 1><Pulmonary Hypertension><Renal Disease><Renal function><Risk><Risk Factors><Sampling><Severities><Sickle Cell Anemia><Somatic Mutation><Statistical Models><Susceptibility><Symptoms><System><TOPMed><TP53><TP53 gene><TRP53><Technology><Testing><Therapeutic><Tissue Growth><Trans-Omics for Precision Medicine><Tumor Protein p53><Tumor Protein p53 Gene><Tyrosine-Protein Kinase JAK2><United States National Institutes of Health><Variant><Variation><Work><acute granulocytic leukemia><acute myeloid leukemia><adult youth><adulthood><adverse consequence><adverse outcome><ages><allelic variant><alpha-Thalassemia><blood cancer><blood cell progenitor><blood disorder><blood progenitor><blood stem cell><blood stem cell transplantation><blood-forming stem cell><cancer of blood><cancer of the blood><cardiac damage><clonal expansions in the blood><clonal hematopoiesis><clone hematopoietic stem cell><clones in hematopoietic cells><co-morbid><co-morbidity><cohort><comorbidity><cost effective><curative intervention><curative therapeutic><curative therapy><curative treatments><customized therapy><customized treatment><damage to kidney><design><designing><developmental><disease of the lung><disorder of the lung><driver lesion><driver mutation><early adulthood><emerging adult><endothelial dysfunction><entire genome><erythrolysis><exome sequencing><exome-seq><full genome><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic variant><genome mutation><genome sequencing><genomic therapy><genomic variant><germ-line defect><germline variant><hDNA methyltransferase 3a><heart damage><heart disorder><hematopoietic cell clones><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor><hematopoietic progenitor cell transplantation><hematopoietic stem cell aging><hematopoietic stem cell clonality><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><incomes><individualized medicine><individualized patient treatment><individualized strategies><individualized therapeutic strategy><individualized therapy><individualized treatment><innovate><innovation><innovative><insight><investigate prevalence><kidney damage><kidney disorder><kidney function><kids><liability to disease><life span><lifespan><lung disorder><lung injury><mortality><multiorgan damage><multiorgan failure><multiple organ system failure><myeloid granulocytic leukemia><myeloproliferative neoplasm><myelosis><novel><ontogeny><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathophysiology><patient specific therapies><patient specific treatment><pediatric><personalized strategies><precancer><precancerous><premalignant><premature><prematurity><prevalence investigation><prevalence research><programs><prospective><protein p53><public health relevance><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><renal><renal damage><renal disorder><sex><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><somatic variant><statistical linear mixed models><statistical linear models><stem cell gene therapy><study prevalence><survey prevalence><tailored medical treatment><tailored therapy><tailored treatment><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment><treatment risk><unique treatment><vascular><whole genome><young adult><young adult age><young adulthood><youngster><α-thalassemia>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mitchell J Weiss

VANDERBILT UNIVERSITY MEDICAL CENTER, NASHVILLE, TN

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$752,202

FY 2026

Project Title

Clonal hematopoiesis and inherited genetic variation in sickle cell disease

Grant Number:

5R01HL168179-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Sickle cell disease (SCD) is associated with chronic hemolysis, systemic endothelial dysfunction, inflammation and vascular occlusion. This complex pathophysiology leads to severe pain, progressive multi-organ damage and premature death with a median lifespan of 48 years in high- inc...

Research Terms

<0-11 years old><21+ years old><AML - Acute Myeloid Leukemia><APOL-I><APOL1><APOL1 gene><Acceleration><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><Adult><Adult Human><Affect><Age><Allogenic><American><Antioncogene Protein p53><Assay><Autologous><Benefits and Risks><Bioassay><Biological Assay><Blood><Blood Cells><Blood Diseases><Blood Precursor Cell><Blood Pressure><Blood Reticuloendothelial System><Blood Vessels><Cardiac Diseases><Cardiac Disorders><Cell division><Cellular Tumor Antigen P53><Cessation of life><Child><Child Youth><Childhood><Children (0-21)><Chronic><Clinical><Clonal Hematopoietic Stem Cell><Clonal expansion of hematopoietic cells><Clonal expansion of hematopoietic stem cells><Clonal hematopoietic expansion><Complex><Country><DNA><DNA Therapy><DNA mutation><DNMT3a><Data><Death><Deoxyribonucleic Acid><Development><Diathesis><Disease><Disease Outcome><Disease susceptibility><Disorder><Dysfunction><Early Intervention><Economic Income><Economical Income><FEV1><FEV1%VC><Forced Expiratory Volume 1 Test><Forced Expiratory Volume in 1 Second><Functional disorder><Future><Gene Transfer Clinical><Gene variant><General Population><General Public><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Diversity><Genetic Intervention><Genetic Variation><Genetic defect><Genetic mutation><Genetic study><Genomics><Genotype><Germ Lines><Germ-Line Mutation><Goals><Granulocytic Leukemia><Growth><HSC aging><HSC transplantation><Hb SS disease><HbSS disease><Heart><Heart Diseases><Hematologic Diseases><Hematological Disease><Hematological Disorder><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hemoglobin><Hemoglobin H Disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemolysis><Hereditary><Hereditary Mutation><Incidence><Income><Individual><Inflammation><Inherited><JAK-2><JAK2><JAK2 gene><JAK2 protein><Janus kinase 2><Kidney><Kidney Diseases><Kidney Urinary System><Life><Link><Lung><Lung Diseases><Lung Respiratory System><Lung damage><MOF syndrome><Malignant Hematopoietic Neoplasm><Measurement><Morbidity><Multiple Organ Dysfunction Syndrome><Multiple Organ Failure><Mutation><Myelocytic Leukemia><Myelogenous Leukemia><Myeloid Disease><Myeloid Leukemia><Myeloid Malignancy><Myeloid Neoplasm><Myeloid Tumor><Myeloproliferative Disorders><Myeloproliferative Tumors><Myeloproliferative disease><NHLBI><NIH><National Heart, Lung, and Blood Institute><National Institutes of Health><Nephropathy><Non-Lymphoblastic Leukemia><Non-Lymphocytic Leukemia><Nonlymphoblastic Leukemia><Nonlymphocytic Leukemia><Oncoprotein p53><Organ><Outcome><P53><PFT/FEV1><Pain><Painful><Patient Selection><Patients><Peripheral Blood Cell><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Physiopathology><Predisposition><Premature Mortality><Prevalence><Probabilistic Models><Probability><Probability Models><Protein TP53><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Function Test/Forced Expiratory Volume 1><Pulmonary Hypertension><Renal Disease><Renal function><Risk><Risk Factors><Sampling><Severities><Sickle Cell Anemia><Somatic Mutation><Statistical Models><Susceptibility><Symptoms><System><TOPMed><TP53><TP53 gene><TRP53><Technology><Testing><Therapeutic><Tissue Growth><Trans-Omics for Precision Medicine><Tumor Protein p53><Tumor Protein p53 Gene><Tyrosine-Protein Kinase JAK2><United States National Institutes of Health><Variant><Variation><Work><acute granulocytic leukemia><acute myeloid leukemia><adult youth><adulthood><adverse consequence><adverse outcome><ages><allelic variant><alpha-Thalassemia><blood cancer><blood cell progenitor><blood disorder><blood progenitor><blood stem cell><blood stem cell transplantation><blood-forming stem cell><cancer of blood><cancer of the blood><cardiac damage><clonal expansions in the blood><clonal hematopoiesis><clone hematopoietic stem cell><clones in hematopoietic cells><co-morbid><co-morbidity><cohort><comorbidity><cost effective><curative intervention><curative therapeutic><curative therapy><curative treatments><customized therapy><customized treatment><damage to kidney><design><designing><developmental><disease of the lung><disorder of the lung><driver lesion><driver mutation><early adulthood><emerging adult><endothelial dysfunction><entire genome><erythrolysis><exome sequencing><exome-seq><full genome><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic variant><genome mutation><genome sequencing><genomic therapy><genomic variant><germ-line defect><germline variant><hDNA methyltransferase 3a><heart damage><heart disorder><hematopoietic cell clones><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor><hematopoietic progenitor cell transplantation><hematopoietic stem cell aging><hematopoietic stem cell clonality><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><incomes><individualized medicine><individualized patient treatment><individualized strategies><individualized therapeutic strategy><individualized therapy><individualized treatment><innovate><innovation><innovative><insight><investigate prevalence><kidney damage><kidney disorder><kidney function><kids><liability to disease><life span><lifespan><lung disorder><lung injury><mortality><multiorgan damage><multiorgan failure><multiple organ system failure><myeloid granulocytic leukemia><myeloproliferative neoplasm><myelosis><novel><ontogeny><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathophysiology><patient specific therapies><patient specific treatment><pediatric><personalized strategies><precancer><precancerous><premalignant><premature><prematurity><prevalence investigation><prevalence research><programs><prospective><protein p53><public health relevance><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><renal><renal damage><renal disorder><sex><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><somatic variant><statistical linear mixed models><statistical linear models><stem cell gene therapy><study prevalence><survey prevalence><tailored medical treatment><tailored therapy><tailored treatment><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment><treatment risk><unique treatment><vascular><whole genome><young adult><young adult age><young adulthood><youngster><α-thalassemia>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hee Cheol Cho

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$717,577

FY 2026

Project Title

mRNA biological pacemaker

Grant Number:

5R01HL176951-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/23/2024

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

For those with symptomatic bradyarrhythmia, implantable pacemakers are the only treatment. While effective, the device therapy is burdened with complications directly related to the indwelling hardware such as device malfunction and infection. As an alternative to device pacing, biological pacemaker...

Research Terms

<21+ years old><Acute><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Atrioventricular Block><Basal Transcription Factor><Basal transcription factor genes><Biodistribution><Biologic Oscillator><Biologic Pacemakers><Biological><Biological Oscillators><Biological Pacemakers><Bradyarrhythmias><Cardiac><Cardiac Block><Cardiac Chronotropism><Cardiac Malformation><Cardiac Muscle Cells><Cardiac Myocytes><Cardiocyte><Cardiomyopathies><Cell Body><Cell Reprogramming><Cells><Childhood><Chronic><Clinical><Clinical Treatment><Clinical Trials><Common Rat Strains><Complex><DNA Therapy><Data><Development><Devices><Dose><Electrophysiology><Electrophysiology (science)><Embryo><Embryonic><Encapsulated><Endogenous Oscillators><Family suidae><Formulation><Gene Delivery><Gene Expression><Gene Transcription><Gene Transfer><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Genetic Intervention><Genetic Transcription><Goals><Heart><Heart Block><Heart Malformation><Heart Muscle Cells><Heart Rate><Heart Research><Heart myocyte><Immune><Immune infiltrates><Immunes><Implant><In Situ><In Vitro><Infection><Inflammatory><Inflammatory Response><Investments><Measures><Messenger RNA><Methods><Modality><Modeling><Muscle Cells><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><Myocytes><Neurophysiology / Electrophysiology><Nodal><Operative Procedures><Operative Surgical Procedures><Pace Stimulators><Pacemakers><Patients><Phenotype><Physiologic><Physiological><Pigs><Population><Position><Positioning Attribute><Production><Proteins><RNA Expression><RNA vaccine><RNA-based vaccine><Rat><Rats Mammals><Rattus><Research><Rest><Risk><Rodent><Rodentia><Rodents Mammals><Route><S-A Node><Safety><Saline><Saline Solution><Sino-Atrial Node><Sinoatrial Node><Sinu-Atrial Node><Sinuatrial Node><Somatic Cell><Suidae><Surgical><Surgical Interventions><Surgical Procedure><Swine><Tachyarrhythmias><Testing><Therapeutic><Time><Toxic effect><Toxicities><Transcend><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transfection><Transgenes><Translating><Translations><Treatment Efficacy><Vaccines><Venous><Ventricular><Viral Genes><Viral Vector><Work><abnormal heart development><adulthood><aortic valve replacement><biologic><biomedical implant><cardiac pacemaker cell><cardiac pacing><cardiac research><cardiac rhythm><cardiomyocyte><cell type><cellular reprogramming><child patients><clinical intervention><clinical therapy><congenital cardiac abnormality><congenital cardiac anomalies><congenital cardiac disease><congenital cardiac disorder><congenital cardiac malformation><congenital heart abnormality><congenital heart anomaly><congenital heart disease><congenital heart disorder><congenital heart malformation><cytokine><developmental><dosage><electrophysiological><first in man><first-in-human><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><global gene expression><global transcription profile><heart rhythm><immune cell infiltrate><implant device><implantable device><implantation><in vivo><indexing><indwelling device><intervention efficacy><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><model of animal><myocardium disease><myocardium disorder><new approaches><nodal myocyte><novel><novel approaches><novel strategies><novel strategy><pacemaker cell><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><pediatric><pediatric patients><pig model><piglet model><porcine><porcine model><pre-clinical><pre-clinical study><preclinical><preclinical study><prevent><preventing><programs><safety and feasibility><sinus node><suid><surgery><swine model><tachyrhythmia><therapeutic efficacy><therapy efficacy><transcription factor><transcriptome><transgene><transgene expression><translation><trial regimen><trial treatment>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAVID P COREY

HARVARD MEDICAL SCHOOL, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$714,835

FY 2026

Project Title

Gene Therapy for Hearing and Balance Disorders

Grant Number:

2R01DC016932-06A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2018

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Despite decades of intensive study, hereditary deafness remains a debilitating class of diseases with few treatment options or definitive cures. Although cochlear implants can assist with communication, they do not provide the full experience of hearing. DFNB1, caused by mutations in...

Research Terms

<21+ years old><AAV vector><AAV-based vector><Accounting><Adult><Adult Human><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Assay><Auditory><Auditory Perception><Base Pairing><Bioassay><Biological Assay><CX26><Capsid><Cell Body><Cell Nucleus><Cell division><Cell model><Cells><Cellular model><Cochlea><Cochlear Implants><Cochlear Organ><Cochlear Prosthesis><Code><Coding System><Collaborations><Communicating Junction><Communication><Connexin-26><Corti Cell><Cortis Organ><Cytosine><DNA Sequence><DNA Therapy><DNA editor><DNA mutation><DNA seq><DNA sequencing><DNAseq><Development><Disease><Disorder><Engineering><Enzyme Gene><Enzymes><Episome><Epithelial Cells><Frame Shift Mutation><Frameshift Mutation><GJB2><GJB2 gene><Gap Junction Protein, 26-KD><Gap Junction Protein, Beta-2><Gap Junctions><Gene Expression><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genomic DNA><Genomic medicine><Guide RNA><Hair Cells><Hearing><Hearing Disorders><Hearing problem><Hereditary Disease><Heritability><Histology><Human><In Vitro><Inborn Genetic Diseases><Inherited disorder><Internal Ear><Interphase Cell><Laboratories><Labyrinth><Lateral><Low-resistance Junction><Measures><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Modification><Murine><Mus><Mutation><N-terminal><NH2-terminal><Neonatal><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Nexus Junction><Non-dividing Cell><Nondividing Cell><Nucleotides><Nucleus><Organ of Corti><Organism><Patients><Physiologic><Physiological><Physiology><Population><Prosthesis><Prosthetic device><Prosthetics><Reading Frame Shift Mutation><Reading Frames><Resting Cell><Spiral Organ><Spiral Organ of Corti><Technology><Testing><Therapeutic><Therapeutic Gene Editing><Time><Transgenes><Translations><Viral Vector><adeno-associated viral vector><adeno-associated virus vector><adulthood><alternative treatment><auditory disease><auditory disorder><auditory dysfunction><auditory problem><balance disorder><balance impairment><base editing><base editor><chromosome replication><clinical candidate><clinical development><clinical translation><clinically translatable><congenital hearing impairment><congenital hearing loss><deafness><developmental><disturbed balance><ear hair cell><equilibration disorder><equilibrium disorder><experience><gDNA><gRNA><gene corrected><gene correction><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene editor><gene repair therapy><gene replacement><gene therapy><gene-based therapy><gene-editing approach><gene-editing therapy><gene-editing toolkit><genetic deafness><genetic hearing impairment><genetic hearing loss><genetic therapy><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome editor><genome medicine><genome mutation><genomic correction><genomic editing><genomic therapy><hearing disease><hearing perception><hearing restoration><hereditary deafness><hereditary disorder><hereditary hearing impairment><hereditary hearing loss><heritable disorder><human disease><iPS><iPSC><iPSCs><in vivo><inborn error><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><inherited deafness><inherited diseases><inherited genetic disease><inherited genetic disorder><inherited hearing impairment><inherited hearing loss><inner ear><innovate><innovation><innovative><living system><low-frequency mutation><model of animal><mouse model><murine model><mutation correction><neuronal><novel><optimism><positive attitude><postmitotic><pre-clinical study><preclinical study><prime editing><prime editor><promoter><promotor><rare allele><rare mutation><rare variant><restoration><restore hearing><sound perception><targeted drug therapy><targeted drug treatments><targeted sequencing><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic editing><therapeutic genome editing><tool><transduction efficiency><transgene><transgene expression><translation><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Benjamin Peter Kleinstiver

HARVARD MEDICAL SCHOOL, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$714,835

FY 2026

Project Title

Gene Therapy for Hearing and Balance Disorders

Grant Number:

2R01DC016932-06A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2018

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Despite decades of intensive study, hereditary deafness remains a debilitating class of diseases with few treatment options or definitive cures. Although cochlear implants can assist with communication, they do not provide the full experience of hearing. DFNB1, caused by mutations in...

Research Terms

<21+ years old><AAV vector><AAV-based vector><Accounting><Adult><Adult Human><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Assay><Auditory><Auditory Perception><Base Pairing><Bioassay><Biological Assay><CX26><Capsid><Cell Body><Cell Nucleus><Cell division><Cell model><Cells><Cellular model><Cochlea><Cochlear Implants><Cochlear Organ><Cochlear Prosthesis><Code><Coding System><Collaborations><Communicating Junction><Communication><Connexin-26><Corti Cell><Cortis Organ><Cytosine><DNA Sequence><DNA Therapy><DNA editor><DNA mutation><DNA seq><DNA sequencing><DNAseq><Development><Disease><Disorder><Engineering><Enzyme Gene><Enzymes><Episome><Epithelial Cells><Frame Shift Mutation><Frameshift Mutation><GJB2><GJB2 gene><Gap Junction Protein, 26-KD><Gap Junction Protein, Beta-2><Gap Junctions><Gene Expression><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genomic DNA><Genomic medicine><Guide RNA><Hair Cells><Hearing><Hearing Disorders><Hearing problem><Hereditary Disease><Heritability><Histology><Human><In Vitro><Inborn Genetic Diseases><Inherited disorder><Internal Ear><Interphase Cell><Laboratories><Labyrinth><Lateral><Low-resistance Junction><Measures><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Modification><Murine><Mus><Mutation><N-terminal><NH2-terminal><Neonatal><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Nexus Junction><Non-dividing Cell><Nondividing Cell><Nucleotides><Nucleus><Organ of Corti><Organism><Patients><Physiologic><Physiological><Physiology><Population><Prosthesis><Prosthetic device><Prosthetics><Reading Frame Shift Mutation><Reading Frames><Resting Cell><Spiral Organ><Spiral Organ of Corti><Technology><Testing><Therapeutic><Therapeutic Gene Editing><Time><Transgenes><Translations><Viral Vector><adeno-associated viral vector><adeno-associated virus vector><adulthood><alternative treatment><auditory disease><auditory disorder><auditory dysfunction><auditory problem><balance disorder><balance impairment><base editing><base editor><chromosome replication><clinical candidate><clinical development><clinical translation><clinically translatable><congenital hearing impairment><congenital hearing loss><deafness><developmental><disturbed balance><ear hair cell><equilibration disorder><equilibrium disorder><experience><gDNA><gRNA><gene corrected><gene correction><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene editor><gene repair therapy><gene replacement><gene therapy><gene-based therapy><gene-editing approach><gene-editing therapy><gene-editing toolkit><genetic deafness><genetic hearing impairment><genetic hearing loss><genetic therapy><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome editor><genome medicine><genome mutation><genomic correction><genomic editing><genomic therapy><hearing disease><hearing perception><hearing restoration><hereditary deafness><hereditary disorder><hereditary hearing impairment><hereditary hearing loss><heritable disorder><human disease><iPS><iPSC><iPSCs><in vivo><inborn error><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><inherited deafness><inherited diseases><inherited genetic disease><inherited genetic disorder><inherited hearing impairment><inherited hearing loss><inner ear><innovate><innovation><innovative><living system><low-frequency mutation><model of animal><mouse model><murine model><mutation correction><neuronal><novel><optimism><positive attitude><postmitotic><pre-clinical study><preclinical study><prime editing><prime editor><promoter><promotor><rare allele><rare mutation><rare variant><restoration><restore hearing><sound perception><targeted drug therapy><targeted drug treatments><targeted sequencing><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic editing><therapeutic genome editing><tool><transduction efficiency><transgene><transgene expression><translation><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kazuki Sugahara

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$683,970

FY 2026

Project Title

Tumor-penetrating stromal modification of β5 integrin-rich pancreatic cancer

Grant Number:

1R01CA307667-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The β5 integrin in the form of the αvβ5 heterodimer is highly expressed in pancreatic ductal adenocarcinoma (PDAC) and serves as a predictor of poor survival in PDAC patients. Genetically deleting β5 integrin in PDAC cells greatly delays tumor growth and metastasis in mice. Our studi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MORIYA TSUJI

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$683,970

FY 2026

Project Title

Tumor-penetrating stromal modification of β5 integrin-rich pancreatic cancer

Grant Number:

1R01CA307667-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY The β5 integrin in the form of the αvβ5 heterodimer is highly expressed in pancreatic ductal adenocarcinoma (PDAC) and serves as a predictor of poor survival in PDAC patients. Genetically deleting β5 integrin in PDAC cells greatly delays tumor growth and metastasis in mice. Our studi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ryoji Amamoto

MASSACHUSETTS EYE AND EAR INFIRMARY, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$663,406

FY 2026

Project Title

Elucidating the molecular mechanisms of secondary cone degeneration in models of Retinitis Pigmentosa

Grant Number:

1R01EY038190-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Retinitis Pigmentosa (RP) is an inherited retinal disease afflicting 1 in 4,000 people worldwide. The disease progresses initially by rod photoreceptor degeneration caused by mutations in rod-specific genes, although different mutations in different genes converge upon the same rod d...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel Evan Bauer

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$658,954

FY 2026

Project Title

Targeting ZNF410 for HbF reactivation

Grant Number:

5R01HL167513-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Hemoglobin disorders, such as sickle cell disease and β-thalassemia, comprise the most common monogenic diseases of the world and yet, current treatments remain largely supportive and inadequate. Induction of fetal hemoglobin (HbF) could bypass the fundamental genetic defects of adult hemog...

Research Terms

<21+ years old><Address><Adult><Adult Human><Affect><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Animals><Assay><Autoregulation><B-thalassemia><Basal Transcription Factor><Basal transcription factor genes><Binding><Bioassay><Biological><Biological Assay><Biological Function><Biological Process><Blood erythrocyte><Bypass><CD154><CD40L><CD40LG><CHD4><CHD4 gene><CRISPR editing screen><CRISPR screen><CRISPR-based screen><CRISPR/Cas9 screen><Cell Body><Cell model><Cells><Cellular model><Chemicals><Chromatin><Chromodomain Helicase DNA-Binding Protein 4><Clinical><Clinical Trials><DNA Therapy><DNA mutation><Dedications><Defect><Development><Disease><Disorder><Drug Therapy><Elements><Erythrocytes><Erythrocytic><Erythroid><Erythropoiesis><Evaluation><Event><Exhibits><Fetal Hb><Fetal Hemoglobin><Future><Gene Action Regulation><Gene Down-Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Targeting><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genome><Genomics><Goals><Growth><Hb SS disease><HbF><HbSS disease><Hematology><Hematopoiesis><Hematopoietic><Hematopoietic Cellular Control Mechanisms><Hemoglobin><Hemoglobin F><Hemoglobin S Disease><Hemoglobin concentration result><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemoglobinopathies><Heterograft><Heterologous Transplantation><Homeostasis><Human><IMiD><IMiD3 cpd><Immune modulatory therapeutic><Immunomodulation><In Vitro><Investigation><Knock-out><Knockout><Lead><Libraries><Logic><Marrow erythrocyte><Medicinal Chemistry><Mendelian disease><Mendelian disorder><Mendelian genetic disorder><Metabolic Protein Degradation><Mi2-Beta><Mice><Mice Mammals><Modern Man><Molecular><Molecular Genetics><Molecular Interaction><Molecular Target><Murine><Mus><Mutation><NuRD><NuRD complex><Nucleosomes><Ortholog><Orthologous Gene><Pb element><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiological Homeostasis><Pomalyst><Population><Protein Turnover><Proteins><Red Blood Cells><Red Cell><Regulation><Regulator Genes><Regulatory Element><Regulatory Protein Degradation><Reporter><Repression><Rest><Role><Safety><Sickle Cell Anemia><Structure-Activity Relationship><System><TNFSF5><TNFSF5 gene><TRAP Gene><Therapeutic><Therapeutic Index><Tissue Growth><Toxic effect><Toxicities><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription Repressor><Transcription factor genes><Transcriptional Regulatory Elements><Transcriptional Repressor><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><Upstream Enhancer><Xenograft><Xenograft procedure><Xenotransplantation><adulthood><beta Thalassemia><biologic><blood cell formation><blood corpuscles><chemical structure function><clustered regularly interspaced short palindromic repeats screen><derepression><developmental><disparity in health><drug development><drug intervention><drug treatment><erythroid development><fetal form of hemoglobin><fetal globin><functional genomics><gamma Globin><gene repair therapy><gene repression><gene therapy><gene-based therapy><genetic repressor><genetic therapy><genetic trans acting element><genome mutation><genomic therapy><health disparity><heavy metal Pb><heavy metal lead><hematopoietic engraftment><hemoglobin level><hemopoietic><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulation><immune modulatory agents><immune modulatory drugs><immune regulation><immunologic reactivity control><immunomodulating agents><immunomodulating drugs><immunomodulator agent><immunomodulator drug><immunomodulator medication><immunomodulator prodrug><immunomodulator therapeutic><immunomodulatory><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><immunoregulation><immunoregulatory><in vivo><inhibitor><lenalidomide><model of animal><monogenic disease><monogenic disorder><mouse development><novel><ontogeny><p-Thalassemia><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pomalidomide><promoter><promotor><protein complex><protein degradation><regulatory gene><scale up><screening><screenings><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><single-gene disease><single-gene disorder><social role><structure function relationship><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic evaluation><therapeutic target><therapeutic testing><tool><trans acting element><transcription factor><ubiquitin ligase><xeno-transplant><xeno-transplantation><β-thalassemia><γ-Globin>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Allison M Bradbury

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$625,164

FY 2026

Project Title

Uncovering mechanisms and developing novel therapeutic strategies for TBCD-related developmental and epileptic encephalopathy

Grant Number:

5R01NS134923-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Variants in the tubulin folding cofactor D (TBCD) gene result in a rare early-onset encephalopathy with neurodevelopmental and neurodegenerative features including developmental regression, epilepsy, microcephaly, hypotonia, and spasticity which progresses to immobilization...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mark Hester

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$625,164

FY 2026

Project Title

Uncovering mechanisms and developing novel therapeutic strategies for TBCD-related developmental and epileptic encephalopathy

Grant Number:

5R01NS134923-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract Variants in the tubulin folding cofactor D (TBCD) gene result in a rare early-onset encephalopathy with neurodevelopmental and neurodegenerative features including developmental regression, epilepsy, microcephaly, hypotonia, and spasticity which progresses to immobilization...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jessica E Thaxton

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$624,194

FY 2026

Project Title

Regulation of Immunometabolism by the Integrated Stress Response in Cancer

Grant Number:

1R01CA310022-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Metabolic stress in the tumor microenvironment (TME) has emerged as a barrier to CD8+ tumor infiltrating lymphocyte (TIL) antitumor function in solid cancers. The integrated stress response (ISR) is an evolutionarily conserved pathway intrinsic to all mammalian cells poised to sense ...

Research Terms

<ATF-4><Acute><Alcohol Drinking><Alcohol consumption><Autoregulation><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><Cancers><Cell Body><Cell Isolation><Cell Segregation><Cell Separation><Cell Separation Technology><Cells><Cellular Metabolic Process><Cellular Stress><Cellular Stress Response><ChIP Sequencing><ChIP-seq><ChIPseq><Checkpoint inhibitor><Chronic><Chronic stress><Clinical Trials><Data><Development><Elements><EtOH drinking><EtOH use><Exhibits><Fatty Acid Metabolism Pathway><Gene Transcription><Genes><Genetic><Genetic Transcription><Genus Hippocampus><HNSCC><Head and Neck Squamous Cell Carcinoma><Homeostasis><Human><Hypoxia><Hypoxic><Hypoxic tumor><Immune checkpoint inhibitor><Immune mediated therapy><Immunity><Immunologically Directed Therapy><Immunotherapy><Impairment><In complete remission><Intermediary Metabolism><Intracellular Accumulation of Lipids><Kinases><LYT3><Lipids><Lymphocyte Function><Malignant Neoplasms><Malignant Tumor><Mammalian Cell><Memory><Metabolic><Metabolic Processes><Metabolic stress><Metabolism><Mice><Mice Mammals><Modern Man><Murine><Mus><Outcome><Oxygen Deficiency><Pathway interactions><Patients><Peripheral><Phase><Phenotype><Phosphotransferase Gene><Phosphotransferases><Physiological Homeostasis><Position><Positioning Attribute><RNA Expression><Regulation><Research><Resistance><Risk Factors><SCCHN><Seahorse><Solid><Stress><T-Cells><T-Lymphocyte><T8 Cells><T8 Lymphocytes><Testing><Tobacco Consumption><Tobacco use><Transcription><Transphosphorylases><Tumor Immunity><Tumor Tissue><Tumor-Infiltrating Lymphocytes><Work><activating transcription factor 4><adipogenesis><alcohol ingestion><alcohol intake><alcohol product use><alcohol use><alcoholic beverage consumption><alcoholic drink intake><anti-tumor immunity><antitumor immunity><attenuation><biological adaptation to stress><cancer cell metabolism><cancer immunity><cancer metabolism><cancer microenvironment><cell metabolism><cell sorting><cell stress><cellular metabaolism><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><clinical development><complete response><developmental><ethanol consumption><ethanol drinking><ethanol ingestion><ethanol intake><ethanol product use><ethanol use><exhaust><exhaustion><fat metabolism><fatty acid metabolism><fatty acid oxidation><gene signatures><genetic signature><head and neck squamous carcinoma><head and neck squamous cell cancer><immune check point><immune check point inhibitor><immune check point therapy><immune checkpoint><immune checkpoint therapy><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immunecheckpoint><immuno therapy><inhibitor><lipid biosynthesis><lipid metabolism><lipidomics><lipogenesis><malignancy><metabolic imaging><metabolism measurement><metabolomics><metabonomics><mouse model><murine model><neoplasm/cancer><novel><overexpress><overexpression><pathway><pharmacologic><programs><reactioncrisis><resistance to therapy><resistant><resistant to therapy><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><stress response><stressreaction><stressor><therapeutic resistance><therapy resistant><thymus derived lymphocyte><tobacco product use><treatment resistance><tumor><tumor cell metabolism><tumor hypoxia><tumor metabolism><tumor microenvironment>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David M Gamm

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$603,053

FY 2026

Project Title

Leveraging mouse models and retinal organoids to optimize a gene therapy for IMPG2-associated retinal degeneration

Grant Number:

1R01EY037934-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY IMPG2 is a crucial extracellular matrix protein for maintaining photoreceptor structure and function. Mutations in IMPG2 are linked to two forms of visual impairment: juvenile-onset rod-cone dystrophy and adult-onset vitelliform macular dystrophy. While no treatment currently exists,...

Research Terms

<21+ years old><Acceleration><Acute><Adeno-Associated Viruses><Adolescent><Adolescent Youth><Adult><Adult Human><Alleles><Allelomorphs><Amino Acid Sequence><Amino Acids><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Best Disease><Biodistribution><Biological Markers><Candidate Disease Gene><Candidate Gene><Capsid><Clinic><Clinical><Code><Coding System><Codon><Codon Nucleotides><Cone Photoreceptors><DNA Therapy><DNA mutation><Dependoparvovirus><Dependovirus><Deposit><Deposition><Development><Diminished Vision><Disease Marker><Doppler OCT><Dose><Dysfunction><ES cell><Electroretinography><Engineering><Ensure><Exhibits><Extracellular Matrix Proteins><Functional disorder><Fundus><GRK1><GRK1 gene><Gene Transfer><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Gliosis><Hereditary><Heterozygote><Human><Image><Individual><Inherited><Injections><KO mice><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Lead><Leanness><Light><Link><Low Vision><Measures><Mediating><Mice><Mice Mammals><Microscopy><Modeling><Modern Man><Murine><Mus><Mutation><Natural History><Null Mouse><OCT Tomography><Optical Coherence Tomography><Organoids><Outcome Measure><Partial Sight><Pathology><Patients><Pb element><Phenotype><Photoradiation><Photoreceptor Cell><Photoreceptors><Photosensitive Cell><Physiopathology><Pigmentary Retinopathy><Predictive Value><Primary Protein Structure><Proteins><Proteoglycan><RHOK><Reduced Vision><Retina><Retinal Cone><Retinal Degeneration><Retinal Detachment><Retinal Diseases><Retinal Disorder><Retinal Dystrophy><Retinitis Pigmentosa><Rods and Cones><Safety><Sight><Structure><Subnormal Vision><Tapetoretinal Degeneration><Testing><Therapeutic><Thinness><Toxic effect><Toxicities><Transgenes><Vertebrate Photoreceptors><Viral><Viral Vector><Virion><Virus Particle><Vision><Visual Receptor><Visual impairment><Vitelliform MD><Vitelliform macular dystrophy><Work><adeno associated virus group><adulthood><aminoacid><best macular dystrophy><bio-markers><biologic marker><biomarker><clinical relevance><clinically relevant><cone cell><degenerative retina diseases><design><designing><develop therapy><developmental><disease model><disorder model><electroretinogram><embryo derived stem cell><embryonal stem cells><embryonic progenitor><embryonic stem cell><expectation><fundus imaging><gene augmentation intervention><gene augmentation therapy><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><hESC><heavy metal Pb><heavy metal lead><heterozygosity><hiPSC><human ES cell><human ESC><human embryonic stem cell><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><imaging><immunocytochemistry><improved><in vitro Model><in vivo><induced human pluripotent stem cells><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><innovate><innovation><innovative><intervention development><juvenile><juvenile human><loss of function mutation><macula><macular><measurable outcome><model of animal><mouse development><mouse model><murine model><neuro-sensory><neurosensory><optical Doppler tomography><optical coherence Doppler tomography><outcome measurement><pathophysiology><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><photoreceptor degeneration><postnatal><pre-clinical><pre-clinical trial><preclinical><preclinical trial><preservation><prevent><preventing><programs><promoter><promotor><protein sequence><response><retina degeneration><retina detachment><retina disease><retina disorder><retinal degenerative><retinal degenerative diseases><retinopathy><rhodopsin kinase><rod and cone dystrophy><rod-cone dystrophy><safety assessment><stem cell of embryonic origin><therapeutic agent development><therapeutic development><therapeutically effective><therapy development><transgene><transgene expression><treatment development><trial design><vector><vision impairment><visual function><visually impaired>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

BENJAMIN D PHILPOT

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$603,053

FY 2026

Project Title

Leveraging mouse models and retinal organoids to optimize a gene therapy for IMPG2-associated retinal degeneration

Grant Number:

1R01EY037934-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2026

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY IMPG2 is a crucial extracellular matrix protein for maintaining photoreceptor structure and function. Mutations in IMPG2 are linked to two forms of visual impairment: juvenile-onset rod-cone dystrophy and adult-onset vitelliform macular dystrophy. While no treatment currently exists,...

Research Terms

<21+ years old><Acceleration><Acute><Adeno-Associated Viruses><Adolescent><Adolescent Youth><Adult><Adult Human><Alleles><Allelomorphs><Amino Acid Sequence><Amino Acids><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Best Disease><Biodistribution><Biological Markers><Candidate Disease Gene><Candidate Gene><Capsid><Clinic><Clinical><Code><Coding System><Codon><Codon Nucleotides><Cone Photoreceptors><DNA Therapy><DNA mutation><Dependoparvovirus><Dependovirus><Deposit><Deposition><Development><Diminished Vision><Disease Marker><Doppler OCT><Dose><Dysfunction><ES cell><Electroretinography><Engineering><Ensure><Exhibits><Extracellular Matrix Proteins><Functional disorder><Fundus><GRK1><GRK1 gene><Gene Transfer><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Gliosis><Hereditary><Heterozygote><Human><Image><Individual><Inherited><Injections><KO mice><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Lead><Leanness><Light><Link><Low Vision><Measures><Mediating><Mice><Mice Mammals><Microscopy><Modeling><Modern Man><Murine><Mus><Mutation><Natural History><Null Mouse><OCT Tomography><Optical Coherence Tomography><Organoids><Outcome Measure><Partial Sight><Pathology><Patients><Pb element><Phenotype><Photoradiation><Photoreceptor Cell><Photoreceptors><Photosensitive Cell><Physiopathology><Pigmentary Retinopathy><Predictive Value><Primary Protein Structure><Proteins><Proteoglycan><RHOK><Reduced Vision><Retina><Retinal Cone><Retinal Degeneration><Retinal Detachment><Retinal Diseases><Retinal Disorder><Retinal Dystrophy><Retinitis Pigmentosa><Rods and Cones><Safety><Sight><Structure><Subnormal Vision><Tapetoretinal Degeneration><Testing><Therapeutic><Thinness><Toxic effect><Toxicities><Transgenes><Vertebrate Photoreceptors><Viral><Viral Vector><Virion><Virus Particle><Vision><Visual Receptor><Visual impairment><Vitelliform MD><Vitelliform macular dystrophy><Work><adeno associated virus group><adulthood><aminoacid><best macular dystrophy><bio-markers><biologic marker><biomarker><clinical relevance><clinically relevant><cone cell><degenerative retina diseases><design><designing><develop therapy><developmental><disease model><disorder model><electroretinogram><embryo derived stem cell><embryonal stem cells><embryonic progenitor><embryonic stem cell><expectation><fundus imaging><gene augmentation intervention><gene augmentation therapy><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><hESC><heavy metal Pb><heavy metal lead><heterozygosity><hiPSC><human ES cell><human ESC><human embryonic stem cell><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><imaging><immunocytochemistry><improved><in vitro Model><in vivo><induced human pluripotent stem cells><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><innovate><innovation><innovative><intervention development><juvenile><juvenile human><loss of function mutation><macula><macular><measurable outcome><model of animal><mouse development><mouse model><murine model><neuro-sensory><neurosensory><optical Doppler tomography><optical coherence Doppler tomography><outcome measurement><pathophysiology><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><photoreceptor degeneration><postnatal><pre-clinical><pre-clinical trial><preclinical><preclinical trial><preservation><prevent><preventing><programs><promoter><promotor><protein sequence><response><retina degeneration><retina detachment><retina disease><retina disorder><retinal degenerative><retinal degenerative diseases><retinopathy><rhodopsin kinase><rod and cone dystrophy><rod-cone dystrophy><safety assessment><stem cell of embryonic origin><therapeutic agent development><therapeutic development><therapeutically effective><therapy development><transgene><transgene expression><treatment development><trial design><vector><vision impairment><visual function><visually impaired>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Isabelle M.A. Lombaert

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$601,942

FY 2026

Project Title

Epigenetic Therapy to Treat Radiation-induced Xerostomia

Grant Number:

5R01DE032014-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Most head-and-neck cancer patients receiving radiotherapy treatment develop life-long adverse effects. Side effects presented as hyposalivation and chronic xerostomia result from radiation damage to nearby salivary glands. Limited palliative options are currently available for these patien...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew Galen Hartwig

DUKE UNIVERSITY, DURHAM, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$597,613

FY 2026

Project Title

Ex Vivo Delivery of Viral-Mediated Gene Therapy for the Amelioration of Post-Transplant Rejection

Grant Number:

1R01AI197208-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary/Abstract This R01 application for the NOSI: Somatic Cell Gene Editing Therapies to Improve Transplantation Outcomes details a novel method of AAV vector delivery during normothermic ex vivo lung perfusion (EVLP) to genetically modify donor lung grafts. While early post-operative outc...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Baodong Sun

DUKE UNIVERSITY, DURHAM, NC

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$597,162

FY 2026

Project Title

Gene therapy for glycogen storage disease type III

Grant Number:

5R01AR079572-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Glycogen storage disease type III (GSD III) is an autosomal recessive inherited disorder caused by deficiency of glycogen debranching enzyme (GDE) that leads to excessive accumulation of abnormal glycogen (limit dextrin) in muscle and liver tissues. The majority of patients (~85%) have both...

Research Terms

<21+ years old><AAV vector><AAV-based vector><Adeno-Associated Viruses><Adult><Adult Human><Affect><Age><Age Months><B. subtilis><Bacillus subtilis><Biochemical><Biological Markers><Blood><Blood Reticuloendothelial System><Blood Serum><Body Tissues><CMV><Canine Species><Canis familiaris><Capsid><Cardiac><Carrying Capacities><Cell Body><Cell-Mediated Lympholytic Cells><Cells><Chickens><Clinical Trials><Complementary DNA><Cori's Disease><Cytolytic T-Cell><Cytomegalovirus><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><DNA Therapy><DNA cassette><DNA mutation><Data><Debrancher Deficiency><Defect><Dependoparvovirus><Dependovirus><Development><Dextrins><Disease><Disorder><Dogs><Dogs Mammals><Dose><Enhancers><Enzyme Gene><Enzymes><Female><Forbes Disease><Foundations><Gallus domesticus><Gallus gallus><Gallus gallus domesticus><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glycogen><Glycogen Debranching Enzyme><Glycogen Debranching Enzyme Deficiency><Glycogen Storage Disease Type III><Glycogenosis 3><Goals><HCMV><Hepatic Cells><Hepatic Cirrhosis><Hepatic Disorder><Hepatic Failure><Hepatic Parenchymal Cell><Hepatocyte><Hepatotoxic effect><Hepatotoxicity><Hereditary><Hereditary Disease><Histologic><Histologically><History><Human><Immune response><Inborn Genetic Diseases><Infant><Inherited><Inherited disorder><Innate Immune Response><Knock-out><Knockout><Laboratories><Lead><Limit Dextrinosis><Liver><Liver Cells><Liver Cirrhosis><Liver Failure><Liver Toxicity><Liver diseases><Measurement><Mediating><Metabolic Diseases><Metabolic Disorder><Mice><Mice Mammals><Modern Man><Morbidity><Murine><Mus><Muscle><Muscle Cells><Muscle Disease><Muscle Disorders><Muscle Fibers><Muscle Tissue><Muscle function><Muscular Diseases><Mutation><Myocardium><Myocytes><Myopathic Conditions><Myopathic Diseases and Syndromes><Myopathic disease or syndrome><Myopathy><Myotubes><ORFs><Open Reading Frames><Organ><Outcome><Patients><Pb element><Protein Coding Region><Recording of previous events><Research><Rhabdomyocyte><Safety><Salivary Gland Viruses><Serotyping><Serum><Skeletal Fiber><Skeletal Muscle><Skeletal Muscle Cell><Skeletal Muscle Fiber><Skeletal Myocytes><Technology><Testing><Thesaurismosis><Tissues><Toxic effect><Toxic effect on liver cells><Toxicities><Translating><Translations><Urine><Voluntary Muscle><adaptive immune response><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><adulthood><aged mice><aged mouse><ages><amylo 1,6 glucosidase deficiency><analog><autosome><beta Actin><bio-markers><biologic marker><biomarker><cDNA><canine><canine animal model><canine model><cardiac muscle><cell type><clinical candidate><clinical translation><clinically translatable><curative intervention><curative therapeutic><curative therapy><curative treatments><cytomegalovirus group><de-immunization><de-immunize><debrancher glycogen storage disease><deimmunization><deimmunize><determine efficacy><develop therapy><developmental><dietary><dog model><domestic dog><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><elderly mice><enhancer cassette><evaluate efficacy><examine efficacy><experience><expression cassette><gene cassette><gene repair therapy><gene therapy><gene-based therapy><genetic cassette><genetic therapy><genome editing><genome mutation><genomic editing><genomic therapy><glycogenosis type III><heart muscle><heavy metal Pb><heavy metal lead><hepatic body system><hepatic disease><hepatic organ system><hepatic toxicity><hepatopathy><hepatoxicity><hereditary disorder><heritable disorder><histories><host response><human disease><humanized mice><humanized mouse><immune system response><immunoresponse><improved><inborn error><inherited diseases><inherited genetic disease><inherited genetic disorder><innovate><innovation><innovative><integration cassette><intervention development><killer T cell><liver disorder><liver function><metabolism disorder><mortality><mouse model><murine model><muscular><muscular disorder><novel><old mice><prevent><preventing><promoter><promoter cassette><promotor><reporter cassette><resistance cassette><response><selectable cassette><selection cassette><sex><skeletal><stop cassette><therapeutic agent development><therapeutic candidate><therapeutic development><therapeutic outcome><therapy development><therapy outcome><transcription cassette><transcriptional cassette><transduction efficiency><transgene cassette><transgene expression><translation><treatment development><urinary><vector><β-Actin><♀>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Raymond Yu Jeang Wang

CHILDREN'S HOSPITAL OF ORANGE COUNTY, ORANGE, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$593,114

FY 2026

Project Title

Combination Gene Therapy for Treatment of Canine Mucopolysaccharidosis Type I

Grant Number:

5R01HD106916-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/5/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

MPS I, historically known as Hurler, Hurler-Scheie, and Scheie syndromes depending upon degree of central nervous system (CNS) involvement and velocity of disease progression, is a deficiency of the α-L-iduronidase (IDUA) enzyme resulting in pansystemic storage of glycosaminoglycans (GAGs). While Hu...

Research Terms

<0-11 years old><AAV vector><AAV-based vector><Activities of Daily Living><Activities of everyday life><Address><Adeno-Associated Viruses><Affect><Anatomic Abnormality><Anatomical Abnormality><Aorta><Associated Viruses><Biochemistry><Biologic Models><Biological Chemistry><Biological Models><Biomechanics><Blood><Blood - brain barrier anatomy><Blood Reticuloendothelial System><Blood-Brain Barrier><Body System><Body Tissues><Brain><Brain Nervous System><Brain imaging><CNS Diseases><CNS Nervous System><CNS disorder><Canine Species><Canis familiaris><Cardiac><Cardiomyopathies><Caring><Cartilage><Cartilaginous Tissue><Central Nervous System><Central Nervous System Diseases><Central Nervous System Disorders><Cerebral cortex><Cessation of life><Child><Child Youth><Children (0-21)><Chondrocytes><Circulation><Clinical Trials><Clinical assessments><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Contracture><DNA Therapy><Data><Death><Decline in mobility><Decrease in mobility><Decreased mobility><Deformity><Degenerative Arthritis><Degenerative polyarthritis><Dependoparvovirus><Dependovirus><Deterioration><Development><Dilatation><Dilatation - action><Diminished mobility><Disease><Disease Progression><Disorder><Disturbance in cognition><Dogs><Dogs Mammals><Dose><Dysplasia><Early treatment><Ellis-Sheldon syndrome><Encephalon><Engraftment><Enzyme Gene><Enzymes><Future><Gene Transfer Clinical><Genes><Genetic Diseases><Genetic Intervention><Glycosaminoglycan alpha-L-iduronohydrolase><Glycosaminoglycan α-L-iduronohydrolase><Glycosaminoglycans><GvHD><HSC transplantation><Heart><Hemato-Encephalic Barrier><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hepatic><Hepatosplenomegaly><Histopathology><Homologous Wasting Disease><Human><Hurler Syndrome Gargoylism><Hurler syndrome><Hurler's Disease><Hyperplasia><Hyperplastic><Hypertrophy><IGF Type 2 Receptor><IGF-2 Receptor><IGF-II Receptor><Iduronidase><Image><Imaging Procedures><Imaging Technics><Imaging Techniques><Immobilization><Immune Tolerance><Immune reaction><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunologic Tolerance><Immunosuppressed Host><Impaired cognition><Infant><Inflammation><Infusion><Infusion procedures><Injections><Insulin-Like Growth Factor II Receptor><Insulin-Like Growth Factor Type 2 Receptor><Intellectual disability><Intellectual functioning disability><Intellectual limitation><Intravenous><Investigators><Johnie McL syndrome><Joint Diseases><Joints><Knowledge><L - iduronidase deficiency><L-Iduronidase><Life><Life Expectancy><Ligaments><Lipochondrodystrophy><Liver><Long-Term Effects><MPS I><MPS I H><MPS I S><MPS type I S><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Mannose-6-Phosphate Receptor><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medical Rehabilitation><Membrana Synovialis Capsulae Articularis><Methods><Mobility decline><Mobility impairment><Modality><Model System><Modeling><Modern Man><Morphology><Mucopolysaccharides><Mucopolysaccharidoses><Mucopolysaccharidosis 1><Mucopolysaccharidosis I><Mucopolysaccharidosis I H><Mucopolysaccharidosis I S><Mucopolysaccharidosis Is><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><NMR Imaging><NMR Tomography><Neonatal Screening><Nerve Cells><Nerve Degeneration><Nerve Unit><Neural Cell><Neuraxis><Neurocognition><Neurocognitive><Neurocyte><Neuron Degeneration><Neurons><Newborn Infant Screening><Nuclear Magnetic Resonance Imaging><Organ System><Osteoarthritis><Osteoarthrosis><Pain><Painful><Pathological Constriction><Pathology><Patients><Penetration><Pennsylvania><Peripheral><Persons><Phenotype><Play><Position><Positioning Attribute><Preclinical data><Progenitor Cell Transplantation><Proliferating><Property><Protein Replacement Therapy><Protocol><Protocols documentation><QOL><Quality of life><Reaction><Recombinants><Recommendation><Reduced mobility><Reduction in mobility><Refractory><Rehabilitation><Rehabilitation therapy><Research Personnel><Researchers><Risk><Role><Runt Disease><Satellite Viruses><Scheie's Syndrome><Services><Spinal Canal><Spinal Cord Diseases><Spinal Cord Disorders><Spleen><Spleen Reticuloendothelial System><Stem Cell Transplantation><Stem cell transplant><Stenosis><Structure><Symptoms><Synovial Membrane><Synovium><Techniques><Testing><Therapeutic><Therapeutic Effect><Tissues><Toxic effect><Toxicities><Translating><Universities><Venous><Work><Zeugmatography><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><alpha-L-Idosiduronase><alpha-L-Iduronidase><alpha-L-iduronidase (IDA, IDUA) deficiency><alpha-L-iduronidase deficiency><arthropathic><arthropathies><arthropathy><biomarker identification><biomechanical><biomechanical analyses><biomechanical analysis><biomechanical assessment><biomechanical characterization><biomechanical evaluation><biomechanical measurement><biomechanical profiling><biomechanical test><blood infection><blood stem cell transplantation><bloodbrain barrier><bloodstream infection><brain visualization><burden of disease><burden of illness><canine><canine animal model><canine model><chondro-osteodystrophy-corneal><cognitive defects><cognitive dysfunction><cognitive function><cognitive loss><combination gene therapy><daily living function><daily living functionality><daily pain><deficiency in alpha - L - iduronidase><degenerative joint disease><design><designing><developmental><disease burden><disease phenotype><dog model><domestic dog><dyscrasia><dysostosis multiplex><dysostotic idiocy-gargoylism-lipochondrodystrophy syndrome><early childhood><early therapy><enzyme activity><enzyme replacement therapy><enzyme replacement treatment><experience><functional ability><functional capacity><gargoylism><gene repair therapy><gene replacement><gene replacement therapy><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic therapy><genomic therapy><graft versus host disease><graft vs host disease><graft vs. host disease><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic engraftment><hematopoietic progenitor cell transplantation><hepatic body system><hepatic organ system><hypertrophic arthritis><identification of biomarkers><identification of new biomarkers><iduronidase deficiency disease><imaging><immune system tolerance><immune unresponsiveness><immunological paralysis><immunoreaction><immunosuppressed patient><improved><infection in the blood><infection of the blood><inflamed joint><infusions><intellectual and developmental disability><joint disorder><joint inflammation><joint swelling><kids><limited intellectual functioning><liver imaging><liver scanning><marker identification><mucopolysaccharide storage disease I><mucopolysaccharidosis (MPS) I><mucopolysaccharidosis type 1><mucopolysaccharidosis type I><multi-modality><multimodality><myelopathy><myocardium disease><myocardium disorder><neonatal period><neonate><neural degeneration><neural imaging><neuro-imaging><neurodegeneration><neurodegenerative><neuroimaging><neurological degeneration><neurological imaging><neuronal><neuronal degeneration><neuropathologic><neuropathological><neuropathology><new approaches><newborn screening><novel><novel approaches><novel strategies><novel strategy><opacities-hepatosplenomegaly mental deficiency syndrome><orthopedic freezing><preclinical findings><preclinical information><prevent><preventing><progenitor transplantation><rehab therapy><rehabilitative><rehabilitative therapy><response><response to therapy><response to treatment><restoration><screening panel><severe form of mucopolysaccharidosis type I><social role><stem and progenitor cell transplantations><substantia alba><symptomatology><tandem mass spectrometry><therapeutic response><therapy response><tractography><transgene expression><treatment response><treatment responsiveness><vertebral canal><white matter><youngster><α-L-Idosiduronase><α-L-Iduronidase>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Scott M. Dehm

THOMAS JEFFERSON UNIVERSITY, PHILADELPHIA, PA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$591,355

FY 2026

Project Title

Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer

Grant Number:

5R01CA262570-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

There is an unmet medical need for development of more efficacious therapies for castrate-resistant (CR) prostate cancer (PC). The castrate resistant state of PC is incurable and results from a failure of androgen deprivation therapy (ADT), which targets androgen receptor (AR) activity in PC cells. ...

Research Terms

<3-D><3-Dimensional><3C-based approach><3C-based assay><3C-based method><3C-based strategy><3C-based technique><3C-based technology><3D><AR gene><Acceleration><Acetates><Androgen Receptor><Androgen Suppression><Androgenic Agents><Androgenic Compounds><Androgens><Automobile Driving><Basal Transcription Factor><Basal transcription factor genes><Binding Site Domain><Blood Serum><Bone Marrow Fibrosis><Cancer Patient><Castration><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cell Survival><Cell Viability><Cells><Cessation of life><ChIP assay><Clinical><Clinical Research><Clinical Study><Combined Modality Therapy><Data><Death><Development><Dihydrotestosterone Receptor><Dimerization><Disease><Disease Progression><Disorder><Distant><EPH- and ELK-Related Tyrosine Kinase><EPH-and ELK-Related Kinase><Ephrin Type-A Receptor 8><Ephrin Type-A Receptor 8 Precursor><FDA approved><Failure><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Generations><Genes><Genetic Transcription><Genome engineering><Growth><Growth and Development><Growth and Development function><Heterograft><Heterologous Transplantation><In Vitro><Intracellular Communication and Signaling><Investigation><Length><Ligand Binding Domain><Malignant neoplasm of prostate><Malignant prostatic tumor><Medical><Messenger RNA><Mice><Mice Mammals><Modeling><Molecular Target><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Myelofibrosis><Myelosclerosis><NGS Method><NGS system><NR3C4><Nuclear Translocation><Nucleus><Pathway interactions><Patients><Phase><Phenotype><Phosphorylation><Prostate CA><Prostate Cancer><Prostate malignancy><Protein Dimerization><Protein Phosphorylation><Protein Tyrosine Kinase><Protein Tyrosine Kinase EEK><Proteins><RNA Expression><RNA Seq><RNA Splicing><RNA sequencing><RNAseq><Receptor Inhibition><Regulation><Residual><Residual state><Resistance><SMAX1><Serum><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Splicing><Surgical Castration><Therapeutic><Therapeutic Androgen><Tissue Growth><Toxic effect><Toxicities><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Translating><Tyrosine Kinase><Tyrosine-Protein Kinase Receptor EEK><Tyrosine-Specific Protein Kinase><Tyrosylprotein Kinase><Variant><Variation><Work><Xenograft><Xenograft procedure><Xenotransplantation><Xtandi><abiraterone><advanced prostate cancer><androgen ablation therapy><androgen blockade therapy><androgen deprivation therapy><androgen deprivation treatment><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen receptor gene><androgen resistance in prostate cancer><androgen resistant prostate cancer><antagonism><antagonist><biological signal transduction><cancer cell genome><cancer genome><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><chromatin conformation capture><chromatin immunoprecipitation><chromosome capture><chromosome conformation capture><clinical development><combination therapy><combined modality treatment><combined treatment><companion diagnostics><determine efficacy><develop therapy><developmental><driving><efficacious therapy><efficacious treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><enzalutamide><evaluate efficacy><examine efficacy><field based data><field learning><field study><field test><global gene expression><global transcription profile><hormone refractory prostate cancer><hydroxyaryl protein kinase><in vivo><in vivo Model><inhibitor><intervention development><mRNA><mRNA Expression><multi-modal therapy><multi-modal treatment><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><next gen sequencing><next generation><next generation sequencing><nextgen sequencing><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><pathway><pharmacologic><phase 2 trial><phase 3 trial><phase II trial><phase III trial><pre-clinical efficacy><pre-clinical study><preclinical efficacy><preclinical study><predict responsiveness><predicting response><prevent><preventing><prostate cancer cell><prostate cancer cell line><prostate cancer metastasis><prostate cancer model><prostate cancer progression><prostate cancer resistant to androgen><prostate tumor cell><prostate tumor model><protein expression><receptor expression><resistant><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><standard of care><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic evaluation><therapeutic testing><therapy development><three dimensional><transcription factor><transcriptome><transcriptome sequencing><transcriptomic sequencing><transcriptomics><treatment development><tumor><tumor genome><tumor growth><tumor xenograft><tyrosyl protein kinase><virtual><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MARJA T NEVALAINEN

THOMAS JEFFERSON UNIVERSITY, PHILADELPHIA, PA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$591,355

FY 2026

Project Title

Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer

Grant Number:

5R01CA262570-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

There is an unmet medical need for development of more efficacious therapies for castrate-resistant (CR) prostate cancer (PC). The castrate resistant state of PC is incurable and results from a failure of androgen deprivation therapy (ADT), which targets androgen receptor (AR) activity in PC cells. ...

Research Terms

<3-D><3-Dimensional><3C-based approach><3C-based assay><3C-based method><3C-based strategy><3C-based technique><3C-based technology><3D><AR gene><Acceleration><Acetates><Androgen Receptor><Androgen Suppression><Androgenic Agents><Androgenic Compounds><Androgens><Automobile Driving><Basal Transcription Factor><Basal transcription factor genes><Binding Site Domain><Blood Serum><Bone Marrow Fibrosis><Cancer Patient><Castration><Cell Body><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cell Survival><Cell Viability><Cells><Cessation of life><ChIP assay><Clinical><Clinical Research><Clinical Study><Combined Modality Therapy><Data><Death><Development><Dihydrotestosterone Receptor><Dimerization><Disease><Disease Progression><Disorder><Distant><EPH- and ELK-Related Tyrosine Kinase><EPH-and ELK-Related Kinase><Ephrin Type-A Receptor 8><Ephrin Type-A Receptor 8 Precursor><FDA approved><Failure><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Generations><Genes><Genetic Transcription><Genome engineering><Growth><Growth and Development><Growth and Development function><Heterograft><Heterologous Transplantation><In Vitro><Intracellular Communication and Signaling><Investigation><Length><Ligand Binding Domain><Malignant neoplasm of prostate><Malignant prostatic tumor><Medical><Messenger RNA><Mice><Mice Mammals><Modeling><Molecular Target><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Myelofibrosis><Myelosclerosis><NGS Method><NGS system><NR3C4><Nuclear Translocation><Nucleus><Pathway interactions><Patients><Phase><Phenotype><Phosphorylation><Prostate CA><Prostate Cancer><Prostate malignancy><Protein Dimerization><Protein Phosphorylation><Protein Tyrosine Kinase><Protein Tyrosine Kinase EEK><Proteins><RNA Expression><RNA Seq><RNA Splicing><RNA sequencing><RNAseq><Receptor Inhibition><Regulation><Residual><Residual state><Resistance><SMAX1><Serum><Signal Induction><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Splicing><Surgical Castration><Therapeutic><Therapeutic Androgen><Tissue Growth><Toxic effect><Toxicities><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Translating><Tyrosine Kinase><Tyrosine-Protein Kinase Receptor EEK><Tyrosine-Specific Protein Kinase><Tyrosylprotein Kinase><Variant><Variation><Work><Xenograft><Xenograft procedure><Xenotransplantation><Xtandi><abiraterone><advanced prostate cancer><androgen ablation therapy><androgen blockade therapy><androgen deprivation therapy><androgen deprivation treatment><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen receptor gene><androgen resistance in prostate cancer><androgen resistant prostate cancer><antagonism><antagonist><biological signal transduction><cancer cell genome><cancer genome><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><chromatin conformation capture><chromatin immunoprecipitation><chromosome capture><chromosome conformation capture><clinical development><combination therapy><combined modality treatment><combined treatment><companion diagnostics><determine efficacy><develop therapy><developmental><driving><efficacious therapy><efficacious treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><enzalutamide><evaluate efficacy><examine efficacy><field based data><field learning><field study><field test><global gene expression><global transcription profile><hormone refractory prostate cancer><hydroxyaryl protein kinase><in vivo><in vivo Model><inhibitor><intervention development><mRNA><mRNA Expression><multi-modal therapy><multi-modal treatment><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><next gen sequencing><next generation><next generation sequencing><nextgen sequencing><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><pathway><pharmacologic><phase 2 trial><phase 3 trial><phase II trial><phase III trial><pre-clinical efficacy><pre-clinical study><preclinical efficacy><preclinical study><predict responsiveness><predicting response><prevent><preventing><prostate cancer cell><prostate cancer cell line><prostate cancer metastasis><prostate cancer model><prostate cancer progression><prostate cancer resistant to androgen><prostate tumor cell><prostate tumor model><protein expression><receptor expression><resistant><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><standard of care><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic evaluation><therapeutic testing><therapy development><three dimensional><transcription factor><transcriptome><transcriptome sequencing><transcriptomic sequencing><transcriptomics><treatment development><tumor><tumor genome><tumor growth><tumor xenograft><tyrosyl protein kinase><virtual><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RONALD G GREGG

UNIVERSITY OF LOUISVILLE, LOUISVILLE, KY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$531,036

FY 2026

Project Title

Preclinical evaluation of a homing endonuclease gene therapy for adRP in models of P23H retinopathy.

Grant Number:

5R01EY032645-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Autosomal dominant Retinitis pigmentosa (adRP) is a blinding eye disease that results in loss of rods and eventually cone photoreceptors. A large fraction of adRP is caused by mutations in the rhodopsin (Rho) gene, and the most common mutation in North America causes a P23H mutation in rhodopsin. Pa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Maureen A McCall

UNIVERSITY OF LOUISVILLE, LOUISVILLE, KY

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$531,036

FY 2026

Project Title

Preclinical evaluation of a homing endonuclease gene therapy for adRP in models of P23H retinopathy.

Grant Number:

5R01EY032645-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Autosomal dominant Retinitis pigmentosa (adRP) is a blinding eye disease that results in loss of rods and eventually cone photoreceptors. A large fraction of adRP is caused by mutations in the rhodopsin (Rho) gene, and the most common mutation in North America causes a P23H mutation in rhodopsin. Pa...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Andrew Findlay

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$527,611

FY 2026

Project Title

Allele Specific Knockdown for LGMDD1

Grant Number:

5R01NS134506-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/21/2024

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY / ABSTRACT While the promise of gene-based therapies for disabling neuromuscular diseases is finally becoming a reality, research efforts thus far have primarily focused on gene replacement strategies for recessive, loss-of-function disorders. Such strategies are not translatable to ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jessica I.W. Morgan

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$521,325

FY 2026

Project Title

Retinal structure, function and response to gene therapy

Grant Number:

5R01EY028601-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2018

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary The Food and Drug Administration's approval of Luxturna marked a new era in the fight to cure blindness caused by inherited retinal degenerations (IRDs). However, despite an approved treatment for RPE65- mediated disease, there are still over 280 molecularly distinct, currently untr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ioannis Karakikes

STANFORD UNIVERSITY, STANFORD, CA

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$507,129

FY 2026

Project Title

Unraveling the pathogenesis of familial dilated cardiomyopathy towards precision medicine

Grant Number:

5R01HL139679-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2018

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Summary Dilated cardiomyopathy (DCM) is a leading cause of heart failure and death. Despite the progress in unraveling the genetic basis of DCM, there is a lack of disease-modifying therapies that target the underlying genetic etiology. In preliminary studies, we identified the transcription factor ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JOSEPH CORBO

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$500,157

FY 2026

Project Title

Targeting Nr2e3 to prevent photoreceptor degeneration

Grant Number:

5R01EY033810-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Retinitis pigmentosa (RP) is the most common form of retinal dystrophy and can be caused by mutations in any one of dozens of rod-enriched genes. The genetic heterogeneity of RP represents a major challenge for the development of effective therapies. For this reason, gene-independent...

Research Terms

<21+ years old><Acute><Adeno-Associated Viruses><Adult><Adult Human><Adverse effects><Affect><Animal Disease Models><Animal Model><Animal Models and Related Studies><Assay><Basal Transcription Factor><Basal transcription factor genes><Behavioral><Behavioral Assay><Bioassay><Biological Assay><Blindness><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Candidate Disease Gene><Candidate Gene><Cas nuclease technology><Cell Body><Cell Reprogramming><Cells><Cessation of life><Clinical Research><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cone><DNA mutation><Data><Death><Dependoparvovirus><Dependovirus><Development><Disabling><Disease><Disease Progression><Disorder><Dysfunction><Electron Microscopy><Electrophysiology><Electrophysiology (science)><Functional disorder><Future><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic><Genetic Change><Genetic Heterogeneity><Genetic defect><Genetic mutation><Goals><Histologic><Histologically><Human><Hybrid Cells><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Knock-out><Knockout><Light><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Morbidity><Morphology><Motivation><Murine><Mus><Mutation><Neurophysiology / Electrophysiology><Patients><Persons><Photoradiation><Photoreceptor Cell><Photoreceptors><Photosensitive Cell><Physiologic><Physiological><Physiopathology><Pigmentary Retinopathy><RNA Seq><RNA sequencing><RNAseq><Retinal Degeneration><Retinal Dystrophy><Retinitis Pigmentosa><Rod><Rod Photoreceptors><Sight><Somatic Cell Hybrids><Source><Structure><Tapetoretinal Degeneration><Testing><Therapeutic><Transcript Expression Analyses><Transcript Expression Analysis><Transcription Factor Proto-Oncogene><Transcription factor genes><Treatment Efficacy><Vision><Vision research><Visual Receptor><Wild Type Mouse><Work><adeno associated virus group><adulthood><analyze gene expression><behavior phenotype><behavioral phenotyping><candidate selection><cell type><cellular reprogramming><degenerative retina diseases><determine efficacy><developmental><disease model><disorder model><effective therapy><effective treatment><effectiveness testing><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><electrophysiological><evaluate efficacy><examine efficacy><gene expression analysis><gene expression assay><genome mutation><inherited retinal degeneration><intervention efficacy><model of animal><mouse model><murine model><neuroprotection><neuroprotective><new approaches><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel><novel approaches><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><overexpress><overexpression><pathophysiology><photoreceptor degeneration><preservation><prevent><preventing><retina degeneration><retinal degenerative><retinal degenerative diseases><retinal rods><rho><rod and cone dystrophy><rod cell><rod-cone dystrophy><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapy efficacy><transcription factor><transcriptional profiling><transcriptome sequencing><transcriptomic sequencing><vision loss><visual function><visual loss><wildtype mouse>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Vladimir Jivkov Kefalov

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

High-opportunity lead · 74/100

Likely hiring

Above-average budget

Very recent

Active award

$500,157

FY 2026

Project Title

Targeting Nr2e3 to prevent photoreceptor degeneration

Grant Number:

5R01EY033810-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Retinitis pigmentosa (RP) is the most common form of retinal dystrophy and can be caused by mutations in any one of dozens of rod-enriched genes. The genetic heterogeneity of RP represents a major challenge for the development of effective therapies. For this reason, gene-independent...

Research Terms

<21+ years old><Acute><Adeno-Associated Viruses><Adult><Adult Human><Adverse effects><Affect><Animal Disease Models><Animal Model><Animal Models and Related Studies><Assay><Basal Transcription Factor><Basal transcription factor genes><Behavioral><Behavioral Assay><Bioassay><Biological Assay><Blindness><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Candidate Disease Gene><Candidate Gene><Cas nuclease technology><Cell Body><Cell Reprogramming><Cells><Cessation of life><Clinical Research><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cone><DNA mutation><Data><Death><Dependoparvovirus><Dependovirus><Development><Disabling><Disease><Disease Progression><Disorder><Dysfunction><Electron Microscopy><Electrophysiology><Electrophysiology (science)><Functional disorder><Future><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic><Genetic Change><Genetic Heterogeneity><Genetic defect><Genetic mutation><Goals><Histologic><Histologically><Human><Hybrid Cells><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Knock-out><Knockout><Light><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Morbidity><Morphology><Motivation><Murine><Mus><Mutation><Neurophysiology / Electrophysiology><Patients><Persons><Photoradiation><Photoreceptor Cell><Photoreceptors><Photosensitive Cell><Physiologic><Physiological><Physiopathology><Pigmentary Retinopathy><RNA Seq><RNA sequencing><RNAseq><Retinal Degeneration><Retinal Dystrophy><Retinitis Pigmentosa><Rod><Rod Photoreceptors><Sight><Somatic Cell Hybrids><Source><Structure><Tapetoretinal Degeneration><Testing><Therapeutic><Transcript Expression Analyses><Transcript Expression Analysis><Transcription Factor Proto-Oncogene><Transcription factor genes><Treatment Efficacy><Vision><Vision research><Visual Receptor><Wild Type Mouse><Work><adeno associated virus group><adulthood><analyze gene expression><behavior phenotype><behavioral phenotyping><candidate selection><cell type><cellular reprogramming><degenerative retina diseases><determine efficacy><developmental><disease model><disorder model><effective therapy><effective treatment><effectiveness testing><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><electrophysiological><evaluate efficacy><examine efficacy><gene expression analysis><gene expression assay><genome mutation><inherited retinal degeneration><intervention efficacy><model of animal><mouse model><murine model><neuroprotection><neuroprotective><new approaches><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel><novel approaches><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><overexpress><overexpression><pathophysiology><photoreceptor degeneration><preservation><prevent><preventing><retina degeneration><retinal degenerative><retinal degenerative diseases><retinal rods><rho><rod and cone dystrophy><rod cell><rod-cone dystrophy><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapy efficacy><transcription factor><transcriptional profiling><transcriptome sequencing><transcriptomic sequencing><vision loss><visual function><visual loss><wildtype mouse>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Thomas Gaj

UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, CHAMPAIGN, IL

Good lead · 68/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$859,980

FY 2026

Project Title

Optimization of an in vivo base editing strategy to treat SOD1-linked ALS

Grant Number:

5U01NS122102-05

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/23/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, paralytic and ultimately fatal disease characterized by the selective loss of motor neurons in the spinal cord and brain. The overarching objective of this application to the Optimization Track of the CREATE Bio Program is...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Pablo Perez-Pinera

UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, CHAMPAIGN, IL

Good lead · 68/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$859,980

FY 2026

Project Title

Optimization of an in vivo base editing strategy to treat SOD1-linked ALS

Grant Number:

5U01NS122102-05

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/23/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, paralytic and ultimately fatal disease characterized by the selective loss of motor neurons in the spinal cord and brain. The overarching objective of this application to the Optimization Track of the CREATE Bio Program is...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAVID A WILLIAMS

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

Good lead · 68/100

Likely hiring

Above-average budget

Active award

Team-scale grant

$828,518

FY 2026

Project Title

Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector

Grant Number:

5U01AI125051-09

Activity Code:

U01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/7/2016

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Gene therapy using autologous CD34+ cells is a promising treatment for primary immunodeficiency, particularly for individuals without optimal allogeneic donors. SCID-X1 is caused by mutations in IL2 Receptor Gamma (IL2RG) which encodes the common gamma chain (γc) of multiple cytokine...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HANS-PETER KIEM

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 66/100

Likely hiring

Large award

Active award

$1,553,325

FY 2026

Project Title

In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure

Grant Number:

5R01AI174304-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/10/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Hematopoietic stem cell (HSC) transplantation can provide durable HIV elimination as exemplified in the “Berlin” patient, the “London” patient, and recently, in a third (“New York”) patient. This gives a strong rationale for HSC gene therapy of HIV/AIDS. Current clinical HSC gene therapy protocols (...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ANDRE Michael LIEBER

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 66/100

Likely hiring

Large award

Active award

$1,553,325

FY 2026

Project Title

In vivo HSC gene therapy using a multi-modular HDAd vector for HIV cure

Grant Number:

5R01AI174304-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/10/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Large budget suggests more room for personnel or project growth.

Project Abstract

Hematopoietic stem cell (HSC) transplantation can provide durable HIV elimination as exemplified in the “Berlin” patient, the “London” patient, and recently, in a third (“New York”) patient. This gives a strong rationale for HSC gene therapy of HIV/AIDS. Current clinical HSC gene therapy protocols (...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lahouaria HADRI

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$824,916

FY 2026

Project Title

The Chromatin Remodeling Factor ARID1a and the Epigenetic Landscape In Pulmonary Arterial Hypertension

Grant Number:

5R01HL173203-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/5/2024

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Pulmonary arterial hypertension (PAH is a rare, progressive, incurable, and fatal cardiopulmonary vascular disease leading to right ventricle failure and ultimately to death. Despite the available treatments and ongoing research efforts, there is currently no curative treatment again...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Tomasz Nowakowski

UNIVERSITY OF CALIFORNIA BERKELEY, BERKELEY, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$788,079

FY 2026

Project Title

Directed Evolution of Novel AAVs and Regulatory Elements for Selective Microglial Gene Expression

Grant Number:

5R01NS126397-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Microglial inflammation has been implicated the pathology of a host of neurological conditions, including neurodevelopmental disorders such as autism and Down Syndrome; neurogenerative disorders such as Alzheimer's disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis (AL...

Research Terms

<21+ years old><AAV vector><AAV-based vector><AD dementia><ASD><ATAC sequencing><ATAC-seq><ATACseq><Adult><Adult Human><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Amyotrophic Lateral Sclerosis><Amyotrophic Lateral Sclerosis Motor Neuron Disease><Assay for Transposase-Accessible Chromatin using sequencing><Autism><Autistic Disorder><Bar Codes><Basal Transcription Factor><Basal transcription factor genes><Binding Sites><Biology><Biomedical Engineering><Body Tissues><Brain><Brain Nervous System><CNS Diseases><CNS Nervous System><CNS disorder><Capsid><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Central Nervous System><Central Nervous System Diseases><Central Nervous System Disorders><Chronic><Clinical Trials><Collaborations><Combining Site><Complement><Complement Proteins><DNA Therapy><Data><Degenerative Neurologic Disorders><Directed Molecular Evolution><Disease><Disorder><Down Syndrome><Early Infantile Autism><Encephalon><Engineering><Enhancers><Exhibits><Future><Gehrig's Disease><Gene Delivery><Gene Expression><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Intervention><Genomics><Hortega cell><Human><Huntington Chorea><Huntington Disease><Huntington's><Huntington's Disease><Huntingtons Disease><Immune signaling><Immunoglobulin Enhancer-Binding Protein><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Infantile Autism><Inflammation><Inflammatory><Inflammatory Response><Injections><Intervention><Intracellular Communication and Signaling><Intravenous><Kanner's Syndrome><Langdon Down syndrome><Libraries><Lou Gehrig Disease><Machine Learning><Mediating><Metallothionein><Methods><Microglia><Modeling><Modern Man><Molecular><Mongolism><NF-kB><NF-kappa B><NF-kappaB><NFKB><NGS Method><NGS system><NHP models><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neuraxis><Neurobiology><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurodevelopmental Disorder><Neurologic><Neurologic Degenerative Conditions><Neurological><Neurological Development Disorder><Neuron Degeneration><Neurons><Neurosciences><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Paralysis Agitans><Parkinson><Parkinson Disease><Pathology><Primary Parkinsonism><Primary Senile Degenerative Dementia><Primates><Primates Mammals><Reactive Site><Receptor Protein><Regulatory Element><Research><Role><Safety><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Single cell seq><Slice><Specificity><Surface><System><Technology><Therapeutic><Tissues><Transcription Factor NF-kB><Transcription Factor Proto-Oncogene><Transcription factor genes><Trisomy 21><Variant><Variation><Viral><Viral Vector><Work><adeno-associated viral vector><adeno-associated virus vector><adulthood><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><autism spectral disorder><autism spectrum disorder><autistic spectrum disorder><barcode><bio-engineered><bio-engineers><bioengineering><biological engineering><biological signal transduction><cell type><chromosome 21 trisomy><chromosome 21 trisomy syndrome><complementation><congenital acromicria syndrome><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><directed evolution><efficacy validation><experience><gene manipulation><gene repair therapy><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><genes therapeutic><genes therapeutics><genetic manipulation><genetic therapy><genetically manipulate><genetically perturb><genome editing><genomic editing><genomic therapy><gitter cell><high risk><human disease><human tissue><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive response><in vivo><innovate><innovation><innovative><insight><kappa B Enhancer Binding Protein><knock-down><knockdown><machine based learning><mesoglia><microglial cell><microgliocyte><morbus Down><mouse model><multidisciplinary><murine model><neural degeneration><neurobiological><neurodegeneration><neurodegenerative><neurodegenerative illness><neurodevelopmental disease><neurological degeneration><neuronal><neuronal degeneration><neuropathic pain><next gen sequencing><next generation sequencing><nextgen sequencing><non-human primate><nonhuman primate><nonhuman primate models><novel><nuclear factor kappa beta><overexpress><overexpression><painful neuropathy><perivascular glial cell><primary degenerative dementia><programs><promoter><promotor><pseudohypertrophic progressive muscular dystrophy><receptor><selective expression><selectively expressed><senile dementia of the Alzheimer type><single cell analysis><single cell next generation sequencing><single cell sequencing><social role><tech development><technology development><technology platform><technology system><therapeutic gene><tool><trafficking><transcription factor><trisomy 21 syndrome><validate efficacy><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAVID V SCHAFFER

UNIVERSITY OF CALIFORNIA BERKELEY, BERKELEY, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$788,079

FY 2026

Project Title

Directed Evolution of Novel AAVs and Regulatory Elements for Selective Microglial Gene Expression

Grant Number:

5R01NS126397-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Microglial inflammation has been implicated the pathology of a host of neurological conditions, including neurodevelopmental disorders such as autism and Down Syndrome; neurogenerative disorders such as Alzheimer's disease (AD), Parkinson’s disease, amyotrophic lateral sclerosis (AL...

Research Terms

<21+ years old><AAV vector><AAV-based vector><AD dementia><ASD><ATAC sequencing><ATAC-seq><ATACseq><Adult><Adult Human><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Amyotrophic Lateral Sclerosis><Amyotrophic Lateral Sclerosis Motor Neuron Disease><Assay for Transposase-Accessible Chromatin using sequencing><Autism><Autistic Disorder><Bar Codes><Basal Transcription Factor><Basal transcription factor genes><Binding Sites><Biology><Biomedical Engineering><Body Tissues><Brain><Brain Nervous System><CNS Diseases><CNS Nervous System><CNS disorder><Capsid><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Central Nervous System><Central Nervous System Diseases><Central Nervous System Disorders><Chronic><Clinical Trials><Collaborations><Combining Site><Complement><Complement Proteins><DNA Therapy><Data><Degenerative Neurologic Disorders><Directed Molecular Evolution><Disease><Disorder><Down Syndrome><Early Infantile Autism><Encephalon><Engineering><Enhancers><Exhibits><Future><Gehrig's Disease><Gene Delivery><Gene Expression><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Intervention><Genomics><Hortega cell><Human><Huntington Chorea><Huntington Disease><Huntington's><Huntington's Disease><Huntingtons Disease><Immune signaling><Immunoglobulin Enhancer-Binding Protein><Immunomodulation><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><In Vitro><Infantile Autism><Inflammation><Inflammatory><Inflammatory Response><Injections><Intervention><Intracellular Communication and Signaling><Intravenous><Kanner's Syndrome><Langdon Down syndrome><Libraries><Lou Gehrig Disease><Machine Learning><Mediating><Metallothionein><Methods><Microglia><Modeling><Modern Man><Molecular><Mongolism><NF-kB><NF-kappa B><NF-kappaB><NFKB><NGS Method><NGS system><NHP models><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neuraxis><Neurobiology><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurodevelopmental Disorder><Neurologic><Neurologic Degenerative Conditions><Neurological><Neurological Development Disorder><Neuron Degeneration><Neurons><Neurosciences><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Paralysis Agitans><Parkinson><Parkinson Disease><Pathology><Primary Parkinsonism><Primary Senile Degenerative Dementia><Primates><Primates Mammals><Reactive Site><Receptor Protein><Regulatory Element><Research><Role><Safety><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Single cell seq><Slice><Specificity><Surface><System><Technology><Therapeutic><Tissues><Transcription Factor NF-kB><Transcription Factor Proto-Oncogene><Transcription factor genes><Trisomy 21><Variant><Variation><Viral><Viral Vector><Work><adeno-associated viral vector><adeno-associated virus vector><adulthood><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><autism spectral disorder><autism spectrum disorder><autistic spectrum disorder><barcode><bio-engineered><bio-engineers><bioengineering><biological engineering><biological signal transduction><cell type><chromosome 21 trisomy><chromosome 21 trisomy syndrome><complementation><congenital acromicria syndrome><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><directed evolution><efficacy validation><experience><gene manipulation><gene repair therapy><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><genes therapeutic><genes therapeutics><genetic manipulation><genetic therapy><genetically manipulate><genetically perturb><genome editing><genomic editing><genomic therapy><gitter cell><high risk><human disease><human tissue><immune modulation><immune regulation><immune suppression><immune suppressive activity><immune suppressive function><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunosuppressive activity><immunosuppressive function><immunosuppressive response><in vivo><innovate><innovation><innovative><insight><kappa B Enhancer Binding Protein><knock-down><knockdown><machine based learning><mesoglia><microglial cell><microgliocyte><morbus Down><mouse model><multidisciplinary><murine model><neural degeneration><neurobiological><neurodegeneration><neurodegenerative><neurodegenerative illness><neurodevelopmental disease><neurological degeneration><neuronal><neuronal degeneration><neuropathic pain><next gen sequencing><next generation sequencing><nextgen sequencing><non-human primate><nonhuman primate><nonhuman primate models><novel><nuclear factor kappa beta><overexpress><overexpression><painful neuropathy><perivascular glial cell><primary degenerative dementia><programs><promoter><promotor><pseudohypertrophic progressive muscular dystrophy><receptor><selective expression><selectively expressed><senile dementia of the Alzheimer type><single cell analysis><single cell next generation sequencing><single cell sequencing><social role><tech development><technology development><technology platform><technology system><therapeutic gene><tool><trafficking><transcription factor><trisomy 21 syndrome><validate efficacy><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kiyotake Ishikawa

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$785,641

FY 2026

Project Title

Cardiac AAV gene delivery for clinical translation

Grant Number:

5R01HL173593-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT ABSTRACT/SUMMARY In the past few years, several gene therapy products using adeno-associated virus (AAV) have been approved for clinical use for treatment of non-cardiac diseases. However, existing data indicate extremely low cardiac uptake of AAV in human hearts, hampering clinical transla...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHU CHEN

UNIVERSITY OF TEXAS HLTH SCIENCE CENTER, SAN ANTONIO, TX

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$771,678

FY 2026

Project Title

Silencing of astrocytic MAGL as a therapy for Alzheimer’s disease

Grant Number:

4R01AG081362-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary Dementia affects millions of people in the United States. Alzheimer’s disease (AD) is one of the most common causes of dementia in aging. However, there are no effective therapies currently available for prevention and treatment of AD. Therefore, it is imperative to develop novel and efficac...

Research Terms

<2-AG><2-arachidonoyl-glycerol><2-arachidonoyl-sn-glycerol><2-arachidonoylglycerol><2-arachidonyl-glycerol><2-arachidonylglycerol><AAV vector><AAV-based vector><AD dementia><AD model><AD patients><AD therapy><AD treatment><Acceleration><Acute myocardial infarct><Acute myocardial infarction><Adverse effects><Affect><Aging><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Disease><Alzheimer's disease model><Alzheimer's disease patient><Alzheimer's disease therapy><Alzheimer's patient><Alzheimer's therapy><Alzheimers Dementia><Amentia><Ammon Horn><Animal Diseases><Animal Model><Animal Models and Related Studies><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Astrocytes><Astrocytus><Astroglia><Attenuated><Body Tissues><Brain><Brain Nervous System><Causality><Cell Body><Cells><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Complex><Cornu Ammonis><DNA Therapy><Degenerative Neurologic Disorders><Dementia><Deterioration><Development><Disease><Disease Progression><Disorder><Disturbance in cognition><Drug Therapy><Early Intervention><Elderly><Encephalon><Endocannabinoids><Endogenous Cannabinoids><Enzyme Gene><Enzymes><Etiology><Gene Expression><Gene Inactivation><Gene Silencing><Gene Transfer Clinical><Genetic Intervention><Genetic study><Glycerol Monoester Hydrolases><Glycerol-ester acylhydrolase><Goals><Hippocampus><Hortega cell><Human><Impaired cognition><Impairment><Incidence><Inflammation><Inflammatory><Injections><Intermediary Metabolism><Learning><Lung Adenocarcinoma><MT-bound tau><Mediating><Memory><Metabolic Processes><Metabolism><Mice><Mice Mammals><Microglia><Modality><Modern Man><Modification><Monoacylglycerol Lipases><Monoglyceride Esterases><Monoglyceride Hydrolase><Monoglyceride Lipases><Motor><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neurons><Organism-Level Process><Organismal Process><Outcome><Pathologic Processes><Pathological Processes><Peripheral><Persons><Pharmacological Treatment><Pharmacotherapy><Physiologic Processes><Physiological Processes><Prevention><Primary Senile Degenerative Dementia><Property><Synapses><Synaptic><Testing><Therapeutic><Tissues><United States><adeno-associated viral vector><adeno-associated virus vector><advanced age><alzheimer model><antagonism><antagonist><astrocytic glia><attenuate><attenuates><bone loss><cardiac function><causation><cell type><cognitive defects><cognitive dysfunction><cognitive function><cognitive loss><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><disease causation><drug intervention><drug treatment><eCB system><effective therapy><effective treatment><efficacious intervention><endocannabinoid system><endogenous cannabinoid system><function of the heart><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><geriatric><gitter cell><heart function><hippocampal><improved><inhibitor><knock-down><knockdown><lipid mediator><memory retention><mesoglia><microglial cell><microgliocyte><microtubule bound tau><microtubule-bound tau><model of animal><mouse model><murine model><neural inflammation><neurodegenerative illness><neuroinflammation><neuroinflammatory><neuronal><neuropathologic><neuropathological><neuropathology><neuroprotection><neuroprotective><neurotoxic><novel><overexpress><overexpression><patient living with Alzheimer's disease><patient suffering from Alzheimer's disease><patient with Alzheimer's><patient with Alzheimer's disease><patients with AD><perivascular glial cell><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><pre-clinical study><preclinical><preclinical study><prevent><preventing><primary degenerative dementia><promoter><promotor><restraint><scRNA sequencing><scRNA-seq><senile dementia of the Alzheimer type><senior citizen><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><synapse><synapse function><synaptic function><tau><tau Proteins><tau factor><therapeutic outcome><therapeutic target><therapy outcome><transcriptional silencing><vector><τ Proteins>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Chengwen Li

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$763,647

FY 2026

Project Title

Genetic determinants of AAV liver transduction and toxicity

Grant Number:

1R01DK142742-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Six adeno-associated virus (AAV) vector based biodrugs have been approved by the FDA to treat genetic disorders. The great therapeutic success of AAV gene transfer has been tempered by the often-associated liver toxicity and, with liver-directed therapies, the concomitant fall in the transgene expre...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

William Valdar

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$763,647

FY 2026

Project Title

Genetic determinants of AAV liver transduction and toxicity

Grant Number:

1R01DK142742-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Six adeno-associated virus (AAV) vector based biodrugs have been approved by the FDA to treat genetic disorders. The great therapeutic success of AAV gene transfer has been tempered by the often-associated liver toxicity and, with liver-directed therapies, the concomitant fall in the transgene expre...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PAUL B WATKINS

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$763,647

FY 2026

Project Title

Genetic determinants of AAV liver transduction and toxicity

Grant Number:

1R01DK142742-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Six adeno-associated virus (AAV) vector based biodrugs have been approved by the FDA to treat genetic disorders. The great therapeutic success of AAV gene transfer has been tempered by the often-associated liver toxicity and, with liver-directed therapies, the concomitant fall in the transgene expre...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PATRICK L SINN

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$753,231

FY 2026

Project Title

Life-long phenotypic correction of CF airways

Grant Number:

5R01HL133089-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2017

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Title: Life-Long Phenotypic Correction of CF Airways Project Summary/Abstract: Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis conductance regulator (CFTR) gene. Knowledge of CFTR function and cell type expression has advanced greatly since its discovery in 1989, with notable disc...

Research Terms

<1H-Purin-6-amine><Ad vector><Address><Adenine><Adenosine Aminohydrolase><Adenoviral Vector><Adenoviridae><Adenovirus Vector><Adenoviruses><Affect><Animal Model><Animal Models and Related Studies><Anions><Basal Cell><Benchmarking><Best Practice Analysis><Body Tissues><CF airway><CF lung disease><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Categories><Cell Body><Cell Line><Cell surface><CellLine><Cells><Chlorides><Chromosomes><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Control Animal><Cystic Fibrosis><DNA Nicking Enzyme><DNA Therapy><DNA Transposons><DNA mutation><Data><Disease><Disease Outcome><Disorder><Dose><Economic Burden><Electroporation><Endonuclease I><Engineering><Epithelial Cells><Family suidae><Fiber><Gene Alteration><Gene Delivery><Gene Mutation><Gene Transfer><Gene Transfer Clinical><Generations><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Goals><Hand><Heterozygote><Human><Hybrids><Immune response><In Situ><In Vitro><Interphase Cell><Ivacaftor><Knowledge><Lung Diseases><Measurement><Measures><Mendelian disease><Mendelian disorder><Mendelian genetic disorder><Methods><Mice><Mice Mammals><Mitotic><Modern Man><Mucolytic Agents><Mucolytics><Mucous body substance><Mucoviscidosis><Mucus><Murine><Mus><Mutation><NGS Method><NGS system><Nickase><Non-dividing Cell><Nondividing Cell><Nonsense Mutation><Outcome><Penetration><Persons><Phenotype><Pigs><Production><Progenitor Cells><Property><Proteins><Public Health><Pulmonary Cystic Fibrosis><Pulmonary Diseases><Pulmonary Disorder><QOL improvement><Reagent><Receptor Protein><Regulator Genes><Reporting><Research><Respiratory Epithelium><Resting Cell><Site><Speed><Stop Codon><Strains Cell Lines><Structure of respiratory epithelium><Suidae><Swine><System><Technology><Termination Codon><Terminator Codon><Testing><Therapeutic Gene Editing><Tissues><Transcriptional Regulatory Elements><Translation Stop Signal><Tropism><VX-770><Viral><Viral Vector><Vitamin B4><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adeno vector><adenosine deaminase><adenovector><aerosolized><airway epithelial stem cells><airway epithelium><airway progenitor><airway stem cells><base editing><base editor><benchmark><burden of disease><burden of illness><cDNA Expression><cell type><cost><cultured cell line><cystic fibrosis airway><cystic fibrosis lung><cystic fibrosis lung disease><delivery vector><delivery vehicle><design><designing><disease burden><disease of the lung><disease phenotype><disorder of the lung><electroporative delivery><experiment><experimental research><experimental study><experiments><expression vector><fully-deleted adenoviral vector><fully-deleted adenovirus vector><functional restoration><gene corrected><gene correction><gene defect><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene electrotransfer><gene repair><gene repair therapy><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><gene-editing approach><gene-editing therapy><gene-editing toolkit><genes therapeutic><genes therapeutics><genetic therapy><genetic trans acting element><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic correction><genomic therapy><gutless adenoviral vector><gutless adenovirus vector><gutted adenoviral vector><gutted adenovirus vector><hands><hdAd><helper-dependent adenoviral vector><helper-dependent adenovirus vector><heterozygosity><host response><immune system response><immunoresponse><improved><improvements in QOL><improvements in quality of life><in vivo><innovate><innovation><innovative><lung disorder><model of animal><monogenic disease><monogenic disorder><mucous><mutant><mutant allele><next gen sequencing><next generation sequencing><nextgen sequencing><non-sense mutation><novel><nuclease><pig model><piglet model><porcine><porcine model><premature><prematurity><promoter><promotor><quality of life improvement><receptor><regulatory gene><repair><repair strategy><repaired><respiratory progenitor><respiratory stem cell><respiratory tract epithelium><restore function><restore functionality><restore lost function><single-gene disease><single-gene disorder><stem cells><stem cells in the airway><success><suid><swine model><therapeutic editing><therapeutic gene><therapeutic genome editing><therapeutic transgene><tool><trans acting element><transduction efficiency><transposon element><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Derek J Dosdall

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$741,503

FY 2026

Project Title

Novel Gene Therapy For Chronic Ischemic Heart Failure

Grant Number:

5R01HL171686-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/16/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Heart failure (HF) is the major cardiac syndrome and treating chronic HFis an unmet need in the United States and worldwide. Therapeutic options for advanced heart failure target systemic stress pathways and sur- prisingly few therapies exist that directly target failing heart muscl...

Research Terms

<Adeno-Associated Viruses><Adrenergic Agents><Adrenergic Drugs><Adrenergics><Amino-terminal pro-brain natriuretic peptide><Animal Model><Animal Models and Related Studies><Animals><Arrhythmia><Associated Viruses><Biological Markers><Biology><Blood Serum><Calcium><Canine Species><Canis familiaris><Cardiac><Cardiac Arrhythmia><Cardiac Muscle Cells><Cardiac Myocytes><Cardiocyte><Cell Membrane Lipid Rafts><Chronic><Clinical><Congestive Cardiomyopathy><Coronary Occlusions><DNA Therapy><Dangerousness><Data><Dependoparvovirus><Dependovirus><Development><Diastolic heart failure><Diffusion><Dilated Cardiomyopathy><Dogs><Dogs Mammals><ECG><EFRAC><EKG><Echocardiogram><Echocardiography><Effectiveness><Ejection Fraction><Electrocardiogram><Electrocardiography><Event><Gene Copy Number><Gene Dosage><Gene Transfer Clinical><Genetic Intervention><Goals><HF with preserved ejection fraction><HFpEF><Health><Heart><Heart Arrhythmias><Heart Muscle Cells><Heart failure><Heart myocyte><Human><Impairment><Incidence><Ions><Ischemia><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Lab Findings><Laboratory Finding><Left Ventricular Function><Life><Maps><Medicine><Membrane><Membrane Microdomains><Mice><Mice Mammals><Mission><Modeling><Modern Man><Monitor><Murine><Mus><Muscle><Muscle Cells><Muscle Tissue><Myocardial Ischemia><Myocardium><Myocytes><N-BNP peptide><N-terminal pro-BNP><NIH><NT-BNP><NT-proBNP><National Institutes of Health><Optics><Pathologic><Pathway interactions><Patients><Preclinical data><Predisposition><Public Health><Recovery of Function><Relaxation><Research><Rodent Model><Role><SERCA2a><Sarcoplasmic Reticulum><Satellite Viruses><Serum><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><Stress><Surface><Susceptibility><Syndrome><Systolic heart failure><Telemetries><Telemetry><Testing><Therapeutic><Translating><Transthoracic Echocardiography><Treatment Efficacy><United States><United States National Institutes of Health><Ventricular Arrhythmia><adeno associated virus group><assess effectiveness><bio-markers><biologic marker><biomarker><canine><canine animal model><canine model><cardiac failure><cardiac function><cardiac ischemia><cardiac muscle><cardiac occlusion><cardiomyocyte><coronary ischemia><determine effectiveness><developmental><diffused><diffuses><diffusing><diffusions><disability><dog model><domestic dog><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><extracellular><falls><function of the heart><functional recovery><functional restoration><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><heart failure with preserved ejection fraction><heart failure with preserved systolic function><heart function><heart ischemia><heart muscle><heart occlusion><heart sonography><hemodynamics><improved><in vivo><intervention efficacy><ischemic cardiomyopathy><lipid raft><membrane structure><model of animal><mortality><muscular><myocardial ischemia/hypoxia><myocardium ischemia><novel><optical><pathway><pre-clinical><preclinical><preclinical findings><preclinical information><preserved ejection fraction heart failure><pro-brain natriuretic peptide (1-76)><proBNP(1-76)><recruit><restore function><restore functionality><restore lost function><reuptake><social role><telemetric><therapeutic efficacy><therapy efficacy><validation studies><voltage>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robin M Shaw

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$741,503

FY 2026

Project Title

Novel Gene Therapy For Chronic Ischemic Heart Failure

Grant Number:

5R01HL171686-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/16/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Heart failure (HF) is the major cardiac syndrome and treating chronic HFis an unmet need in the United States and worldwide. Therapeutic options for advanced heart failure target systemic stress pathways and sur- prisingly few therapies exist that directly target failing heart muscl...

Research Terms

<Adeno-Associated Viruses><Adrenergic Agents><Adrenergic Drugs><Adrenergics><Amino-terminal pro-brain natriuretic peptide><Animal Model><Animal Models and Related Studies><Animals><Arrhythmia><Associated Viruses><Biological Markers><Biology><Blood Serum><Calcium><Canine Species><Canis familiaris><Cardiac><Cardiac Arrhythmia><Cardiac Muscle Cells><Cardiac Myocytes><Cardiocyte><Cell Membrane Lipid Rafts><Chronic><Clinical><Congestive Cardiomyopathy><Coronary Occlusions><DNA Therapy><Dangerousness><Data><Dependoparvovirus><Dependovirus><Development><Diastolic heart failure><Diffusion><Dilated Cardiomyopathy><Dogs><Dogs Mammals><ECG><EFRAC><EKG><Echocardiogram><Echocardiography><Effectiveness><Ejection Fraction><Electrocardiogram><Electrocardiography><Event><Gene Copy Number><Gene Dosage><Gene Transfer Clinical><Genetic Intervention><Goals><HF with preserved ejection fraction><HFpEF><Health><Heart><Heart Arrhythmias><Heart Muscle Cells><Heart failure><Heart myocyte><Human><Impairment><Incidence><Ions><Ischemia><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Lab Findings><Laboratory Finding><Left Ventricular Function><Life><Maps><Medicine><Membrane><Membrane Microdomains><Mice><Mice Mammals><Mission><Modeling><Modern Man><Monitor><Murine><Mus><Muscle><Muscle Cells><Muscle Tissue><Myocardial Ischemia><Myocardium><Myocytes><N-BNP peptide><N-terminal pro-BNP><NIH><NT-BNP><NT-proBNP><National Institutes of Health><Optics><Pathologic><Pathway interactions><Patients><Preclinical data><Predisposition><Public Health><Recovery of Function><Relaxation><Research><Rodent Model><Role><SERCA2a><Sarcoplasmic Reticulum><Satellite Viruses><Serum><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><Stress><Surface><Susceptibility><Syndrome><Systolic heart failure><Telemetries><Telemetry><Testing><Therapeutic><Translating><Transthoracic Echocardiography><Treatment Efficacy><United States><United States National Institutes of Health><Ventricular Arrhythmia><adeno associated virus group><assess effectiveness><bio-markers><biologic marker><biomarker><canine><canine animal model><canine model><cardiac failure><cardiac function><cardiac ischemia><cardiac muscle><cardiac occlusion><cardiomyocyte><coronary ischemia><determine effectiveness><developmental><diffused><diffuses><diffusing><diffusions><disability><dog model><domestic dog><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><extracellular><falls><function of the heart><functional recovery><functional restoration><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><heart failure with preserved ejection fraction><heart failure with preserved systolic function><heart function><heart ischemia><heart muscle><heart occlusion><heart sonography><hemodynamics><improved><in vivo><intervention efficacy><ischemic cardiomyopathy><lipid raft><membrane structure><model of animal><mortality><muscular><myocardial ischemia/hypoxia><myocardium ischemia><novel><optical><pathway><pre-clinical><preclinical><preclinical findings><preclinical information><preserved ejection fraction heart failure><pro-brain natriuretic peptide (1-76)><proBNP(1-76)><recruit><restore function><restore functionality><restore lost function><reuptake><social role><telemetric><therapeutic efficacy><therapy efficacy><validation studies><voltage>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JESSE M ENGREITZ

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$737,575

FY 2026

Project Title

Mapping, programming, and correcting gene regulatory sequences for Alagille Syndrome

Grant Number:

5R01HL171609-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2023

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Regulatory DNA elements, including enhancers and promoters, encode multiple transcription factor binding sites (TFBS) that quantitatively tune gene expression in a cell-type specific fashion. Understanding and engineering regulatory DNA could unlock new therapeutic approaches — for e...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Marlene Rabinovitch

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$737,575

FY 2026

Project Title

Mapping, programming, and correcting gene regulatory sequences for Alagille Syndrome

Grant Number:

5R01HL171609-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2023

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Regulatory DNA elements, including enhancers and promoters, encode multiple transcription factor binding sites (TFBS) that quantitatively tune gene expression in a cell-type specific fashion. Understanding and engineering regulatory DNA could unlock new therapeutic approaches — for e...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Manoj Bhasin

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$734,244

FY 2026

Project Title

Vascular-targeted Atheroprotective Gene therapies to Prevent Vein Graft Failure

Grant Number:

5R01HL173557-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/25/2024

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Autologous vein grafts (VG) are the most commonly used conduits in revascularization procedures for coronary artery disease (CAD) and peripheral arterial disease (PAD). However, VG failure rates remain high, reaching 30- 50% for lower extremity bypass and over 50% for coronary artery bypass grafts (...

Research Terms

<(TNF)-α><ASCVD><Acceleration><Accounting><Address><Adeno-Associated Viruses><Angiogram><Angiography><Animal Model><Animal Models and Related Studies><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Aortocoronary Bypass><Apoptosis><Apoptosis Pathway><Apoptotic><Area><Arteries><Articulation><Atherogenicity><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Autologous><Biology><Biomedical Engineering><Blood Vessels><Body Tissues><Bypass><Cachectin><Canine Species><Canis familiaris><Cause of Death><Cell Body><Cell Growth in Number><Cell Locomotion><Cell Migration><Cell Movement><Cell Multiplication><Cell Proliferation><Cell-Extracellular Matrix><Cells><Cellular Migration><Cellular Motility><Cellular Proliferation><Cessation of life><Clinical><Collaborations><Common Femoral Artery><Common carotid artery><Complex><Coronary Arteriosclerosis><Coronary Artery Bypass><Coronary Artery Bypass Grafting><Coronary Artery Bypass Surgery><Coronary Artery Disease><Coronary Artery Disorder><Coronary Atherosclerosis><Coronary arterial bypass><DNA Therapy><Data><Death><Dependoparvovirus><Dependovirus><Development><Dogs><Dogs Mammals><Domestic Rabbit><ECM><Effectiveness><Endothelial Cells><Endothelium><Engineering><Ensure><Evaluation><Exhibits><Exploratory/Developmental Grant><Exposure to><Extracellular Matrix><Failure><Funding><Gene Therapy Vectors><Gene Transcription><Gene Transduction Agent><Gene Transduction Vectors><Gene Transfer Clinical><Genes><Genetic Intervention><Genetic Transcription><Government><Harvest><Hour><Human><Human Engineering><Hybrids><Hyperplasia><Hyperplastic><Image><Immune><Immunes><Immunoblotting><In Vitro><Inflammation><Inflammatory><Injury><Investigational Drugs><Investigational New Drugs><Laboratories><Lead><Leiomyocyte><Lesion><Load Bearing><Lower Extremity><Lower Limb><Macrophage><Macrophage-Derived TNF><Maps><Medical><Membrum inferius><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Profiling><Monocyte-Derived TNF><Morbidity><Mφ><Operative Procedures><Operative Surgical Procedures><Oryctolagus cuniculus><Outcome><Pathogenesis><Pathogenicity><Pathologic><Pathological Constriction><Patients><Pb element><Perfusion><Peripheral arterial disease><Persons><Phenotype><Pilot Projects><Procedures><Programmed Cell Death><Proliferating><Property><Proteins><Proteomics><R21 Mechanism><R21 Program><RNA Expression><Rabbits><Rabbits Mammals><Regimen><Research><Resistance><Risk Factors><Safety><Saphenous Vein><Scheme><Smooth Muscle Cells><Smooth Muscle Myocytes><Smooth Muscle Tissue Cell><Stenosis><Surgical><Surgical Interventions><Surgical Procedure><System><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Technology><Temperature><Testing><Therapeutic><Therapeutic Agents><Therapeutic Studies><Therapy Research><Thrombosis><Time><Tissues><Toxic effect><Toxicities><Transcription><Transgenes><Trauma><Tropism><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Vascular Diseases><Vascular Disorder><Vascular remodeling><Vein graft><Veins><Weight Bearing><Weight-Bearing state><Western Blotting><Western Immunoblotting><Western World><adeno associated virus group><angiographic imaging><atheromatosis><atheroprotection><atheroprotective><atherosclerotic coronary disease><atherosclerotic disease><atherosclerotic vascular disease><bio-engineered><bio-engineers><bioengineering><biological engineering><blood vessel disorder><canine><cell motility><cephalic vein><circular RNA><clinic ready><clinical applicability><clinical application><clinical implementation><clinical ready><clinical translation><clinically translatable><closed circular RNA><coronary arterial disease><coronary bypass><developmental><domestic dog><efficacy study><ex vivo perfusion><exploratory developmental study><external jugular vein><gene regulatory network><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><global gene expression><global transcription profile><graft failure><heavy metal Pb><heavy metal lead><hemodynamics><human disease><imaging><implantation><improved><in vivo><injuries><model of animal><molecular profile><molecular signature><mortality><new technology><novel><novel technologies><pathogenicity gene><peripheral artery disease><pilot study><pre-clinical><preclinical><prevent><preventing><protein blotting><protein expression><recruit><resistant><response><revascularization><revascularization surgery><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><surgery><thrombotic><thrombotic disease><thrombotic disorder><tissue culture><transcriptome><transcriptomics><transgene><transgene expression><vascular><vascular dysfunction><vascular inflammation><vascular smooth muscle cell migration><vasculopathy><vector><viral RNA><virulence gene><virulent gene><virus RNA>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHRISTIANE FERRAN

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$734,244

FY 2026

Project Title

Vascular-targeted Atheroprotective Gene therapies to Prevent Vein Graft Failure

Grant Number:

5R01HL173557-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/25/2024

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Autologous vein grafts (VG) are the most commonly used conduits in revascularization procedures for coronary artery disease (CAD) and peripheral arterial disease (PAD). However, VG failure rates remain high, reaching 30- 50% for lower extremity bypass and over 50% for coronary artery bypass grafts (...

Research Terms

<(TNF)-α><ASCVD><Acceleration><Accounting><Address><Adeno-Associated Viruses><Angiogram><Angiography><Animal Model><Animal Models and Related Studies><Animals><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Aortocoronary Bypass><Apoptosis><Apoptosis Pathway><Apoptotic><Area><Arteries><Articulation><Atherogenicity><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Autologous><Biology><Biomedical Engineering><Blood Vessels><Body Tissues><Bypass><Cachectin><Canine Species><Canis familiaris><Cause of Death><Cell Body><Cell Growth in Number><Cell Locomotion><Cell Migration><Cell Movement><Cell Multiplication><Cell Proliferation><Cell-Extracellular Matrix><Cells><Cellular Migration><Cellular Motility><Cellular Proliferation><Cessation of life><Clinical><Collaborations><Common Femoral Artery><Common carotid artery><Complex><Coronary Arteriosclerosis><Coronary Artery Bypass><Coronary Artery Bypass Grafting><Coronary Artery Bypass Surgery><Coronary Artery Disease><Coronary Artery Disorder><Coronary Atherosclerosis><Coronary arterial bypass><DNA Therapy><Data><Death><Dependoparvovirus><Dependovirus><Development><Dogs><Dogs Mammals><Domestic Rabbit><ECM><Effectiveness><Endothelial Cells><Endothelium><Engineering><Ensure><Evaluation><Exhibits><Exploratory/Developmental Grant><Exposure to><Extracellular Matrix><Failure><Funding><Gene Therapy Vectors><Gene Transcription><Gene Transduction Agent><Gene Transduction Vectors><Gene Transfer Clinical><Genes><Genetic Intervention><Genetic Transcription><Government><Harvest><Hour><Human><Human Engineering><Hybrids><Hyperplasia><Hyperplastic><Image><Immune><Immunes><Immunoblotting><In Vitro><Inflammation><Inflammatory><Injury><Investigational Drugs><Investigational New Drugs><Laboratories><Lead><Leiomyocyte><Lesion><Load Bearing><Lower Extremity><Lower Limb><Macrophage><Macrophage-Derived TNF><Maps><Medical><Membrum inferius><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Profiling><Monocyte-Derived TNF><Morbidity><Mφ><Operative Procedures><Operative Surgical Procedures><Oryctolagus cuniculus><Outcome><Pathogenesis><Pathogenicity><Pathologic><Pathological Constriction><Patients><Pb element><Perfusion><Peripheral arterial disease><Persons><Phenotype><Pilot Projects><Procedures><Programmed Cell Death><Proliferating><Property><Proteins><Proteomics><R21 Mechanism><R21 Program><RNA Expression><Rabbits><Rabbits Mammals><Regimen><Research><Resistance><Risk Factors><Safety><Saphenous Vein><Scheme><Smooth Muscle Cells><Smooth Muscle Myocytes><Smooth Muscle Tissue Cell><Stenosis><Surgical><Surgical Interventions><Surgical Procedure><System><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Technology><Temperature><Testing><Therapeutic><Therapeutic Agents><Therapeutic Studies><Therapy Research><Thrombosis><Time><Tissues><Toxic effect><Toxicities><Transcription><Transgenes><Trauma><Tropism><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Vascular Diseases><Vascular Disorder><Vascular remodeling><Vein graft><Veins><Weight Bearing><Weight-Bearing state><Western Blotting><Western Immunoblotting><Western World><adeno associated virus group><angiographic imaging><atheromatosis><atheroprotection><atheroprotective><atherosclerotic coronary disease><atherosclerotic disease><atherosclerotic vascular disease><bio-engineered><bio-engineers><bioengineering><biological engineering><blood vessel disorder><canine><cell motility><cephalic vein><circular RNA><clinic ready><clinical applicability><clinical application><clinical implementation><clinical ready><clinical translation><clinically translatable><closed circular RNA><coronary arterial disease><coronary bypass><developmental><domestic dog><efficacy study><ex vivo perfusion><exploratory developmental study><external jugular vein><gene regulatory network><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><global gene expression><global transcription profile><graft failure><heavy metal Pb><heavy metal lead><hemodynamics><human disease><imaging><implantation><improved><in vivo><injuries><model of animal><molecular profile><molecular signature><mortality><new technology><novel><novel technologies><pathogenicity gene><peripheral artery disease><pilot study><pre-clinical><preclinical><prevent><preventing><protein blotting><protein expression><recruit><resistant><response><revascularization><revascularization surgery><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><surgery><thrombotic><thrombotic disease><thrombotic disorder><tissue culture><transcriptome><transcriptomics><transgene><transgene expression><vascular><vascular dysfunction><vascular inflammation><vascular smooth muscle cell migration><vasculopathy><vector><viral RNA><virulence gene><virulent gene><virus RNA>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Gerd A Blobel

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$729,938

FY 2026

Project Title

Targeted protein degraders for the treatment of b-hemoglobinopathies

Grant Number:

5R01HL176850-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Globally, 300,000 babies are born annually with Sickle Cell Disease (SCD). Current therapies for SCD revolve around induction of fetal hemoglobin (HbF), as it critically antagonizes red blood cell sickling. For example, hydroxyurea, a ribonucleotide reductase inhibitor, increases HbF levels. While h...

Research Terms

<21+ years old><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Assay><Attention><B-globin><Basal Transcription Factor><Basal transcription factor genes><Binding><Bioassay><Bioavailability><Biological><Biological Assay><Biological Availability><Birth><Blood><Blood Reticuloendothelial System><Body Tissues><Bone Marrow><Bone Marrow Reticuloendothelial System><CD34><CD34 gene><CHD4><CHD4 gene><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Carrying Capacities><Cas nuclease technology><Casein Kinase 1><Cell Body><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Survival><Cell Viability><Cell surface><Cells><Cellular Proliferation><Chromodomain Helicase DNA-Binding Protein 4><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Collaborations><Complete Blood Count><Control Animal><Crystallization><DNA Therapy><DNA mutation><Data><Disease><Disorder><Drug Therapy><Drugs><E3 Ligase><E3 Ubiquitin Ligase><Enhancers><Erythroid><Erythroid Cells><Fetal Hb><Fetal Hemoglobin><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Gene Expression><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generations><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic Screening><Genetic defect><Genetic mutation><Globin><HPCA1><HPLC><Hb SS disease><HbF><HbSS disease><Hemoglobin><Hemoglobin F><Hemoglobin S Disease><Hemoglobin concentration result><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemoglobinopathies><High Performance Liquid Chromatography><High Pressure Liquid Chromatography><High Speed Liquid Chromatography><Histologic><Histologically><Human><Hydroxycarbamid><Hydroxycarbamide><Hypoxia><Hypoxic><IMiD><IMiD3 cpd><Immune modulatory therapeutic><In vivo analysis><K562 Cells><Laboratories><Libraries><Luciferase Immunologic><Luciferases><Measurement><Medical><Medication><Medicinal Chemistry><Messenger RNA><Metabolic><Methods><Mi2-Beta><Mice><Mice Mammals><Modern Man><Molecular><Molecular Interaction><Monitor><Murine><Mus><Mutation><O element><O2 element><Oral><Osmolar Concentration><Osmolarity><Oxygen><Oxygen Deficiency><Parturition><Patients><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiologic Availability><Point Mutation><Prevention><Production><Proliferating><Property><Protein Kinase CK1><Protein Kinase CKI><Proteins><Publishing><Renal function><Reticulocyte Number><Reticulocyte count><Ribonucleotide Reductase Inhibitor><Risk><Severity of illness><Sickle Cell><Sickle Cell Anemia><Specificity><Spleen><Spleen Reticuloendothelial System><Structure><System><Therapeutic><Tissues><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Promotion><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Urine><Variant><Variation><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adulthood><analog><beta Globin><biologic><casein kinase I><co-repressor><corepressor><cost><disease model><disease severity><disorder model><drug intervention><drug treatment><drug/agent><experience><fetal><fetal form of hemoglobin><fetal globin><flow cytophotometry><gamma Globin><gene co-repressor><gene corepressor><gene editing method><gene editing methodology><gene editing strategy><gene editing techniques><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-editing approach><gene-targeted therapy><gene-targeted treatment><genetic co-repressor><genetic corepressor><genetic therapy><genome mutation><genomic therapy><global gene expression><global transcription profile><hemoglobin level><humanized mice><humanized mouse><hydroxy-urea><hydroxyurea><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulatory agents><immune modulatory drugs><immunomodulating agents><immunomodulating drugs><immunomodulator agent><immunomodulator drug><immunomodulator medication><immunomodulator prodrug><immunomodulator therapeutic><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><improved><in vivo><in vivo evaluation><in vivo testing><kidney function><lenalidomide><mRNA><member><model of animal><mouse model><murine model><novel><p-Globin><patient variability><patient variation><peripheral blood><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><preclinical><prevent><preventing><sickle RBC><sickle cell crisis><sickle cell disease><sickle cell disorder><sickle crisis><sickle disease><sickle erythrocyte><sickle erythroid><sickle red blood cell><sicklemia><sickling><standard of care><therapeutic agent development><therapeutic development><transcription factor><transcriptome><tumor><ubiquitin-protein ligase><variability between patients><variation between patients><β-globin><γ-Globin>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CRAIG M CREWS

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$729,938

FY 2026

Project Title

Targeted protein degraders for the treatment of b-hemoglobinopathies

Grant Number:

5R01HL176850-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Globally, 300,000 babies are born annually with Sickle Cell Disease (SCD). Current therapies for SCD revolve around induction of fetal hemoglobin (HbF), as it critically antagonizes red blood cell sickling. For example, hydroxyurea, a ribonucleotide reductase inhibitor, increases HbF levels. While h...

Research Terms

<21+ years old><Adult><Adult Human><Animal Model><Animal Models and Related Studies><Assay><Attention><B-globin><Basal Transcription Factor><Basal transcription factor genes><Binding><Bioassay><Bioavailability><Biological><Biological Assay><Biological Availability><Birth><Blood><Blood Reticuloendothelial System><Body Tissues><Bone Marrow><Bone Marrow Reticuloendothelial System><CD34><CD34 gene><CHD4><CHD4 gene><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Carrying Capacities><Cas nuclease technology><Casein Kinase 1><Cell Body><Cell Growth in Number><Cell Multiplication><Cell Proliferation><Cell Survival><Cell Viability><Cell surface><Cells><Cellular Proliferation><Chromodomain Helicase DNA-Binding Protein 4><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Collaborations><Complete Blood Count><Control Animal><Crystallization><DNA Therapy><DNA mutation><Data><Disease><Disorder><Drug Therapy><Drugs><E3 Ligase><E3 Ubiquitin Ligase><Enhancers><Erythroid><Erythroid Cells><Fetal Hb><Fetal Hemoglobin><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Gene Expression><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generations><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic Screening><Genetic defect><Genetic mutation><Globin><HPCA1><HPLC><Hb SS disease><HbF><HbSS disease><Hemoglobin><Hemoglobin F><Hemoglobin S Disease><Hemoglobin concentration result><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hemoglobinopathies><High Performance Liquid Chromatography><High Pressure Liquid Chromatography><High Speed Liquid Chromatography><Histologic><Histologically><Human><Hydroxycarbamid><Hydroxycarbamide><Hypoxia><Hypoxic><IMiD><IMiD3 cpd><Immune modulatory therapeutic><In vivo analysis><K562 Cells><Laboratories><Libraries><Luciferase Immunologic><Luciferases><Measurement><Medical><Medication><Medicinal Chemistry><Messenger RNA><Metabolic><Methods><Mi2-Beta><Mice><Mice Mammals><Modern Man><Molecular><Molecular Interaction><Monitor><Murine><Mus><Mutation><O element><O2 element><Oral><Osmolar Concentration><Osmolarity><Oxygen><Oxygen Deficiency><Parturition><Patients><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiologic Availability><Point Mutation><Prevention><Production><Proliferating><Property><Protein Kinase CK1><Protein Kinase CKI><Proteins><Publishing><Renal function><Reticulocyte Number><Reticulocyte count><Ribonucleotide Reductase Inhibitor><Risk><Severity of illness><Sickle Cell><Sickle Cell Anemia><Specificity><Spleen><Spleen Reticuloendothelial System><Structure><System><Therapeutic><Tissues><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Promotion><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Urine><Variant><Variation><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adulthood><analog><beta Globin><biologic><casein kinase I><co-repressor><corepressor><cost><disease model><disease severity><disorder model><drug intervention><drug treatment><drug/agent><experience><fetal><fetal form of hemoglobin><fetal globin><flow cytophotometry><gamma Globin><gene co-repressor><gene corepressor><gene editing method><gene editing methodology><gene editing strategy><gene editing techniques><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-editing approach><gene-targeted therapy><gene-targeted treatment><genetic co-repressor><genetic corepressor><genetic therapy><genome mutation><genomic therapy><global gene expression><global transcription profile><hemoglobin level><humanized mice><humanized mouse><hydroxy-urea><hydroxyurea><immune modulating agents><immune modulating drug><immune modulating therapeutics><immune modulatory agents><immune modulatory drugs><immunomodulating agents><immunomodulating drugs><immunomodulator agent><immunomodulator drug><immunomodulator medication><immunomodulator prodrug><immunomodulator therapeutic><immunomodulatory agents><immunomodulatory drugs><immunomodulatory therapeutics><improved><in vivo><in vivo evaluation><in vivo testing><kidney function><lenalidomide><mRNA><member><model of animal><mouse model><murine model><novel><p-Globin><patient variability><patient variation><peripheral blood><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><preclinical><prevent><preventing><sickle RBC><sickle cell crisis><sickle cell disease><sickle cell disorder><sickle crisis><sickle disease><sickle erythrocyte><sickle erythroid><sickle red blood cell><sicklemia><sickling><standard of care><therapeutic agent development><therapeutic development><transcription factor><transcriptome><tumor><ubiquitin-protein ligase><variability between patients><variation between patients><β-globin><γ-Globin>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Saswati Chatterjee

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$718,682

FY 2026

Project Title

High Fidelity Genome Editing for the Correction of MECP2 Mutations and Physiologic Regulation of Expression in Rett Syndrome

Grant Number:

5R01NS138604-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Rett syndrome (RTT) is an acquired progressively debilitating neurodevelopmental disorder caused by de novo mutations in the X-linked MECP2 gene that is almost exclusively observed in heterozygous females while hemizygous mutant males rarely survive. RTT is characterized by reduced brain gr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VINODH NARAYANAN

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$718,682

FY 2026

Project Title

High Fidelity Genome Editing for the Correction of MECP2 Mutations and Physiologic Regulation of Expression in Rett Syndrome

Grant Number:

5R01NS138604-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/15/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Rett syndrome (RTT) is an acquired progressively debilitating neurodevelopmental disorder caused by de novo mutations in the X-linked MECP2 gene that is almost exclusively observed in heterozygous females while hemizygous mutant males rarely survive. RTT is characterized by reduced brain gr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mai ElMallah

DUKE UNIVERSITY, DURHAM, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$718,315

FY 2026

Project Title

Alveolar injury and repair in Pompe Disease

Grant Number:

5R01HL177642-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/29/2025

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Pompe disease is a rare autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase (GAA) – a lysosomal enzyme that hydrolyzes glycogen. GAA deficiency results in glycogen accumulation in the lysosomes of cardiac, skeletal, and smooth muscle as well as moto...

Research Terms

<1,4-alpha-D-Glucan glucohydrolase><AGTR2><AGTR2 gene><AT2><Acid Maltase><Acid Maltase Deficiency Disease><Adeno-Associated Viruses><Affect><Air Bladder><Air Sacs><Airway failure><Airway infections><Alveolar><Alveolar Cell><Alveolar wall><Alveoli progenitor><Alveoli stem cell><Amyloglucosidase><Architecture><Area><Autophagocytosis><Autophagosome><Autopsy><Autoregulation><Biochemical><Cause of Death><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Function><Cell Interaction><Cell Physiology><Cell Process><Cell Signaling><Cell-to-Cell Interaction><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chemicals><Clinical><DNA Therapy><Dependoparvovirus><Dependovirus><Diaphragm><Disease><Disorder><Engineering / Architecture><Enzyme Gene><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exo-1,4-alpha-Glucosidase><FDA approved><Failure><Future><GaAs><Gene Abnormality><Gene Expression><Gene Transfer Clinical><Generalized Glycogenosis><Genetic><Genetic Intervention><Glucan 1,4-alpha-Glucosidase><Glucan 1,4-α-Glucosidase><Glucoamylase><Glycogen><Glycogen storage disease type II><Glycogenosis 2><Glycogenosis Type II><Goals><Histologic><Histologically><Homeostasis><Human><Impairment><Injury><Intracellular Communication and Signaling><Involuntary Muscle><Laboratories><Lung><Lung Diseases><Lung Parenchyma><Lung Protein D><Lung Respiratory System><Lung Tissue><Lung Tissue Fibrosis><Lung damage><Lysosomal alpha-1,4-Glucosidase Deficiency Disease><Lysosomal alpha-Glucosidase><Lysosomal α-Glucosidase><Lysosomes><Mice><Mice Mammals><Modern Man><Molecular><Morbidity><Motor Cell><Motor Neurons><Murine><Mus><Muscle><Muscle Tissue><Muscle Weakness><Muscular Weakness><Myocardium><Natural regeneration><Organoids><Outcome><Pathology><Patients><Physiological Homeostasis><Pneumonia><Pompe Disease><Progenitor Cells><Proliferating><Protein Replacement Therapy><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Fibrosis><Pulmonary Surfactant Protein D><Pulmonary Surfactant-Associated Protein D><Rapamune><Rapamycin><Recombinants><Recurrence><Recurrent><Regeneration><Respiratory Diaphragm><Respiratory Failure><Respiratory Infections><Respiratory Insufficiency><Respiratory Muscles><Respiratory Tract Infections><Respiratory physiology><SP-D><SYS-TX><Series><Signal Transduction><Signal Transduction Systems><Signaling><Sirolimus><Skeletal Muscle><Smooth Muscle><Structure of parenchyma of lung><Subcellular Process><Surfactant Protein D><Surfactant-Associated Glycoprotein D><Swimbladder><Systemic Therapy><Techniques><Therapeutic Intervention><Transportation><Ventilatory Muscles><Viral Diseases><Virus Diseases><Voluntary Muscle><Work><acid alpha glucosidase><acid maltase deficiency><acid α-glucosidase><adeno associated virus group><airway epithelial stem cells><airway progenitor><airway smooth muscle><airway stem cells><alpha 1,4 glucosidase deficiency><alveolar progenitor><alveolar stem cell><aspirate><autophagy><autosome><behavior study><behavioral study><biological signal transduction><cardiac muscle><cellular pathology><clinical care><clinical relevance><clinically relevant><disease of the lung><disorder of the lung><enzyme replacement therapy><enzyme replacement treatment><epigenetically><experience><experiment><experimental research><experimental study><experiments><fibrosis in the lung><gallium arsenide><gamma-Amylase><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><heart muscle><in vivo><injuries><injury and repair><innovate><innovation><innovative><intervention therapy><lung disorder><lung fibrosis><lung function><lung injury><lung preservation><lung repair><lung tissue repair><lysosomal acid alpha glucosidase><lysosomal acid α glucosidase><mTOR Inhibitor><mortality><motoneuron><mouse model><murine model><muscular><necropsy><novel><postmortem><pulmonary damage><pulmonary function><pulmonary injury><pulmonary repair><pulmonary tissue damage><pulmonary tissue injury><regenerate><repair><repaired><respiratory><respiratory function><respiratory progenitor><respiratory smooth muscle><respiratory stem cell><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><stem cells><stem cells in the airway><surfactant><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aleksandra Tata

DUKE UNIVERSITY, DURHAM, NC

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$718,315

FY 2026

Project Title

Alveolar injury and repair in Pompe Disease

Grant Number:

5R01HL177642-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/29/2025

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Pompe disease is a rare autosomal recessive disorder caused by a deficiency of acid alpha-glucosidase (GAA) – a lysosomal enzyme that hydrolyzes glycogen. GAA deficiency results in glycogen accumulation in the lysosomes of cardiac, skeletal, and smooth muscle as well as moto...

Research Terms

<1,4-alpha-D-Glucan glucohydrolase><AGTR2><AGTR2 gene><AT2><Acid Maltase><Acid Maltase Deficiency Disease><Adeno-Associated Viruses><Affect><Air Bladder><Air Sacs><Airway failure><Airway infections><Alveolar><Alveolar Cell><Alveolar wall><Alveoli progenitor><Alveoli stem cell><Amyloglucosidase><Architecture><Area><Autophagocytosis><Autophagosome><Autopsy><Autoregulation><Biochemical><Cause of Death><Cell Body><Cell Communication><Cell Communication and Signaling><Cell Function><Cell Interaction><Cell Physiology><Cell Process><Cell Signaling><Cell-to-Cell Interaction><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chemicals><Clinical><DNA Therapy><Dependoparvovirus><Dependovirus><Diaphragm><Disease><Disorder><Engineering / Architecture><Enzyme Gene><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exo-1,4-alpha-Glucosidase><FDA approved><Failure><Future><GaAs><Gene Abnormality><Gene Expression><Gene Transfer Clinical><Generalized Glycogenosis><Genetic><Genetic Intervention><Glucan 1,4-alpha-Glucosidase><Glucan 1,4-α-Glucosidase><Glucoamylase><Glycogen><Glycogen storage disease type II><Glycogenosis 2><Glycogenosis Type II><Goals><Histologic><Histologically><Homeostasis><Human><Impairment><Injury><Intracellular Communication and Signaling><Involuntary Muscle><Laboratories><Lung><Lung Diseases><Lung Parenchyma><Lung Protein D><Lung Respiratory System><Lung Tissue><Lung Tissue Fibrosis><Lung damage><Lysosomal alpha-1,4-Glucosidase Deficiency Disease><Lysosomal alpha-Glucosidase><Lysosomal α-Glucosidase><Lysosomes><Mice><Mice Mammals><Modern Man><Molecular><Morbidity><Motor Cell><Motor Neurons><Murine><Mus><Muscle><Muscle Tissue><Muscle Weakness><Muscular Weakness><Myocardium><Natural regeneration><Organoids><Outcome><Pathology><Patients><Physiological Homeostasis><Pneumonia><Pompe Disease><Progenitor Cells><Proliferating><Protein Replacement Therapy><Pulmonary Diseases><Pulmonary Disorder><Pulmonary Fibrosis><Pulmonary Surfactant Protein D><Pulmonary Surfactant-Associated Protein D><Rapamune><Rapamycin><Recombinants><Recurrence><Recurrent><Regeneration><Respiratory Diaphragm><Respiratory Failure><Respiratory Infections><Respiratory Insufficiency><Respiratory Muscles><Respiratory Tract Infections><Respiratory physiology><SP-D><SYS-TX><Series><Signal Transduction><Signal Transduction Systems><Signaling><Sirolimus><Skeletal Muscle><Smooth Muscle><Structure of parenchyma of lung><Subcellular Process><Surfactant Protein D><Surfactant-Associated Glycoprotein D><Swimbladder><Systemic Therapy><Techniques><Therapeutic Intervention><Transportation><Ventilatory Muscles><Viral Diseases><Virus Diseases><Voluntary Muscle><Work><acid alpha glucosidase><acid maltase deficiency><acid α-glucosidase><adeno associated virus group><airway epithelial stem cells><airway progenitor><airway smooth muscle><airway stem cells><alpha 1,4 glucosidase deficiency><alveolar progenitor><alveolar stem cell><aspirate><autophagy><autosome><behavior study><behavioral study><biological signal transduction><cardiac muscle><cellular pathology><clinical care><clinical relevance><clinically relevant><disease of the lung><disorder of the lung><enzyme replacement therapy><enzyme replacement treatment><epigenetically><experience><experiment><experimental research><experimental study><experiments><fibrosis in the lung><gallium arsenide><gamma-Amylase><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><heart muscle><in vivo><injuries><injury and repair><innovate><innovation><innovative><intervention therapy><lung disorder><lung fibrosis><lung function><lung injury><lung preservation><lung repair><lung tissue repair><lysosomal acid alpha glucosidase><lysosomal acid α glucosidase><mTOR Inhibitor><mortality><motoneuron><mouse model><murine model><muscular><necropsy><novel><postmortem><pulmonary damage><pulmonary function><pulmonary injury><pulmonary repair><pulmonary tissue damage><pulmonary tissue injury><regenerate><repair><repaired><respiratory><respiratory function><respiratory progenitor><respiratory smooth muscle><respiratory stem cell><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><stem cells><stem cells in the airway><surfactant><viral infection><virus infection><virus-induced disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rachel M Bailey

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$712,158

FY 2026

Project Title

Gene Therapy Delivery for Age-related Neurodegenerative Diseases

Grant Number:

5R01AG078417-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Age-related neurodegenerative disorders, such as Alzheimer’s disease and related tauopathies, are a major therapeutic challenge. There are critical brain regions implicated in disease pathogenesis and overtime the whole or a large portion of the brain is affected. Therefore,...

Research Terms

<21+ years old><AAV delivered><AAV delivery><AAV vector><AAV-based delivery><AAV-based vector><AAV-based viral delivery><AAV-mediated delivery><AAV9 delivery><AAV9 mediated delivery><AAV9 vector delivery><AAV9 viral delivery><AAV9 virus to deliver><AD dementia><Adeno-Associated Viruses><Adeno-associated-virus-based delivery><Adult><Adult Human><Affect><Age><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimers Dementia><Animal Model><Animal Models and Related Studies><Animals><BBB crossing><BBB disruption><Biochemical><Blood><Blood - brain barrier anatomy><Blood Reticuloendothelial System><Blood-Brain Barrier><Brain><Brain Nervous System><Brain region><Capsid><Causality><Cell Body><Cells><Cephalic><Cerebrospinal Fluid><Clinical Treatment><Clinical Trials><Coupled><Cranial><DNA Therapy><Data><Degenerative Neurologic Disorders><Dependoparvovirus><Dependovirus><Disease><Disorder><Distal><Dorsal Root Ganglia><Dose><Encephalon><Engineering><Etiology><Exposure to><Focused Ultrasound><Gene Delivery><Gene Transfer><Gene Transfer Clinical><Genetic Intervention><Genetic Materials><Goals><Grant><Hemato-Encephalic Barrier><Hepatotoxic effect><Hepatotoxicity><Hind Brain><Histopathology><Human><Immune response><Immunize><Injections><Insertional Mutagenesis><Interphase Cell><Intervention><Intrathecal Injections><Intravenous><Kinetics><Liver Toxicity><MT-bound tau><Mediating><Medulla Spinalis><Methods><Mice><Mice Mammals><MicroRNAs><Modern Man><Murine><Mus><Nerve Cells><Nerve Unit><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neurologic Disorders><Neurological Disorders><Neurons><Non-dividing Cell><Nondividing Cell><Outcome><Pathogenesis><Primary Senile Degenerative Dementia><Procedures><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Research><Resting Cell><Rhombencephalon><Risk><Route><Safety><Serotyping><Site><Skull><Specificity><Spinal Cord><Spinal Ganglia><Tauopathies><Testing><Therapeutic><Toxic effect><Toxic effect on liver cells><Toxicities><Translating><Trauma><Tropism><Viral><Viral Vector><Weight><Work><aberrant tau><aberrant tau protein><abnormal tau><abnormal tau protein><adeno associated virus group><adeno-associated viral vector><adeno-associated viral vector 9 delivery><adeno-associated viral vector delivery><adeno-associated virus 9 delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adeno-associated virus vector><adenovirus mediated delivery><adulthood><age associated neurodegeneration><age associated neurodegenerative disease><age associated neurodegenerative disorder><age dependent neurodegeneration><age dependent neurodegenerative condition><age dependent neurodegenerative disease><age dependent neurodegenerative disorder><age related neurodegeneration><age-driven neurodegenerative disorders><age-related neurodegenerative disease><age-related neurodegenerative disorder><ages><aging associated neurodegeneration><aging associated neurodegenerative disease><aging related neurodegeneration><aging related neurodegenerative disease><aging related neurodegenerative disorder><behavior test><behavioral test><blood-brain barrier crossing><blood-brain barrier disruption><bloodbrain barrier><bloodbrain barrier crossing><bloodbrain barrier disruption><brain parenchyma><causation><cerebral spinal fluid><clinical intervention><clinical therapy><cost><cranium><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><delivered with AAV><delivery vector><delivery vehicle><delivery with AAV><disease causation><dorsal root ganglion><gene repair therapy><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genes therapeutic><genes therapeutics><genetic therapy><genomic therapy><hepatic toxicity><hepatoxicity><hindbrain><host response><immune system response><immunoresponse><improved><knock-down><knockdown><manufacture><miRNA><microtubule associated protein tau mutation><microtubule bound tau><microtubule-associated protein tau mutation><microtubule-bound tau><model of animal><mouse model><murine model><mutant tau><mutant tau protein><mutation in microtubule associated protein tau><mutation in microtubule-associated protein tau><neurodegenerative illness><neurological disease><neuronal><neuropathologic tau><neuropathological tau><neutralizing antibody><new approaches><novel><novel approaches><novel strategies><novel strategy><particle><pathogenic tau><pathogenic tau gene mutation><pathogenic tau protein><pathological change in tau><pathological tau><pathological tau protein><primary degenerative dementia><promoter><promotor><rAAV><recombinant AAV><senile dementia of the Alzheimer type><spinal fluid><tau><tau Proteins><tau abnormality><tau associated neurodegeneration><tau associated neurodegenerative process><tau driven neurodegeneration><tau factor><tau induced degeneration><tau induced neurodegeneration><tau intronic mutation><tau mediated neurodegeneration><tau mutation><tau neurodegenerative disease><tau neuropathology><tau pathological change><tau pathology><tau pathophysiology><tau proteinopathy><tau related neurodegeneration><tau-induced pathology><tauopathic neurodegenerative disorder><tauopathy><therapeutic gene><therapeutic outcome><therapeutically effective><therapy outcome><transduction efficiency><transgene expression><trial regimen><trial treatment><vector><weights><τ Proteins><τ mutation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Patric Liang

BETH ISRAEL DEACONESS MEDICAL CENTER, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$710,174

FY 2026

Project Title

Targeted Gene Therapies for the Prevention of Prosthetic Bypass Graft Failure

Grant Number:

5R01HL177355-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/26/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT This scientific proposal addresses the dismal outcomes of prosthetic bypass grafts that are currently used to treat patients with critical blockages of arterial blood flow in the lower extremities. While the use of greater saphenous vein conduits for lower extremity bypass surgery is the go...

Research Terms

<21+ years old><ACAMP-81><Acute><Address><Adherence><Adult><Adult Human><Affect><Amputation><Anastomosis><Anastomosis - action><Animal Model><Animal Models and Related Studies><Apoptotic><Applications Grants><Arterial Injury><Arterial Lines><Arteries><Atherogenicity><Automobile Driving><Biocompatible Materials><Biological><Biological Agent><Biological Products><Biomaterials><Blood Vessels><Blood flow><Body Tissues><Bypass><Canine Species><Canis familiaris><Cardiovascular><Cardiovascular Body System><Cardiovascular Diseases><Cardiovascular Organ System><Cardiovascular system><Cell Body><Cell Nucleus><Cells><Chemistry><Chronic><Circulation><Clinical><Common Rat Strains><DNA Therapy><Development><Differential Gene Expression><Diffusion><Distal><Dogs><Dogs Mammals><Domestic Rabbit><Dysfunction><Endothelial Cells><Ensure><Ethene, tetrafluoro-, homopolymer><Extremities><Failure><Fibroblasts><Functional disorder><Gangrene><Gel><Gelatin><Gene Delivery><Gene Expression><Gene Inactivation><Gene Silencing><Gene Targeting><Gene Transfer Clinical><Genes><Genetic Intervention><Genomics><Grant Proposals><Health Care Costs><Health Costs><Heart Vascular><Hydrogels><Hyperplasia><Hyperplastic><Image><Immune><Immunes><Implant><Inflammatory><Intervention><Intra-Arterial Lines><Investigation><Ipsilateral><Ischemia><Leg><Leiomyocyte><Length><Limb structure><Limbs><Link><Lower Extremity><Lower Limb><MARCKS gene><MARCKS protein><Maps><Mechanics><Mediating><Membrum inferius><Methods><Modeling><Molecular><Morbidity><Myristoylated alanine-rich protein kinase C substrate><Non-Trunk><Nucleus><Operating Rooms><Operative Procedures><Operative Surgical Procedures><Oryctolagus cuniculus><Outcome><PET><PET Scan><PET imaging><PETSCAN><PETT><PRKCSL><PTFE><Pain><Painful><Pathogenicity><Pathologic><Pathologic Processes><Pathological Processes><Patients><Pattern><Penetration><Peripheral arterial disease><Phenotype><Physiopathology><Polyethylene Terephthalates><Polytef><Polytetrafluoroethylene><Positron Emission Tomography Medical Imaging><Positron Emission Tomography Scan><Positron-Emission Tomography><Predisposition><Prevention therapy><Prosthesis><Prosthetic device><Prosthetics><RNA based therapeutics><RNA based therapy><RNA therapy><Rabbits><Rabbits Mammals><Rad.-PET><Rat><Rats Mammals><Rattus><Recurrent disease><Relapsed Disease><Rest><Risk><Risk Reduction><Route><Saphenous Vein><Severities><Short interfering RNA><Side><Signaling Factor Proto-Oncogene><Signaling Pathway Gene><Signaling Protein><Single-Nucleus Sequencing><Smooth Muscle Cells><Smooth Muscle Myocytes><Smooth Muscle Tissue Cell><Surgical><Surgical Anastomosis><Surgical Interventions><Surgical Procedure><Susceptibility><Symptoms><TSP-2><TSP2><Technology><Therapeutic><Thrombosis><Thrombospondin II><Time><Tissue-Specific Differential Gene Expression><Tissue-Specific Gene Expression><Tissues><Tube><United States><Vascular Endothelium><Vein graft><Work><adulthood><atheroprotection><atheroprotective><biocompatibility><biologic><biological material><biologics><biomaterial compatibility><biopharmaceutical><biotherapeutic agent><burden of disease><burden of illness><canine><canine animal model><canine model><cardiovascular disorder><chemical property><chronic ulcer><circulatory system><clinical applicability><clinical application><clinical translation><clinically translatable><combinatorial><dacron><deliver short interfering RNA><deliver siRNA><deliver small interfering RNA><delivery system for siRNA><delivery system for small interfering RNA><delivery vectors for siRNA><design><designing><determine efficacy><developmental><diffused><diffuses><diffusing><diffusions><disease burden><dog model><domestic dog><driving><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><foot><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic therapy><genomic profiles><genomic therapy><global gene expression><global transcription profile><graft failure><high risk><imaging><implantation><improved><in vivo><injury to the vasculature><knock-down><knockdown><limb loss><lost limb><mechanic><mechanical><model of animal><myristoylated alanine-rich C kinase substrate><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><non-healing ulcer><nonhealing ulcer><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><overexpress><overexpression><pathogenicity gene><pathophysiology><peripheral artery disease><physical property><positron emission tomographic (PET) imaging><positron emission tomographic imaging><positron emitting tomography><pre-clinical><preclinical><prevent><preventing><programs><protein kinase C substrate, 80-KD, light chain><protein kinase substrate 80KD protein, light chain><reduce risk><reduce risks><reduce that risk><reduce the risk><reduce these risks><reduces risk><reduces the risk><reducing risk><reducing the risk><response><revascularization><risk-reducing><sNuc-Seq><short interfering RNA delivery><siRNA><siRNA delivery><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA sequencing><snRNA-seq><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><success><surgery><therapeutic RNA><thrombospondin 2><thrombotic disease><thrombotic disorder><time interval><transcriptional silencing><transcriptome><vascular><vascular injury><virulence gene><virulent gene>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

William Russell Renthal

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$704,068

FY 2026

Project Title

Next Generation Gene Therapy for Refractory Pain

Grant Number:

5R01NS119476-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Chronic pain affects over 25 million adults in the United States and is a major cause of disability. Currently available pain treatments such as opioids are often ineffective and associated with unacceptable side effects including respiratory depression and addiction. A major goal fo...

Research Terms

<21+ years old><Absence of pain sensation><Absence of sensibility to pain><Adult><Adult Human><Affect><Afferent Neurons><Animal Model><Animal Models and Related Studies><Assay><Atlases><Bar Codes><Bioassay><Bioinformatics><Biological Assay><CNS Nervous System><CRE Recombinase><Cell Body><Cell Nucleus><Cells><Central Nervous System><Characteristics><Chromatin><Chromatin Structure><Cognition><Communities><DNA Therapy><Dangerousness><Data><Distal><Dorsal Root Ganglia><Drugs><Elements><Engineering><Enhancers><Enterobacteria phage P1 Cre recombinase><Esthesia><Expression Signature><Feels no pain><Food and Drug Administration><Gene Action Regulation><Gene Expression><Gene Expression Profile><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Gene Transfer><Gene Transfer Clinical><Generations><Genes><Genetic><Genetic Intervention><Genetic Transcription><Genomics><Goals><Heterogeneity><Histone Acetylation><Human><In Situ Hybridization><Intractable Pain><Ion Channel><Ionic Channels><Libraries><Maps><Mediating><Medication><Medicine><Membrane Channels><Mice><Mice Mammals><Modern Man><Molecular><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neuraxis><Neurocyte><Neurons><Neuropathy><No sensitivity to pain><Nociceptors><Nucleus><Opiates><Opioid><Out-patients><Outpatients><Pain><Pain Control><Pain Disorder><Pain Research><Pain Therapy><Pain management><Painful><Patients><Peripheral><Pharmaceutical Preparations><Position><Positioning Attribute><Procedures><Property><RNA Expression><Refractory><Refractory Pain><Regulatory Element><Research><Resolution><Respiratory Depression><Safety><Sensation><Sensory Ganglia><Sensory Neurons><Single-Nucleus Sequencing><Specificity><Spinal Ganglia><Therapeutic><Transcription><Translating><Transmission><Transposase><USFDA><United States><United States Food and Drug Administration><Ventilatory Depression><Viral><Viral Vector><Virus><Wild Type Mouse><addiction><addictive disorder><adulthood><analgesia><bacteriophage P1 recombinase Cre><barcode><cell type><chronic pain><clinical pain><depressed breathing><depression of breathing><design><designing><disability><dorsal root ganglion><drug/agent><epigenomics><experience><gene conservation><gene expression pattern><gene expression signature><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome scale><genome-wide><genomewide><genomic therapy><improved><in situ Hybridization Genetics><in situ Hybridization Staining Method><in vivo><infancy><infantile><insight><intractable pain syndrome><model of animal><neuronal><neuropathic><neuropathic pain><next generation><nociceptive neurons><optogenetics><pain intervention><pain model><pain signal><pain treatment><pain-sensing neurons><pain-sensing sensory neurons><pain-sensing somatosensory neurons><painful neuropathy><promoter><promotor><resolutions><sNuc-Seq><screening><screenings><selective expression><selectively expressed><side effect><single cell genomics><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA sequencing><snRNA-seq><stem><tool><transcriptional profile><transcriptional signature><translational applications><transmission process><wildtype mouse>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

YUQING Eugene CHEN

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$693,375

FY 2026

Project Title

Targeted editing of ASGR1 for cardiovascular diseases

Grant Number:

5R01HL169976-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2024

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT The contribution of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) to the development of cardiovascular disease (CVD) is critical in atherogenesis. Recent therapeutic advances considerably reduced the incidence of CVD. Despite the progress of clinica...

Research Terms

<(hydroxymethylglutaryl-CoA reductase (NADPH)) kinase><5'-AMP-activated protein kinase><AAV vector><AAV-based vector><AMP-activated kinase><AMP-activated protein kinase><AMPK enzyme><ASCVD><ASGP-R><Address><Adopted><Animal Model><Animal Models and Related Studies><Animals><Asialoglycoprotein Receptor><Asialoglycoproteins><Asialoorosomucoid Receptor><Asialoorosomucoid-Binding Protein><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Blood Serum><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CVD prevention><Cardiovascular Agents><Cardiovascular Diseases><Cardiovascular Drugs><Cardiovascular Models><Cas nuclease technology><Cause of Death><Cell Body><Cells><Cholesterol><Cholesterol Synthesis Inhibition><Clinical Treatment><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><DNA><DNA Double Strand Break><DNA Therapy><Dangerousness><Deoxyribonucleic Acid><Desialylated Glycoproteins><Development><Diet><Domestic Rabbit><Dose><Drugs><Duchene><Duchenne><Duchenne muscular dystrophy><Duchenne-Griesinger syndrome><Dyslipidemias><Elements><Ellis-van Creveld (EvC) syndrome><Engineering><Event><Excretory function><FDA approved><Family suidae><Frequencies><Gametes><Gene Transfer Clinical><Generations><Genes><Genetic Intervention><Genetic study><Genome><Germ Cells><Germ-Line Cells><Glycoproteins><Guide RNA><Guidelines><HDL><HDL Cholesterol><HDL Cholesterol Lipoproteins><HDL Lipoproteins><HMG CoA reductase (NADPH) kinase><HMG CoA reductase kinase><HMG coenzyme A reductase (NADPH) kinase><Heavy Lipoproteins><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocyte><High Density Lipoprotein Cholesterol><High Density Lipoproteins><Human><Human Genetics><Hyperlipemia><Hyperlipidemia><Immune response><In Vitro><Incidence><Innovative Therapy><Knowledge><LDL><LDL Cholesterol><LDL Cholesterol Lipoproteins><LDL Lipoproteins><Lesion><Light><Link><Lipids><Liver Cells><Low Density Lipoprotein Cholesterol><Low-Density Lipoproteins><Mediating><Medication><Methods><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><New Zealand><Nonsense Mutation><Oryctolagus cuniculus><Patients><Pharmaceutical Preparations><Photoradiation><Pigs><Point Mutation><Position><Positioning Attribute><Pre-Clinical Model><Prebeta-Lipoproteins><Preclinical Models><Proteins><Pseudohypertrophic Muscular Dystrophy><Rabbits><Rabbits Mammals><Recommendation><Recurrence><Recurrent><Reporting><Reproductive Cells><Research><Residual><Residual state><Ribonucleoproteins><Risk><Route><Running><Safety><Serum><Sex Cell><Suidae><Swine><Technology><Testing><Therapeutic><Therapeutic Gene Editing><Transcript><Treatment Efficacy><Triacylglycerol><Triglycerides><Tumorigenicity><VLDL><VLDL Lipoproteins><Very low density lipoprotein><Viral><Virus-like particle><X-linked dilated cardiomyopathy><X-linked muscular dystrophy><X-linked recessive muscular dystrophy><adeno-associated viral vector><adeno-associated virus vector><alpha-Lipoprotein Cholesterol><alpha-Lipoproteins><atherogenesis><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><atorvastatin><base editing><base editor><basolateral membrane><benign X-linked recessive muscular dystrophy><beta-Lipoprotein Cholesterol><beta-Lipoproteins><cardiac disease prevention><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disease therapy><cardiovascular disorder><cardiovascular disorder prevention><cardiovascular disorder risk><cardiovascular disorder therapy><cardiovascular risk><cardiovascular risk factor><childhood pseudohypertrophic muscular dystrophy><classic X-linked recessive muscular dystrophy><clinical applicability><clinical application><clinical intervention><clinical relevance><clinical therapy><clinically relevant><curative intervention><curative therapeutic><curative therapy><curative treatments><determine efficacy><developmental><diets><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><excretion><experience><experiment><experimental research><experimental study><experiments><fat metabolism><gRNA><gene editing platform><gene editing system><gene editing technology><gene editing tools><gene repair therapy><gene therapy><gene-based therapy><gene-editing therapy><gene-editing toolkit><genetic therapy><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genomic editing><genomic therapy><genotoxicity><host response><human disease><hydroxymethylglutaryl-CoA-reductase kinase><immune system response><immunoresponse><in vivo><inhibitor><initial cell><insight><intervention efficacy><knockout gene><lipid metabolism><lipitor><loss of function mutation><mild X-linked recessive muscular dystrophy><model of animal><mouse model><murine model><neuronal><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><non-sense mutation><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><particle><plasmid DNA><porcine><progressive muscular dystrophy of childhood><pseudohypertrophic adult muscular dystrophy><pseudohypertrophic muscular paralysis><safety engineering><sexual cell><spatial and temporal><spatial temporal><spatiotemporal><suid><therapeutic agent development><therapeutic development><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapeutic target><therapy efficacy><tool><translational study><trial regimen><trial treatment><uptake><virus-like nanoparticles><viruslike particle>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Renzhi Han

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$693,375

FY 2026

Project Title

Targeted editing of ASGR1 for cardiovascular diseases

Grant Number:

5R01HL169976-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2024

End Date:

2/28/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT The contribution of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) to the development of cardiovascular disease (CVD) is critical in atherogenesis. Recent therapeutic advances considerably reduced the incidence of CVD. Despite the progress of clinica...

Research Terms

<(hydroxymethylglutaryl-CoA reductase (NADPH)) kinase><5'-AMP-activated protein kinase><AAV vector><AAV-based vector><AMP-activated kinase><AMP-activated protein kinase><AMPK enzyme><ASCVD><ASGP-R><Address><Adopted><Animal Model><Animal Models and Related Studies><Animals><Asialoglycoprotein Receptor><Asialoglycoproteins><Asialoorosomucoid Receptor><Asialoorosomucoid-Binding Protein><Atherosclerosis><Atherosclerotic Cardiovascular Disease><Blood Serum><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CVD prevention><Cardiovascular Agents><Cardiovascular Diseases><Cardiovascular Drugs><Cardiovascular Models><Cas nuclease technology><Cause of Death><Cell Body><Cells><Cholesterol><Cholesterol Synthesis Inhibition><Clinical Treatment><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><DNA><DNA Double Strand Break><DNA Therapy><Dangerousness><Deoxyribonucleic Acid><Desialylated Glycoproteins><Development><Diet><Domestic Rabbit><Dose><Drugs><Duchene><Duchenne><Duchenne muscular dystrophy><Duchenne-Griesinger syndrome><Dyslipidemias><Elements><Ellis-van Creveld (EvC) syndrome><Engineering><Event><Excretory function><FDA approved><Family suidae><Frequencies><Gametes><Gene Transfer Clinical><Generations><Genes><Genetic Intervention><Genetic study><Genome><Germ Cells><Germ-Line Cells><Glycoproteins><Guide RNA><Guidelines><HDL><HDL Cholesterol><HDL Cholesterol Lipoproteins><HDL Lipoproteins><HMG CoA reductase (NADPH) kinase><HMG CoA reductase kinase><HMG coenzyme A reductase (NADPH) kinase><Heavy Lipoproteins><Hepatic Cells><Hepatic Parenchymal Cell><Hepatocyte><High Density Lipoprotein Cholesterol><High Density Lipoproteins><Human><Human Genetics><Hyperlipemia><Hyperlipidemia><Immune response><In Vitro><Incidence><Innovative Therapy><Knowledge><LDL><LDL Cholesterol><LDL Cholesterol Lipoproteins><LDL Lipoproteins><Lesion><Light><Link><Lipids><Liver Cells><Low Density Lipoprotein Cholesterol><Low-Density Lipoproteins><Mediating><Medication><Methods><Mice><Mice Mammals><Modeling><Modern Man><Murine><Mus><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><New Zealand><Nonsense Mutation><Oryctolagus cuniculus><Patients><Pharmaceutical Preparations><Photoradiation><Pigs><Point Mutation><Position><Positioning Attribute><Pre-Clinical Model><Prebeta-Lipoproteins><Preclinical Models><Proteins><Pseudohypertrophic Muscular Dystrophy><Rabbits><Rabbits Mammals><Recommendation><Recurrence><Recurrent><Reporting><Reproductive Cells><Research><Residual><Residual state><Ribonucleoproteins><Risk><Route><Running><Safety><Serum><Sex Cell><Suidae><Swine><Technology><Testing><Therapeutic><Therapeutic Gene Editing><Transcript><Treatment Efficacy><Triacylglycerol><Triglycerides><Tumorigenicity><VLDL><VLDL Lipoproteins><Very low density lipoprotein><Viral><Virus-like particle><X-linked dilated cardiomyopathy><X-linked muscular dystrophy><X-linked recessive muscular dystrophy><adeno-associated viral vector><adeno-associated virus vector><alpha-Lipoprotein Cholesterol><alpha-Lipoproteins><atherogenesis><atheromatosis><atherosclerotic disease><atherosclerotic vascular disease><atorvastatin><base editing><base editor><basolateral membrane><benign X-linked recessive muscular dystrophy><beta-Lipoprotein Cholesterol><beta-Lipoproteins><cardiac disease prevention><cardiovascular disease prevention><cardiovascular disease risk><cardiovascular disease therapy><cardiovascular disorder><cardiovascular disorder prevention><cardiovascular disorder risk><cardiovascular disorder therapy><cardiovascular risk><cardiovascular risk factor><childhood pseudohypertrophic muscular dystrophy><classic X-linked recessive muscular dystrophy><clinical applicability><clinical application><clinical intervention><clinical relevance><clinical therapy><clinically relevant><curative intervention><curative therapeutic><curative therapy><curative treatments><determine efficacy><developmental><diets><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><excretion><experience><experiment><experimental research><experimental study><experiments><fat metabolism><gRNA><gene editing platform><gene editing system><gene editing technology><gene editing tools><gene repair therapy><gene therapy><gene-based therapy><gene-editing therapy><gene-editing toolkit><genetic therapy><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genomic editing><genomic therapy><genotoxicity><host response><human disease><hydroxymethylglutaryl-CoA-reductase kinase><immune system response><immunoresponse><in vivo><inhibitor><initial cell><insight><intervention efficacy><knockout gene><lipid metabolism><lipitor><loss of function mutation><mild X-linked recessive muscular dystrophy><model of animal><mouse model><murine model><neuronal><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><non-sense mutation><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><particle><plasmid DNA><porcine><progressive muscular dystrophy of childhood><pseudohypertrophic adult muscular dystrophy><pseudohypertrophic muscular paralysis><safety engineering><sexual cell><spatial and temporal><spatial temporal><spatiotemporal><suid><therapeutic agent development><therapeutic development><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapeutic target><therapy efficacy><tool><translational study><trial regimen><trial treatment><uptake><virus-like nanoparticles><viruslike particle>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Tanya Kalin

UNIVERSITY OF ARIZONA, TUCSON, AZ

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$683,697

FY 2026

Project Title

Theraputic targeting of pulmonary endothelial cells to inhibit pathological lung remodeling

Grant Number:

5R01HL177800-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary Existing anti-fibrotic treatments for pulmonary fibrosis have not significantly improved survival. There is a critical need for new therapeutic approaches. Pulmonary fibrosis results from dysregulated lung repair and involves multiple cell types. The role of endothelial cells (EC) in lung fi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kevin J Bender

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$672,761

FY 2026

Project Title

CRISPRa-based rescue of sensorimotor deficits in the Scn2a+/- mouse model of autism spectrum disorder

Grant Number:

5R01MH136475-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Title: CRISPRa-based rescue of sensorimotor deficits in the Scn2a+/- mouse model of autism spectrum disorder Project Summary: Heterozygous loss-of-function mutations in the sodium channel gene SCN2A are strongly associated with autism spectrum disorder. SCN2A encodes the neuronal sodium channel NaV1...

Research Terms

<12-20 years old><21+ years old><ASD><Action Potentials><Acute><Adolescence><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Alleles><Allelic Loss><Allelomorphs><Animals><Area><Autism><Autistic Disorder><Axon><Behavior><Behavioral><Biological Markers><Brain><Brain Nervous System><Brain region><CRISPR activation><CRISPR activator><CRISPR based activation><CRISPR gene activation><CRISPR transcription activation><CRISPR transcriptional activation><CRISPR-Cas-9-mediated gene activation><CRISPR-based gene activation><CRISPR-dCAS9 Activator><CRISPR-mediated transcriptional activation><CRISPR/CAS9 activation><CRISPR/CAS9 gene activation><CRISPR/dCas9 activation><CRISPR/dCas9-based transcriptional activation><CRISPRa><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cerebellum><Code><Coding System><Cytoplasmic Granules><DNA Therapy><Data><Dendrites><Development><Disease><Disorder><Dysfunction><EEG><Early Infantile Autism><Electrocorticogram><Electroencephalogram><Electroencephalography><Encephalon><Enhancers><Exhibits><Frequencies><Functional disorder><Gene Expression><Gene Transfer Clinical><Genes><Genetic><Genetic Intervention><Goals><High-Throughput Nucleotide Sequencing><High-Throughput Sequencing><Human><Impairment><Infantile Autism><Intervention><Kanner's Syndrome><Laboratories><Learning><Link><Loss of Heterozygosity><Maps><Membrane><Methods><Mice><Mice Mammals><Modeling><Modern Man><Morbid Obesity><Motor><Murine><Mus><Nav1.2><Neocortex><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neurons><Phenotype><Physiologic><Physiological><Physiology><Physiopathology><Population><Position><Positioning Attribute><Prefrontal Cortex><Preparation><Proteins><Purkinje Cells><Purkinje's Corpuscles><Pyramidal Cells><Reagent><Reflex><Reflex action><Risk-associated variant><SCN2A protein><Sensory><Severe obesity><Sodium Channel><Sodium Ion Channels><Somatosensory Cortex><Space Perception><Spatial Discrimination><Specificity><Subcellular Process><Synapses><Synaptic><Synaptic plasticity><System><Testing><Therapeutic><Therapeutic Intervention><Touch><Touch sensation><Transcription Activator><Transcription Coactivator><Transcription Factor Coactivator><Transcriptional Activator/Coactivator><Transmission><Upregulation><Vibrissae><Visual><Whiskers><Work><activating CRISPR technology><adolescence (12-20)><adulthood><assess effectiveness><autism model><autism spectral disorder><autism spectrum disorder><autistic spectrum disorder><behavior phenotype><behavioral impairment><behavioral phenotyping><bio-markers><biologic marker><biomarker><cerebellar Purkinje cell><critical developmental period><critical period><determine effectiveness><determine efficacy><developmental><effective intervention><effectiveness assessment><effectiveness evaluation><effectiveness testing><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><electrocorticography><evaluate effectiveness><evaluate efficacy><examine effectiveness><examine efficacy><experiment><experimental research><experimental study><experiments><extreme obesity><functional genomics><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><granule><granule cell><homotypical cortex><iPS><iPSC><iPSCs><impaired behavior><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><intervention therapy><isocortex><juvenile><juvenile human><loss of function><loss of function mutation><membrane structure><model of autism spectrum disorder><mouse model><murine model><na(v)1.2><neocortical><neopallium><neural><neurodevelopmental disease><neuronal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oculovestibular reflex><pathophysiology><perceptual spatial orientation><postsynaptic><preparations><promoter><promotor><repetitive behavior><response><risk allele><risk gene><risk genotype><risk loci><risk locus><risk variant><sensory cortex><social communication impairment><somatosensory><somesthetic sensory cortex><spatial orientation><spatial perception><synapse><synapse function><synaptic function><tactile sensation><transmission process><vestibo-ocular reflexes><vestibulo-occular system><vestibulo-ocular reflex><vestibulo-oculomotor reflex><vestibuloocular reflexes><voltage>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel Feldman

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$672,761

FY 2026

Project Title

CRISPRa-based rescue of sensorimotor deficits in the Scn2a+/- mouse model of autism spectrum disorder

Grant Number:

5R01MH136475-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Title: CRISPRa-based rescue of sensorimotor deficits in the Scn2a+/- mouse model of autism spectrum disorder Project Summary: Heterozygous loss-of-function mutations in the sodium channel gene SCN2A are strongly associated with autism spectrum disorder. SCN2A encodes the neuronal sodium channel NaV1...

Research Terms

<12-20 years old><21+ years old><ASD><Action Potentials><Acute><Adolescence><Adolescent><Adolescent Youth><Adult><Adult Human><Affect><Alleles><Allelic Loss><Allelomorphs><Animals><Area><Autism><Autistic Disorder><Axon><Behavior><Behavioral><Biological Markers><Brain><Brain Nervous System><Brain region><CRISPR activation><CRISPR activator><CRISPR based activation><CRISPR gene activation><CRISPR transcription activation><CRISPR transcriptional activation><CRISPR-Cas-9-mediated gene activation><CRISPR-based gene activation><CRISPR-dCAS9 Activator><CRISPR-mediated transcriptional activation><CRISPR/CAS9 activation><CRISPR/CAS9 gene activation><CRISPR/dCas9 activation><CRISPR/dCas9-based transcriptional activation><CRISPRa><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Cerebellum><Code><Coding System><Cytoplasmic Granules><DNA Therapy><Data><Dendrites><Development><Disease><Disorder><Dysfunction><EEG><Early Infantile Autism><Electrocorticogram><Electroencephalogram><Electroencephalography><Encephalon><Enhancers><Exhibits><Frequencies><Functional disorder><Gene Expression><Gene Transfer Clinical><Genes><Genetic><Genetic Intervention><Goals><High-Throughput Nucleotide Sequencing><High-Throughput Sequencing><Human><Impairment><Infantile Autism><Intervention><Kanner's Syndrome><Laboratories><Learning><Link><Loss of Heterozygosity><Maps><Membrane><Methods><Mice><Mice Mammals><Modeling><Modern Man><Morbid Obesity><Motor><Murine><Mus><Nav1.2><Neocortex><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neurons><Phenotype><Physiologic><Physiological><Physiology><Physiopathology><Population><Position><Positioning Attribute><Prefrontal Cortex><Preparation><Proteins><Purkinje Cells><Purkinje's Corpuscles><Pyramidal Cells><Reagent><Reflex><Reflex action><Risk-associated variant><SCN2A protein><Sensory><Severe obesity><Sodium Channel><Sodium Ion Channels><Somatosensory Cortex><Space Perception><Spatial Discrimination><Specificity><Subcellular Process><Synapses><Synaptic><Synaptic plasticity><System><Testing><Therapeutic><Therapeutic Intervention><Touch><Touch sensation><Transcription Activator><Transcription Coactivator><Transcription Factor Coactivator><Transcriptional Activator/Coactivator><Transmission><Upregulation><Vibrissae><Visual><Whiskers><Work><activating CRISPR technology><adolescence (12-20)><adulthood><assess effectiveness><autism model><autism spectral disorder><autism spectrum disorder><autistic spectrum disorder><behavior phenotype><behavioral impairment><behavioral phenotyping><bio-markers><biologic marker><biomarker><cerebellar Purkinje cell><critical developmental period><critical period><determine effectiveness><determine efficacy><developmental><effective intervention><effectiveness assessment><effectiveness evaluation><effectiveness testing><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><electrocorticography><evaluate effectiveness><evaluate efficacy><examine effectiveness><examine efficacy><experiment><experimental research><experimental study><experiments><extreme obesity><functional genomics><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><granule><granule cell><homotypical cortex><iPS><iPSC><iPSCs><impaired behavior><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><intervention therapy><isocortex><juvenile><juvenile human><loss of function><loss of function mutation><membrane structure><model of autism spectrum disorder><mouse model><murine model><na(v)1.2><neocortical><neopallium><neural><neurodevelopmental disease><neuronal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oculovestibular reflex><pathophysiology><perceptual spatial orientation><postsynaptic><preparations><promoter><promotor><repetitive behavior><response><risk allele><risk gene><risk genotype><risk loci><risk locus><risk variant><sensory cortex><social communication impairment><somatosensory><somesthetic sensory cortex><spatial orientation><spatial perception><synapse><synapse function><synaptic function><tactile sensation><transmission process><vestibo-ocular reflexes><vestibulo-occular system><vestibulo-ocular reflex><vestibulo-oculomotor reflex><vestibuloocular reflexes><voltage>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Roland W. Herzog

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$668,207

FY 2026

Project Title

Capsid- and genome-modified AAV3 vectors for hemophilia gene therapy.

Grant Number:

5R01HL177230-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2024

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT: Remarkable progress has been made in gene therapy of hemophilia B as well as hemophilia A using recombinant adeno-associated virus (AAV) vectors. The United States Food and Drug Administration (USFDA) granted approval Hemgenix for gene therapy of hemophilia B in November 2...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Arun Srivastava

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$668,207

FY 2026

Project Title

Capsid- and genome-modified AAV3 vectors for hemophilia gene therapy.

Grant Number:

5R01HL177230-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2024

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT: Remarkable progress has been made in gene therapy of hemophilia B as well as hemophilia A using recombinant adeno-associated virus (AAV) vectors. The United States Food and Drug Administration (USFDA) granted approval Hemgenix for gene therapy of hemophilia B in November 2...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

James F Martin

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$664,697

FY 2026

Project Title

Hippo-YAP signaling in cardiac regenerative repair

Grant Number:

5R01HL173242-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/10/2025

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary This R01 application will investigate a novel signaling pathway, the Hippo-YAP pathway, in mammalian heart injury. The long-term goal is to develop new treatments for patients with heart failure by generating treatments that promote a productive response to injury. The objectives of ...

Research Terms

<21+ years old><AP-1><AP-1 Enhancer-Binding Protein><AP1><AP1 protein><Activator Protein-1><Acute><Address><Adult><Adult Human><Area><Basal Transcription Factor><Basal transcription factor genes><Biology><Body Tissues><CDK Inhibitor Protein><CDKI Protein><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Ca2+-Activated Protease><Calcium-Activated Neutral Protease><Calcium-Activated Neutral Proteinase><Calcium-Activated Protease><Calcium-Dependent Neutral Protease><Calcium-Dependent Neutral Proteinase><Calpain><Cardiac><Cardiac Muscle Cells><Cardiac Myocytes><Cardiac infarction><Cardiocyte><Cas nuclease technology><Cause of Death><Cell Aging><Cell Body><Cell Communication and Signaling><Cell Cycle><Cell Cycle Progression><Cell Division Cycle><Cell Senescence><Cell Signaling><Cell division><Cells><Cellular Aging><Cellular Senescence><Characteristics><Chromatin><Clinic><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cyclin Kinase Inhibitor><Cyclin-Dependent Kinase Inhibitor><DNA Binding><DNA Binding Interaction><DNA Therapy><DNA bound><Data><Defect><Desminase><Dysfunction><Enhancer-Binding Protein AP1><Enzyme Gene><Enzymes><Event><Failure><Family suidae><Fibrosis><Functional disorder><Gene Expression><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic Intervention><Genetic Transcription><Goals><Heart><Heart Injuries><Heart Muscle Cells><Heart failure><Heart myocyte><Induced Cardiomyocytes><Intracellular Communication and Signaling><Ischemia><Ischemic Heart><Ischemic Heart Disease><Ischemic myocardium><Kinases><Mammalia><Mammals><Maps><Mediating><Methods><Mice><Mice Mammals><Mitotic><Modeling><Murine><Mus><Myocardial Infarct><Myocardial Infarction><Myocardial Ischemia><Myocardium><Natural regeneration><Papain-Like Cysteine Protease><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Phenotype><Phosphorylation><Phosphotransferase Gene><Phosphotransferases><Physiopathology><Pigs><Productivity><Proliferating><Protein Phosphorylation><Proteins><Pump><RNA Expression><Regeneration><Replicative Senescence><Research><Sarcomeres><Secondary to><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid><Spectrin><Suidae><Swine><Technology><Testing><Tissues><Transcription><Transcription Factor AP-1><Transcription Factor Proto-Oncogene><Transcription factor genes><Transphosphorylases><United States><adulthood><biological signal transduction><cardiac failure><cardiac function><cardiac infarct><cardiac injury><cardiac ischemia><cardiac muscle><cardiac repair><cardiomyocyte><cofactor><coronary attack><coronary infarct><coronary infarction><coronary ischemia><fetal><fetal cell><fetus cell><function of the heart><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><heart attack><heart function><heart infarct><heart infarction><heart ischemia><heart muscle><heart repair><icardiomyocytes><improved><induced cardiac myocytes><inhibitor><injury response><innovate><innovation><innovative><insight><ischemic cardiomyopathy><knock-down><knockdown><mouse model><multiomics><multiple omics><murine model><myocardial ischemia/hypoxia><myocardium ischemia><novel><panomics><pathophysiology><pathway><patient oriented outcomes><pig model><piglet model><porcine><porcine model><pre-clinical><preclinical><programs><proliferation capability><proliferation capacity><proliferation potential><proliferative capability><proliferative capacity><proliferative potential><regenerate><regeneration potential><regenerative><regenerative potential><regenerative repair><repair><repaired><replicative aging><response to injury><scRNA sequencing><scRNA-seq><senescence><senescent><senescent cell><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell genomics><single cell transcriptomic profiling><single-cell RNA sequencing><suid><swine model><transcription factor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Toloo Taghian

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$659,245

FY 2026

Project Title

Development of a Gene Therapy for UBA5 Deficiency

Grant Number:

1R01NS146452-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project summary/Abstract Variants in the ubiquitin like modifier activating enzyme 5 (UBA5) result in an ultra-rare autosomal recessive disease with neurological presentations. UBA5 patients present with infantile spasms, failure to thrive, hypotonia, developmental delay, microcephaly, intellectual ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PAUL B MCCRAY

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$642,680

FY 2026

Project Title

Adenine Base Edited Correction of Cystic Fibrosis Airways

Grant Number:

5R01HL171035-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Knowledge of CFTR function and cell type expression has advanced greatly since its discovery in 1989. Indeed, drug therapies such as Ivacafter and Trikafta restore function for most CFTR mutation classes; however, ~10% of people with CF cannot benefit from these drugs because their CFTR proteins are...

Research Terms

<1H-Purin-6-amine><AAV vector><AAV-based vector><Address><Adenine><Adeno-Associated Viruses><Adenosine Aminohydrolase><Affect><Air><Animals><Area><Basal Cell><Bronchi><CF airway><CF patients><CFTR><CFTR Mouse><CFTR Protein><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Capsid><Cas nuclease technology><Categories><Cell Body><Cells><Chlorides><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Control Animal><Cystic Fibrosis Transmembrane Conductance Regulator><Cystic Fibrosis Transmembrane Conductance Regulator mouse><DNA Double Strand Break><DNA Nicking Enzyme><DNA Therapy><DNA cassette><DNA mutation><Data><Daughter><Dependoparvovirus><Dependovirus><Disease><Disorder><Dose><Drug Therapy><Drugs><Economic Burden><Electroporation><Endonuclease I><Engineering><Epithelial Cells><Ethmoid Sinus><Ethmoid sinus structure><Event><Exons><Family suidae><Gene Delivery><Gene Modified><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genome><Glycoproteins><Goals><Goblet Cells><Guanine><Guide RNA><Head><Human><IL-13><IL13><Immunoblotting><In Situ><In Vitro><Inbred CFTR Mice><Inflammation><Interleukin-13><Interphase Cell><Intervening Protein Sequence><Knock-in><Knowledge><Length><Liquid substance><Lung><Lung Diseases><Lung Respiratory System><Mediating><Medication><Mendelian disease><Mendelian disorder><Mendelian genetic disorder><Metaplasia><Metaplastic Change><Methods><Mice><Mice Mammals><Microscopy><Modeling><Modern Man><Mucins><Mucolytic Agents><Mucolytics><Mucous body substance><Mucus><Mucus Glycoprotein><Murine><Mus><Mutation><NGS Method><NGS system><Nasal><Nasal Passages Nose><Nickase><Non-dividing Cell><Nondividing Cell><Nonsense Codon><Nonsense Mutation><Nose><Organ><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Pigs><Premature Stop Codon><Production><Progenitor Cells><Protein Introns><Proteins><Public Health><Pulmonary Diseases><Pulmonary Disorder><QOL improvement><Reagent><Reporter><Reporter Genes><Reporting><Research><Respiratory Epithelium><Respiratory System, Nose, Nasal Passages><Resting Cell><Ribonucleoproteins><Rodent><Rodentia><Rodents Mammals><Site><Structure of respiratory epithelium><Study models><Suidae><Surface><Swine><Testing><Therapeutic><Trachea><Trachea Proper><Transgenic Organisms><Tropism><Variant><Variation><Viral><Viral Vector><Virus-like particle><Vitamin B4><Western Blotting><Western Immunoblotting><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><adenosine deaminase><airway epithelial stem cells><airway epithelium><airway progenitor><airway stem cells><base editing><base editor><bioelectric><bioelectricity><bioluminescence imaging><bioluminescent imaging><burden of disease><burden of illness><cell type><curative intervention><curative therapeutic><curative therapy><curative treatments><cystic fibrosis airway><cystic fibrosis patients><cystic fibrosis transmembrane regulator><delivery vector><delivery vehicle><disease burden><disease of the lung><disorder of the lung><drug intervention><drug treatment><drug/agent><electroporative delivery><enhancer cassette><experiment><experimental research><experimental study><experiments><expression cassette><fluid><functional restoration><gRNA><gene cassette><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene electrotransfer><gene modification><gene repair><gene repair therapy><gene therapy><gene-based therapy><gene-editing approach><gene-editing toolkit><genetic cassette><genetic therapy><genetically modified><genome mutation><genomic therapy><homologous recombination><improved><improvements in QOL><improvements in quality of life><in vivo><in vivo Model><individuals with CF><individuals with cystic fibrosis><integration cassette><intein><knockin><liquid><lung disorder><methacholine><monogenic disease><monogenic disorder><mouse model><mucous><murine model><next gen sequencing><next generation sequencing><nextgen sequencing><non-sense mutation><nuclease><particle><patients with CF><patients with cystic fibrosis><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pig model><piglet model><porcine><porcine model><promoter cassette><protein blotting><quality of life improvement><repair><repair strategy><repaired><reporter cassette><resistance cassette><respiratory progenitor><respiratory stem cell><respiratory tract epithelium><restore function><restore functionality><restore lost function><selectable cassette><selection cassette><single-gene disease><single-gene disorder><stem><stem cells><stem cells in the airway><stop cassette><success><suid><swine model><tool><transcription cassette><transcriptional cassette><transgene cassette><transgenic><uptake><vector><virus-like nanoparticles><viruslike particle><windpipe>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

PATRICK L SINN

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$642,680

FY 2026

Project Title

Adenine Base Edited Correction of Cystic Fibrosis Airways

Grant Number:

5R01HL171035-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Knowledge of CFTR function and cell type expression has advanced greatly since its discovery in 1989. Indeed, drug therapies such as Ivacafter and Trikafta restore function for most CFTR mutation classes; however, ~10% of people with CF cannot benefit from these drugs because their CFTR proteins are...

Research Terms

<1H-Purin-6-amine><AAV vector><AAV-based vector><Address><Adenine><Adeno-Associated Viruses><Adenosine Aminohydrolase><Affect><Air><Animals><Area><Basal Cell><Bronchi><CF airway><CF patients><CFTR><CFTR Mouse><CFTR Protein><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Capsid><Cas nuclease technology><Categories><Cell Body><Cells><Chlorides><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Control Animal><Cystic Fibrosis Transmembrane Conductance Regulator><Cystic Fibrosis Transmembrane Conductance Regulator mouse><DNA Double Strand Break><DNA Nicking Enzyme><DNA Therapy><DNA cassette><DNA mutation><Data><Daughter><Dependoparvovirus><Dependovirus><Disease><Disorder><Dose><Drug Therapy><Drugs><Economic Burden><Electroporation><Endonuclease I><Engineering><Epithelial Cells><Ethmoid Sinus><Ethmoid sinus structure><Event><Exons><Family suidae><Gene Delivery><Gene Modified><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genome><Glycoproteins><Goals><Goblet Cells><Guanine><Guide RNA><Head><Human><IL-13><IL13><Immunoblotting><In Situ><In Vitro><Inbred CFTR Mice><Inflammation><Interleukin-13><Interphase Cell><Intervening Protein Sequence><Knock-in><Knowledge><Length><Liquid substance><Lung><Lung Diseases><Lung Respiratory System><Mediating><Medication><Mendelian disease><Mendelian disorder><Mendelian genetic disorder><Metaplasia><Metaplastic Change><Methods><Mice><Mice Mammals><Microscopy><Modeling><Modern Man><Mucins><Mucolytic Agents><Mucolytics><Mucous body substance><Mucus><Mucus Glycoprotein><Murine><Mus><Mutation><NGS Method><NGS system><Nasal><Nasal Passages Nose><Nickase><Non-dividing Cell><Nondividing Cell><Nonsense Codon><Nonsense Mutation><Nose><Organ><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Pigs><Premature Stop Codon><Production><Progenitor Cells><Protein Introns><Proteins><Public Health><Pulmonary Diseases><Pulmonary Disorder><QOL improvement><Reagent><Reporter><Reporter Genes><Reporting><Research><Respiratory Epithelium><Respiratory System, Nose, Nasal Passages><Resting Cell><Ribonucleoproteins><Rodent><Rodentia><Rodents Mammals><Site><Structure of respiratory epithelium><Study models><Suidae><Surface><Swine><Testing><Therapeutic><Trachea><Trachea Proper><Transgenic Organisms><Tropism><Variant><Variation><Viral><Viral Vector><Virus-like particle><Vitamin B4><Western Blotting><Western Immunoblotting><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><adenosine deaminase><airway epithelial stem cells><airway epithelium><airway progenitor><airway stem cells><base editing><base editor><bioelectric><bioelectricity><bioluminescence imaging><bioluminescent imaging><burden of disease><burden of illness><cell type><curative intervention><curative therapeutic><curative therapy><curative treatments><cystic fibrosis airway><cystic fibrosis patients><cystic fibrosis transmembrane regulator><delivery vector><delivery vehicle><disease burden><disease of the lung><disorder of the lung><drug intervention><drug treatment><drug/agent><electroporative delivery><enhancer cassette><experiment><experimental research><experimental study><experiments><expression cassette><fluid><functional restoration><gRNA><gene cassette><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene electrotransfer><gene modification><gene repair><gene repair therapy><gene therapy><gene-based therapy><gene-editing approach><gene-editing toolkit><genetic cassette><genetic therapy><genetically modified><genome mutation><genomic therapy><homologous recombination><improved><improvements in QOL><improvements in quality of life><in vivo><in vivo Model><individuals with CF><individuals with cystic fibrosis><integration cassette><intein><knockin><liquid><lung disorder><methacholine><monogenic disease><monogenic disorder><mouse model><mucous><murine model><next gen sequencing><next generation sequencing><nextgen sequencing><non-sense mutation><nuclease><particle><patients with CF><patients with cystic fibrosis><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pig model><piglet model><porcine><porcine model><promoter cassette><protein blotting><quality of life improvement><repair><repair strategy><repaired><reporter cassette><resistance cassette><respiratory progenitor><respiratory stem cell><respiratory tract epithelium><restore function><restore functionality><restore lost function><selectable cassette><selection cassette><single-gene disease><single-gene disorder><stem><stem cells><stem cells in the airway><stop cassette><success><suid><swine model><tool><transcription cassette><transcriptional cassette><transgene cassette><transgenic><uptake><vector><virus-like nanoparticles><viruslike particle><windpipe>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeffery D Molkentin

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$584,016

FY 2026

Project Title

Thrombospondin 4 regulates adaptive ER stress responseRenewal - Resubmission - 1

Grant Number:

5R01HL105924-15

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2011

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Similar to skeletal muscle myofibers, cardiomyocytes in the heart appear to be particularly susceptible to membrane instability and rupture during disease, in part because of their contractile status that produces ongoing mechanical deformation. Mutations in genes that disrupt or weaken the...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Catherine A Makarewich

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$581,971

FY 2026

Project Title

Developing DWORF gene therapy to treat heart failure and muscular dystrophy

Grant Number:

5R01HL171221-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2023

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Calcium is an essential regulator of muscle function and its dysregulation contributes significantly to the common pathogenic signaling cascades that drive multiple striated muscle diseases including heart failure and muscular dystrophy. The sarcoplasmic reticulum (SR) is the major c...

Research Terms

<21+ years old><Abscission><Address><Adeno-Associated Viruses><Adult><Adult Human><Affect><Affinity><Alleles><Allelomorphs><Amino Acids><Animal Model><Animal Models and Related Studies><Animals><Arginine><Arrhythmia><Associated Viruses><Attenuated><Autoregulation><Binding><Blood Vessels><Calcium><Calcium Ion Signaling><Calcium Signaling><Capsid><Cardiac><Cardiac Arrhythmia><Cardiac Muscle Cells><Cardiac Myocytes><Cardiac infarction><Cardiocyte><Causality><Cell Communication and Signaling><Cell Signaling><Characteristics><Clinical><Clinical Trials><Complex><Congestive Cardiomyopathy><Cytoplasm><DNA Therapy><DNA mutation><DWORF><Data><Defect><Dependoparvovirus><Dependovirus><Dilated Cardiomyopathy><Disease><Disorder><Duchene><Duchenne><Duchenne muscular dystrophy><Duchenne-Griesinger syndrome><Dysfunction><Dystrophin><Dystrophin-Related Protein><Dystrophin-Related Protein 1><Echocardiogram><Echocardiography><Ellis-van Creveld (EvC) syndrome><Etiology><Excision><Exhibits><Extirpation><Failure><Female><Functional disorder><Future><Gene Deletion><Gene Delivery><Gene Transfer Clinical><Gene therapy trial><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Heart><Heart Arrhythmias><Heart Muscle Cells><Heart failure><Heart myocyte><Heterozygote><Homeostasis><Human><Impairment><Individual><Injections><Injury><Intracellular Communication and Signaling><Investigators><KI mice><Knock-in Mouse><L-Arginine><Lead><Mediating><Membrane><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Muscle><Muscle Cell Contraction><Muscle Cells><Muscle Contraction><Muscle Development><Muscle Disease><Muscle Disorders><Muscle Tissue><Muscle function><Muscular Contraction><Muscular Development><Muscular Diseases><Muscular Dystrophies><Mutation><Myocardial Infarct><Myocardial Infarction><Myocardium><Myocytes><Myodystrophica><Myodystrophy><Myopathic Conditions><Myopathic Diseases and Syndromes><Myopathic disease or syndrome><Myopathy><Nature><Necrosis><Necrotic><Pathogenesis><Pathogenicity><Patients><Pb element><Penetration><Persons><Phenotype><Physiological Homeostasis><Physiopathology><Play><Position><Positioning Attribute><Property><Proteins><Pseudohypertrophic Muscular Dystrophy><Relaxation><Removal><Research Personnel><Researchers><Role><Rupture><SERCA2a><SERCA3><Sarcoplasmic Reticulum><Satellite Viruses><Signal Transduction><Signal Transduction Systems><Signaling><Site><Skeletal Muscle><Striated Muscles><Surgical Removal><System><Technology><Testing><Therapeutic><Time><Transgenes><Transthoracic Echocardiography><UTRN Protein><Utrophin><Ventricular Arrhythmia><Virus><Visit><Voluntary Muscle><X-linked dilated cardiomyopathy><X-linked muscular dystrophy><X-linked recessive muscular dystrophy><adeno associated virus group><adulthood><aged><aminoacid><attenuate><attenuates><benign X-linked recessive muscular dystrophy><biological signal transduction><cardiac failure><cardiac function><cardiac infarct><cardiac muscle><cardiomyocyte><cardioprotectant><cardioprotection><cardioprotective><causation><childhood pseudohypertrophic muscular dystrophy><classic X-linked recessive muscular dystrophy><clinical relevance><clinically relevant><coronary attack><coronary infarct><coronary infarction><disease causation><dwarf open reading frame><family genetics><function of the heart><gene deletion mutation><gene repair therapy><gene therapeutics><gene therapy><gene transfer trial><gene-based therapeutic><gene-based therapeutics><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genes therapeutic><genes therapeutics><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><heart attack><heart function><heart infarct><heart infarction><heart muscle><heart sonography><heavy metal Pb><heavy metal lead><heterozygosity><human disease><humanized mice><humanized mouse><improved><in vivo><in vivo monitoring><injuries><knockin mice><membrane skeleton><membrane structure><mild X-linked recessive muscular dystrophy><mitochondrial><model of animal><mouse model><murine model><muscle dystrophy><muscular><muscular disorder><neonate><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><overexpress><overexpression><pathophysiology><phospholamban><postnatal><pressure><prevent><preventing><progressive muscular dystrophy of childhood><pseudohypertrophic adult muscular dystrophy><pseudohypertrophic muscular paralysis><resection><reuptake><sarcoplasmic reticulum calcium ATPase><social role><symptom treatment><symptomatic treatment><therapeutic evaluation><therapeutic gene><therapeutic target><therapeutic testing><tool><transgene><translational study><treat symptom><uptake><vascular><vector><♀>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeffery D Molkentin

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$581,971

FY 2026

Project Title

Developing DWORF gene therapy to treat heart failure and muscular dystrophy

Grant Number:

5R01HL171221-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/11/2023

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Calcium is an essential regulator of muscle function and its dysregulation contributes significantly to the common pathogenic signaling cascades that drive multiple striated muscle diseases including heart failure and muscular dystrophy. The sarcoplasmic reticulum (SR) is the major c...

Research Terms

<21+ years old><Abscission><Address><Adeno-Associated Viruses><Adult><Adult Human><Affect><Affinity><Alleles><Allelomorphs><Amino Acids><Animal Model><Animal Models and Related Studies><Animals><Arginine><Arrhythmia><Associated Viruses><Attenuated><Autoregulation><Binding><Blood Vessels><Calcium><Calcium Ion Signaling><Calcium Signaling><Capsid><Cardiac><Cardiac Arrhythmia><Cardiac Muscle Cells><Cardiac Myocytes><Cardiac infarction><Cardiocyte><Causality><Cell Communication and Signaling><Cell Signaling><Characteristics><Clinical><Clinical Trials><Complex><Congestive Cardiomyopathy><Cytoplasm><DNA Therapy><DNA mutation><DWORF><Data><Defect><Dependoparvovirus><Dependovirus><Dilated Cardiomyopathy><Disease><Disorder><Duchene><Duchenne><Duchenne muscular dystrophy><Duchenne-Griesinger syndrome><Dysfunction><Dystrophin><Dystrophin-Related Protein><Dystrophin-Related Protein 1><Echocardiogram><Echocardiography><Ellis-van Creveld (EvC) syndrome><Etiology><Excision><Exhibits><Extirpation><Failure><Female><Functional disorder><Future><Gene Deletion><Gene Delivery><Gene Transfer Clinical><Gene therapy trial><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Heart><Heart Arrhythmias><Heart Muscle Cells><Heart failure><Heart myocyte><Heterozygote><Homeostasis><Human><Impairment><Individual><Injections><Injury><Intracellular Communication and Signaling><Investigators><KI mice><Knock-in Mouse><L-Arginine><Lead><Mediating><Membrane><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Muscle><Muscle Cell Contraction><Muscle Cells><Muscle Contraction><Muscle Development><Muscle Disease><Muscle Disorders><Muscle Tissue><Muscle function><Muscular Contraction><Muscular Development><Muscular Diseases><Muscular Dystrophies><Mutation><Myocardial Infarct><Myocardial Infarction><Myocardium><Myocytes><Myodystrophica><Myodystrophy><Myopathic Conditions><Myopathic Diseases and Syndromes><Myopathic disease or syndrome><Myopathy><Nature><Necrosis><Necrotic><Pathogenesis><Pathogenicity><Patients><Pb element><Penetration><Persons><Phenotype><Physiological Homeostasis><Physiopathology><Play><Position><Positioning Attribute><Property><Proteins><Pseudohypertrophic Muscular Dystrophy><Relaxation><Removal><Research Personnel><Researchers><Role><Rupture><SERCA2a><SERCA3><Sarcoplasmic Reticulum><Satellite Viruses><Signal Transduction><Signal Transduction Systems><Signaling><Site><Skeletal Muscle><Striated Muscles><Surgical Removal><System><Technology><Testing><Therapeutic><Time><Transgenes><Transthoracic Echocardiography><UTRN Protein><Utrophin><Ventricular Arrhythmia><Virus><Visit><Voluntary Muscle><X-linked dilated cardiomyopathy><X-linked muscular dystrophy><X-linked recessive muscular dystrophy><adeno associated virus group><adulthood><aged><aminoacid><attenuate><attenuates><benign X-linked recessive muscular dystrophy><biological signal transduction><cardiac failure><cardiac function><cardiac infarct><cardiac muscle><cardiomyocyte><cardioprotectant><cardioprotection><cardioprotective><causation><childhood pseudohypertrophic muscular dystrophy><classic X-linked recessive muscular dystrophy><clinical relevance><clinically relevant><coronary attack><coronary infarct><coronary infarction><disease causation><dwarf open reading frame><family genetics><function of the heart><gene deletion mutation><gene repair therapy><gene therapeutics><gene therapy><gene transfer trial><gene-based therapeutic><gene-based therapeutics><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genes therapeutic><genes therapeutics><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><heart attack><heart function><heart infarct><heart infarction><heart muscle><heart sonography><heavy metal Pb><heavy metal lead><heterozygosity><human disease><humanized mice><humanized mouse><improved><in vivo><in vivo monitoring><injuries><knockin mice><membrane skeleton><membrane structure><mild X-linked recessive muscular dystrophy><mitochondrial><model of animal><mouse model><murine model><muscle dystrophy><muscular><muscular disorder><neonate><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><overexpress><overexpression><pathophysiology><phospholamban><postnatal><pressure><prevent><preventing><progressive muscular dystrophy of childhood><pseudohypertrophic adult muscular dystrophy><pseudohypertrophic muscular paralysis><resection><reuptake><sarcoplasmic reticulum calcium ATPase><social role><symptom treatment><symptomatic treatment><therapeutic evaluation><therapeutic gene><therapeutic target><therapeutic testing><tool><transgene><translational study><treat symptom><uptake><vascular><vector><♀>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

David Michael Langenau

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$539,997

FY 2026

Project Title

Mechanisms of aggressive Rhabdomyosarcoma.

Grant Number:

5R01CA276116-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma in the United States and displays features of skeletal muscle arrested at early stages of development. The aggressive MYOD1L122R mutated spindle/sclerosing RMS subtype accounts for 10% of pediatric diagnoses and have an...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alice Berger

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$530,439

FY 2026

Project Title

Expanding the cancer paralog genetic interaction map to enable precision oncology

Grant Number:

5R01CA262556-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2024

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Recent advances in targeted therapies have prolonged the survival of non-small cell lung cancer patients. However, lung cancer still remains the leading cause of cancer deaths in the U.S. and worldwide, and the 5-year survival rate for non-small cell lung cancer is a dismal ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Benjamin Will Darbro

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$526,144

FY 2026

Project Title

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

Grant Number:

5R01NS119322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis-1 (NF1). MPNSTs arise in NF1 patients from benign plexiform neurofibromas (PNFs) but it is unclear why only ~30% of PNFs transform into MPNSTs. Recent studies suggest...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rebecca D Dodd

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$526,144

FY 2026

Project Title

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

Grant Number:

5R01NS119322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis-1 (NF1). MPNSTs arise in NF1 patients from benign plexiform neurofibromas (PNFs) but it is unclear why only ~30% of PNFs transform into MPNSTs. Recent studies suggest...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

DAWN E QUELLE

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Above-average budget

Recent

Active award

$526,144

FY 2026

Project Title

Ink4a/ARF/Ink4b locus in Neurofibromatosis Type 1

Grant Number:

5R01NS119322-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Summary/Abstract Malignant peripheral nerve sheath tumors (MPNSTs) are the leading cause of death in patients with neurofibromatosis-1 (NF1). MPNSTs arise in NF1 patients from benign plexiform neurofibromas (PNFs) but it is unclear why only ~30% of PNFs transform into MPNSTs. Recent studies suggest...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ling Cai

DUKE UNIVERSITY, DURHAM, NC

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$497,972

FY 2026

Project Title

Targeting EZH2 in advanced prostate cancer

Grant Number:

1R01CA291848-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Standard treatment of prostate cancer (PCa) with anti-androgen agents fails due to development of therapy resistance and castration-resistant prostate cancer (CRPC), a terminal disease. Enhancer of Zeste Homolog 2 (EZH2), a histone methyltransferase and catalytic subunit of ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Songhai Chen

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$497,084

FY 2026

Project Title

Role of the CTLH E3 ubiquitin ligase in breast cancer progression

Grant Number:

5R01CA282699-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary / Abstract HER2-positive breast cancers are highly aggressive and associated with poor prognosis. HER2-targeted therapy is the preferred treatment for these cancers, but drug resistance is a major problem. Our previous studies demonstrated that dysregulation of G protein coupled rec...

Research Terms

<APF-1><ASVSRC1><ATP-Dependent Proteolysis Factor 1><Anti-ERB-2><Anti-HER2/c-erbB2 Monoclonal Antibody><Anti-c-ERB-2><Anti-c-erbB2 Monoclonal Antibody><Anti-erbB-2><Anti-erbB2 Monoclonal Antibody><Anti-p185-HER2><Automobile Driving><BAF47><BAF47 Gene><Breast Cancer><Breast Carcinoma><Breast Neoplasms><Breast Tumors><Cancer Treatment><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Complex><D-Glucose><Data><Development><Dextrose><Drug resistance><Drugs><E3 Ligase><E3 Ubiquitin Ligase><ERBB2><ERBB2 gene><Effectiveness><Enhancers><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><G Protein Go><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G Protein-Coupled Receptor Signaling><G(o) Protein><G-Protein-Coupled Receptors><G-Proteins><GPCR><GPCR Signaling><GTP-Binding Proteins><GTP-Regulatory Proteins><Gene Deletion><Gene Transcription><Generalized Growth><Genetic><Genetic Transcription><Glucose><Go Alpha Subunit><Go Subunit G-Protein><Growth><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Guanine Nucleotide-Binding Protein Go><HER -2><HER-2><HER2><HER2 Genes><HER2 Monoclonal Antibody><HER2/neu><HMG-20><Herceptin><High Mobility Protein 20><INI1><INI1 Gene><Inhibitory Go G-Protein><Intracellular Communication and Signaling><Knowledge><Malignant Breast Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mammary Cancer><Mammary Carcinoma><Mammary Neoplasms><Mediating><Medication><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><MoAb HER2><Modeling><NEU Oncogene><NEU protein><Neoplasm Metastasis><Nuclear><Nuclear Translocation><Oncogene ErbB2><Oncogenesis><Oncogenic><Ortholog><Orthologous Gene><PDX model><PI-3K/AKT><PI3K/AKT><Pathway interactions><Patient derived xenograft><Pharmaceutical Preparations><Prognosis><Proteins><RNA Expression><Recurrent Neoplasm><Recurrent tumor><Resistance><Role><SMARCB1><SMARCB1 gene><SNF5><SNF5 Gene><SNF5L1><SNF5L1 Gene><SRC Family Gene><SRC gene><SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene><Scaffolding Protein><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Factor Proto-Oncogene><Signaling Pathway Gene><Signaling Protein><Strains Cell Lines><Subgroup><TKR1><Testing><Tissue Growth><Transcription><Transgenic Mice><Trastuzumab><Tumor Cell><Tumor Promotion><Tumor Suppressor Proteins><Ubiquitilation><Ubiquitin><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Upregulation><Yeasts><anti-cancer therapy><biological signal transduction><breast cancer progression><c src><c-erb-2 Monoclonal Antibody><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><c-src Genes><c-src Proto-Oncogenes><cancer initiation><cancer metastasis><cancer progression><cancer therapy><cancer-directed therapy><clinical relevance><clinically relevant><cultured cell line><developmental><driving><drug resistant><drug/agent><epigenetically><erbB-2 Genes><expression subtypes><gene deletion mutation><hSNF5/INI1 Gene><herstatin><improved><lapatinib><lung metastasis><malignant breast tumor><mammary><mammary tumor><metastasize to the lung><molecular sub-types><molecular subsets><molecular subtypes><mouse model><murine model><neoplasm progression><neoplasm recurrence><neoplastic cell><neoplastic progression><neu Genes><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><ontogeny><overexpress><overexpression><pathway><patient derived xenograft model><prevent><preventing><programs><pulmonary metastasis><recruit><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><response><rhuMAb HER2><scaffold><scaffolding><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><treatment resistance><tumor><tumor cell metastasis><tumor growth><tumor initiation><tumor progression><tumor suppressor><tumorigenesis><tumorigenic><ubiquination><ubiquitin conjugation><ubiquitin ligase><ubiquitin-protein ligase><v-SRC Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RONALD J WEIGEL

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$497,084

FY 2026

Project Title

Role of the CTLH E3 ubiquitin ligase in breast cancer progression

Grant Number:

5R01CA282699-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary / Abstract HER2-positive breast cancers are highly aggressive and associated with poor prognosis. HER2-targeted therapy is the preferred treatment for these cancers, but drug resistance is a major problem. Our previous studies demonstrated that dysregulation of G protein coupled rec...

Research Terms

<APF-1><ASVSRC1><ATP-Dependent Proteolysis Factor 1><Anti-ERB-2><Anti-HER2/c-erbB2 Monoclonal Antibody><Anti-c-ERB-2><Anti-c-erbB2 Monoclonal Antibody><Anti-erbB-2><Anti-erbB2 Monoclonal Antibody><Anti-p185-HER2><Automobile Driving><BAF47><BAF47 Gene><Breast Cancer><Breast Carcinoma><Breast Neoplasms><Breast Tumors><Cancer Treatment><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Complex><D-Glucose><Data><Development><Dextrose><Drug resistance><Drugs><E3 Ligase><E3 Ubiquitin Ligase><ERBB2><ERBB2 gene><Effectiveness><Enhancers><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><G Protein Go><G Protein-Complex Receptor><G Protein-Coupled Receptor Genes><G Protein-Coupled Receptor Signaling><G(o) Protein><G-Protein-Coupled Receptors><G-Proteins><GPCR><GPCR Signaling><GTP-Binding Proteins><GTP-Regulatory Proteins><Gene Deletion><Gene Transcription><Generalized Growth><Genetic><Genetic Transcription><Glucose><Go Alpha Subunit><Go Subunit G-Protein><Growth><Guanine Nucleotide Coupling Protein><Guanine Nucleotide Regulatory Proteins><Guanine Nucleotide-Binding Protein Go><HER -2><HER-2><HER2><HER2 Genes><HER2 Monoclonal Antibody><HER2/neu><HMG-20><Herceptin><High Mobility Protein 20><INI1><INI1 Gene><Inhibitory Go G-Protein><Intracellular Communication and Signaling><Knowledge><Malignant Breast Neoplasm><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mammary Cancer><Mammary Carcinoma><Mammary Neoplasms><Mediating><Medication><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><MoAb HER2><Modeling><NEU Oncogene><NEU protein><Neoplasm Metastasis><Nuclear><Nuclear Translocation><Oncogene ErbB2><Oncogenesis><Oncogenic><Ortholog><Orthologous Gene><PDX model><PI-3K/AKT><PI3K/AKT><Pathway interactions><Patient derived xenograft><Pharmaceutical Preparations><Prognosis><Proteins><RNA Expression><Recurrent Neoplasm><Recurrent tumor><Resistance><Role><SMARCB1><SMARCB1 gene><SNF5><SNF5 Gene><SNF5L1><SNF5L1 Gene><SRC Family Gene><SRC gene><SWI/SNF Related, Matrix Associated, Actin Dependent Regulator of Chromatin, Subfamily B, Member 1 Gene><Scaffolding Protein><Secondary Neoplasm><Secondary Tumor><Signal Transduction><Signal Transduction Systems><Signaling><Signaling Factor Proto-Oncogene><Signaling Pathway Gene><Signaling Protein><Strains Cell Lines><Subgroup><TKR1><Testing><Tissue Growth><Transcription><Transgenic Mice><Trastuzumab><Tumor Cell><Tumor Promotion><Tumor Suppressor Proteins><Ubiquitilation><Ubiquitin><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><Ubiquitin Protein Ligase><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitinoylation><Upregulation><Yeasts><anti-cancer therapy><biological signal transduction><breast cancer progression><c src><c-erb-2 Monoclonal Antibody><c-erbB-2><c-erbB-2 Genes><c-erbB-2 Proto-Oncogenes><c-src Genes><c-src Proto-Oncogenes><cancer initiation><cancer metastasis><cancer progression><cancer therapy><cancer-directed therapy><clinical relevance><clinically relevant><cultured cell line><developmental><driving><drug resistant><drug/agent><epigenetically><erbB-2 Genes><expression subtypes><gene deletion mutation><hSNF5/INI1 Gene><herstatin><improved><lapatinib><lung metastasis><malignant breast tumor><mammary><mammary tumor><metastasize to the lung><molecular sub-types><molecular subsets><molecular subtypes><mouse model><murine model><neoplasm progression><neoplasm recurrence><neoplastic cell><neoplastic progression><neu Genes><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><ontogeny><overexpress><overexpression><pathway><patient derived xenograft model><prevent><preventing><programs><pulmonary metastasis><recruit><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><response><rhuMAb HER2><scaffold><scaffolding><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><treatment resistance><tumor><tumor cell metastasis><tumor growth><tumor initiation><tumor progression><tumor suppressor><tumorigenesis><tumorigenic><ubiquination><ubiquitin conjugation><ubiquitin ligase><ubiquitin-protein ligase><v-SRC Avian Sarcoma (Schmidt-Ruppin A-2) Viral Oncogene Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bin Zhang

CLEVELAND CLINIC LERNER COM-CWRU, CLEVELAND, OH

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$492,171

FY 2026

Project Title

Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII

Grant Number:

5R01HL169427-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2024

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Title of project: Developing hemophilia A therapeutics by targeting translational and posttranslational regulation of FVIII Abstract: Hemophilia A (HA) is an X-linked inherited disease due to mutations in the gene encoding the blood coagulation factor VIII (FVIII), which affects 1 in every 5,000 mal...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lei Cao

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$487,463

FY 2026

Project Title

Next generation of AAV vector targeting adipose tissue

Grant Number:

5R01DK137431-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Adeno-associated viral (AAV) vectors are mainstream delivery platforms in gene therapy because of its safety profile and promising results in clinical trials. AAV has ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wei Hu

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$482,312

FY 2026

Project Title

Novel Treg inactivating approach for cancer immunotherapy via targeted protein degradation

Grant Number:

1R01CA295942-01A1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/2/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Despite the growing success of immunotherapies, such as chimeric antigen receptor-based cell therapy, cytokine therapy, and immune checkpoint blockade (ICB), a substantial number of cancers remain unresponsive. Furthermore, these therapies can lead to off-target toxicities, known as ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nicholas E. Todd

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$469,886

FY 2026

Project Title

Improved Delivery of Gene Therapies to the Central Nervous System by Focused Ultrasound-Mediated Disruption of the Blood-Brain Barrier

Grant Number:

5R01NS123557-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2022

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary: A major challenge faced by all gene therapies directed to the central nervous system is delivering the therapy across the blood-brain barrier (BBB) in a way that achieves adequate central exposure while minimizing toxicity in non-targeted tissues. The two most common routes of admin...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Scott M. Dehm

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$403,130

FY 2026

Project Title

AR Gene Rearrangements and AR Signaling in Prostate Cancer

Grant Number:

5R01CA174777-14

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2013

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Prostate cancer (PC) is the most frequently diagnosed male cancer. Surgery or radiation therapy are curative treatments for localized PC while systemic endocrine therapies are standard-of-care for advanced or metastatic PC. The molecular target of endocrine therapy is the an...

Research Terms

<5 alpha-Dihydrotestosterone><5-alpha-DHT><AR gene><Acceleration><Acetates><Address><Affinity><Androgen Receptor><Androgen Suppression><Androgenic Agents><Androgenic Compounds><Androgens><Androstanolone><Anti-Oncogenes><Antioncogenes><Architecture><Autoregulation><Basal Transcription Factor><Basal transcription factor genes><Binding><Binding Site Domain><Biological><Biological Markers><Body Tissues><Cancer Patient><Cancer Suppressor Genes><Cancers><Cell Body><Cells><Cessation of life><Complex><Computing Methodologies><DNA Rearrangement><DNA seq><DNA sequencing><DNAseq><Data><Death><Diagnosis><Dihydrotestosterone><Dihydrotestosterone Receptor><Disease><Disorder><Drugs><Emerogenes><Endocrine><Endocrine Therapy><Engineering / Architecture><Exons><Failure><Feedback><Frequencies><Future><GEM model><GEMM model><Gene Rearrangement><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Generations><Genetic Transcription><Genetically Engineered Mouse><Genome><Genome Mappings><Genotype><Goals><Gonadotropin-Releasing Hormone Analog><Growth><Heterogeneity><Homeostasis><Hormonal Therapy><In Vitro><Knock-out><Knockout><Knowledge><LH-RH Analogs><Length><Ligand Binding Domain><Luteinizing Hormone-Releasing Hormone analogs><MMAC1><MMAC1 protein><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Medication><Medicine><Metastatic Prostate Cancer><Mice><Mice Mammals><Modeling><Molecular><Molecular Interaction><Molecular Target><Murine><Mus><Mutated in Multiple Advanced Cancers 1><NR3C4><Nobel Prize><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Operative Procedures><Operative Surgical Procedures><Optics><Outcome><Output><PDX model><PHTS gene><PHTS protein><PI-3K/AKT><PI3K/AKT><PTEN><PTEN gene><PTEN protein><PTEN1><Pathway interactions><Patient derived xenograft><Patients><Pattern><Pharmaceutical Preparations><Phenotype><Phosphatase and Tensin Homolog><Phosphatase and Tensin Homolog Deleted on Chromosome 10><Physiological Homeostasis><Physiology><Production><Proliferating><Prostate><Prostate CA><Prostate CA therapy><Prostate Cancer><Prostate Cancer therapy><Prostate Carcinoma Metastatic><Prostate Gland><Prostate malignancy><Prostatic Gland><Protein Analysis><QOL><Quality of life><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Radiation therapy><Radiotherapeutics><Radiotherapy><Receptor Signaling><Recessive Oncogenes><Recurrence><Recurrent><Recurrent Neoplasm><Recurrent tumor><Regulation><Repression><Research Specimen><Resistance><Role><SMAX1><Specimen><Stanolone><Structure><Surgical><Surgical Interventions><Surgical Procedure><Techniques><Testing><Testosterone><Therapeutic><Therapeutic Androgen><Therapeutic Androstanolone><Therapeutic Steroid Hormone><Therapeutic Testosterone><Tissue Growth><Tissues><Trans-Testosterone><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tumor Suppressing Genes><Tumor Suppressor Genes><Variant><Variation><Whole Organism><Work><Xtandi><abiraterone><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen receptor gene><androgen resistance in prostate cancer><androgen resistant prostate cancer><antagonism><antagonist><anti-cancer research><bio-markers><biologic><biologic marker><biomarker><cancer research><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><clinical relevance><clinically relevant><combat><computational methodology><computational methods><computer based method><computer methods><computing method><curative intervention><curative therapeutic><curative therapy><curative treatments><drug/agent><enzalutamide><genetically engineered mouse model><genetically engineered murine model><hormone refractory prostate cancer><hormone therapy><improved><in vivo><male><malignancy><mortality><mouse model><murine model><mutated in multiple advanced cancers 1 protein><neoplasm recurrence><neoplasm/cancer><neoplastic cell><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><oncosuppressor gene><ontogeny><optical><pathway><patient derived xenograft model><phosphatase and tensin homologue on chromosome ten><pressure><programs><prostate cancer cell><prostate cancer model><prostate cancer progression><prostate cancer resistant to androgen><prostate cancer treatment><prostate tumor cell><prostate tumor model><protein function><radiation treatment><receptor expression><resistance mechanism><resistance to therapy><resistant><resistant mechanism><resistant to therapy><response><screening><screenings><social role><standard of care><steroid hormone><structural mutation><structural variant><structural variation><surgery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic agent development><therapeutic development><therapeutic resistance><therapy resistant><transcription factor><transcriptome sequencing><transcriptomic sequencing><treatment resistance><treatment with radiation><tumor><♂>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Conor McClenaghan

RUTGERS BIOMEDICAL AND HEALTH SCIENCES, Newark, NJ

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$392,500

FY 2026

Project Title

Exploiting structure-function of potassium channels for modulation

Grant Number:

1R35GM162430-01

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary This project aims to identify approaches for modulating the activity of select potassium (K+) ion channels. A diverse family of K+ channels controls electrical signaling throughout the body, critical for myriad physiological processes. Consequently, K+ channel dysfunction can result ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel John Siegwart

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$391,721

FY 2026

Project Title

Multiplexed nanoparticle delivery to increase CRISPR/Cas gene editing for enhanced cancer therapy

Grant Number:

5R01CA269787-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2022

End Date:

2/28/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary The programmable CRISPR/Cas gene editing system has great potential for cancer treatment due to the ability to precisely inactivate or repair cancer-related genes. However, delivery of CRISPR to solid tumors for efficient cancer therapy remains limited by the uniquely stiff and fibro...

Research Terms

<3D cell culture><3D culture><Affect><Antibodies><Applications Grants><B7-H1><Biological Markers><Body Tissues><Brain><Brain Nervous System><CD274><CRISPR><CRISPR/Cas system><Cancer Model><Cancer Treatment><CancerModel><Cancers><Cell Body><Cell-Extracellular Matrix><Cells><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Coupled><Data><ECM><Encapsulated><Encephalon><Endocytosis><Exhibits><Extracellular Matrix><Focal Adhesion Kinase 1><Formulation><Future><GEM model><GEMM model><Gene Inactivation><Gene Proteins><Gene Silencing><Generalized Growth><Genes><Genetic Enhancement><Genetic Suppression><Genetically Engineered Mouse><Grant Proposals><Growth><Hepatic Cancer><Hepatocarcinoma><Hepatocarcinoma model><Hepatocellular Carcinoma><Hepatocellular cancer><Hepatoma><Immune infiltrates><Intravenous><Kinetics><Lipids><Liver><Liver Cells Carcinoma><Lung><Lung Respiratory System><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of liver><Malignant neoplasm of lung><Measures><Mechanics><Mediating><Messenger RNA><Mice><Mice Mammals><Modeling><Modification><Murine><Mus><Muscle><Muscle Tissue><NSCLC><NSCLC - Non-Small Cell Lung Cancer><Non-Small Cell Lung Cancer><Non-Small-Cell Lung Carcinoma><Nucleic Acids><Organ><Outcome><PD-L1><PDL-1><PTK2 Protein Tyrosine Kinase 2><Pathway interactions><Penetration><Primary carcinoma of the liver cells><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Protein Gene Products><Proteins><Pulmonary Cancer><Pulmonary malignant Neoplasm><Series><Short interfering RNA><Single-Stranded DNA><Solid Neoplasm><Solid Tumor><Spleen><Spleen Reticuloendothelial System><System><Therapeutic><Therapeutic Gene Editing><Tissue Growth><Tissues><Toxic effect><Toxicities><Treatment Efficacy><Tropism><Tumor Burden><Tumor Cell><Tumor Load><Tumor Tissue><Work><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><bio-markers><biologic marker><biomarker><cancer immunotherapy><cancer microenvironment><cancer progression><cancer therapy><cancer-directed therapy><deliver mRNA><deliver messenger RNA><delivery system for mRNA><design><designing><endogenous substrate pp120><focal adhesion kinase><focal adhesion protein tyrosine kinase><focal adhesion-associated protein tyrosine kinase pp125FAK><gene corrected><gene correction><gene editing platform><gene editing system><gene editing technology><gene editing tools><gene repair><gene-editing therapy><gene-editing toolkit><genetically engineered mouse model><genetically engineered murine model><genome editing><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genomic correction><genomic editing><hepatic body system><hepatic organ system><hepatocellular carcinoma cancer model><hepatocellular carcinoma model><immune cell infiltrate><immune-based cancer therapies><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><innovate><innovation><innovative><intervention efficacy><intravenous administration><knock-down><knockdown><lipid based nanoparticle><lipid nanoparticle><liver cancer><liver cancer model><liver carcinoma><liver malignancy><lung cancer><lung cancer cell><mRNA><mRNA delivery><malignancy><malignant liver tumor><mechanic><mechanical><mechanical force><mechanical properties><messenger RNA delivery><muscular><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><nucleic acid delivery><ontogeny><pathway><programmed cell death ligand 1><programmed cell death protein ligand 1><protein death-ligand 1><repair><repaired><siRNA><spheroids><ssDNA><synergism><therapeutic editing><therapeutic efficacy><therapeutic genome editing><therapy efficacy><three dimensional cell culture><transcriptional silencing><tumor><tumor microenvironment><tumor progression><uptake>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kyle Fink

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$384,496

FY 2026

Project Title

MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Grant Number:

5R01NS102486-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2017

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Huntington's disease (HD) is a neurodegenerative disorder with no cure, and there is a critical unmet need for disease- modifying treatments. We are developing a novel therapy for HD: implantation of human Mesenchymal Stem/Stromal Cells (MSCs) engineered to secrete Brain-Derived Neurotrophi...

Research Terms

<21+ years old><Acceleration><Address><Adult><Adult Human><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Apoptosis><Apoptosis Pathway><Area><Assay><Atrophic><Atrophy><Award><BDNF><Basal Transcription Factor><Basal transcription factor genes><Binding><Bioassay><Biological Assay><Brain><Brain Nervous System><Brain region><Brain-Derived Neurotrophic Factor><CRISPR><CRISPR approach><CRISPR based approach><CRISPR based therapeutics><CRISPR based treatment><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR therapeutics><CRISPR tools><CRISPR treatment><CRISPR-CAS-9><CRISPR-Cas based therapeutics><CRISPR-based disease therapeutics><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based therapy><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas therapeutics><CRISPR/Cas9><CRISPR/Cas9 technology><CRISPR/Cas9 therapeutics><CRISPR/Cas9 therapy><CRISPR/Cas9 treatment><CRISPR/Cas9-based therapy><Cas nuclease technology><Cas9 based therapeutics><Cell Body><Cell Communication and Signaling><Cell Locomotion><Cell Migration><Cell Movement><Cell Signaling><Cell Therapy><Cell secretion><Cells><Cellular Migration><Cellular Motility><Cellular Secretion><Cerebellomedullary Cistern><Chromatin><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats based therapeutics><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Clustered Regularly Interspaced Short Palindromic Repeats therapeutics><Combined Modality Therapy><Corpus Striatum><Corpus striatum structure><DNA Binding Domain><DNA Therapy><DNA-Binding Protein Motifs><Data><Degenerative Neurologic Disorders><Disease><Disorder><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Encephalon><Engineering><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Evaluation><Funding><Future><Gene Alteration><Gene Down-Regulation><Gene Inactivation><Gene Mutation><Gene Silencing><Gene Targeting><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generations><Genes><Genetic Intervention><Genetic Transcription><Glycoproteins><Grant><Growth Agents><Growth Factor><Growth Substances><Guide RNA><HD Gene><HD protein><Half-Life><Heterochromatin><Human><Huntingtin><Huntingtin Protein><Huntington Chorea><Huntington Disease><Huntington gene><Huntington protein><Huntington's><Huntington's Disease><Huntington's disease gene product><Huntingtons Disease><IT15 gene><Immune><Immunes><Impairment><Induced pluripotent stem cell derived neurons><Injections><Intracellular Communication and Signaling><Intraventricular><Investigational Drugs><Investigational New Drugs><Knowledge><Laboratories><Length><Link><Liquid substance><Lyssavirus><Medulla Spinalis><Mesenchymal><Methods><Mice><Mice Mammals><Mission><Modern Man><Molecular Interaction><Mouse Strains><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NGS Method><NGS system><NINDS><National Institute of Neurological Diseases and Stroke><National Institute of Neurological Disorders and Stroke><Nerve Cells><Nerve Unit><Nervous System><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neural Degenerative Diseases><Neural Stem Cell><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Body System><Neurologic Degenerative Conditions><Neurologic Disorders><Neurologic Organ System><Neurological Disorders><Neuron from iPSC><Neuron from induced pluripotent stem cells><Neurons><Non-Polyadenylated RNA><NuRD><NuRD complex><Pathway interactions><Patients><Phase 3 Clinical Trials><Phase III Clinical Trials><Position><Positioning Attribute><Precipitation><Precision therapeutics><Production><Programmed Cell Death><Proteins><Proteins Growth Factors><Protocol><Protocols documentation><Publishing><RNA><RNA Expression><RNA Gene Products><Recovery><Repression><Reproducibility><Research><Ribonucleic Acid><Rodent Model><Route><Safety><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Spinal Cord><Striate Body><Striatum><Stromal Cells><Techniques><Technology><Testing><Therapeutic><Transcription><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription Repressor><Transcription factor genes><Transcriptional Repressor><Transgenic Organisms><Tropism><Upregulation><VSV><Validation><Variant><Variation><Vesicle><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Work><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adulthood><animal data><anxiety reduction><assess effectiveness><biological signal transduction><cell based intervention><cell engineering><cell mediated intervention><cell mediated therapies><cell motility><cell type><cell-based therapeutic><cell-based therapy><cellular engineering><cellular therapeutic><cellular therapy><cisterna magna><combination therapy><combined modality treatment><combined treatment><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><delivery vector><delivery vehicle><design and construct><design and construction><determine effectiveness><develop therapy><disease phenotype><effectiveness assessment><effectiveness evaluation><efficacy study><engineered progenitor cells><engineered stem cells><epigenetically><evaluate effectiveness><examine effectiveness><excitotoxic><excitotoxicity><fluid><gRNA><gene defect><gene repair therapy><gene repression><gene therapy><gene-based therapy><genetic repressor><genetic therapy><genomic therapy><good laboratory practice><hypoimmunity><iPS neurons><iPSC derived-neurons><immune deficiency><immunodeficiency><implantation><induced pluripotent stem cell neurons><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><interesting transcript 15><intervention development><knock-down><knockdown><liquid><model of animal><mouse model><multi-modal therapy><multi-modal treatment><murine model><mutant><mutant allele><nano engineering><nanoengineering><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodegenerative illness><neurogenesis><neurogenic progenitors><neurogenic stem cell><neurological disease><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neurons derived from induced pluripotent stem cells><neurons differentiated from induced pluripotent stem cells><neuropathologic><neuropathological><neuropathology><neuroprogenitor><neuroprotection><neuroprotective><neurorestoration><neurorestorative><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oxidative damage><oxidative injury><pathway><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><phase 1 trial><phase I trial><phase III protocol><precipitations><precision therapies><precision treatment><preservation><progenitor and neural stem cells><progenitor cell delivery><progenitor delivery><rabies virus G protein><rabies virus glycoprotein><rabies virus glycoprotein G><recruit><restoration><stem><stem cell delivery><striatal><therapy development><tool><transcription factor><transcriptional silencing><transgenic><treatment development><validations><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jan A. Nolta

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$384,496

FY 2026

Project Title

MSCS ENGINEERED TO PRODUCE BDNF AND GENE EDITING CARGO FOR THE TREATMENT OF HUNTINGTON'S DISEASE

Grant Number:

5R01NS102486-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2017

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Huntington's disease (HD) is a neurodegenerative disorder with no cure, and there is a critical unmet need for disease- modifying treatments. We are developing a novel therapy for HD: implantation of human Mesenchymal Stem/Stromal Cells (MSCs) engineered to secrete Brain-Derived Neurotrophi...

Research Terms

<21+ years old><Acceleration><Address><Adult><Adult Human><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Apoptosis><Apoptosis Pathway><Area><Assay><Atrophic><Atrophy><Award><BDNF><Basal Transcription Factor><Basal transcription factor genes><Binding><Bioassay><Biological Assay><Brain><Brain Nervous System><Brain region><Brain-Derived Neurotrophic Factor><CRISPR><CRISPR approach><CRISPR based approach><CRISPR based therapeutics><CRISPR based treatment><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR therapeutics><CRISPR tools><CRISPR treatment><CRISPR-CAS-9><CRISPR-Cas based therapeutics><CRISPR-based disease therapeutics><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based therapy><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas therapeutics><CRISPR/Cas9><CRISPR/Cas9 technology><CRISPR/Cas9 therapeutics><CRISPR/Cas9 therapy><CRISPR/Cas9 treatment><CRISPR/Cas9-based therapy><Cas nuclease technology><Cas9 based therapeutics><Cell Body><Cell Communication and Signaling><Cell Locomotion><Cell Migration><Cell Movement><Cell Signaling><Cell Therapy><Cell secretion><Cells><Cellular Migration><Cellular Motility><Cellular Secretion><Cerebellomedullary Cistern><Chromatin><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats based therapeutics><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Clustered Regularly Interspaced Short Palindromic Repeats therapeutics><Combined Modality Therapy><Corpus Striatum><Corpus striatum structure><DNA Binding Domain><DNA Therapy><DNA-Binding Protein Motifs><Data><Degenerative Neurologic Disorders><Disease><Disorder><Dose><Double-Blind Method><Double-Blind Study><Double-Blinded><Double-Masked Method><Double-Masked Study><Encephalon><Engineering><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Evaluation><Funding><Future><Gene Alteration><Gene Down-Regulation><Gene Inactivation><Gene Mutation><Gene Silencing><Gene Targeting><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Generations><Genes><Genetic Intervention><Genetic Transcription><Glycoproteins><Grant><Growth Agents><Growth Factor><Growth Substances><Guide RNA><HD Gene><HD protein><Half-Life><Heterochromatin><Human><Huntingtin><Huntingtin Protein><Huntington Chorea><Huntington Disease><Huntington gene><Huntington protein><Huntington's><Huntington's Disease><Huntington's disease gene product><Huntingtons Disease><IT15 gene><Immune><Immunes><Impairment><Induced pluripotent stem cell derived neurons><Injections><Intracellular Communication and Signaling><Intraventricular><Investigational Drugs><Investigational New Drugs><Knowledge><Laboratories><Length><Link><Liquid substance><Lyssavirus><Medulla Spinalis><Mesenchymal><Methods><Mice><Mice Mammals><Mission><Modern Man><Molecular Interaction><Mouse Strains><Multimodal Therapy><Multimodal Treatment><Murine><Mus><NGS Method><NGS system><NINDS><National Institute of Neurological Diseases and Stroke><National Institute of Neurological Disorders and Stroke><Nerve Cells><Nerve Unit><Nervous System><Nervous System Degenerative Diseases><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neural Degenerative Diseases><Neural Stem Cell><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Body System><Neurologic Degenerative Conditions><Neurologic Disorders><Neurologic Organ System><Neurological Disorders><Neuron from iPSC><Neuron from induced pluripotent stem cells><Neurons><Non-Polyadenylated RNA><NuRD><NuRD complex><Pathway interactions><Patients><Phase 3 Clinical Trials><Phase III Clinical Trials><Position><Positioning Attribute><Precipitation><Precision therapeutics><Production><Programmed Cell Death><Proteins><Proteins Growth Factors><Protocol><Protocols documentation><Publishing><RNA><RNA Expression><RNA Gene Products><Recovery><Repression><Reproducibility><Research><Ribonucleic Acid><Rodent Model><Route><Safety><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Spinal Cord><Striate Body><Striatum><Stromal Cells><Techniques><Technology><Testing><Therapeutic><Transcription><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription Repressor><Transcription factor genes><Transcriptional Repressor><Transgenic Organisms><Tropism><Upregulation><VSV><Validation><Variant><Variation><Vesicle><Vesicular Stomatitis Virus><Vesicular stomatitis Indiana virus><Work><Zinc Finger Domain><Zinc Finger Motifs><Zinc Fingers><adulthood><animal data><anxiety reduction><assess effectiveness><biological signal transduction><cell based intervention><cell engineering><cell mediated intervention><cell mediated therapies><cell motility><cell type><cell-based therapeutic><cell-based therapy><cellular engineering><cellular therapeutic><cellular therapy><cisterna magna><combination therapy><combined modality treatment><combined treatment><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><delivery vector><delivery vehicle><design and construct><design and construction><determine effectiveness><develop therapy><disease phenotype><effectiveness assessment><effectiveness evaluation><efficacy study><engineered progenitor cells><engineered stem cells><epigenetically><evaluate effectiveness><examine effectiveness><excitotoxic><excitotoxicity><fluid><gRNA><gene defect><gene repair therapy><gene repression><gene therapy><gene-based therapy><genetic repressor><genetic therapy><genomic therapy><good laboratory practice><hypoimmunity><iPS neurons><iPSC derived-neurons><immune deficiency><immunodeficiency><implantation><induced pluripotent stem cell neurons><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><interesting transcript 15><intervention development><knock-down><knockdown><liquid><model of animal><mouse model><multi-modal therapy><multi-modal treatment><murine model><mutant><mutant allele><nano engineering><nanoengineering><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurodegenerative illness><neurogenesis><neurogenic progenitors><neurogenic stem cell><neurological disease><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neurons derived from induced pluripotent stem cells><neurons differentiated from induced pluripotent stem cells><neuropathologic><neuropathological><neuropathology><neuroprogenitor><neuroprotection><neuroprotective><neurorestoration><neurorestorative><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oxidative damage><oxidative injury><pathway><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><phase 1 trial><phase I trial><phase III protocol><precipitations><precision therapies><precision treatment><preservation><progenitor and neural stem cells><progenitor cell delivery><progenitor delivery><rabies virus G protein><rabies virus glycoprotein><rabies virus glycoprotein G><recruit><restoration><stem><stem cell delivery><striatal><therapy development><tool><transcription factor><transcriptional silencing><transgenic><treatment development><validations><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuwen Zhu

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$355,706

FY 2026

Project Title

The GPR171 pathway in cancer immunotherapy

Grant Number:

5R01CA279398-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/25/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Scientific Abstract of proposed research project Immune checkpoint blocker therapy has revolutionized our clinical approach in cancer therapy. However, the overall response rate still has room for improvement and varies greatly in different cancer types. The redundant but unique role...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JAGADANANDA GHOSH

HENRY FORD HEALTH SYSTEM, DETROIT, MI

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$347,700

FY 2026

Project Title

Neuroendocrine differentiation post anti-androgenic therapy: Role of Tribbles 2

Grant Number:

5R01CA269635-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/20/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Anti-androgenic therapy is the mainstay for both primary and disseminated forms of prostate cancer. FDA- approved enzalutamide (Xtandi) is at the forefront of anti-androgens with superior patient profile and is the one most prescribed. However, enzalutamide resistant prostate cancer (ERPC) invariabl...

Research Terms

<20S Catalytic Proteasome><20S Core Proteasome><20S Proteasome><20S Proteosome><Address><Adenocarcinoma><Age><Androgen Antagonists><Androgen Receptor><Anti-Androgen><Anti-Androgen Agents><Antioncogene Protein p53><Apoptosis><Apoptosis Pathway><Basal Transcription Factor><Basal transcription factor genes><Binding><Bypass><Cancer Cell Growth><Castrate sensitive prostate cancer><Castration><Cell Body><Cell Culture Techniques><Cell Line><CellLine><Cells><Cellular Tumor Antigen P53><Cessation of life><Characteristics><Chromogranin A><Clinic><Clinical><Death><Development><Distant Cancer><Distant Metastasis><Dose><ENX-1><EZH1><EZH2><EZH2 gene><Enhancer of Zeste 2 Polycomb Repressive Complex 2 Subunit><Environment><Epithelium of Human Prostate Gland><Exons><FDA approved><Family><Gene Chips><Gene Expression><Gene Expression Chip><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Targeting><GeneChip><General Transcription Factor Gene><General Transcription Factors><Generations><Goals><Health><Heterograft><Heterologous Transplantation><Image><Immune Precipitation><Immunoprecipitation><In Vitro><Injections><KMT6><KMT6A><KO mice><Kidney><Kidney Urinary System><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Knowledge><LNCaP><Link><Liver><Luciferase Immunologic><Luciferases><Lung><Lung Respiratory System><Macropain><Macroxyproteinase><Malignant Adenoma><Malignant neoplasm of prostate><Malignant prostatic tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Medical><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Metastatic to><Mice><Mice Mammals><Modeling><Molecular><Molecular Interaction><Molecular Target><Monitor><Movement><Multicatalytic Proteinase><Murine><Mus><Neoplasm Metastasis><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neuroendocrine><Neuroendocrine System><Neuroendocrine Therapy><Neuron-Specific Enolase><Neurons><Neurosecretory Systems><Null Mouse><Oncoprotein p53><P53><Parathyroid Secretory Protein 1><Pathologic><Patients><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Pituitary Secretory Protein I><Play><Population><Prevention><Programmed Cell Death><Prosome><Prostate><Prostate CA><Prostate Cancer><Prostate Gland><Prostate Neoplasms><Prostate Neuroendocrine Neoplasm><Prostate Neuroendocrine Tumor><Prostate Tumor><Prostate malignancy><Prostatic Epithelium><Prostatic Gland><Prostatic Neoplasia><Prostatic Neoplasms><Proteasome><Proteasome Endopeptidase Complex><Protein TP53><Proteins><Proteosome><Public Health><Regimen><Regulation><Research><Resistance><Role><SCID Mice><Sampling><Secondary Neoplasm><Secondary Tumor><Seminal><Severe Combined Immunodeficient Mice><Strains Cell Lines><Surgical Castration><Synaptic Vesicle P38 Membrane Protein><Synaptic Vesicle Protein P38><Synaptophysin><TP53><TP53 gene><TRP53><Testing><Therapeutic><Transcript Expression Analyses><Transcript Expression Analysis><Transcription Factor Proto-Oncogene><Transcription factor genes><Transgenic Mice><Transgenic Organisms><Tumor Protein p53><Tumor Protein p53 Gene><Upregulation><Work><Xenograft><Xenograft procedure><Xenotransplantation><Xtandi><abiraterone><ages><analyze gene expression><androgen inhibitor><androgen sensitive prostate cancer><androgenic><body movement><bone><cancer metastasis><cancer progression><cell culture><cell cultures><cell killing><cell type><clinical relevance><clinically relevant><cultured cell line><design><designing><develop therapy><developmental><effective therapy><effective treatment><enzalutamide><expression array><gene expression analysis><gene expression assay><gene expression microarray><hepatic body system><hepatic organ system><hormone sensitive prostate cancer><imaging><in vivo><in vivo Model><inhibitor><intervention development><knock-down><knockdown><knockout gene><male><member><molecular biomarker><molecular marker><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><mouse model><multicatalytic endopeptidase complex><murine model><neoplasm progression><neoplastic progression><neuroendocrine differentiation><neuroendocrine phenotype><neuronal><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><overexpress><overexpression><p53 Antigen><p53 Genes><p53 Tumor Suppressor><patient profile><pre-clinical><preclinical><profiles in patients><prostate cancer cell><prostate cancer cell line><prostate cancer model><prostate cancer progression><prostate tumor cell><prostate tumor model><protein p53><receptor function><renal><resistance to therapy><resistant><resistant to therapy><social role><therapeutic resistance><therapy development><therapy resistant><transcription factor><transcriptional profiling><transdifferentiation><transgenic><treatment development><treatment resistance><tumor><tumor cell metastasis><tumor growth><tumor progression><xeno-transplant><xeno-transplantation><♂>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ashok Kumar

WAYNE STATE UNIVERSITY, DETROIT, MI

Good lead · 66/100

Likely hiring

Solid budget

Very recent

Active award

$320,273

FY 2026

Project Title

Targeting NAD metabolism to ameliorate bacterial endophthalmitis

Grant Number:

5R01EY026964-10

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2017

End Date:

3/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Bacterial endophthalmitis is a vision-threatening complication commonly occurring post penetrating eye injuries and ocular surgeries. Despite aggressive antibiotics and surgical interventions, endophthalmitis often results in partial or complete vision loss. The long-term goal of our...

Research Terms

<3-Pyridinecarboxamide><3-Pyridinecarboxylic Acid><ATP-NMN Adenylyltransferase><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Autoregulation><Bacterial Infections><Bioenergetics><Biosensor><Blindness><Body Tissues><Cataract><Cell Body><Cell Communication and Signaling><Cell Death><Cell Signaling><Cells><Citric Acid Cycle><Communicable Diseases><Complement><Complement Proteins><Complication><Consumption><Cultured Cells><DNA Therapy><DPN hydrolase><DPNase><Data><Dihydronicotinamide Adenine Dinucleotide><Diphosphopyridine Nucleotidase><Diphosphopyridine Nucleotide><Disease><Disorder><Drug Therapy><Endophthalmitis><Energy Expenditure><Energy Metabolism><Enzyme Gene><Enzymes><Exhibits><Eye><Eye Infections><Eyeball><Funding><Gene Transfer Clinical><Generations><Genes><Genetic><Genetic Intervention><Global Change><Goals><Homeostasis><Impairment><In Vitro><Incidence><Individual><Infection><Infectious Diseases><Infectious Disorder><Inflammation><Inflammatory Response><Innate Immunity><Intermediary Metabolism><Intracellular Communication and Signaling><KO mice><Knock-out Mice><Knockout Mice><Krebs Cycle><Link><Measurement><Mediating><Metabolic><Metabolic Processes><Metabolism><Mice><Mice Mammals><Miscellaneous Antibiotic><Mitochondria><Murine><Mus><NAD Pyrophosphorylase><NAD+ Glycohydrolase><NAD+ Nucleosidase><NADase><NMN Adenylyltransferase><NMN pyrophosphorylase><Nadide><Native Immunity><Natural Immunity><Niacin><Niacinamide><Nicotinamide><Nicotinamide Mononucleotide><Nicotinamide Mononucleotide Adenylyltransferase><Nicotinamide adenine dinucleotide><Nicotinamide-Adenine Dinucleotide><Nicotinamide-Nucleotide Adenylyltransferase><Nicotinamidum><Nicotinic Acids><Nicotinic acid amide><Nicotylamide><Non-Specific Immunity><Nonspecific Immunity><Null Mouse><Ocular Infections><Operative Procedures><Operative Surgical Procedures><Ophthalmia><Ophthalmologic Surgical Procedures><Ophthalmological Surgery><Ophthalmological Surgical Procedures><Oxidation-Reduction><Pathogenesis><Pathway interactions><Patients><Pellagra-Preventing Factor><Penetrating Eye Injuries><Pharmacological Treatment><Pharmacotherapy><Physiological Homeostasis><Protein Kinase Interaction><Receptor Activation><Receptor-Interacting Protein><Redox><Research><Retina><Role><S aureus><S. aureus><S. aureus infection><Severities><Sight><Signal Transduction><Signal Transduction Systems><Signaling><Silent Mating Type Information Regulator 2-like Proteins><Sir2-like Proteins><Sirtuins><Staph aureus><Staph aureus infection><Staphylococcus aureus><Staphylococcus aureus infection><Supplementation><Surgical><Surgical Interventions><Surgical Procedure><TCA cycle><Testing><Therapeutic><Tissues><Tricarboxylic Acid Cycle><Vision><Vitamin B 3><Vitamin B3><Vitamin PP><aged group><aged groups><aged individual><aged individuals><aged people><aged person><aged persons><aged population><aged populations><aging population><bacteria infection><bacterial disease><bacterial endophthalmitis><biological sensor><biological signal transduction><cataractogenesis><cataractous lenses><cell type><complementation><drug intervention><drug treatment><eye surgery><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><infected with S. aureus><infected with Staph aureus><infected with Staphylococcus aureus><insight><intravitreal injection><metabolism measurement><metabolomics><metabonomics><mitochondrial><mouse genetics><necrocytosis><nicotinamide phosphoribosyltransferase><overexpress><overexpression><oxidation reduction reaction><pathogen><pathway><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><population aging><prevent><preventing><restoration><social role><surgery><therapeutic target><tool><transcriptomics><treatment strategy><vision loss><visual function><visual loss>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

RONALD G CRYSTAL

WEILL MEDICAL COLL OF CORNELL UNIV, NEW YORK, NY

Good lead · 62/100

Large award

Very recent

Active award

Team-scale grant

$3,252,734

FY 2026

Project Title

Gene Therapy for APOE4 Homozygous Alzheimer's Disease

Grant Number:

1UG3AG098024-01

Activity Code:

UG3

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract. Variants of APOE are the major genetic risk factors for Alzheimer’s disease (AD). APOE has 3 common variants; APOE3 average risk, APOE4 high risk and APOE2 protective. This data, and in E2E4 heterozygotes, E2 cancels out deleterious effects of E4, led to the concept that gene therapy of a ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mauricio A Martins

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$861,082

FY 2026

Project Title

Overcoming pre-existing immunity to AAV to enhance AAV-based HIV immunotherapies

Grant Number:

5R01AI175007-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/5/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Adeno-associated virus (AAV)-mediated gene therapy with broadly (b) neutralizing (n) antibodies (Abs) holds great promise for preventing and treating HIV infection. This approach is unique in that host cells, after receiving the relevant genes through AAV transduction, can immediate...

Research Terms

<7S Gamma Globulin><AACTG><AAV delivered><AAV delivery><AAV vector><AAV-based delivery><AAV-based vector><AAV-based viral delivery><AAV-mediated delivery><ACTG><AIDS Virus><AIDS clinical trial group><AIDS prevention><AIDS/HIV><Abscission><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adeno-Associated Viruses><Adeno-associated-virus-based delivery><Africa South of the Sahara><Animals><Antibodies><Area><Benchmarking><Best Practice Analysis><Biological Agent><Biological Products><Blood Serum><Bypass><Capsid><Cell Body><Cells><Circulation><Clinic><Clinical><Clinical Research><Clinical Study><Clinical Treatment Moab><Clinical Trials><Country><Cross Reactions><DNA Therapy><Dependoparvovirus><Dependovirus><Developed Countries><Dose><Endopeptidases><Epidemic><Epidemiology><Excision><Exclusion><Extirpation><Fc Receptor><FcRn><FcRn neonatal transfer protein><Gene Transfer Clinical><Genes><Genetic Intervention><Genome><Geography><Goals><HIV><HIV Infections><HIV Prevention><HIV Vaccine Trials Network><HIV burden><HIV cure><HIV disease burden><HIV epidemic burden><HIV functional cure><HIV global burden><HIV health burden><HIV individuals><HIV infected individuals><HIV infected persons><HIV intervention><HIV people><HIV positive individuals><HIV positive people><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV virus infection><HIV-1 cure><HIV-1 functional cure><HIV-1 infection><HIV-1 intervention><HIV-1 prevention><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV/AIDS><HIV/AIDS cure><HIV/AIDS prevention><HVTN><High Prevalence><Home><Human><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Viruses><Humoral Immunities><IgG><Immune mediated therapy><Immunity><Immunoglobulin G><Immunologically Directed Therapy><Immunotherapy><Individual><Industrialized Countries><Industrialized Nations><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infusion><Infusion procedures><Injections><Interruption><Intervention><Intramuscular><Knowledge><LAV-HTLV-III><Lymphadenopathy-Associated Virus><M mulatta><M. mulatta><Macaca><Macaca mulatta><Macaca rhesus><Macaque><Mediating><Modern Man><Monitor><Monkeys><Monoclonal Antibodies><Monoclonal Antibody Therapy><Muscle><Muscle Cells><Muscle Tissue><Myocytes><PLWH><PWH><Peptide Peptidohydrolases><Persons><Plasmapheresis><Prevalence><Prevent HIV><Primates><Primates Mammals><Production><Removal><Research><Resistance><Rhesus Macaque><Rhesus Monkey><Role><SIV><Series><Seroprevalences><Serotyping><Serum><Sight><Simian Immunodeficiency Viruses><Sub-Saharan Africa><Subsaharan Africa><Surgical Removal><Testing><Therapeutic Plasma Exchange><Therapeutic Plasmapheresis><Time><Transgenes><Translating><Viral Diseases><Virus Diseases><Virus Replication><Virus-HIV><Vision><acquired immunodeficiency syndrome clinical trial group><adeno associated virus group><adeno-associated viral vector><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adeno-associated virus vector><adenovirus mediated delivery><antibody receptor><antibody-based immunity><antiretroviral therapy><antiretroviral treatment><benchmark><biologics><biopharmaceutical><biotherapeutic agent><clinical relevance><clinically relevant><combat><cross reactivity><delivered with AAV><delivery with AAV><developed country><developed nation><developed nations><efficacy testing><epidemiologic><epidemiological><experiment><experimental research><experimental study><experiments><gene product><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><homes><human immunodeficiency virus burden><human immunodeficiency virus cure><human immunodeficiency virus global burden><human immunodeficiency virus infection><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><in vivo><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected with HIV><infected with human immunodeficiency virus><infusions><inhibitor><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><mindfulness><monoclonal Abs><muscular><neonatal Fc receptor><non-human primate><nonhuman primate><pandemic><pandemic disease><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><pharmacologic><pre-clinical study><preclinical study><prevent AIDS><prevent human immunodeficiency virus><resection><resistant><serology survey><seropositive><serosurvey><social role><success><tool><transgene><transgene expression><treat HIV><treat Human Immunodeficiency Virus><vector><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease><visual function>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher W Peterson

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$819,721

FY 2026

Project Title

Developing Durable, Env-Boosted CAR T Cells for HIV Cure

Grant Number:

5R01AI170214-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/2/2022

End Date:

10/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Modification of autologous T cells with chimeric antigen receptor (CAR) molecules was first proposed nearly 30 years ago as a therapy for people living with HIV. Since then, CAR-T cells have emerged as a potent and highly successful therapy for liquid tumors, while HIV-speci...

Research Terms

<2019-nCoV vaccine><AIDS Virus><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Alleles><Allelomorphs><Allogeneic Transplantation><Animal Model><Animal Models and Related Studies><Animals><Antibodies><Antigens><Assay><Autologous><B-Cells><B-Lymphocytes><B-cell><BNT 162b2><BNT162b2><Bar Codes><Benchmarking><Berlin><Best Practice Analysis><Bioassay><Biological Assay><Biology><Blood Plasma><Blood Precursor Cell><C-C CKR-5><C-C CKR-5 Gene><C-C Chemokine Receptor Type 5><C-C Chemokine Receptor Type 5 Gene><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CC Chemokine Receptor 5><CC-CKR-5><CC-CKR-5 Gene><CC-CKR5><CCCKR5><CCCKR5 Gene><CCR-5><CCR-5 Gene><CCR5><CCR5 Protein><CCR5 Receptors><CCR5 gene><CD152><CD152 Antigen><CD152 Gene><CD195 Antigen><CD195 Antigen Gene><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CHEMR13><CHEMR13 Gene><CKR-5><CKR-5 Gene><CKR5><CKR5 Gene><CKR5 Receptors><CMKBR5><CMKBR5 Gene><COVID-19 vaccination><COVID-19 vaccine><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CTLA 4><CTLA-4 Gene><CTLA4><CTLA4 gene><CTLA4-TM><Cancer Patient><Cancers><Cas nuclease technology><Cell Body><Cell Communication><Cell Function><Cell Interaction><Cell Line><Cell Physiology><Cell Process><Cell Therapy><Cell surface><Cell-to-Cell Interaction><CellLine><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chemokine (C-C Motif) Receptor 5><Chemokine (C-C) Receptor 5><Chemokine (C-C) Receptor 5 Gene><Chromosomal dislocation><Chromosomal translocation><Clinic><Clinical Research><Clinical Study><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Cytotoxic T-Lymphocyte Protein 4><Cytotoxic T-Lymphocyte-Associated Antigen 4><Cytotoxic T-Lymphocyte-Associated Protein 4><Cytotoxic T-Lymphocyte-Associated Serine Esterase-4><DNA Therapy><Data><Developing Countries><Developing Nations><Disease><Disease remission><Disorder><Dose><Early-Stage Clinical Trials><Env trimer><Envelope Protein><Environment><Event><Experimental Designs><External Domain><Extracellular Domain><FDA approved><Future><Gene Transfer Clinical><Genes><Genetic Intervention><Genetic Translocation><Goals><Graft-Versus-Tumor Induction><HIV><HIV Env><HIV Infections><HIV cure><HIV envelope><HIV envelope protein><HIV functional cure><HIV glycoprotein Env><HIV individuals><HIV infected individuals><HIV infected persons><HIV infection persistence><HIV intervention><HIV people><HIV persistence><HIV positive individuals><HIV positive people><HIV therapeutic><HIV therapy><HIV treatment><HIV viral infection><HIV viral persistence><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 Fusion Co-Receptor><HIV-1 Fusion Co-Receptor Gene><HIV-1 cure><HIV-1 envelope><HIV-1 functional cure><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 intervention><HIV-1 persistence><HIV-1 therapeutic><HIV-1 therapy><HIV-1 treatment><HIV-I><HIV/AIDS cure><HIV1><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Homologous Transplantation><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus therapy><Human Immunodeficiency Virus treatment><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human immunodeficiency virus 1><Immune><Immunes><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Interruption><K-562><K562><K562 Cells><K562 blasts><Knowledge><LAV-HTLV-III><Learning><Less-Developed Countries><Less-Developed Nations><Leukemic Cell><Liquid substance><London><Lymphadenopathy-Associated Virus><Lymphoma cell><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Malignant><Malignant - descriptor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Malignant Neoplasms><Malignant Tumor><Messenger RNA><Modification><Molecular><NHP models><Nature><New York><PD 1><PD-1><PD-1 antibody><PD-1 blockade><PD1><PD1 antibody><PD1 blockade><PLWH><PWH><Pathway interactions><Patients><Pfizer covid19 vaccine><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pfizer/BioNTech vaccine><Phase 1 Clinical Trials><Phase I Clinical Trials><Plasma><Plasma Serum><Population Study><Procedures><Property><Public Health><Recrudescences><Refractory><Remission><Reporting><Research Design><Resistance><Reticuloendothelial System, Serum, Plasma><Rhesus Macaque><Rhesus Monkey><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><SIV><Safety><Series><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Simian Immunodeficiency Viruses><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Study Type><Subcellular Process><Supplementation><Supporting Cell><T cells for CAR><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><Technology><Third-World Countries><Third-World Nations><Time><Under-Developed Countries><Under-Developed Nations><Validation><Viral><Viral Antigens><Viral Burden><Viral Envelope Proteins><Viral Load><Viral Load result><Viral reservoir><Virus><Virus reservoir><Virus-HIV><aPD-1><aPD1><anti programmed cell death 1><anti-PD-1><anti-PD-1 Ab><anti-PD-1 antibodies><anti-PD-1 blockade><anti-PD-1 monoclonal antibodies><anti-PD1><anti-PD1 Ab><anti-PD1 antibodies><anti-PD1 blockade><anti-PD1 monoclonal antibodies><anti-programmed cell death protein 1><anti-programmed cell death protein 1 antibodies><anti-programmed death-1 antibody><antiPD-1><antiretroviral therapy><antiretroviral treatment><barcode><benchmark><blood cancer><blood cell progenitor><blood progenitor><blood stem cell><blood-forming stem cell><cancer cell><cancer of blood><cancer of the blood><cell based intervention><cell immortalization><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><challenge in rhesus macaques><check point blockade><checkpoint blockade><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><chromosome dislocation><chromosome translocation><clinical translation><clinically translatable><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><cytotoxic T-lymphocyte antigen 4><developing country><developing nation><env Antigens><env Gene Products><env Glycoproteins><env Polyproteins><env Protein><exhaustion><experiment><experimental research><experimental study><experiments><fluid><gene editing method><gene editing methodology><gene editing strategy><gene editing techniques><gene repair therapy><gene therapy><gene-based therapy><gene-editing approach><genetic therapy><genomic therapy><genotoxicity><graft-versus-tumor><hematopoietic progenitor><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><human immunodeficiency virus cure><human immunodeficiency virus infection><human immunodeficiency virus persistence><immune check point><immune check point blockade><immune checkpoint><immune checkpoint blockade><immunecheckpoint><immunogen><in vivo><individuals infected with HIV><individuals with HIV><individuals with human immunodeficiency virus><infected rhesus macaques><infected rhesus monkey><infected with HIV><infected with human immunodeficiency virus><infection in rhesus macaques><infection of rhesus macaques><interest><latent HIV reservoir><latent HIV-1 reservoir><latent HIV1 reservoir><lipid based nanoparticle><lipid nanoparticle><liquid><mRNA><mRNA lipid nano particle vaccine><mRNA-LNP based vaccine><mRNA-LNP combination vaccines><mRNA-LNP vaccines><malignancy><manufacturing process><model of animal><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle delivery><nanoparticle delivered><nanoparticle delivery><neoplasm/cancer><next generation><non-human primate><nonhuman primate><nonhuman primate models><novel><pathway><people infected with HIV><people infected with human immunodeficiency virus><people living with HIV><people with HIV><people with human immunodeficiency virus><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><phase I protocol><population research study><population survey><population-based study><population-level study><prevent><preventing><programmed cell death 1><programmed cell death protein 1><programmed death 1><programs><resistant><rhesus challenge><rhesus macaque challenge><rhesus monkey infection><safety assessment><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><sle2><stable cell line><study design><success><systemic lupus erythematosus susceptibility 2><thymus derived lymphocyte><trafficking><treat HIV><treat Human Immunodeficiency Virus><tumor><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccines preventing COVID><vaccines to prevent COVID><validations><viral rebound><virus antigen><virus rebound><αPD-1><αPD1>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexander Marson

J. DAVID GLADSTONE INSTITUTES, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$749,187

FY 2026

Project Title

Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy

Grant Number:

5R01CA276368-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Engineered T cell-based cancer therapies are a major advancement in cancer treatment; however the majority of cancers still do not respond to adoptive cellular therapy. We need to “design” new T cell therapies with increased potency, and we need to overcome cell dysfunction that occurs as T...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kole T Roybal

J. DAVID GLADSTONE INSTITUTES, SAN FRANCISCO, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$749,187

FY 2026

Project Title

Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy

Grant Number:

5R01CA276368-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Engineered T cell-based cancer therapies are a major advancement in cancer treatment; however the majority of cancers still do not respond to adoptive cellular therapy. We need to “design” new T cell therapies with increased potency, and we need to overcome cell dysfunction that occurs as T...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Abraam M. Yakoub

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$747,248

FY 2026

Project Title

Autophagon: an Autophagy-Functionalizing Gene Therapy Tool for Neurodegenerative Diseases

Grant Number:

5R01AG074899-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Neurodegenerative diseases, especially Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), affect millions of people globally and represent a US major healthcare burden. AD is the world’s most common cause of dementia, and is the sixth leading cause of death in the US. PD is motor...

Research Terms

<3-D><3-Dimensional><3D><AD dementia><AD model><AD therapy><AD treatment><Abnormal Movements><Abscission><Affect><Alzheimer Type Dementia><Alzheimer beta-Protein><Alzheimer disease dementia><Alzheimer disease treatment><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer treatment><Alzheimer's><Alzheimer's Amyloid beta-Protein><Alzheimer's Disease><Alzheimer's amyloid><Alzheimer's disease model><Alzheimer's disease therapy><Alzheimer's therapy><Alzheimers Dementia><Amentia><Ammon Horn><Amyloid Alzheimer's Dementia Amyloid Protein><Amyloid Beta-Peptide><Amyloid Protein A4><Amyloid beta-Protein><Amyloid β><Amyloid β-Peptide><Amyloid β-Protein><Animal Model><Animal Models and Related Studies><Animals><Arrhythmia><Artificial Genes><Autophagocytosis><Autophagosome><Aβ><Basic Research><Basic Science><Brain><Brain Nervous System><Brain region><Cardiac Arrhythmia><Cause of Death><Cell Aggregation><Cell Body><Cells><Chemicals><Chimera Protein><Chimeric Proteins><Clinical Evaluation><Clinical Testing><Clinical Trials><Cognitive><Cognitive deficits><Cornu Ammonis><DNA Therapy><DNA mutation><Dangerousness><Degenerative Neurologic Disorders><Degradation Pathway><Degradative Pathway><Dementia><Deposit><Deposition><Development><Disabling condition><Disabling health condition><Disease><Disorder><Drug Therapy><Drug usage><Drugs><Dyskinesias><Dyskinetic syndrome><EGFP protein><Encephalon><Engineering><Excision><Exhibits><Extirpation><Foundations><Fusion Protein><Future><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glutamates><Heart Arrhythmias><Hippocampus><Human><Impairment><In Vitro><Induced pluripotent stem cell derived human neuron><Injections><Knock-in><L-Glutamate><Learning><Licensing><Medication><Memory Deficit><Memory impairment><Mice><Mice Mammals><Modern Man><Motor><Murine><Mus><Mutation><NAC precursor><Names><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neuron Degeneration><Neurons><Organoids><Outcome><PARK1 protein><PARK4 protein><PSEN1><Paralysis Agitans><Parkinson><Parkinson Disease><Pathogenesis><Pathogenicity><Pathway interactions><Patients><Peptides><Persons><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Poly A><Poly(rA)><Population><Precision therapeutics><Preclinical Testing><Primary Parkinsonism><Primary Senile Degenerative Dementia><Process><Proteins><Psychoses><Receptor Protein><Removal><S182 protein><SNCA><SNCA protein><Specificity><Substantia Nigra><Substantia nigra structure><Surgical Removal><Synapses><Synaptic><Synthetic Genes><Testing><Therapeutic><Therapeutic Effect><Toxic effect><Toxicities><Vesicle><Viral Vector><a beta peptide><a-syn><a-synuclein><abeta><abeta accumulation><abeta aggregation><alleviate symptom><alpha synuclein><alpha synuclein gene><alphaSP22><alzheimer model><ameliorating symptom><amyloid beta><amyloid beta accumulation><amyloid beta aggregation><amyloid β accumulation><amyloid β aggregation><amyloid-b protein><asyn><autophagy><aβ accumulation><aβ aggregation><beta amyloid fibril><beta-synuclein><clinical test><cognitive defects><decrease symptom><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><delivery vector><delivery vehicle><design><designing><develop therapy><developmental><disease model><disorder model><drug candidate><drug intervention><drug treatment><drug use><drug/agent><effective therapy><effective treatment><enhanced green fluorescent protein><fewer symptoms><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><glutamatergic><health care burden><hiPSC-derived neurons><hippocampal><human iPSC-derived sensory neuron><human induced pluripotent stem cell derived sensory neuron><iPS><iPSC><iPSC-derived human neuron><iPSCs><in vivo><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><inducible pluripotent stem cell derived human neuron><inducible pluripotent stem cell derived human sensory neuron><innovate><innovation><innovative><insoluble aggregate><intervention development><knockin><memory dysfunction><model of animal><motor deficit><mouse model><murine model><mutant><name><named><naming><nerve cell death><nerve cell loss><neural degeneration><neural inflammation><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroinflammation><neuroinflammatory><neurological degeneration><neuron cell death><neuron cell loss><neuron death><neuron loss><neuron toxicity><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal degeneration><neuronal loss><neuronal survival><neuronal toxicity><neurons differentiated from human induced pluripotent stem cells><neurotoxicity><non A-beta component of AD amyloid><non A4 component of amyloid precursor><novel><pathway><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><phosphoneuroprotein 14><polyadenylate><pre-clinical testing><precision therapies><precision treatment><presenilin 1 protein><presenilin-1><prevent><preventing><primary degenerative dementia><promoter><promotor><protein aggregate><protein aggregation><receptor><recruit><reduce symptoms><relieves symptoms><research clinical testing><resection><senile dementia of the Alzheimer type><side effect><soluble amyloid precursor protein><symptom alleviation><symptom reduction><symptom relief><synapse><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic evaluation><therapeutic testing><therapy development><three dimensional><tool><treatment development><α synuclein gene><α-syn><α-synuclein>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ANTONIO C BIANCO

UNIVERSITY OF CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$709,544

FY 2026

Project Title

Thyroid Physiology Studies of Inherited Disorders

Grant Number:

5R01DK015070-52

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/15/1979

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The broad objective of this research proposal is to advance our understanding of thyroid physiology through the study of genetic defects at key regulatory processes. In addition to identification of new syndromes and gene defects, research centers on regulation of gene expression and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alexandra Mihaela Dumitrescu

UNIVERSITY OF CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$709,544

FY 2026

Project Title

Thyroid Physiology Studies of Inherited Disorders

Grant Number:

5R01DK015070-52

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/15/1979

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The broad objective of this research proposal is to advance our understanding of thyroid physiology through the study of genetic defects at key regulatory processes. In addition to identification of new syndromes and gene defects, research centers on regulation of gene expression and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Samuel Refetoff

UNIVERSITY OF CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$709,544

FY 2026

Project Title

Thyroid Physiology Studies of Inherited Disorders

Grant Number:

5R01DK015070-52

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/15/1979

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The broad objective of this research proposal is to advance our understanding of thyroid physiology through the study of genetic defects at key regulatory processes. In addition to identification of new syndromes and gene defects, research centers on regulation of gene expression and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher W Peterson

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$699,738

FY 2026

Project Title

In Vivo Gene Editing of B cells with NICE-AAV Vectors

Grant Number:

5R01AI167004-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/16/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT HIV-specific gene therapies are a powerful and promising means to achieve HIV cure/stable remission in the absence of antiretroviral therapy (ART). Broadly neutralizing antibodies (bNAbs) and analogous molecules such as eCD4-Ig offer one of the clearest paths to a cure, but are hindered by ...

Research Terms

<2019 novel corona virus><2019 novel coronavirus><2019-nCoV><7S Gamma Globulin><AAV vector><AAV-based vector><AIDS Virus><AIDS/HIV><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome Virus><Address><Adeno-Associated Viruses><Anatomic Sites><Anatomic structures><Anatomy><Animals><Antibodies><Antibody Therapy><Antigens><Assay><Autoimmune Diseases><B-Cells><B-Lymphocytes><B-cell><Bioassay><Biological Assay><Blood Serum><Body Tissues><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><COVID-19 virus><COVID19 virus><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cancers><Capsid><Cas nuclease technology><Cell Body><Cells><Clinical><Clinical Research><Clinical Study><Clinical Treatment Moab><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><CoV-2><CoV2><Communicable Diseases><DNA Therapy><Data><Dependoparvovirus><Dependovirus><Disease remission><Dose><Drugs><Engineering><Env trimer><Experimental Designs><Failure><Gene Therapy Vectors><Gene Transduction Agent><Gene Transduction Vectors><Gene Transfer Clinical><Genes><Genetic><Genetic Intervention><Goals><HIV><HIV Antibodies><HIV Env><HIV Infections><HIV cure><HIV envelope><HIV envelope protein><HIV functional cure><HIV glycoprotein Env><HIV infection persistence><HIV persistence><HIV viral infection><HIV viral persistence><HIV virus infection><HIV-1><HIV-1 Env><HIV-1 cure><HIV-1 envelope><HIV-1 functional cure><HIV-1 glycoprotein Env><HIV-1 infection><HIV-1 persistence><HIV-Associated Antibodies><HIV-I><HIV/AIDS><HIV/AIDS cure><HIV1><HTLV-III Antibodies><HTLV-III-LAV Antibodies><Human><Human Immunodeficiency Virus Type 1><Human Immunodeficiency Virus-1><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Antibodies><Human immunodeficiency virus 1><IGH><IGH@ gene cluster><IgG><IgH locus><Immune response><Immune system><Immunocompetent><Immunodeficient Mouse><Immunoglobulin G><Immunoglobulin Heavy Chain Genes><Immunoglobulin Heavy Gene><Immunoglobulin Heavy Locus><Individual><Infection><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Injections><Knock-in><LAV Antibodies><LAV-HTLV-III><Libraries><Link><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lymphadenopathy-Associated Antibodies><Lymphadenopathy-Associated Virus><Lymphatic cell><Lymphocyte><Lymphocytic><M mulatta><M. mulatta><Macaca mulatta><Macaca rhesus><Malignant Neoplasms><Malignant Tumor><Measures><Medication><Methodology><Methods><Modality><Modern Man><Monoclonal Antibodies><Monoclonal Antibody Therapy><NHP models><Nature><PBMC><Pathology><Peripheral Blood Mononuclear Cell><Pharmaceutical Preparations><Phenotype><Proteins><Publications><Publishing><Regimen><Remission><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Rhesus Macaque><Rhesus Monkey><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SHIV><Scientific Publication><Secondary to><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Site><Specificity><T cells for CAR><Technology><Testing><Therapeutic><Therapeutic Effect><Therapeutic antibodies><Time><Tissues><Transgenes><Tropism><Variant><Variation><Viral><Viral Antigens><Viremia><Virus><Virus Replication><Virus-HIV><Withdrawal><Wuhan coronavirus><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antiretroviral therapy><antiretroviral treatment><autoimmune condition><autoimmune disorder><autoimmunity disease><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical applicability><clinical application><coronavirus disease 2019 virus><coronavirus disease-19 virus><delivery vector><delivery vehicle><drug/agent><experiment><experimental research><experimental study><experiments><fighting><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene repair therapy><gene therapy><gene-based therapy><gene-editing approach><gene-editing toolkit><genetic information><genetic therapy><genomic therapy><global health><hCoV19><host response><human immunodeficiency virus cure><human immunodeficiency virus infection><human immunodeficiency virus persistence><humanized mice><humanized mouse><immune competent><immune system response><immunogen><immunogenic><immunogenicity><immunoglobulin heavy chain locus><immunoresponse><in vivo><infected with HIV><infected with human immunodeficiency virus><innovate><innovation><innovative><knockin><lymph cell><mAB-based therapy><mAb therapy><mAb-based therapeutics><mAbs><malignancy><monoclonal Abs><mouse model><murine model><nCoV2><neoplasm/cancer><neutralizing antibody><non-human primate><nonhuman primate><nonhuman primate models><novel><persistent HIV><persistent HIV-1><persistent human immunodeficiency virus><pre-clinical study><preclinical study><programs><screening><screenings><simian HIV><simian human immunodeficiency virus><success><tool><trafficking><transduction efficiency><transgene><vector><vector biodistribution><viraemia><viral multiplication><viral rebound><viral replication><viral sepsis><virus antigen><virus multiplication><virus rebound><virusemia>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Markus Grompe

OREGON HEALTH & SCIENCE UNIVERSITY, PORTLAND, OR

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$686,129

FY 2026

Project Title

Intraductal gene therapy for liver cirrhosis.

Grant Number:

1R01DK145923-01

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/16/2026

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary The liver is one of the most important organs for gene therapy of both inherited and acquired disorders. In non-fibrotic livers, the hepatocytes are accessible from the systemic blood circulation due to the fenestration of hepatic sinusoids. For this reason, most liver-directed gene ...

Research Terms

<21+ years old><Adult><Adult Human><Bile><Bile Juice><Bile fluid><Biliary><Biodistribution><Blood Circulation><Blood Volume><Bloodstream><Capillarity><Capsid><Childhood><Circulation><Cirrhosis><Clinical><Common Rat Strains><DNA Therapy><Data><Diagnostic><Disadvantaged><Disease><Disorder><Dose><Drugs><Duct><Duct (organ) structure><Eligibility><Eligibility Determination><Encapsulated><Endoscopic Retrograde Cholangiopancreatography><Exposure to><Future><Gastroenterologist><Gene Therapy Agent><Gene Therapy Vectors><Gene Transduction Agent><Gene Transduction Vectors><Gene Transfer Clinical><Genes><Genetic Intervention><Hepatic><Hepatic Cells><Hepatic Cirrhosis><Hepatic Disorder><Hepatic Parenchymal Cell><Hepatocyte><Hepatotoxic effect><Hepatotoxicity><Hereditary><Human><IGF-1><IGF-I><IGF-I-SmC><Inherited><Injections><Insulin-Like Growth Factor 1><Insulin-Like Growth Factor I><Insulin-Like Somatomedin Peptide I><Lead><Legal patent><Liver><Liver Cells><Liver Cirrhosis><Liver Toxicity><Liver diseases><Medication><Messenger RNA><Methods><Mice><Mice Mammals><Modality><Modern Man><Murine><Mus><Non-Polyadenylated RNA><Organ><Patents><Pathology><Patients><Pb element><Pharmaceutical Preparations><Procedures><Production><Protocol Screening><RNA><RNA Gene Products><Rat><Rats Mammals><Rattus><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Retrotransposon><Ribonucleic Acid><Route><Serotyping><Somatomedin C><System><Techniques><Testing><Therapeutic><Therapeutic Intervention><Toxic effect on liver cells><Work><adulthood><bile duct><bile ductule><cirrhotic><clinical implementation><drug/agent><efficacy testing><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic therapy><genomic therapy><heavy metal Pb><heavy metal lead><hepatic body system><hepatic disease><hepatic organ system><hepatic sinusoid><hepatic toxicity><hepatopathy><hepatoxicity><improved><intervention therapy><intravenous injection><lipid based nanoparticle><lipid nanoparticle><liver disorder><mRNA><nano particle><nano particle delivery><nano-sized particle><nanoparticle><nanoparticle delivered><nanoparticle delivery><nanosized particle><neutralizing antibody><pediatric><pharmacologic><rAAV><recombinant AAV><response><side effect><transduction efficiency><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Reuben Kapur

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$683,109

FY 2026

Project Title

Hypoxia's role in regulating stressed hematopoietic stem cells

Grant Number:

5R01DK139505-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

(PLEASE KEEP IN WORD, DO NOT PDF) Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Hematopoietic stem cells (HSCs) reside in the bone marrow microenvironment (BM-ME) with distinctive low oxygen tension. In contrast t...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ngoc Tung Tran

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$683,109

FY 2026

Project Title

Hypoxia's role in regulating stressed hematopoietic stem cells

Grant Number:

5R01DK139505-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

(PLEASE KEEP IN WORD, DO NOT PDF) Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. Hematopoietic stem cells (HSCs) reside in the bone marrow microenvironment (BM-ME) with distinctive low oxygen tension. In contrast t...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric J Brown

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$676,415

FY 2026

Project Title

Developing biomarkers of response for a new therapy in ovarian cancer

Grant Number:

5R01CA285965-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Clear cell ovarian cancer (CCOC) is one of the most challenging subtypes of ovarian cancer (OVCA) to treat, as it is resistant to standard chemotherapy and is associated with poor outcomes. CCOCs likely arise from endometriosis, supporting their unique molecular landscape with ARID1...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

FIONA SIMPKINS

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$676,415

FY 2026

Project Title

Developing biomarkers of response for a new therapy in ovarian cancer

Grant Number:

5R01CA285965-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2024

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Clear cell ovarian cancer (CCOC) is one of the most challenging subtypes of ovarian cancer (OVCA) to treat, as it is resistant to standard chemotherapy and is associated with poor outcomes. CCOCs likely arise from endometriosis, supporting their unique molecular landscape with ARID1...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yan Liu

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$663,582

FY 2026

Project Title

Dysregulated epigenetic control in leukemogenesis

Grant Number:

5R01CA298152-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/10/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Acute myeloid leukemia (AML) is an aggressive blood cancer that affects roughly three million Americans, and five hundred thousand people die from AML each year. Previous studies indicate that AML is initiated and maintained by a rare population of leukemia-initiating cells (LICs) th...

Research Terms

<3-D><3-Dimensional><3D><AML - Acute Myeloid Leukemia><ATAC sequencing><ATAC-seq><ATACseq><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Affect><American><Anti-Oncogenes><Antibodies><Antioncogene Protein p53><Antioncogenes><Apoptosis-Related Cysteine Protease Caspase 1><Assay><Assay for Transposase-Accessible Chromatin using sequencing><BAF155><BAF155 Gene><Beta Proprotein Interleukin 1><Bioassay><Biochemical><Biological Assay><Blood Precursor Cell><Bone Marrow><Bone Marrow Reticuloendothelial System><CASP-1><CASP1><CASP1 gene><CRACC1 Gene><Cancer Suppressor Genes><Caspase-1><Caspase-1 Gene><Cellular Tumor Antigen P53><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Remodeling Complex><Chromatin Remodeling Complex BAF155 Subunit Gene><Chromatin Remodeling Factor><Chromatin Structure><Complex><DNA Loop><DNA mutation><Development><Emerogenes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Gene Expression><Gene Transcription><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Goals><HSC regeneration><HSC self-renewal><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hi-C><Higher Order Chromatin Folding><Higher Order Chromatin Structure><Higher Order Structure><Histones><Human><ICE Protease><IL-1 beta><IL-1 beta Convertase><IL-1 beta-Converting Enzyme><IL-1 β><IL-1-b><IL-1BC><IL-1b Converting Enzyme><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1B-Convertase><IL1BC><IL1BCE><IL1F2><IL1β><Immune Precipitation><Immunoprecipitation><Impairment><In Vitro><Inflammasome><Inflammatory><Interleukin 1-B Converting Enzyme><Interleukin 1-Beta Convertase><Interleukin 1beta><Interleukin-1 Beta Converting Enzyme><Interleukin-1 Converting Enzyme><Interleukin-1 beta><Interleukin-1β><Karyotype><Knowledge><Leukemic Cell><Macromolecular Protein Complexes><Malignant><Malignant - descriptor><Malignant Hematopoietic Neoplasm><Mammalian Chromatin Remodeling Complex, BRG1-Associated Factor 155 Gene><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mating Type Switching/Sucrose Nonfermenting Protein><Mediating><Membrane><Mice><Mice Mammals><Modern Man><Molecular><Multiprotein Complexes><Murine><Mus><Mutant Strains Mice><Mutation><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncoprotein p53><Outcome><P53><Patients><Persons><Phosphoprotein P53><Phosphoprotein pp53><Population><Preinterleukin 1 Beta><Prognosis><Protein TP53><Proteins><Proteomics><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recessive Oncogenes><Regulation><Regulator Genes><Relapse><Research><Resistance><Role><SMARCC1><SMARCC1 gene><SRG3 Gene><SWI/SNF Complex><SWI/SNF Complex 155 kDa Subunit Gene><SWI/SNF Family Complex><SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily C, Member 1 Gene><SWI3 Gene><Sampling><Somatic Mutation><Structure><TP53><TP53 gene><TP53 mutated AML><TP53 mutated acute myeloid leukemia><TP53-mutant AML><TP53-mutant acute myeloid leukemia><TRP53><Transcription><Transcriptional Regulatory Elements><Treatment outcome><Tumor Protein p53><Tumor Protein p53 Gene><Tumor Suppressing Genes><Tumor Suppressor Genes><acute granulocytic leukemia><acute granulocytic leukemia cell><acute myeloblastic leukemia cell><acute myelocytic leukemia cell><acute myelogenous leukemia cell><acute myeloid leukemia><acute myeloid leukemia cell><acute nonlymphocytic leukemia cell><aposome><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><blood cancer><blood cell progenitor><blood progenitor><blood stem cell><blood stem cell regeneration><blood stem cell self-renewal><blood-forming stem cell><cancer of blood><cancer of the blood><caspase-activating complex><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><chromatin modifier><chromatin remodeling><cytokine><developmental><disease risk><disorder risk><epigenetic therapy><epigenetically><epigenome><fitness><gain of function><gene signatures><genetic signature><genetic trans acting element><genome mutation><genome scale><genome-wide><genomewide><hematopoietic progenitor><hematopoietic progenitor cell self-renewal><hematopoietic stem cell regeneration><hematopoietic stem cell self-renewal><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><improved><in vivo><inhibitor><karyogram><knock-down><knockdown><leukemia><leukemia initiating cell><leukemia treatment><leukemic therapy><leukemogenesis><membrane structure><mouse mutant><multidisciplinary><mutant><myeloid leukemia cell><neutralizing antibody><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><oncosuppressor gene><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pharmacologic><progenitor><protein p53><regeneration of blood stem cells><regulatory gene><resistance to therapy><resistant><resistant to therapy><self - renewal in hematopoietic stem cells><self-renew><self-renewal><social role><somatic variant><therapeutic resistance><therapy resistant><three dimensional><trans acting element><transcriptome sequencing><transcriptomic sequencing><treatment resistance>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

MADINA SUKHANOVA

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$663,582

FY 2026

Project Title

Dysregulated epigenetic control in leukemogenesis

Grant Number:

5R01CA298152-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/10/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Acute myeloid leukemia (AML) is an aggressive blood cancer that affects roughly three million Americans, and five hundred thousand people die from AML each year. Previous studies indicate that AML is initiated and maintained by a rare population of leukemia-initiating cells (LICs) th...

Research Terms

<3-D><3-Dimensional><3D><AML - Acute Myeloid Leukemia><ATAC sequencing><ATAC-seq><ATACseq><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Affect><American><Anti-Oncogenes><Antibodies><Antioncogene Protein p53><Antioncogenes><Apoptosis-Related Cysteine Protease Caspase 1><Assay><Assay for Transposase-Accessible Chromatin using sequencing><BAF155><BAF155 Gene><Beta Proprotein Interleukin 1><Bioassay><Biochemical><Biological Assay><Blood Precursor Cell><Bone Marrow><Bone Marrow Reticuloendothelial System><CASP-1><CASP1><CASP1 gene><CRACC1 Gene><Cancer Suppressor Genes><Caspase-1><Caspase-1 Gene><Cellular Tumor Antigen P53><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Remodeling Complex><Chromatin Remodeling Complex BAF155 Subunit Gene><Chromatin Remodeling Factor><Chromatin Structure><Complex><DNA Loop><DNA mutation><Development><Emerogenes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Gene Expression><Gene Transcription><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Goals><HSC regeneration><HSC self-renewal><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hi-C><Higher Order Chromatin Folding><Higher Order Chromatin Structure><Higher Order Structure><Histones><Human><ICE Protease><IL-1 beta><IL-1 beta Convertase><IL-1 beta-Converting Enzyme><IL-1 β><IL-1-b><IL-1BC><IL-1b Converting Enzyme><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1B-Convertase><IL1BC><IL1BCE><IL1F2><IL1β><Immune Precipitation><Immunoprecipitation><Impairment><In Vitro><Inflammasome><Inflammatory><Interleukin 1-B Converting Enzyme><Interleukin 1-Beta Convertase><Interleukin 1beta><Interleukin-1 Beta Converting Enzyme><Interleukin-1 Converting Enzyme><Interleukin-1 beta><Interleukin-1β><Karyotype><Knowledge><Leukemic Cell><Macromolecular Protein Complexes><Malignant><Malignant - descriptor><Malignant Hematopoietic Neoplasm><Mammalian Chromatin Remodeling Complex, BRG1-Associated Factor 155 Gene><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mating Type Switching/Sucrose Nonfermenting Protein><Mediating><Membrane><Mice><Mice Mammals><Modern Man><Molecular><Multiprotein Complexes><Murine><Mus><Mutant Strains Mice><Mutation><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncoprotein p53><Outcome><P53><Patients><Persons><Phosphoprotein P53><Phosphoprotein pp53><Population><Preinterleukin 1 Beta><Prognosis><Protein TP53><Proteins><Proteomics><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recessive Oncogenes><Regulation><Regulator Genes><Relapse><Research><Resistance><Role><SMARCC1><SMARCC1 gene><SRG3 Gene><SWI/SNF Complex><SWI/SNF Complex 155 kDa Subunit Gene><SWI/SNF Family Complex><SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily C, Member 1 Gene><SWI3 Gene><Sampling><Somatic Mutation><Structure><TP53><TP53 gene><TP53 mutated AML><TP53 mutated acute myeloid leukemia><TP53-mutant AML><TP53-mutant acute myeloid leukemia><TRP53><Transcription><Transcriptional Regulatory Elements><Treatment outcome><Tumor Protein p53><Tumor Protein p53 Gene><Tumor Suppressing Genes><Tumor Suppressor Genes><acute granulocytic leukemia><acute granulocytic leukemia cell><acute myeloblastic leukemia cell><acute myelocytic leukemia cell><acute myelogenous leukemia cell><acute myeloid leukemia><acute myeloid leukemia cell><acute nonlymphocytic leukemia cell><aposome><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><blood cancer><blood cell progenitor><blood progenitor><blood stem cell><blood stem cell regeneration><blood stem cell self-renewal><blood-forming stem cell><cancer of blood><cancer of the blood><caspase-activating complex><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><chromatin modifier><chromatin remodeling><cytokine><developmental><disease risk><disorder risk><epigenetic therapy><epigenetically><epigenome><fitness><gain of function><gene signatures><genetic signature><genetic trans acting element><genome mutation><genome scale><genome-wide><genomewide><hematopoietic progenitor><hematopoietic progenitor cell self-renewal><hematopoietic stem cell regeneration><hematopoietic stem cell self-renewal><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><improved><in vivo><inhibitor><karyogram><knock-down><knockdown><leukemia><leukemia initiating cell><leukemia treatment><leukemic therapy><leukemogenesis><membrane structure><mouse mutant><multidisciplinary><mutant><myeloid leukemia cell><neutralizing antibody><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><oncosuppressor gene><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pharmacologic><progenitor><protein p53><regeneration of blood stem cells><regulatory gene><resistance to therapy><resistant><resistant to therapy><self - renewal in hematopoietic stem cells><self-renew><self-renewal><social role><somatic variant><therapeutic resistance><therapy resistant><three dimensional><trans acting element><transcriptome sequencing><transcriptomic sequencing><treatment resistance>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Feng Yue

NORTHWESTERN UNIVERSITY AT CHICAGO, CHICAGO, IL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$663,582

FY 2026

Project Title

Dysregulated epigenetic control in leukemogenesis

Grant Number:

5R01CA298152-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/10/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Acute myeloid leukemia (AML) is an aggressive blood cancer that affects roughly three million Americans, and five hundred thousand people die from AML each year. Previous studies indicate that AML is initiated and maintained by a rare population of leukemia-initiating cells (LICs) th...

Research Terms

<3-D><3-Dimensional><3D><AML - Acute Myeloid Leukemia><ATAC sequencing><ATAC-seq><ATACseq><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Affect><American><Anti-Oncogenes><Antibodies><Antioncogene Protein p53><Antioncogenes><Apoptosis-Related Cysteine Protease Caspase 1><Assay><Assay for Transposase-Accessible Chromatin using sequencing><BAF155><BAF155 Gene><Beta Proprotein Interleukin 1><Bioassay><Biochemical><Biological Assay><Blood Precursor Cell><Bone Marrow><Bone Marrow Reticuloendothelial System><CASP-1><CASP1><CASP1 gene><CRACC1 Gene><Cancer Suppressor Genes><Caspase-1><Caspase-1 Gene><Cellular Tumor Antigen P53><ChIP Sequencing><ChIP-seq><ChIPseq><Chromatin><Chromatin Loop><Chromatin Loop Domains><Chromatin Remodeling Complex><Chromatin Remodeling Complex BAF155 Subunit Gene><Chromatin Remodeling Factor><Chromatin Structure><Complex><DNA Loop><DNA mutation><Development><Emerogenes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Gene Expression><Gene Transcription><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Goals><HSC regeneration><HSC self-renewal><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hi-C><Higher Order Chromatin Folding><Higher Order Chromatin Structure><Higher Order Structure><Histones><Human><ICE Protease><IL-1 beta><IL-1 beta Convertase><IL-1 beta-Converting Enzyme><IL-1 β><IL-1-b><IL-1BC><IL-1b Converting Enzyme><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1B-Convertase><IL1BC><IL1BCE><IL1F2><IL1β><Immune Precipitation><Immunoprecipitation><Impairment><In Vitro><Inflammasome><Inflammatory><Interleukin 1-B Converting Enzyme><Interleukin 1-Beta Convertase><Interleukin 1beta><Interleukin-1 Beta Converting Enzyme><Interleukin-1 Converting Enzyme><Interleukin-1 beta><Interleukin-1β><Karyotype><Knowledge><Leukemic Cell><Macromolecular Protein Complexes><Malignant><Malignant - descriptor><Malignant Hematopoietic Neoplasm><Mammalian Chromatin Remodeling Complex, BRG1-Associated Factor 155 Gene><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Mating Type Switching/Sucrose Nonfermenting Protein><Mediating><Membrane><Mice><Mice Mammals><Modern Man><Molecular><Multiprotein Complexes><Murine><Mus><Mutant Strains Mice><Mutation><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncoprotein p53><Outcome><P53><Patients><Persons><Phosphoprotein P53><Phosphoprotein pp53><Population><Preinterleukin 1 Beta><Prognosis><Protein TP53><Proteins><Proteomics><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recessive Oncogenes><Regulation><Regulator Genes><Relapse><Research><Resistance><Role><SMARCC1><SMARCC1 gene><SRG3 Gene><SWI/SNF Complex><SWI/SNF Complex 155 kDa Subunit Gene><SWI/SNF Family Complex><SWI/SNF-Related, Matrix-Associated, Actin-Dependent Regulator of Chromatin, Subfamily C, Member 1 Gene><SWI3 Gene><Sampling><Somatic Mutation><Structure><TP53><TP53 gene><TP53 mutated AML><TP53 mutated acute myeloid leukemia><TP53-mutant AML><TP53-mutant acute myeloid leukemia><TRP53><Transcription><Transcriptional Regulatory Elements><Treatment outcome><Tumor Protein p53><Tumor Protein p53 Gene><Tumor Suppressing Genes><Tumor Suppressor Genes><acute granulocytic leukemia><acute granulocytic leukemia cell><acute myeloblastic leukemia cell><acute myelocytic leukemia cell><acute myelogenous leukemia cell><acute myeloid leukemia><acute myeloid leukemia cell><acute nonlymphocytic leukemia cell><aposome><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><blood cancer><blood cell progenitor><blood progenitor><blood stem cell><blood stem cell regeneration><blood stem cell self-renewal><blood-forming stem cell><cancer of blood><cancer of the blood><caspase-activating complex><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><chromatin modifier><chromatin remodeling><cytokine><developmental><disease risk><disorder risk><epigenetic therapy><epigenetically><epigenome><fitness><gain of function><gene signatures><genetic signature><genetic trans acting element><genome mutation><genome scale><genome-wide><genomewide><hematopoietic progenitor><hematopoietic progenitor cell self-renewal><hematopoietic stem cell regeneration><hematopoietic stem cell self-renewal><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><high risk><improved><in vivo><inhibitor><karyogram><knock-down><knockdown><leukemia><leukemia initiating cell><leukemia treatment><leukemic therapy><leukemogenesis><membrane structure><mouse mutant><multidisciplinary><mutant><myeloid leukemia cell><neutralizing antibody><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><oncosuppressor gene><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pharmacologic><progenitor><protein p53><regeneration of blood stem cells><regulatory gene><resistance to therapy><resistant><resistant to therapy><self - renewal in hematopoietic stem cells><self-renew><self-renewal><social role><somatic variant><therapeutic resistance><therapy resistant><three dimensional><trans acting element><transcriptome sequencing><transcriptomic sequencing><treatment resistance>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert F. Schwabe

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$655,429

FY 2026

Project Title

Understanding and Targeting Transcriptional Master Regulators in Hepatocellular Carcinoma

Grant Number:

5R01CA289606-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Hepatocellular carcinoma (HCC) causes nearly 800,000 deaths worldwide and represents one of the fastest- rising tumors in the US. Despite recent FDA approval of combination therapies for HCC, the majority of patients die within two years. A major challenge in this context is the high genetic diversi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kirk J Wangensteen

COLUMBIA UNIVERSITY HEALTH SCIENCES, NEW YORK, NY

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$655,429

FY 2026

Project Title

Understanding and Targeting Transcriptional Master Regulators in Hepatocellular Carcinoma

Grant Number:

5R01CA289606-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Hepatocellular carcinoma (HCC) causes nearly 800,000 deaths worldwide and represents one of the fastest- rising tumors in the US. Despite recent FDA approval of combination therapies for HCC, the majority of patients die within two years. A major challenge in this context is the high genetic diversi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Elise Chong

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$650,210

FY 2026

Project Title

Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation

Grant Number:

5R01CA288473-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Our previous groundbreaking research, published in 2020 and 2023, unveiled the remarkable synergy achieved by combining oral Vancomycin with radiation therapy (RT) or Chimeric Antigen Receptor T-cell therapy (CART) in enhancing the antitumor response. This innovative approach exploited Vancomycin's ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Andrea Facciabene

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$650,210

FY 2026

Project Title

Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation

Grant Number:

5R01CA288473-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Our previous groundbreaking research, published in 2020 and 2023, unveiled the remarkable synergy achieved by combining oral Vancomycin with radiation therapy (RT) or Chimeric Antigen Receptor T-cell therapy (CART) in enhancing the antitumor response. This innovative approach exploited Vancomycin's ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Boyu Hu

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$650,210

FY 2026

Project Title

Targeting Lymphoma: A Multimodal Approach using Radiation, CART-19 Therapy, and Gut Microbiome Modulation

Grant Number:

5R01CA288473-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Our previous groundbreaking research, published in 2020 and 2023, unveiled the remarkable synergy achieved by combining oral Vancomycin with radiation therapy (RT) or Chimeric Antigen Receptor T-cell therapy (CART) in enhancing the antitumor response. This innovative approach exploited Vancomycin's ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Taofeek K Owonikoko

UNIVERSITY OF MARYLAND BALTIMORE, BALTIMORE, MD

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$646,115

FY 2026

Project Title

Targeting polo-like kinase 1 (PLK1) for treatment of small cell lung cancer

Grant Number:

5R01CA273216-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Small cell lung cancer (SCLC) is a significant health problem projected to afflict more than 35,000 new patients in the US in 2021. Less than 20% of newly diagnosed patients survive beyond 2 years. New and effective treatments are urgently needed to improve the poor outcome ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Niclas Emanuel Bengtsson

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$629,584

FY 2026

Project Title

Expression of dystrophins with enhanced function

Grant Number:

5R01AR082814-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/22/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Duchenne muscular dystrophy (DMD) is an X-linked, lethal recessive genetic disorder resulting from mutations in the DMD gene, which encodes the protein dystrophin (Dys). The 2.2 MB gene displays the highest new mutation rate of any human gene, reflecting the high DMD prevale...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JEFFREY S CHAMBERLAIN

UNIVERSITY OF WASHINGTON, SEATTLE, WA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$629,584

FY 2026

Project Title

Expression of dystrophins with enhanced function

Grant Number:

5R01AR082814-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/22/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary/Abstract Duchenne muscular dystrophy (DMD) is an X-linked, lethal recessive genetic disorder resulting from mutations in the DMD gene, which encodes the protein dystrophin (Dys). The 2.2 MB gene displays the highest new mutation rate of any human gene, reflecting the high DMD prevale...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hideki Aihara

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$619,646

FY 2026

Project Title

Structural studies of viral replication and invasion

Grant Number:

5R35GM118047-10

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/1/2016

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Abstract Viruses are a major threat to human health. Our laboratory uses various structural biology techniques to dissect molecular mechanisms of how viruses replicate and invade the host cell or its genome. One area of our major interest is retroviral integration, a critical step in the lifecycle o...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aravind Asokan

DUKE UNIVERSITY, DURHAM, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$616,213

FY 2026

Project Title

Dissecting AAV silencing in humanized mice

Grant Number:

5R01DK134408-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The liver has emerged as a promising target for expressing therapeutic transgenes utilizing Adeno-Associated Viral (AAV) vector-mediated delivery. Despite numerous clinical trials and continued progress several challenges have been identified for AAV gene therapy. In this proposal w...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Karl-Dimiter Bissig

DUKE UNIVERSITY, DURHAM, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$616,213

FY 2026

Project Title

Dissecting AAV silencing in humanized mice

Grant Number:

5R01DK134408-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The liver has emerged as a promising target for expressing therapeutic transgenes utilizing Adeno-Associated Viral (AAV) vector-mediated delivery. Despite numerous clinical trials and continued progress several challenges have been identified for AAV gene therapy. In this proposal w...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Aadel Chaudhuri

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$602,200

FY 2026

Project Title

Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer

Grant Number:

5R01CA286127-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/6/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The deadliest form of advanced-stage prostate cancer is treatment-resistant metastatic castration- resistant prostate cancer (mCRPC), which occurs in ~35% of patients after exposure to androgen receptor (AR)-directed therapies such as Abiraterone and Enzalutamide, resulting in a dism...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher A Maher

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$602,200

FY 2026

Project Title

Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer

Grant Number:

5R01CA286127-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/6/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The deadliest form of advanced-stage prostate cancer is treatment-resistant metastatic castration- resistant prostate cancer (mCRPC), which occurs in ~35% of patients after exposure to androgen receptor (AR)-directed therapies such as Abiraterone and Enzalutamide, resulting in a dism...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Russell K. Pachynski

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$602,200

FY 2026

Project Title

Novel ctDNA biomarker for androgen therapy in metastatic prostate cancer

Grant Number:

5R01CA286127-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/6/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The deadliest form of advanced-stage prostate cancer is treatment-resistant metastatic castration- resistant prostate cancer (mCRPC), which occurs in ~35% of patients after exposure to androgen receptor (AR)-directed therapies such as Abiraterone and Enzalutamide, resulting in a dism...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Marc A Sommer

DUKE UNIVERSITY, DURHAM, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$589,591

FY 2026

Project Title

Enhancement, mapping, and validation of viral vectors for primate optogenetics

Grant Number:

5R01NS125843-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/15/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Mapping the visual and visuomotor circuits of the brain using opsins and other actuators to target and control neurons is a central goal of modern neuroscience. Actuators have become key to studying neuronal circuits, modeling brain disorders, and developing new therapies. Neural act...

Research Terms

<Adeno-Associated Viruses><Anatomic Sites><Anatomic structures><Anatomy><Animal Model><Animal Models and Related Studies><Animals><Anterior Quadrigeminal Body><Area><Atlases><Basic Research><Basic Science><Behavior><Brain><Brain Diseases><Brain Disorders><Brain Nervous System><Capsid><Cell Body><Cells><Chronic><Complex><DNA Therapy><Dedications><Dependoparvovirus><Dependovirus><Disease><Disorder><Drug Therapy><Electrophysiology><Electrophysiology (science)><Encephalon><Encephalon Diseases><Enzyme Gene><Enzymes><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Gene Expression><Gene Transfer Clinical><Genes><Genetic><Genetic Intervention><Glycoproteins><Goals><Histologic><Histologically><Human><Immune response><Immune system><Immunology><Immunomodulation><In vivo analysis><Injections><Innate Immune Response><Intervention><Intracranial CNS Disorders><Intracranial Central Nervous System Disorders><Lentiviral Vector><Lentivirinae><Lentivirus><Lentivirus Vector><Light><Macaca><Macaque><Maps><Mediating><Methods><Modeling><Modern Man><Modernization><Molecular><Monkeys><Nerve Cells><Nerve Unit><Neural Cell><Neurobiology><Neurocyte><Neurons><Neurophysiology / Electrophysiology><Neurosciences><Oculomotor Muscles><Opsin><Optic Tectum><Outcome><Output><Pattern><Pharmacological Treatment><Pharmacotherapy><Photoradiation><Physiologic><Physiological><Population Forecasts><Population Projection><Primates><Primates Mammals><Proteins><Protocol><Protocols documentation><Rapamune><Rapamycin><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Regimen><Research><Rod-Opsin><Rodent><Rodentia><Rodents Mammals><Role><Sight><Sirolimus><Site><Specificity><Superior Colliculus><System><T-Cells><T-Lymphocyte><Techniques><Technology><Topoisomerase><Topoisomerase Inhibitors><Transgenes><Transportation><V1 neuron><Validation><Viral><Viral Vector><Virus><Vision><Vision research><Visual><Visual System><Work><adaptive immune response><adeno associated virus group><arm><brain disorder therapy><cell type><constitutive expression><constitutive gene expression><determine efficacy><drug intervention><drug treatment><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><efficacy validation><electrophysiological><evaluate efficacy><examine efficacy><extraocular muscle><frontal eye fields><gene repair therapy><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><genes therapeutic><genes therapeutics><genetic therapy><genomic therapy><host response><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><improved><in vivo><in vivo evaluation><in vivo testing><inhibitor><insight><interest><model of animal><neural><neural circuit><neural circuitry><neurobiological><neurocircuitry><neuronal><neuronal circuit><neuronal circuitry><neurophysiological><neurophysiology><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ocular motor><ocularmotor><oculomotor><optogenetics><orbit muscle><orbital muscle><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><prevent><preventing><promoter><promotor><rAAV><reagent testing><recombinant AAV><recruit><retinotopic map><retrograde transport><social role><success><superior colliculus Corpora quadrigemina><synaptic circuit><synaptic circuitry><therapeutic gene><thymus derived lymphocyte><tool><transgene><transgene delivery><transgene expression><validate efficacy><validations><vector><virology><visual control><visual field map><visual function><visual map><visual motor><visual neuroscience><visual tectum><visuomotor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Di Zhao

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$588,065

FY 2026

Project Title

Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer

Grant Number:

5R01CA275990-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT More than 60% of metastatic castration-resistant prostate cancers (CRPC) contain PTEN and TP53 gene deletions and mutations. To date, there are limited treatment options for this molecular subtype. The overall objective of this application is to elucidate the complex role of B7-H3 signaling...

Research Terms

<Anti-androgen Therapy><Anti-androgen Treatment><Antibody-drug conjugates><Antioncogene Protein p53><B7-H3><B7H3><Biological><Biological Function><Biological Process><Biology><CD276><CD276 gene><CTLA-4 blockade><CTLA4 blockade><Cancer Patient><Cancers><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cellular Tumor Antigen P53><Clinical><Clinical Treatment Moab><Combination immunotherapy><Complex><Cytometry><DNA mutation><Data><Defect><Development><Disease><Disease Progression><Disorder><GEM model><GEMM model><Gene Deletion><Genetic Change><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Goals><Human><Immune><Immunes><Impairment><In Vitro><Infiltration><Intracellular Communication and Signaling><MMAC1><MMAC1 protein><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Malignant neoplasm of prostate><Malignant prostatic tumor><Mediating><Modeling><Modern Man><Molecular><Monoclonal Antibodies><Mutated in Multiple Advanced Cancers 1><Mutation><Myeloid Cells><Myeloid-derived suppressor cells><Nature><Oncoprotein p53><Outcome><P53><PD 1><PD-1><PD1><PDX model><PHTS gene><PHTS protein><PTEN><PTEN gene><PTEN protein><PTEN1><Pathway interactions><Patient derived xenograft><Patients><Phenotype><Phosphatase and Tensin Homolog><Phosphatase and Tensin Homolog Deleted on Chromosome 10><Phosphoprotein P53><Phosphoprotein pp53><Pilot Projects><Play><Pre-Clinical Model><Preclinical Models><Prostate><Prostate CA><Prostate Cancer><Prostate Gland><Prostate malignancy><Prostatic Gland><Protein TP53><RB1><RB1 gene><Receptor Protein><Recurrent Malignant Neoplasm><Recurrent Malignant Tumor><Research><Resistance><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><T cell infiltration><T-Cells><T-Lymphocyte><TP53><TP53 gene><TRP53><Testing><Therapeutic><Time><Tumor Protein p53><Tumor Protein p53 Gene><Tumor-associated macrophages><Variant><Variation><advanced prostate cancer><androgen ablation therapy><androgen blockade therapy><androgen deprivation therapy><androgen deprivation treatment><androgen independent prostate cancer><androgen indifferent prostate cancer><androgen insensitive prostate cancer><androgen resistance in prostate cancer><androgen resistant prostate cancer><anti-tumor effect><antitumor effect><biologic><biological signal transduction><biomarker driven><cancer cell><cancer microenvironment><cancer recurrence><castration resistant CaP><castration resistant PCa><castration resistant prostate cancer><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><clinical relevance><clinically relevant><combinatorial immunotherapy><developmental><dual immunotherapy><expression subtypes><gene deletion mutation><genetically engineered mouse model><genetically engineered murine model><genome mutation><hormone refractory prostate cancer><immune check point><immune check point therapy><immune checkpoint><immune checkpoint therapy><immunecheckpoint><immunosuppressive myeloid cells><in vivo><inhibitor><mAbs><malignancy><molecular biomarker><molecular marker><molecular sub-types><molecular subsets><molecular subtypes><monoclonal Abs><mouse model><murine model><mutated in multiple advanced cancers 1 protein><myeloid suppressor cells><myeloid-derived suppressive cells><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><overexpress><overexpression><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient derived xenograft model><phosphatase and tensin homologue on chromosome ten><pilot study><predict responsiveness><predicting response><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><programmed cell death 1><programmed cell death protein 1><programmed death 1><prostate cancer model><prostate cancer progression><prostate cancer resistant to androgen><prostate tumor model><protein p53><receptor><resistance to therapy><resistant><resistant to therapy><response><retinoblastoma-1><sle2><social role><suppressive myeloid cells><systemic lupus erythematosus susceptibility 2><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><thymus derived lymphocyte><tool><transcriptome profiling><transcriptomic profiling><transcriptomics><treatment resistance><tumor><tumor microenvironment>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

TERRY A BRAUN

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$579,133

FY 2026

Project Title

Optimizing Genetic Testing for Deafness for Clinical Diagnostics

Grant Number:

5R01DC012049-15

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/21/2011

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Hearing loss is the most common sensory deficit in humans. It affects more than 360 million people worldwide and broadly impacts their quality of life. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. no...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Thomas L. Casavant

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$579,133

FY 2026

Project Title

Optimizing Genetic Testing for Deafness for Clinical Diagnostics

Grant Number:

5R01DC012049-15

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/21/2011

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Hearing loss is the most common sensory deficit in humans. It affects more than 360 million people worldwide and broadly impacts their quality of life. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. no...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael John Schnieders

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$579,133

FY 2026

Project Title

Optimizing Genetic Testing for Deafness for Clinical Diagnostics

Grant Number:

5R01DC012049-15

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/21/2011

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Hearing loss is the most common sensory deficit in humans. It affects more than 360 million people worldwide and broadly impacts their quality of life. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. no...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard J.H. Smith

UNIVERSITY OF IOWA, IOWA CITY, IA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$579,133

FY 2026

Project Title

Optimizing Genetic Testing for Deafness for Clinical Diagnostics

Grant Number:

5R01DC012049-15

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/21/2011

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Hearing loss is the most common sensory deficit in humans. It affects more than 360 million people worldwide and broadly impacts their quality of life. Although causality is multifactorial, in developed countries a large fraction of hearing loss is genetic and non-syndromic, i.e. no...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Terence Marques Williams

BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, DUARTE, CA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$578,672

FY 2026

Project Title

Tumor-Selective Radiosensitization by Targeting Hypoxia in Rectal Cancer

Grant Number:

5R01CA297752-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY The paradigm for treatment of locally advanced rectal cancer (LARC) has shifted to total neoadjuvant therapy (TNT), where preoperative chemotherapy and radiation therapy (RT) are delivered prior to surgery. Utilizing this approach, pathologic complete response rates of ~30% have been...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lin Zhang

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$552,778

FY 2026

Project Title

KAT6A as a novel druggable target for cancer treatment: mechanisms and therapeutic implications in KAT6A-dependent tumors

Grant Number:

5R01CA288850-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY High-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) exhibit shared clinical and genomic characteristics, including poor prognosis, homologous recombination deficiencies, and potential immunoreactivity. These diseases present a pressing and unmet medical ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

GUO-FU HU

TUFTS MEDICAL CENTER, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$552,261

FY 2026

Project Title

Angiogenin and plexin-B2 in therapeutic resistance and disease relapse of GBM

Grant Number:

5R01CA289424-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Glioblastoma (GBM) is a fatal disease. The standard of care of GBM has not changed over decades. Tumor recurrence occurs universally and the recurred GBM lacks effective therapeutics. Glioma stem cells (GSCs), which are resistant to radio- and chemo-therapy, are a major cause of GBM ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jung-Bum Shin

UNIVERSITY OF VIRGINIA, CHARLOTTESVILLE, VA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$550,334

FY 2026

Project Title

Significance of Myo7a isoforms in hair cell function

Grant Number:

2R01DC018842-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2020

End Date:

1/31/2031

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Hair cells in the cochlea rely on Myosin 7a (MYO7A) for mechanotransduction (MET), with MYO7A playing a key role in tip-link tension and sensitivity. Our previous studies revealed multiple MYO7A isoforms with distinct expression patterns in inner (IHCs) and outer hair cells (OHCs), suggesting functi...

Research Terms

<21+ years old><AAV delivered><AAV delivery><AAV-based delivery><AAV-based viral delivery><AAV-mediated delivery><ATP phosphohydrolase><ATPase><Actin-Activated ATPase><Adeno-associated-virus-based delivery><Adenosine Triphosphatase><Adult><Adult Human><Affect><Apical><Automobile Driving><Auxins><Basal Transcription Factor><Basal transcription factor genes><Binding><Binding Sites><CDH23><CDH23 gene><CDHR23><Cadherin-23><Cadherin-Related Family, Member 23><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Mechanotransduction><Cellular Physiology><Cellular Process><ChIP Sequencing><ChIP-seq><ChIPseq><Cochlea><Cochlear Organ><Combining Site><Complex><Corti Cell><Cortis Organ><Cryo-electron Microscopy><Cryoelectron Microscopy><DNA Therapy><DNA mutation><Data><Detection><Development><Doppler OCT><Electron Cryomicroscopy><Electron Microscopy><Electrophysiology><Electrophysiology (science)><Enhancers><Ensure><Exhibits><Frequencies><Funding><Gene Modified><Gene Transcription><Gene Transfer Clinical><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic Transcription><Genetic defect><Genetic mutation><Hair><Hair Cells><Hearing><Hour><Immunofluorescence><Immunofluorescence Immunologic><Individual><Inner Hair Cells><Inner ear hair cells><Internal Ear><Isoforms><KI mice><Knock-in Mouse><Knock-out><Knockout><Labyrinth><Link><MYO7A><MYO7A gene><MYO7A gene product><Measures><Mechanical Signal Transduction><Mechanics><Mechanosensory Transduction><Mice><Mice Mammals><Modeling><Molecular><Molecular Interaction><Motor><Murine><Mus><Mutate><Mutation><Myosin A><Myosin ATPase><Myosin Adenosine Triphosphatase><Myosin Adenosinetriphosphatase><Myosin IIA><Myosins><N-terminal><NH2-terminal><Natural regeneration><Neurophysiology / Electrophysiology><Non-Muscle Myosin Type IIA><Nonmuscle Myosin Type IIA><OCT Tomography><Optical Coherence Tomography><Organ of Corti><Otocadherin><Outer Hair Cells><Pattern><Permeability><Phenotype><Phytohormones><Plant Growth Regulators><Plant Hormones><Play><Position><Positioning Attribute><Presbyacusis><Presbycusis><Probability><Process><Property><Protein Isoforms><Proteins><Publishing><RNA Expression><Reactive Site><Recovery><Regeneration><Regulatory Element><Research><Rest><Role><Scanning Electron Microscopy><Sensory><Site><Spiral Organ><Spiral Organ of Corti><Subcellular Process><System><Testing><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transcriptional Control><Transcriptional Regulation><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adenovirus mediated delivery><adulthood><age associated hearing loss><age induced hearing loss><age related decline in hearing><age related hearing deficits><age related hearing impairment><age related hearing loss><aging associated hearing loss><aging induced hearing loss><aging related decline in hearing><aging related hearing deficits><aging related hearing impairment><aging related hearing loss><base><bases><cell type><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><conditional knock-out><conditional knockout><cryo-EM><cryoEM><cryogenic electron microscopy><deafness><delivered with AAV><delivery with AAV><density><developmental><differential expression><differentially expressed><driving><ear hair cell><electrophysiological><gene modification><gene repair therapy><gene replacement><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic hearing impairment><genetic hearing loss><genetic therapy><genetically modified><genome mutation><genomic therapy><hearing restoration><hereditary hearing impairment><hereditary hearing loss><in silico><inherited hearing impairment><inherited hearing loss><inner ear><insight><knockin mice><long read seq><long-read sequencing><long-read transcript sequencing><loss of function><mechanic><mechanical><mechanosensing><mechanotransduction><mouse model><murine model><mutant><myosin VIIa><optical Doppler tomography><optical coherence Doppler tomography><promoter><promotor><regenerate><repair><repaired><restoration><restore hearing><social role><sound><transcription factor><transcriptional differences>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wenge Zhu

GEORGE WASHINGTON UNIVERSITY, WASHINGTON, DC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$542,424

FY 2026

Project Title

The role of And-1 in R-loop and endocrine resistance in breast cancer

Grant Number:

5R01CA288337-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary As one type of endocrine therapy (ET) drugs, aromatase inhibitors (AIs) are the first line of treatment for ER+ breast cancer; however over 20% of patients eventually develop AI resistance during treatment. Changes in the estrogen receptor 1 (ESR1) gene, including mutations, are one ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHRISTIAN T FARRAR

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$511,947

FY 2026

Project Title

Clinically Translatable MRI Reporter Genes and Imaging Methods with Ultra-High Specificity and Sensitivity

Grant Number:

5R01EB031008-06

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2021

End Date:

12/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Magnetic resonance (MR) reporter genes have the potential to monitor transgene expression non- invasively in real time at high resolution. These genes can be applied to interrogate the efficacy of gene therapy, monitor oncolytic virotherapy, and assess cellular differentiation, cell...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jeremy N Kay

DUKE UNIVERSITY, DURHAM, NC

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$511,878

FY 2026

Project Title

Molecular and cellular requirements for Crb1 gene function in the onset and therapeutic rescue of an inherited retinal degeneration

Grant Number:

5R01EY035637-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

ABSTRACT Mutations that impair function of the CRB1 gene are among the most prevalent causes of inherited retinal de- generation. The events leading to degeneration when CRB1 is lost are unknown. To answer this question it is essential to understand the function of CRB1 at each site where it is expr...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eric T Wang

UNIVERSITY OF FLORIDA, GAINESVILLE, FL

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$508,865

FY 2026

Project Title

Smarter gene therapies: alternative splicing cassettes for tissue-and self-regulated cargo expression

Grant Number:

5R01NS132538-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/8/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

AAV-mediated gene replacement is a powerful approach to treat genetically defined disease. It is often believed that there is a straightforward path to the clinic once gene replacement efficacy is shown in preclinical models. However, major obstacles limit safe and effective gene therapy for many di...

Research Terms

<3' Untranslated Regions><3'UTR><AAV delivered><AAV delivery><AAV-based delivery><AAV-based viral delivery><AAV-mediated delivery><Adeno-associated-virus-based delivery><Alternate Splicing><Alternative RNA Splicing><Alternative Splicing><Aran-Duchenne disease><Behavior><Binding Sites><Bioinformatics><Body Tissues><CNS Nervous System><Ca2+-Activated Protease><Calcium-Activated Neutral Protease><Calcium-Activated Neutral Proteinase><Calcium-Activated Protease><Calcium-Dependent Neutral Protease><Calcium-Dependent Neutral Proteinase><Calpain><Capsid><Cell Culture Techniques><Central Nervous System><Cerebroatrophic Hyperammonemia><Clinic><Code><Coding System><Combining Site><Cruveilhier disease><DNA Replication><DNA Synthesis><DNA Therapy><DNA biosynthesis><DNA cassette><DNA mutation><DNA seq><DNA sequencing><DNAseq><Desminase><Development><Differential Gene Expression><Disease><Disorder><Dorsal Root Ganglia><Dose><Elements><Engineering><Exons><FDA approved><Focus Groups><Freidreich's Ataxia><Friedreich Ataxia><Friedreich Disease><Friedreich Spinocerebellar Ataxia><Friedreich's Familial Ataxia><Friedreich's Hereditary Ataxia><Friedreich's Hereditary Spinal Ataxia><Friedreich's tabes><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Gene Transfer Clinical><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic Transcription><Genetic defect><Genetic mutation><Genome><Heart><Hereditary Spinal Sclerosis><Individual><Intervening Sequences><Introns><Leber congenital amaurosis><Leber's amaurosis><Leber's congenital amaurosis><Limb-Girdle Muscular Dystrophies><Liver><MeCP-2 protein><MeCP2><MeCP2 protein><Measures><Mediating><Medicine><Methods><Methyl CpG binding protein MeCP2><Methyl-CpG-Binding Protein 2><Methyl-DNA binding protein MECP2><MicroRNAs><Modality><Modeling><Motor Neuron Disease><Muscle><Muscle Tissue><Mutate><Mutation><Neuraxis><Nuclear Export><Output><Papain-Like Cysteine Protease><Pattern><Phenotype><Physiologic><Physiological><Pre-Clinical Model><Preclinical Models><Proteins><Public Health><RNA Expression><RNA Processing><RNA Seq><RNA Splicing><RNA sequencing><RNA-Binding Proteins><RNAseq><Reactive Site><Regulation><Reporter><Research><Rett Disorder><Rett Syndrome><Site><Skeletal Muscle><Spinal Ganglia><Spinal Muscular Atrophy><Splicing><TAR DNA-binding protein 43><TDP-43><TDP43><Testing><Therapeutic><Tissue-Specific Differential Gene Expression><Tissue-Specific Gene Expression><Tissue-Specific Splicing><Tissues><Toxic effect><Toxicities><Tracer><Transcription><Translations><Tropism><Variant><Variation><Viral Burden><Viral Load><Viral Load result><Voluntary Muscle><Work><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adenovirus mediated delivery><amaurosis congenita of Leber><cell culture><cell cultures><cell type><congenital amaurosis of retinal origin><degenerative disorder of motor neurons><delivered with AAV><delivery with AAV><design><designing><developmental><direct application><disease model><disorder model><dorsal root ganglion><enhancer cassette><expression cassette><family ataxia><frataxin><gene cassette><gene repair therapy><gene replacement><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><genes therapeutic><genes therapeutics><genetic cassette><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><global gene expression><global transcription profile><hepatic body system><hepatic organ system><hnRNP A1><iPS><iPSC><iPSCs><improved><in vivo><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><integration cassette><knock-down><knockdown><limb-girdle muscular weakness and atrophy><limb-girdle syndrome><miRNA><miniaturize><miniaturized><muscular><myopathic limb-girdle syndrome><overexpress><overexpression><preference><preservation><promoter><promoter cassette><promotor><protein TDP-43><protein TDP43><prototype><rational design><reporter cassette><repurposing><resistance cassette><selectable cassette><selection cassette><stop cassette><therapeutic gene><transcription cassette><transcriptional cassette><transcriptome><transcriptome sequencing><transcriptomic sequencing><transduction efficiency><transgene cassette><translation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Stella M Papa

EMORY UNIVERSITY, ATLANTA, GA

Good lead · 60/100

Likely hiring

Above-average budget

Active award

$507,831

FY 2026

Project Title

Gene therapy targeting striatal dysfunction for Parkinson’s disease

Grant Number:

5R01NS126924-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.
• Award size is strong enough to merit immediate review.

Project Abstract

Project Summary Parkinson’s disease (PD) is characterized by motor abnormalities primarily caused by loss of midbrain dopamine (DA) cells, which significantly modulate striatal neurons. DA depletion is thus associated with altered function of striatal projection neurons (SPNs). SPN dysregulation is ...

Research Terms

<1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Poisoning><Abnormal Movements><Affect><Animal Model><Animal Models and Related Studies><Area><Attention><Behavior><Behavioral><Bilateral><Binding Sites><Brain><Brain Nervous System><Brain region><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell membrane><Cells><Chronic><Clinical><Clinical Trials><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive Manifestations><Cognitive Symptoms><Cognitive decline><Cognitive deficits><Cognitive function abnormal><Combining Site><Common Rat Strains><Corpus Striatum><Corpus striatum structure><Cytoplasmic Membrane><D1 receptor><D2 receptor><DNA Therapy><DRD2 Receptor><Data><Development><Disease><Disease Progression><Disorder><Disturbance in cognition><Dopamine><Dopamine D1 Receptor><Dopamine D2 Receptor><Dose><Drug Therapy><Dysfunction><Dyskinesias><Dyskinetic syndrome><Electrophysiology><Electrophysiology (science)><Encephalon><Evaluation><Evolution><Functional disorder><Gene Expression><Gene Inactivation><Gene Silencing><Gene Transfer Clinical><Genes><Genetic><Genetic Intervention><Glutamates><Grant><Health><Hydroxytyramine><Hyperactivity><Impaired cognition><Injections><Intracellular Communication and Signaling><L-Dopa><L-Glutamate><Learning><Levodopa><MPTP Neurotoxicity Syndrome><MPTP Poisoning><MPTP injury><MPTP lesion><MPTP lesioning><MPTP macaque><MPTP model><MPTP monkey><MPTP neurotoxicity><MPTP non-human primate><MPTP primate><MPTP toxicity><MPTP-Induced Parkinsonism><Measures><Memory><Mesencephalon><Mid-brain><Midbrain><Midbrain structure><Modeling><Morphology><Motor><Motor disability><Movement><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurons><Neurophysiology / Electrophysiology><Outcome Measure><Paralysis Agitans><Parkinson><Parkinson Disease><Parkinsonian><Parkinsonian Condition><Parkinsonian Diseases><Parkinsonian Disorders><Parkinsonian Syndrome><Parkinsonism><Pathologic><Patients><Performance><Periodicals><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiologic><Physiological><Physiopathology><Plasma Membrane><Play><Primary Parkinsonism><Primates><Primates Mammals><Rat><Rats Mammals><Rattus><Reactive Site><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Regulation><Research><Resolution><Rodent><Rodentia><Rodents Mammals><Role><Safety><Signal Transduction><Signal Transduction Systems><Signaling><Standard Model><Striate Body><Striatum><Structure><Synapses><Synaptic><Testing><Therapeutic Effect><Upregulation><Viral Vector><Virus><biological signal transduction><body movement><cognitive assessment><cognitive change><cognitive defects><cognitive dysfunction><cognitive loss><cognitive testing><determine efficacy><developmental><disability><disease model><disorder model><drug action><drug intervention><drug treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><electrophysiological><evaluate efficacy><examine efficacy><functional restoration><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic therapy><genomic therapy><glutamate signaling><glutamatergic><glutamatergic dendrodendritic synapses><glutamatergic signaling><improved><improved mobility><in vivo><inhibitor><knock-down><knockdown><measurable outcome><mobility enhancement><mobility improvement><model of animal><motor deficit><motor disease><motor disorder><motor dysfunction><motor impairment><motor symptom><movement impairment><movement limitation><neuronal><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><nigrostriatal degeneration><non-human primate><nonhuman primate><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><optimized mobility><optogenetics><outcome measurement><parkinsonian NHP><parkinsonian monkey><parkinsonian non-human primate><parkinsonian primate><pathophysiology><periodic><periodical><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><plasmalemma><pre-clinical study><preclinical study><promoter><promotor><rAAV><recombinant AAV><resolutions><response><restore function><restore functionality><restore lost function><safety assessment><shRNA><short hairpin RNA><social role><striatal><synapse><synapse function><synaptic function><therapeutic target><tool><toxic effects of MPTP><transcriptional silencing><translational study><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Guocai Zhong

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$487,740

FY 2026

Project Title

Synthetic RNA Switch-Based Temporal and Dose Control of in Vivo Gene Therapies

Grant Number:

5R01EB037025-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY One-time in vivo gene therapies, based on adeno-associated viral (AAV) vector delivery of genes encoding therapeutic proteins, noncoding RNAs, or genome/epigenome editors, may provide long-lasting (years of, or even lifelong) treatments or cures for many rare and common diseases. How...

Research Terms

<2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><3' Untranslated Regions><3'UTR><AAV delivered><AAV delivery><AAV vector><AAV-based delivery><AAV-based vector><AAV-based viral delivery><AAV-mediated delivery><ACE2><Adeno-associated-virus-based delivery><Adverse Experience><Adverse effects><Adverse event><Anemia><Animals><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Biological><Biological Agent><Biological Products><COVID-19><COVID-19 infection><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus infection><COVID19 infection><CV-19><Catalytic RNA><Cell Culture Techniques><Chemicals><Chronic><Circulation><Communicable Diseases><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><DNA Therapy><DNA editor><Development><Devices><Disease><Disease Progression><Disorder><Dose><Drugs><Duchene><Duchenne><Duchenne muscular dystrophy><Duchenne-Griesinger syndrome><ECSF><Ebola><Ellis-van Creveld (EvC) syndrome><Endocrine Gland Secretion><Engineering><Episome><Epoetin><Erythropoietin><Friends><Functional RNA><Gene Delivery><Gene Expression><Gene Transfer Clinical><Genetic><Genetic Intervention><Genome><Goals><HIV Infections><HIV viral infection><HIV virus infection><HIV-1 infection><Half-Life><Hormones><Human><Immune><Immunes><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunosuppressed Host><Individual><Infection by HIV-1><Infection from HIV-1><Infection of HIV-1><Infectious Diseases><Infectious Disorder><Interphase Cell><Kinetics><Ligands><Luciferase Immunologic><Luciferases><Mediating><Medication><Mice><Mice Mammals><Miscellaneous Antibiotic><Modern Man><Murine><Mus><Muscle><Muscle Tissue><Non-Polyadenylated RNA><Non-dividing Cell><Noncoding RNA><Nondividing Cell><Nontranslated RNA><Oligo><Oligonucleotides><Orthocoronavirinae><Overdose><Peripheral><Pharmaceutical Preparations><Prophylactic treatment><Prophylaxis><Proteins><Pseudohypertrophic Muscular Dystrophy><RNA><RNA Gene Products><Rapamune><Rapamycin><Receptor Protein><Regulation><Reporter><Repression><Resting Cell><Ribonucleic Acid><Ribozymes><SARS-CoV-2 infection><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2 infection><Safety><Serious Adverse Event><Severe Adverse Event><Severe acute respiratory syndrome coronavirus 2 infection><Sirolimus><Somatic Cell><System><Technology><Tetracyclines><Therapeutic><Therapeutic Hormone><Time><Transgenes><Untranslated RNA><Viral><Viral Genes><Viral Vector><X-linked dilated cardiomyopathy><X-linked muscular dystrophy><X-linked recessive muscular dystrophy><adeno-associated viral vector><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adeno-associated virus vector><adenovirus mediated delivery><angiotensin converting enzyme 2><angiotensin converting enzyme II><benign X-linked recessive muscular dystrophy><biologic><biologics><biopharmaceutical><biotherapeutic agent><cell culture><cell cultures><childhood pseudohypertrophic muscular dystrophy><classic X-linked recessive muscular dystrophy><corona virus><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease-19><coronavirus infectious disease-19><coronavirus of pandemic concern><coronavirus of pandemic potential><coronavirus with pandemic potential><cytokine><delivered with AAV><delivery with AAV><developmental><drug/agent><epigenome><erythrocyte colony stimulating factor><expression vector><feasibility testing><gene editor><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome editor><genomic therapy><hematopoietin><high risk group><high risk individual><high risk people><high risk population><human disease><human immunodeficiency virus infection><immunosuppressed patient><improved><in vivo><infected with COVID-19><infected with COVID19><infected with HIV><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with human immunodeficiency virus><infected with severe acute respiratory syndrome coronavirus 2><infection with SARS-CoV-2><mild X-linked recessive muscular dystrophy><mouse model><murine model><muscular><native protein drug><neuron toxicity><neuronal toxicity><neurotoxicity><neutralizing antibody><noncoding><novel><oligos><pandemic coronavirus><pandemic threat coronavirus><pharmaceutical protein><progressive muscular dystrophy of childhood><protein drug agent><protein-based drug><prototype><pseudohypertrophic adult muscular dystrophy><pseudohypertrophic muscular paralysis><rare genetic disease><rare genetic disorder><receptor><serious adverse experience><serious adverse reaction><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><side effect><therapeutic protein><transgene><transgene expression>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Isaac Hilton

RICE UNIVERSITY, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$484,203

FY 2026

Project Title

Engineering therapeutic cellular functions using robust and highly programmable extrachromosomal genetic technologies

Grant Number:

5R01EB036003-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/1/2024

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT Current strategies to engineer human cells for cell-based therapeutics and biotechnologies rely upon the genomic integration of transgenic payloads. Although these approaches have catalyzed transformative medical advances, the integration of transgenic DNA permanently disrup...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yongsheng Shi

UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$479,905

FY 2026

Project Title

Mechanisms and regulation of mRNA 3' processing

Grant Number:

5R35GM149294-04

Activity Code:

R35

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project summary: The long-term goal of my research program is to understand, in detail, the mechanisms of mammalian mRNA 3’ processing and its regulation. mRNA 3’-end formation, typically involving an endonucleolytic cleavage followed by polyadenylation, is an essential step of eukaryotic gene expre...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Stephen D. Nimer

UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, CORAL GABLES, FL

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$456,796

FY 2026

Project Title

Targeted therapy for t(8;21)+ AML

Grant Number:

5R01CA166835-13

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/17/2012

End Date:

2/28/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Acute myeloid leukemia (AML) remains one of the most difficult-to-treat malignancies, with most patients receiving decades old chemotherapy agents and experiencing relapse and/or refractory disease. Finally, targeted therapies are making their way into the treatment of AML, and we ar...

Research Terms

<21+ years old><AKT><AML - Acute Myeloid Leukemia><AML1><AML1-ETO><AML1-ETO fusion protein><AML1-MTG8><AMLCR1><Acetylation><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Acute leukemia><Adult><Adult Human><Affect><Akt protein><BA2R><Basal Transcription Factor><Basal transcription factor genes><Behavior><Binding><Biochemical><Biological><Biology><Bromodomain><CBFA2><CCG1><Cancers><Cell Communication and Signaling><Cell Cycle Gene 1><Cell Signaling><Childhood Leukemia><Chromatin><Complex><DNA><Data><Deoxyribonucleic Acid><Development><Disease><Disorder><E1A Binding Protein p300><EP300><EP300 gene><ETS Family Protein><ETS Protein><ETS Variant Gene 6><ETS-Domain Transcription Factor><ETV6><ETV6 gene><Eight-Twenty-One><Enhancers><Event><FLK2><FLT3><FLT3 gene><FMS-like tyrosine kinase 3><Fms-Related Tyrosine Kinase 3><Gene Activation><Gene Down-Regulation><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic Transcription><Growth><HSC regeneration><HSC self-renewal><Human Cell Line><Impairment><Intracellular Communication and Signaling><KAT3B><L-Lysine><LYL1><LYL1 gene><Link><Lymphoblastic Leukemia Derived Sequence 1><Lysine><MLL rearranged><MLL rearrangement><MLL-rearranged leukemia><Maintenance><Malignant Neoplasms><Malignant Tumor><Mediating><Molecular><Molecular Interaction><Mutate><Myelogenous><Myeloid><Oncogenic><PEBP2A2><PEBP2aB><Pathway interactions><Patients><Pediatric Leukemia><Proliferating><Protein Kinase B><Proteins><Proto-Oncogene Proteins c-akt><RAC-PK protein><RNA Expression><RUNX1><RUNX1 gene><Recurrent disease><Refractory Disease><Regulation><Relapsed Disease><Repression><Repressor Proteins><Role><STK-1 kinase><STK1><Signal Pathway><Signal Transduction><Signal Transduction Pathway><Signal Transduction Systems><Signaling><Signaling Molecule><Stem Cell Tyrosine Kinase 1><TAF1><TAF1 RNA Polymerase II TATA Box Binding Protein-Associated Factor 250-kD><TAF1 gene><TAF12><TAF12 gene><TAF2A><TAF2J><TAFII20><TAFII250><TATA Box-Binding Protein-Associated Factor 2A><TBP-Associated Factor RNA Polymerase II 250-kD><TEL Gene><TFIID><Testing><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription factor genes><Upregulation><acute granulocytic leukemia><acute myeloid leukemia><adulthood><biologic><biological signal transduction><blood stem cell regeneration><blood stem cell self-renewal><c-akt protein><chemotherapy><children with leukemia><cofactor><developmental><experience><fetal liver kinase-2><fetal liver kinase-3><gene repression><genomic data><genomic dataset><hematopoietic progenitor cell self-renewal><hematopoietic stem cell regeneration><hematopoietic stem cell self-renewal><histone acetyltransferase p300><inhibitor><leukemia><leukemia in children><leukemogenesis><malignancy><mouse model><murine model><neoplasm/cancer><novel><ontogeny><p300><pathway><progenitor cell regeneration><progenitor cell self renewal><progenitor regeneration><progenitor self renewal><proto-oncogene protein RAC><proto-oncogene protein akt><rac protein kinase><regeneration of blood stem cells><related to A and C-protein><repressor complex><self - renewal in hematopoietic stem cells><self-renew><self-renewal><social role><stem and progenitor cell regeneration><stem and progenitor cell self renewal><stem cell regeneration><stem cell self renewal><t(821)><t(821) AML><t(821) acute myeloid leukemia><t(821)(q22q22)><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcription factor><treatment strategy>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sami Nimer Malek

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$450,501

FY 2026

Project Title

Genes regulating stem and progenitor cell expansion and relapse in Acute Myeloid Leukemia

Grant Number:

5R01CA291806-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/10/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Acute myelogenous leukemia (AML) is diagnosed in 21,450 adult patients in the US per year with a five-year survival rate of 29%. Standard AML therapy comprises chemotherapy induction to achieve leukemia cytoreduction, followed by cycles of consolidation chemotherapy alone and/or followed by allogene...

Research Terms

<21+ years old><AML - Acute Myeloid Leukemia><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Adult><Adult Human><Affect><Age><Allo BMT><Allogeneic BMT><Allogeneic Bone Marrow Transplantation><Antioncogene Protein p53><Apical><Area><B23><Blood Cells><Blood Precursor Cell><Bone Marrow><Bone Marrow Reticuloendothelial System><C-K-RAS><CD34><CD34 gene><CRISPR approach><CRISPR based approach><CRISPR editing screen><CRISPR method><CRISPR methodology><CRISPR screen><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based screen><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 screen><CRISPR/Cas9 technology><Candidate Disease Gene><Candidate Gene><Cas nuclease technology><Cell Body><Cell Survival><Cell Viability><Cells><Cellular Tumor Antigen P53><Cerubidin><Cessation of life><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Clinical><Clonal expansion of hematopoietic cells><Clonal expansion of hematopoietic stem cells><Clonal hematopoietic expansion><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Combination Chemotherapy Regimen><Credentialing><Cytogenetics><DNA mutation><DNMT3a><Data><Dauno-Rubidomycine><Daunoblastina><Daunoblastine><Daunomycin><Daunorrubicina><Daunorubicin><Death><Development><Diagnosis><Disease><Disease remission><Disorder><Dose><Effectiveness><Exposure to><FLK2><FLT3><FLT3 gene><FMS-like tyrosine kinase 3><Fms-Related Tyrosine Kinase 3><Gene Alteration><Gene Inactivation><Gene Mutation><Gene Pool><Gene Silencing><General Prognostic Factor><Generalized Growth><Genes><Genetic><Genetic Change><Genetic defect><Genetic mutation><Goals><Growth><HPCA1><Hematopoiesis><Hematopoietic Cellular Control Mechanisms><Hematopoietic Progenitor Cells><Hematopoietic stem cells><Heterograft><Heterologous Transplantation><Human><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KRAS><KRAS2><KRAS2 gene><Ki-RAS><Leukaemomycin C><Leukemic Cell><Leukemic progenitor and stem cell><Life><Measurement><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><Mutation><N-RAS><NPM><NPM1><NPM1 gene><NRAS gene><Neuroblastoma RAS viral oncogene><Non-Malignant><Oncogene K-Ras><Oncoprotein p53><Ondena><P53><Pathogenesis><Pathway interactions><Patients><Peripheral Blood Cell><Phase><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Population><Preleukemia><Process><Productivity><Progenitor Cells><Prognostic Factor><Prognostic/Survival Factor><Property><Protein TP53><Publishing><Quimioterapia><R Plasmids><RASK2><Recurrence><Recurrent><Recurrent disease><Relapse><Relapsed Disease><Remission><Resistance><Risk><Rubidomycin><Rubilem><Rubomycin><Rubomycin C><STK-1 kinase><STK1><Sampling><Spinal Column><Spine><Stem Cell Tyrosine Kinase 1><Survival Rate><TP53><TP53 gene><TRP53><Therapeutic><Tissue Growth><Tumor Protein p53><Tumor Protein p53 Gene><Validation><Vertebral column><Work><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><acute granulocytic leukemia><acute granulocytic leukemia cell><acute leukemia cell><acute myeloblastic leukemia cell><acute myelocytic leukemia cell><acute myelogenous leukemia cell><acute myeloid leukemia><acute myeloid leukemia cell><acute nonlymphocytic leukemia cell><adulthood><ages><allogeneic bone marrow transplant><allogenic bone marrow transplant><backbone><blood cell formation><blood cell progenitor><blood progenitor><blood stem cell><blood-forming stem cell><bone marrow allograft><cancer chemotherapy><cell type><cerubidine><chemotherapy><clinical practice><clinical remission><clonal expansions in the blood><clonal hematopoiesis><clones in hematopoietic cells><clustered regularly interspaced short palindromic repeats screen><developmental><fetal liver kinase-2><fetal liver kinase-3><gene defect><genome mutation><hDNA methyltransferase 3a><hematopoietic cell clones><hematopoietic progenitor><hematopoietic stem cell clonality><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><human model><human progenitor><human stem cells><improved><innovate><innovation><innovative><interest><irradiation><leukemia><leukemia relapse><leukemia stem/initiating cells><leukemia treatment><leukemic progenitor><leukemic stem cell><leukemic therapy><leukemic transformation><model of human><mutant allele><nonmalignant><novel><ontogeny><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><progenitor biology><progenitor cell biology><progenitor cell expansion><progenitor expansion><protein p53><recurrent leukemia><resistance factors><resistant><response><scRNA sequencing><scRNA-seq><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><stem><stem and progenitor biology><stem and progenitor cell expansion><stem cell biology><stem cell expansion><stem cells><transcriptional silencing><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog><validations><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Heather M O'Hagan

INDIANA UNIVERSITY INDIANAPOLIS, INDIANAPOLIS, IN

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$437,183

FY 2026

Project Title

Targeting LSD1 to prevent therapy-induced transdifferentiation in BRAF mutant colorectal cancer

Grant Number:

5R01CA286090-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY/ABSTRACT BRAF activating mutations occur in approximately 10% of metastatic colorectal cancers (CRCs) and are associated with worse prognosis due to an inferior response to standard chemotherapies. Current standard of care for patients with metastatic BRAFV600E CRC who have received ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rodolfo E De la Vega Amador

MAYO CLINIC ROCHESTER, ROCHESTER, MN

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$432,145

FY 2026

Project Title

A novel, clinically expedient, AAV-based gene therapy for bone healing

Grant Number:

5R01AR085016-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract This project will develop a novel gene therapy for bone healing based upon new insights from our laboratory on the osteogenic properties of transgenic bone morphogenetic protein-2 (BMP-2), its modulation by inflammatory mediators, especially interleukin-1 (IL-1), and the biology of the heal...

Research Terms

<21+ years old><Abscission><Ad vector><Adeno-Associated Viruses><Adenoviral Vector><Adenoviridae><Adenovirus Vector><Adenoviruses><Adult><Adult Human><Allografting><Animals><Antibody titer measurement><Area><Arg-Gly-Asp><Arginine-Glycine-Aspartic Acid Cell Adhesion Domain><Arthritis><Autologous><BMP-2><BMP-2A><BMP2><BMP2 gene><BMP2A Gene><Biological><Biology><Blood><Blood Reticuloendothelial System><Body Tissues><Bone Formation><Bone Grafting><Bone Growth><Bone Morphogenetic Protein 2 Gene><Bone Morphogenetic Protein 2A Gene><Bone Transplantation><Cadaver><Capsid><Cell Body><Cells><Chondrogenesis><Clinical><Clinical Trials><Collagen><Common Rat Strains><Complementary DNA><DNA Therapy><Data><Defect><Degenerative Arthritis><Degenerative polyarthritis><Dependoparvovirus><Dependovirus><Development><Dose><ELISA><Early-Stage Clinical Trials><Effectiveness><Engineering><Enzyme-Linked Immunosorbent Assay><Excision><Extirpation><FDA approved><Female><Femur><Fracture><Gene Transfer><Gene Transfer Clinical><Genetic Intervention><Genetic Markers><Genetic Materials><Grafting Procedure><Green Fluorescent Proteins><Harvest><Histology><Human><IL-1><IL-1ra><IL1><IL1 febrile inhibitor><IL1RN><Implant><In Situ Hybridization><In Vitro><Inferior><Inflammation Mediators><Inflammatory><Inflammatory Response><Integrin Binding><Interleukin I><Interleukin-1><Interleukin-1 Receptor Antagonist><Knee joint><Laboratories><Lesion><Location><Luciferase Immunologic><Luciferases><Lymphocyte-Stimulating Hormone><Macrophage Cell Factor><Measures><Mechanics><Mediating><Medical Care Costs><Mesenchymal Progenitor Cell><Mesenchymal Stem Cells><Mesenchymal progenitor><Mesenchymal stromal/stem cells><Mind><Modeling><Modern Man><Morbidity><Natural regeneration><Operative Procedures><Operative Surgical Procedures><Organ Transplantation><Organ Transplants><Orthopedic><Orthopedic Surgical Profession><Orthopedics><Osteoarthritis><Osteoarthrosis><Osteogenesis><Pathway interactions><Patients><Phase 1 Clinical Trials><Phase I Clinical Trials><Physiologic Ossification><Physiological Ossification><Porifera><Position><Positioning Attribute><Procedures><Property><RGD (sequence)><RGD Cell Adhesion Domain><RGD Domain><RGD Motif><RGD Tripeptide Sequence><RGD peptide><RGD tripeptide><RT-PCR><Rat><Rats Mammals><Rattus><Regeneration><Removal><Research><Reverse Transcriptase Polymerase Chain Reaction><Route><Serotyping><Site><Source><Sponges><Surgical><Surgical Interventions><Surgical Procedure><Surgical Removal><T Helper Factor><Testing><Thigh><Thigh structure><Time><Tissues><Transgenic Organisms><Translating><Translational Research><Translational Science><Tropism><United States><Work><X-ray microtomography><Xray microtomography><adeno associated virus group><adeno vector><adenovector><adulthood><allogenic bone graft><allogenic bone transplantation><allograft bone transplant><anakinra><antibody titering><arginyl-glycyl-aspartic acid><arthritic><biologic><bone><bone allograft><bone fracture><bone healing><bone morphogenetic protein 2><bone tissue formation><bone transplant><bone wound healing><cDNA><cadaveric><cadavers><cell transduction><cellular transduction><clinical translation><clinically translatable><cost><degenerative joint disease><developmental><differentiation factors><disability><enzyme linked immunoassay><gene biomarker><gene expression biomarker><gene marker><gene repair therapy><gene signature biomarker><gene therapy><gene-based therapy><genetic biomarker><genetic therapy><genomic therapy><graft failure><healing><hypertrophic arthritis><imaging system><implantation><in situ Hybridization Genetics><in situ Hybridization Staining Method><in vivo><inflammatory mediator><inflammatory modulation><insight><integrin bound><interleukin 1 receptor antagonist protein><lymphocyte activating factor><male><mechanic><mechanical><medical costs><medical expenses><mesenchymal stromal cell><mesenchymal stromal progenitor cells><mesenchymal-derived stem cells><micro CT><micro computed tomography><microCT><microtomography><milligram><morphogenic factors><morphogens><neutralizing antibody><normal ossification><novel><organ allograft><organ graft><organ xenograft><osseous wound healing><ossification><osteogenic><pathway><phase I protocol><pre-clinical development><preclinical development><profound disability><recombinant human bone morphogenetic protein-2><regenerate><resection><reverse transcriptase PCR><rhBMP-2><scRNA sequencing><scRNA-seq><serious disability><severe disability><sex><side effect><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><skeletal><standard care><standard treatment><surgery><transduced cells><transduction efficiency><transgene expression><transgenic><translation research><translational investigation><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><vector><♀><♂>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CHRISTOPHER Howard EVANS

MAYO CLINIC ROCHESTER, ROCHESTER, MN

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$432,145

FY 2026

Project Title

A novel, clinically expedient, AAV-based gene therapy for bone healing

Grant Number:

5R01AR085016-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2025

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract This project will develop a novel gene therapy for bone healing based upon new insights from our laboratory on the osteogenic properties of transgenic bone morphogenetic protein-2 (BMP-2), its modulation by inflammatory mediators, especially interleukin-1 (IL-1), and the biology of the heal...

Research Terms

<21+ years old><Abscission><Ad vector><Adeno-Associated Viruses><Adenoviral Vector><Adenoviridae><Adenovirus Vector><Adenoviruses><Adult><Adult Human><Allografting><Animals><Antibody titer measurement><Area><Arg-Gly-Asp><Arginine-Glycine-Aspartic Acid Cell Adhesion Domain><Arthritis><Autologous><BMP-2><BMP-2A><BMP2><BMP2 gene><BMP2A Gene><Biological><Biology><Blood><Blood Reticuloendothelial System><Body Tissues><Bone Formation><Bone Grafting><Bone Growth><Bone Morphogenetic Protein 2 Gene><Bone Morphogenetic Protein 2A Gene><Bone Transplantation><Cadaver><Capsid><Cell Body><Cells><Chondrogenesis><Clinical><Clinical Trials><Collagen><Common Rat Strains><Complementary DNA><DNA Therapy><Data><Defect><Degenerative Arthritis><Degenerative polyarthritis><Dependoparvovirus><Dependovirus><Development><Dose><ELISA><Early-Stage Clinical Trials><Effectiveness><Engineering><Enzyme-Linked Immunosorbent Assay><Excision><Extirpation><FDA approved><Female><Femur><Fracture><Gene Transfer><Gene Transfer Clinical><Genetic Intervention><Genetic Markers><Genetic Materials><Grafting Procedure><Green Fluorescent Proteins><Harvest><Histology><Human><IL-1><IL-1ra><IL1><IL1 febrile inhibitor><IL1RN><Implant><In Situ Hybridization><In Vitro><Inferior><Inflammation Mediators><Inflammatory><Inflammatory Response><Integrin Binding><Interleukin I><Interleukin-1><Interleukin-1 Receptor Antagonist><Knee joint><Laboratories><Lesion><Location><Luciferase Immunologic><Luciferases><Lymphocyte-Stimulating Hormone><Macrophage Cell Factor><Measures><Mechanics><Mediating><Medical Care Costs><Mesenchymal Progenitor Cell><Mesenchymal Stem Cells><Mesenchymal progenitor><Mesenchymal stromal/stem cells><Mind><Modeling><Modern Man><Morbidity><Natural regeneration><Operative Procedures><Operative Surgical Procedures><Organ Transplantation><Organ Transplants><Orthopedic><Orthopedic Surgical Profession><Orthopedics><Osteoarthritis><Osteoarthrosis><Osteogenesis><Pathway interactions><Patients><Phase 1 Clinical Trials><Phase I Clinical Trials><Physiologic Ossification><Physiological Ossification><Porifera><Position><Positioning Attribute><Procedures><Property><RGD (sequence)><RGD Cell Adhesion Domain><RGD Domain><RGD Motif><RGD Tripeptide Sequence><RGD peptide><RGD tripeptide><RT-PCR><Rat><Rats Mammals><Rattus><Regeneration><Removal><Research><Reverse Transcriptase Polymerase Chain Reaction><Route><Serotyping><Site><Source><Sponges><Surgical><Surgical Interventions><Surgical Procedure><Surgical Removal><T Helper Factor><Testing><Thigh><Thigh structure><Time><Tissues><Transgenic Organisms><Translating><Translational Research><Translational Science><Tropism><United States><Work><X-ray microtomography><Xray microtomography><adeno associated virus group><adeno vector><adenovector><adulthood><allogenic bone graft><allogenic bone transplantation><allograft bone transplant><anakinra><antibody titering><arginyl-glycyl-aspartic acid><arthritic><biologic><bone><bone allograft><bone fracture><bone healing><bone morphogenetic protein 2><bone tissue formation><bone transplant><bone wound healing><cDNA><cadaveric><cadavers><cell transduction><cellular transduction><clinical translation><clinically translatable><cost><degenerative joint disease><developmental><differentiation factors><disability><enzyme linked immunoassay><gene biomarker><gene expression biomarker><gene marker><gene repair therapy><gene signature biomarker><gene therapy><gene-based therapy><genetic biomarker><genetic therapy><genomic therapy><graft failure><healing><hypertrophic arthritis><imaging system><implantation><in situ Hybridization Genetics><in situ Hybridization Staining Method><in vivo><inflammatory mediator><inflammatory modulation><insight><integrin bound><interleukin 1 receptor antagonist protein><lymphocyte activating factor><male><mechanic><mechanical><medical costs><medical expenses><mesenchymal stromal cell><mesenchymal stromal progenitor cells><mesenchymal-derived stem cells><micro CT><micro computed tomography><microCT><microtomography><milligram><morphogenic factors><morphogens><neutralizing antibody><normal ossification><novel><organ allograft><organ graft><organ xenograft><osseous wound healing><ossification><osteogenic><pathway><phase I protocol><pre-clinical development><preclinical development><profound disability><recombinant human bone morphogenetic protein-2><regenerate><resection><reverse transcriptase PCR><rhBMP-2><scRNA sequencing><scRNA-seq><serious disability><severe disability><sex><side effect><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><skeletal><standard care><standard treatment><surgery><transduced cells><transduction efficiency><transgene expression><transgenic><translation research><translational investigation><urine IL-1 inhibitor><urine interleukin 1 inhibitor><urine-derived IL1 inhibitor><vector><♀><♂>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Erinn B Rankin

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$429,345

FY 2026

Project Title

The role of the RNA demethylase FTO in metabolic reprogramming of renal cell carcinoma

Grant Number:

5R01CA272432-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/10/2023

End Date:

2/29/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Kidney cancer is increasing in prevalence and is one of the top 10 most common cancers world-wide. Clear cell renal cell carcinoma (ccRCC) is the most common and aggressive type of kidney cancer. While primary ccRCC is treated with surgery, 30% of patients are diagnosed with regionally adva...

Research Terms

<3-D><3-Dimensional><3D><Address><Amino Acid Channel><Amino Acid Transport Systems><Amino Acid Transporter><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Inhibitors><Angiostatic Agents><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><Apoptosis><Apoptosis Pathway><Assay><Automobile Driving><Bioassay><Biological Assay><Biological Markers><CAT scan><CT X Ray><CT Xray><CT imaging><CT scan><Cancers><Carcinoma Cell><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><Cell Survival><Cell Viability><CellLine><Cells><Cellular Expansion><Cellular Growth><Cerebroretinal Angiomatosis><Clear cell renal cell carcinoma><Clinic><Combined Modality Therapy><Compensation><Computed Tomography><Consumption><Data><Development><Diagnosis><Disease><Disorder><Familial Cerebello-Retinal Angiomatosis><Familial Cerebelloretinal Angiomatosis><Foundations><Generalized Growth><Gln><Glutamine><Grawitz Tumor><Growth><Hippel Lindau syndrome><Hippel-Lindau Disease><Hypernephroid Carcinoma><Hypernephroma><Hypoxia><Hypoxic><Immune mediated therapy><Immunocompetent><Immunologically Directed Therapy><Immunotherapy><Intermediary Metabolism><Intracellular Communication and Signaling><Kidney Cancer><Kidney Carcinoma><Knowledge><L-Glutamine><Lindau Disease><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Malignant Cell><Malignant Epithelial Cell><Malignant Neoplasms><Malignant Tumor><Maps><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Messenger RNA><Metabolic><Metabolic Processes><Metabolism><Methylation><Mission><Modeling><Modification><Molecular><Monitor><Multimodal Therapy><Multimodal Treatment><NIH><NMR Imaging><NMR Tomography><National Institutes of Health><Neovascularization Inhibitors><Nephroid Carcinoma><Non-Polyadenylated RNA><Nuclear Magnetic Resonance Imaging><Oncogenic><Operative Procedures><Operative Surgical Procedures><Oxygen Deficiency><PDX model><PET/CT><PET/CT scan><Patient derived xenograft><Patients><Phenocopy><Play><Prevalence><Programmed Cell Death><Proliferating><Proteins><Public Health><Q Levoglutamide><Q. Levoglutamide><RNA><RNA Gene Products><RNA methylation><Reader><Renal Adenocarcinoma><Renal Cancer><Renal Carcinoma><Renal Cell Adenocarcinoma><Renal Cell Cancer><Renal Cell Carcinoma><Research><Resistance><Ribonucleic Acid><Role><SYS-TX><Safety><Signal Transduction><Signal Transduction Systems><Signaling><Site><Strains Cell Lines><Surgical><Surgical Interventions><Surgical Procedure><Survival Rate><Systemic Therapy><Testing><Therapeutic><Therapeutic Agents><Time><Tissue Growth><Tomodensitometry><Translating><Translations><Tumor Suppressor Proteins><Tumor Weights><United States National Institutes of Health><VHL gene><Von Hippel-Lindau Syndrome><Woman><Work><X-Ray CAT Scan><X-Ray Computed Tomography><X-Ray Computerized Tomography><Xray CAT scan><Xray Computed Tomography><Xray computerized tomography><Zeugmatography><advanced disease><advanced illness><angiogenesis><antiangiogenic><bio-markers><biologic marker><biological signal transduction><biomarker><cancer cell><cancer cell metabolism><cancer metabolism><cancer microenvironment><carboxylation><catscan><ccRCC><cell growth><clinical development><combination therapy><combined modality treatment><combined treatment><computed axial tomography><computer tomography><computerized axial tomography><computerized tomography><cultured cell line><demethylation><determine efficacy><developmental><driving><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><epitranscriptomics><evaluate efficacy><examine efficacy><fat and obesity-associated protein><fat mass and obesity-associated><fat mass and obesity-associated protein><human model><immune competent><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><inhibitor><innovate><innovation><innovative><insight><kidney adenocarcinoma><knock-down><knockdown><loss of function><mRNA><mRNA Decay><malignancy><men><metabolism measurement><metabolomics><metabonomics><model of human><molecular imaging><molecule imaging><mouse model><multi-modal therapy><multi-modal treatment><multidisciplinary><murine model><neoplasm/cancer><non-contrast CT><noncontrast CT><noncontrast computed tomography><novel><obesity intervention><obesity therapy><obesity treatment><objective response rate><ontogeny><patient derived xenograft model><positron emission computed tomography><precision medicine><precision-based medicine><prognostic><resistant><response><social role><stable isotope><surgery><synthetic lethal interaction><synthetic lethality><targeted cancer therapy><therapeutic target><three dimensional><time use><translation><tumor><tumor cell metabolism><tumor growth><tumor metabolism><tumor microenvironment><tumor suppressor><uptake><von Hippel Lindau Tumor Supressor Gene><von Hippel Lindau disease gene><von Hippel Lindau gene><von Hippel-Lindau Disease>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jill A Rafael-Fortney

OHIO STATE UNIVERSITY, Columbus, OH

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$416,861

FY 2026

Project Title

Mechanisms of mineralocorticoid receptor antagonism on inflammation in muscular dystrophy

Grant Number:

5R01NS124681-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Gene therapy for Duchenne Muscular Dystrophy (DMD) is currently being tested in clinical trials in young patients. However, limitations of the adeno-associated virus (AAV) delivery system, including its small carrying capacity and its low efficiency transfection of muscle stem cells,...

Research Terms

<1, 2-Dehydrocortisone><1,2-Dehydrohydrocortisone><21+ years old><AAV delivered><AAV delivery><AAV-based delivery><AAV-based viral delivery><AAV-mediated delivery><Ablation><Acute><Address><Adeno-Associated Viruses><Adeno-associated-virus-based delivery><Adult><Adult Human><Agonist><Aldosterone><Aldosterone Receptor><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Antiinflammatory Effect><Becker Muscular Dystrophinopathies><Becker Muscular Dystrophy><Becker dystrophy><Becker pseudohypertrophic muscular dystrophy><Becker type progressive muscular dystrophy><Becker-Kiener muscular dystrophy><Binding><Cardiac><Cardiomyopathies><Carrying Capacities><Cell Body><Cells><Cellular Immune Function><Chronic><Clinical><Clinical Data><Clinical Trials><Code><Coding System><Cytokine Receptor Gene><DMD cardiomyopathy><DNA Therapy><Data><Dehydrocortisone><Delta(1)-Cortisone><Delta(1)Hydrocortisone><Delta-F><Delta1-dehydro-hydrocortisone><Deltacortisone><Deltadehydrocortisone><Deltahydrocortisone><Dependoparvovirus><Dependovirus><Drug Combinations><Drug usage><Duchene><Duchenne><Duchenne cardiomyopathy><Duchenne muscular dystrophy><Duchenne muscular dystrophy cardiomyopathy><Duchenne-Griesinger syndrome><Duchenne/Becker muscular dystrophy><Dystrophin><Ellis-van Creveld (EvC) syndrome><Exercise><Expression Signature><FDA approved><Fibrosis><Gene Expression><Gene Expression Profile><Gene Transfer><Gene Transfer Clinical><Genetic Intervention><Genotype><Glucocorticoids><Human><Immune><Immune response><Immunes><Infiltration><Inflammation><Inflammatory><Injury><Lead><Length><Macrophage><Measurement><Membrane><Metacortandracin><Metacortandralone><Methods><Mice><Mice Mammals><Mineralocorticoid Receptor><Modeling><Modern Man><Molecular><Molecular Interaction><Murine><Mus><Muscle><Muscle Atrophy><Muscle Fibers><Muscle Tissue><Muscle satellite cell><Muscular Atrophy><Muscular Dystrophies><Myelogenous><Myeloid><Myeloid Cells><Myocardial Diseases><Myocardial Disorder><Myocardiopathies><Myodystrophica><Myodystrophy><Myotubes><Mφ><Neuromuscular Diseases><Outcome><Pathogenesis><Pathology><Patients><Pb element><Population><Prednisolonum><Prednisone><Prednisonum><Prevention><Property><Proteins><Pseudohypertrophic Muscular Dystrophy><Publishing><Receptor Activation><Receptor Inhibition><Receptor Protein><Receptor Signaling><Rhabdomyocyte><Skeletal Fiber><Skeletal Muscle><Skeletal Muscle Cell><Skeletal Muscle Fiber><Skeletal Myocytes><Sorting><Spinal Fractures><Spirolactone><Spironolactone><System><Testing><Transfection><Transgenes><Translating><Verospirone><Voluntary Muscle><X-linked dilated cardiomyopathy><X-linked muscular dystrophy><X-linked recessive muscular dystrophy><adeno associated virus group><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adenovirus mediated delivery><adulthood><antagonism><antagonist><anti-inflammatory effect><benign X-linked recessive muscular dystrophy><boys><childhood pseudohypertrophic muscular dystrophy><classic X-linked recessive muscular dystrophy><conditional knock-out><conditional knockout><cytokine><delivered with AAV><delivery with AAV><delta-Cortisone><drug efficacy><drug use><efficacy outcomes><eplerenone><fiber cell><gene expression pattern><gene expression signature><gene function><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><heavy metal Pb><heavy metal lead><host response><immune function><immune system response><immunoresponse><improved><injuries><mdx mouse><membrane structure><micro-dystrophin><microdystrophin><mid life><mid-life><middle age><middle aged><midlife><mild X-linked recessive muscular dystrophy><miniaturize><miniaturized><mouse model><murine model><muscle breakdown><muscle degradation><muscle deterioration><muscle dystrophy><muscle loss><muscle progenitor><muscle progenitor cell><muscle regeneration><muscle stem cell><muscle wasting><muscular><muscular dystrophy mouse model><myocardium disease><myocardium disorder><myoneural disorder><neuromuscular><neuromuscular degenerative disorder><neuromuscular disorder><novel><pre-clinical efficacy><preclinical efficacy><prednisolone><prevent><preventing><progressive muscular dystrophy of childhood><pseudohypertrophic adult muscular dystrophy><pseudohypertrophic muscular paralysis><receptor><repair><repaired><satellite cell><side effect><spine fracture><standard of care><transcriptional profile><transcriptional signature><transgene><transgene expression><vertebral fracture><younger age>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yingbin Fu

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$400,150

FY 2026

Project Title

Mechanistic study and therapeutic application of AIBP in AMD

Grant Number:

5R01EY033805-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

8/1/2023

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Choroidal neovascularization (CNV), the wet type of age-related macular degeneration (AMD), is a major cause of blindness in the elderly. Current anti-vascular endothelial growth factor (VEGF) therapy has a number of serious limitations including: 1) many patients respond poorly or n...

Research Terms

<Adeno-Associated Viruses><Affect><Age related macular degeneration><Age-Related Maculopathy><Alternative Therapies><Alternative intervention><Angiogenesis Factor><Angiogenic Factor><Apo A-1><Apo A-I><Apo A1><Apo AI><ApoA-1><ApoA-I><Apolipoprotein A-1><Apolipoprotein A-I><Apolipoprotein A1><Apolipoprotein AI><Binding><Binding Proteins><Blindness><Blood Vessels><Blood capillaries><Caliber><Cell Communication and Signaling><Cell Membrane Lipid Rafts><Cell Signaling><Cholesterol><Choroid Neovascularization><Choroidal Neovascularization><Clinical><Combined Modality Therapy><DNA Synthesis Factor><Dependoparvovirus><Dependovirus><Diabetic Retinopathy><Disease><Disorder><Elderly><Endothelial Cell Growth Factor><Endothelial Cells><FGF><FLK1><Feedback><Fibroblast Growth Factor><Fibroblast Growth Factor Gene Family><Fibroblast Growth Regulatory Factor><Gene Action Regulation><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><HDL><HDL Lipoproteins><Heavy Lipoproteins><High Density Lipoproteins><Homolog of Drosophila TOLL><Hyperactivity><Inflammation><Inflammatory><Intracellular Communication and Signaling><KDR gene><Knock-out><Knockout><Laser Electromagnetic><Laser Radiation><Lasers><Ligand Binding Protein><Ligand Binding Protein Gene><Macrophage><Membrane Microdomains><Mice><Mice Mammals><Modeling><Molecular Interaction><Multimodal Therapy><Multimodal Treatment><Murine><Mus><Mφ><Outcome><Oxidative Stress><Pathologic Angiogenesis><Pathologic Neovascularization><Pathological Angiogenesis><Pathological Neovascularization><Patients><Play><Protein Binding><Protein Overexpression><QOL><Quality of life><Regulation><Resistance><Retina><Retinal Vein Occlusion><Risk><Role><Safety><Signal Transduction><Signal Transduction Systems><Signaling><Site><Sphingolipid Microdomains><Sphingolipid-Cholesterol Rafts><Structure><TLR4><TLR4 gene><Testing><Therapeutic><Toll Homologue><Treatment Efficacy><Treatment Factor><VEGF><VEGF Receptors><VEGFR><VEGFR-2><VEGFR2><VEGFs><VPF Receptor><Vascular Diseases><Vascular Disorder><Vascular Endothelial Cell Growth Factor Receptor><Vascular Endothelial Growth Factor Receptor 2><Vascular Endothelial Growth Factors><Vascular Permeabilities><Vascular Permeability Factor Receptor><adeno associated virus group><advanced age><age dependent macular degeneration><age induced macular degeneration><age related macular disease><age related macular dystrophy><aged mice><aged mouse><alpha-Lipoproteins><arteriole><biological signal transduction><blood vessel disorder><bound protein><capillary><combat><combination gene therapy><combination therapy><combined modality treatment><combined treatment><comparable efficacy><comparative efficacy><compare efficacy><cytokine><design><designing><determine efficacy><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><elderly mice><evaluate efficacy><examine efficacy><geriatric><improved><intervention efficacy><intravitreal injection><lipid raft><loss of function><matrigel><mid life><mid-life><middle age><middle aged><midlife><mouse model><multi-modal therapy><multi-modal treatment><murine model><mutant><old mice><overexpress><overexpression><recruit><resistant><senile macular disease><senior citizen><social role><subretinal injection><therapeutic efficacy><therapy efficacy><toll-like receptor 4><vascular><vascular dysfunction><vasculopathy><vision loss><visual loss>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rafet Basar

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$370,575

FY 2026

Project Title

Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.

Grant Number:

5R01CA280827-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary: CD19 directed CAR-T cells have transformed the treatment landscape of B-cell lymphoid malignancies. However, despite high initial complete remission rates, relapses occur within the first year of therapy in approximately 50% of patients who receive commercially available autologous CAR19 T-...

Research Terms

<APAF-3><APAF3><Adoptive Transfer><Allogenic><Antigen Targeting><Antigens><Apaf-3 protein><Apoptosis-Related Cysteine Protease Caspase 9><Apoptosis-Related Cysteine Protease Gene Caspase 9><Apoptotic Protease Activating Factor 3><Apoptotic Protease Activating Factor 3 Gene><Apoptotic Protease MCH-6><Apoptotic Protease MCH-6 Gene><Autologous><B-Cells><B-Lymphocytes><B-cell><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CASP-9><CASP9><CASP9 Protein><CASP9 gene><CD19><CD19 gene><CD27 ligand><CD27L><CD70 antigen><CIS Gene><CIS protein><CIS-1 Gene><CIS-1 Protein><CISH Protein><CISH gene><Cancer Center><Caspase-9 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Therapy><Cells><Classification><Clinic><Clinical><Clinical Protocols><Clinical Research><Clinical Study><Cord Blood><Cryofixation><Cryopreservation><Cytokine Inducible SH2-Containing Protein><Cytokine-Inducible Inhibitor of Signaling Type 1B><Cytokine-Inducible Inhibitor of Signaling Type 1B Gene><Cytokine-Inducible SH2-Containing Protein Gene><Cytotoxic cell><Data><Disease remission><Dose><Effector Cell><Endowment><Event><Exhibits><FDA approved><Failure><G18><G18 Gene><Gene Modified><Generations><Genes><Good Manufacturing Process><Good manufacturing practice><GvHD><Homologous Wasting Disease><Human><ICE-LAP6><ICE-LAP6 Gene><ICE-LAP6 protein><ICE-Like Apoptotic Protease 6><ICE-Like Apoptotic Protease 6 Gene><IL-15><IL15><IL15 Protein><IRB><IRBs><Immune><Immune Targeting><Immunes><In Vitro><Institutional Review Boards><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><Link><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Lymphocytic Neoplasm><Lymphocytic Tumor><Lymphocytic and Plasma Cell Neoplasm><Lymphocytic and Plasma Cell Tumour><Lymphocytic and Plasmacytic Neoplasm><Lymphoid Cell><Lymphoid Tumor><Lymphoid and Plasma Cell Tumour><Lymphoid and Plasmacytic Neoplasm><Lymphoid and Plasmacytic Tumour><Lymphoma cell><MCH6><MGC9721><Malignant lymphoid neoplasm><Mch6 protein><Mediating><Modern Man><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pattern><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Population><Preparation><Prognosis><Proliferating><Protein Deficiency><Proteins><Proteomics><Protocol><Protocols documentation><Publishing><Receptor Protein><Refractory><Relapse><Remission><Research><Resistance><Retroviral Vector><Retrovirus Vector><Runt Disease><SOCS Gene><Safety><Sampling><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Suppressor of Cytokine Signaling><Suppressor of Cytokine Signaling Gene><Systematics><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Testing><Toxic effect><Toxicities><Translations><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Umbilical Cord Blood><Viral><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><aerobic glycolysis><biobank><biological signal transduction><biorepository><c myc><c-myc Genes><cancer antigens><caspase-9><cell based intervention><cell mediated intervention><cell mediated therapies><cell transduction><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transduction><check point inhibition><checkpoint inhibition><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cmyc><cold preservation><cold storage><cost><cost effective therapy><cost effective treatment><cytokine><deficiency of protein><design><designing><engineered NK cell><engineered immune system><engineered natural killer cell><exhaustion><fetal cord blood><first in man><first-in-human><fitness><gene modification><genetically engineered cells><genetically modified><genetically modified cells><graft versus host disease><graft vs host disease><graft vs. host disease><human study><immune check point><immune check point inhibition><immune checkpoint><immune checkpoint inhibition><immune engineering><immunecheckpoint><immunoengineering><immunogen><improved outcome><in vivo><innovate><innovation><innovative><interest><knockout gene><lymph gland><lymph nodes><lymphnodes><lymphoid cancers><lymphoid malignancy><lymphoid neoplasm><manufacture><manufacturing process><metabolic fitness><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cellular therapy><natural killer therapy><neoplastic cell><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><next generation><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapy target><overexpress><overexpression><patient oriented outcomes><patient population><peripheral blood><pharmacologic><point of care><preparations><pressure><prevent><preventing><receptor><resistant><safety testing><senescence><senescent><suicide gene><therapeutic T-cell platform><thymus derived lymphocyte><transcriptomics><transduced cells><translation><tumor><tumor-specific antigen><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

May Daher

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$370,575

FY 2026

Project Title

Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.

Grant Number:

5R01CA280827-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary: CD19 directed CAR-T cells have transformed the treatment landscape of B-cell lymphoid malignancies. However, despite high initial complete remission rates, relapses occur within the first year of therapy in approximately 50% of patients who receive commercially available autologous CAR19 T-...

Research Terms

<APAF-3><APAF3><Adoptive Transfer><Allogenic><Antigen Targeting><Antigens><Apaf-3 protein><Apoptosis-Related Cysteine Protease Caspase 9><Apoptosis-Related Cysteine Protease Gene Caspase 9><Apoptotic Protease Activating Factor 3><Apoptotic Protease Activating Factor 3 Gene><Apoptotic Protease MCH-6><Apoptotic Protease MCH-6 Gene><Autologous><B-Cells><B-Lymphocytes><B-cell><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CASP-9><CASP9><CASP9 Protein><CASP9 gene><CD19><CD19 gene><CD27 ligand><CD27L><CD70 antigen><CIS Gene><CIS protein><CIS-1 Gene><CIS-1 Protein><CISH Protein><CISH gene><Cancer Center><Caspase-9 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Therapy><Cells><Classification><Clinic><Clinical><Clinical Protocols><Clinical Research><Clinical Study><Cord Blood><Cryofixation><Cryopreservation><Cytokine Inducible SH2-Containing Protein><Cytokine-Inducible Inhibitor of Signaling Type 1B><Cytokine-Inducible Inhibitor of Signaling Type 1B Gene><Cytokine-Inducible SH2-Containing Protein Gene><Cytotoxic cell><Data><Disease remission><Dose><Effector Cell><Endowment><Event><Exhibits><FDA approved><Failure><G18><G18 Gene><Gene Modified><Generations><Genes><Good Manufacturing Process><Good manufacturing practice><GvHD><Homologous Wasting Disease><Human><ICE-LAP6><ICE-LAP6 Gene><ICE-LAP6 protein><ICE-Like Apoptotic Protease 6><ICE-Like Apoptotic Protease 6 Gene><IL-15><IL15><IL15 Protein><IRB><IRBs><Immune><Immune Targeting><Immunes><In Vitro><Institutional Review Boards><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><Link><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Lymphocytic Neoplasm><Lymphocytic Tumor><Lymphocytic and Plasma Cell Neoplasm><Lymphocytic and Plasma Cell Tumour><Lymphocytic and Plasmacytic Neoplasm><Lymphoid Cell><Lymphoid Tumor><Lymphoid and Plasma Cell Tumour><Lymphoid and Plasmacytic Neoplasm><Lymphoid and Plasmacytic Tumour><Lymphoma cell><MCH6><MGC9721><Malignant lymphoid neoplasm><Mch6 protein><Mediating><Modern Man><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pattern><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Population><Preparation><Prognosis><Proliferating><Protein Deficiency><Proteins><Proteomics><Protocol><Protocols documentation><Publishing><Receptor Protein><Refractory><Relapse><Remission><Research><Resistance><Retroviral Vector><Retrovirus Vector><Runt Disease><SOCS Gene><Safety><Sampling><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Suppressor of Cytokine Signaling><Suppressor of Cytokine Signaling Gene><Systematics><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Testing><Toxic effect><Toxicities><Translations><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Umbilical Cord Blood><Viral><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><aerobic glycolysis><biobank><biological signal transduction><biorepository><c myc><c-myc Genes><cancer antigens><caspase-9><cell based intervention><cell mediated intervention><cell mediated therapies><cell transduction><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transduction><check point inhibition><checkpoint inhibition><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cmyc><cold preservation><cold storage><cost><cost effective therapy><cost effective treatment><cytokine><deficiency of protein><design><designing><engineered NK cell><engineered immune system><engineered natural killer cell><exhaustion><fetal cord blood><first in man><first-in-human><fitness><gene modification><genetically engineered cells><genetically modified><genetically modified cells><graft versus host disease><graft vs host disease><graft vs. host disease><human study><immune check point><immune check point inhibition><immune checkpoint><immune checkpoint inhibition><immune engineering><immunecheckpoint><immunoengineering><immunogen><improved outcome><in vivo><innovate><innovation><innovative><interest><knockout gene><lymph gland><lymph nodes><lymphnodes><lymphoid cancers><lymphoid malignancy><lymphoid neoplasm><manufacture><manufacturing process><metabolic fitness><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cellular therapy><natural killer therapy><neoplastic cell><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><next generation><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapy target><overexpress><overexpression><patient oriented outcomes><patient population><peripheral blood><pharmacologic><point of care><preparations><pressure><prevent><preventing><receptor><resistant><safety testing><senescence><senescent><suicide gene><therapeutic T-cell platform><thymus derived lymphocyte><transcriptomics><transduced cells><translation><tumor><tumor-specific antigen><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Katy Rezvani

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$370,575

FY 2026

Project Title

Next Generation Engineered NK Cells for Lymphoma Patients after CD19 CAR-T Cell Failure.

Grant Number:

5R01CA280827-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary: CD19 directed CAR-T cells have transformed the treatment landscape of B-cell lymphoid malignancies. However, despite high initial complete remission rates, relapses occur within the first year of therapy in approximately 50% of patients who receive commercially available autologous CAR19 T-...

Research Terms

<APAF-3><APAF3><Adoptive Transfer><Allogenic><Antigen Targeting><Antigens><Apaf-3 protein><Apoptosis-Related Cysteine Protease Caspase 9><Apoptosis-Related Cysteine Protease Gene Caspase 9><Apoptotic Protease Activating Factor 3><Apoptotic Protease Activating Factor 3 Gene><Apoptotic Protease MCH-6><Apoptotic Protease MCH-6 Gene><Autologous><B-Cells><B-Lymphocytes><B-cell><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><CASP-9><CASP9><CASP9 Protein><CASP9 gene><CD19><CD19 gene><CD27 ligand><CD27L><CD70 antigen><CIS Gene><CIS protein><CIS-1 Gene><CIS-1 Protein><CISH Protein><CISH gene><Cancer Center><Caspase-9 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Therapy><Cells><Classification><Clinic><Clinical><Clinical Protocols><Clinical Research><Clinical Study><Cord Blood><Cryofixation><Cryopreservation><Cytokine Inducible SH2-Containing Protein><Cytokine-Inducible Inhibitor of Signaling Type 1B><Cytokine-Inducible Inhibitor of Signaling Type 1B Gene><Cytokine-Inducible SH2-Containing Protein Gene><Cytotoxic cell><Data><Disease remission><Dose><Effector Cell><Endowment><Event><Exhibits><FDA approved><Failure><G18><G18 Gene><Gene Modified><Generations><Genes><Good Manufacturing Process><Good manufacturing practice><GvHD><Homologous Wasting Disease><Human><ICE-LAP6><ICE-LAP6 Gene><ICE-LAP6 protein><ICE-Like Apoptotic Protease 6><ICE-Like Apoptotic Protease 6 Gene><IL-15><IL15><IL15 Protein><IRB><IRBs><Immune><Immune Targeting><Immunes><In Vitro><Institutional Review Boards><Interleukin-15><Interleukin-15 Precursor><Intracellular Communication and Signaling><K lymphocyte><Link><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphatic nodes><Lymphocytic Neoplasm><Lymphocytic Tumor><Lymphocytic and Plasma Cell Neoplasm><Lymphocytic and Plasma Cell Tumour><Lymphocytic and Plasmacytic Neoplasm><Lymphoid Cell><Lymphoid Tumor><Lymphoid and Plasma Cell Tumour><Lymphoid and Plasmacytic Neoplasm><Lymphoid and Plasmacytic Tumour><Lymphoma cell><MCH6><MGC9721><Malignant lymphoid neoplasm><Mch6 protein><Mediating><Modern Man><NK Cells><NK cell immune therapy><NK cell immunotherapy><NK cell therapy><NK cell treatment><NK cell-based immune therapy><NK cell-based immunotherapy><NK cell-based therapy><NK cell-based treatment><NK cellular immunotherapy><NK cellular therapy><NK immunotherapy><NK therapy><NK treatment><Natural Killer Cell Immunotherapy><Natural Killer Cells><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pattern><Phase 1/2 Clinical Trial><Phase I/II Clinical Trial><Population><Preparation><Prognosis><Proliferating><Protein Deficiency><Proteins><Proteomics><Protocol><Protocols documentation><Publishing><Receptor Protein><Refractory><Relapse><Remission><Research><Resistance><Retroviral Vector><Retrovirus Vector><Runt Disease><SOCS Gene><Safety><Sampling><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Suppressor of Cytokine Signaling><Suppressor of Cytokine Signaling Gene><Systematics><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><Testing><Toxic effect><Toxicities><Translations><Tumor Antigens><Tumor Cell><Tumor-Associated Antigen><Umbilical Cord Blood><Viral><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><aerobic glycolysis><biobank><biological signal transduction><biorepository><c myc><c-myc Genes><cancer antigens><caspase-9><cell based intervention><cell mediated intervention><cell mediated therapies><cell transduction><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transduction><check point inhibition><checkpoint inhibition><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cmyc><cold preservation><cold storage><cost><cost effective therapy><cost effective treatment><cytokine><deficiency of protein><design><designing><engineered NK cell><engineered immune system><engineered natural killer cell><exhaustion><fetal cord blood><first in man><first-in-human><fitness><gene modification><genetically engineered cells><genetically modified><genetically modified cells><graft versus host disease><graft vs host disease><graft vs. host disease><human study><immune check point><immune check point inhibition><immune checkpoint><immune checkpoint inhibition><immune engineering><immunecheckpoint><immunoengineering><immunogen><improved outcome><in vivo><innovate><innovation><innovative><interest><knockout gene><lymph gland><lymph nodes><lymphnodes><lymphoid cancers><lymphoid malignancy><lymphoid neoplasm><manufacture><manufacturing process><metabolic fitness><natural killer cell based immune therapy><natural killer cell based immunotherapy><natural killer cell therapy><natural killer cell treatment><natural killer cell-based therapy><natural killer cellular therapy><natural killer therapy><neoplastic cell><new approaches><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><next generation><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel therapeutic target><novel therapy target><overexpress><overexpression><patient oriented outcomes><patient population><peripheral blood><pharmacologic><point of care><preparations><pressure><prevent><preventing><receptor><resistant><safety testing><senescence><senescent><suicide gene><therapeutic T-cell platform><thymus derived lymphocyte><transcriptomics><transduced cells><translation><tumor><tumor-specific antigen><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sangpil Yoon

UNIVERSITY OF OKLAHOMA, NORMAN, OK

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$367,757

FY 2026

Project Title

Development of protein-based nanostructures activated by ultrasound

Grant Number:

5R01GM152704-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary / Abstract The development of site specific nucleases for precise gene engineering has advanced basic understanding of genes and their connection to phenotype-causing mutations and physiologically relevant endpoints and treatment strategies to cure human diseases and medical disorder...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Thomas Gaj

UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN, CHAMPAIGN, IL

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$365,804

FY 2026

Project Title

Development of a CRISPR-Cas13 Gene Therapy for SOD1-Linked ALS

Grant Number:

5R01NS123556-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, paralytic disorder characterized by the selective loss of motor neurons in the spinal cord and brain. While most cases of ALS are sporadic, toxic gain-of-function mutations in superoxide dismutase 1 (SOD1) are responsible ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

WILLIAM G HAWKINS

MEDICAL UNIVERSITY OF SOUTH CAROLINA, CHARLESTON, SC

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$345,411

FY 2026

Project Title

Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy

Grant Number:

5R01CA276378-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/29/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Scientific abstract Epithelial ovarian cancer (EOC) and pancreatic ductal adenocarcinoma (PDAC) are two of the most devastating human malignancies in desperate need for improved treatment concepts. Treatment resistance in cancer therapy frequently includes, among others, reduced drug uptake, increas...

Research Terms

<(TNF)-α><Abraxane><Address><Anticholesteremic Agents><Anticholesteremic Drugs><Anticholesteremics><Anzatax><Apopain><Apoptosis><Apoptosis Pathway><Apoptosis-Related Cysteine Protease Caspase 3><Asotax><Bristaxol><CASP-3><CASP3><CASP3 gene><CPP-32><CPP32><CPP32 protein><CPP32B><CPP32beta><Cachectin><Cancer Induction><Cancer Patient><Cancer Treatment><Cancers><Caspase><Caspase Gene><Cell Body><Cell Communication and Signaling><Cell Death><Cell Line><Cell Signaling><Cell Survival><Cell Viability><Cell-Death Protease><CellLine><Cells><Chemicals><Cholesterol><Cholesterol Inhibitors><Cholesterol-Lowering Drugs><Cholesterol-Lowering agents><Clinical><Cysteine Endopeptidases><Cysteine Protease><Cysteine Protease CPP32><Cysteine Protease CPP32 Gene><Cysteine Proteinases><DNA Damage><DNA Injury><Data><Development><Difluorodeoxycytidine><Dose><Drug Combinations><Drug Delivery><Drug Delivery Systems><Drug Efflux><Drug Formulations><Drug Kinetics><Drug Therapy><Drug resistance><Drugs><Enhancers><Epithelial ovarian cancer><Evaluation><Excipients><Foundations><Frequencies><Goals><Gold><Grant><Human><IAP Family Gene><IAP Family Protein><ICE-like protease><In Vitro><Inhibition of Apoptosis><Intracellular Communication and Signaling><Lead><Ligands><Link><Lytotoxicity><Macrophage-Derived TNF><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Pancreatic Neoplasm><Malignant Tumor><Malignant Tumor of the Ovary><Malignant neoplasm of ovary><Malignant neoplasm of pancreas><Maximal Tolerated Dose><Maximally Tolerated Dose><Maximum Tolerated Dose><Mediating><Medication><Mitochondria><Modern Man><Monocyte-Derived TNF><Ovarian><Ovary Cancer><PARP Cleavage Protease><PARP Cleavage Protease Gene><Paclitaxel><Paclitaxel (Taxol)><Pancreas Adenocarcinoma><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreatic Adenocarcinoma><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pb element><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Pharmacological Treatment><Pharmacotherapy><Praxel><Pre-Clinical Model><Preclinical Models><Programmed Cell Death><Regimen><Resistance><Route><SCA-1><SCA-1 Gene><SREBP Cleavage Activity 1><SREBP Cleavage Activity 1 Gene><Signal Transduction><Signal Transduction Systems><Signaling><Sodium Chloride><Specificity><Strains Cell Lines><Stress><TNBC><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Taxol><Taxol A><Taxol Konzentrat><Testing><Therapeutic><Toxic effect><Toxicities><Treatment Protocols><Treatment Regimen><Treatment Schedule><Tumor Cell><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Variant><Variation><Work><Yama><Yama protein><anti-cancer therapy><anti-cholesterol agents><anti-cholesterol drugs><antihypercholesterolemic agent><biological signal transduction><cancer cell><cancer therapy><cancer-directed therapy><carcinogenesis><caspase-3><chemical conjugate><chemotherapy><combination cancer therapy><cultured cell line><cystein protease><cystein proteinase><cysteine endopeptidase><cysteine protease P32><cytotoxic><cytotoxicity><dFdC><dFdCyd><determine efficacy><developmental><drug candidate><drug development><drug intervention><drug resistant><drug treatment><drug/agent><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><gemcitabine><gene signatures><genetic signature><heavy metal Pb><heavy metal lead><improved><in vivo><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><inhibitor-of-apoptosis protein><innovate><innovation><innovative><malignancy><mitochondrial><mouse model><multi-modal cancer therapy><multi-modal neoplasm therapy><multimodality cancer therapy><multimodality neoplasm therapy><murine model><necrocytosis><neoplasm/cancer><neoplastic cell><new drug combination><new drug treatments><new drugs><new pharmacological therapeutic><new pharmacotherapy combination><new therapeutics><new therapy><next generation therapeutics><novel><novel drug combination><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy combination><novel therapeutics><novel therapy><ovarian cancer><pancreatic malignancy><pathway><patient oriented outcomes><performance tests><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><pre-clinical development><preclinical><preclinical development><promoter><promotor><resistance mechanism><resistance to Drug><resistance to therapy><resistant><resistant mechanism><resistant to Drug><resistant to therapy><response><salt><sigma-2 receptor><standard of care><systemic toxicity><targeted cancer therapy><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapy resistant><treatment resistance><triple-negative breast cancer><triple-negative invasive breast carcinoma><tumor><tumor eradication><uptake><x-linked inhibitor of apoptosis protein>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

IVO Kalajzic

UNIVERSITY OF CONNECTICUT SCH OF MED/DNT, FARMINGTON, CT

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$341,258

FY 2026

Project Title

Cellular Therapy for Osteogenesis Imperfecta

Grant Number:

5R01AR084284-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/1/2025

End Date:

3/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Osteogenesis imperfecta (OI) is a genetic disease that causes abnormal type I collagen production leading to bone fragility. Current pharmacological approaches result in an increase in the amount of defective matrix, without addressing the underlying collagen defect. An alternate approach ...

Research Terms

<0-11 years old><Address><Adipose tissue><Affect><Allogeneic Transplantation><Anatomic Abnormality><Anatomical Abnormality><BM Stem Cell><BM derived progenitor><BM progenitor><BM- derived Stem Cells><Bone Formation><Bone Grafting><Bone Growth><Bone Marrow><Bone Marrow Grafting><Bone Marrow Purging><Bone Marrow Reticuloendothelial System><Bone Marrow Stem Cell><Bone Marrow Transplant><Bone Marrow Transplantation><Bone Marrow progenitor><Bone Matrix><Bone Transplantation><Breeding><Brittle bone disorder><Cancellous bone><Cell Body><Cell Lineage><Cell Therapy><Cells><Child><Child Youth><Children (0-21)><Clinical><Clinical Research><Clinical Study><Collagen><Collagen Type I><DNA Therapy><DNA mutation><Data><Defect><Deformity><Detection><Development><Engraftment><Evaluation><Exhibits><Extremities><Fatty Tissue><Femur><Fracture><Fragilitas Ossium><Gene Transfer Clinical><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Goals><Growth><Hematopoietic><Homologous Transplantation><Human><Individual><Injury><Investigators><Laboratories><Limb structure><Limbs><Lineage Tracing><MSC transplantation><Marrow Transplantation><Mesenchymal Progenitor Cell><Mesenchymal Stem Cell Transplantation><Mesenchymal Stem Cells><Mesenchymal progenitor><Mesenchymal stromal/stem cells><Methods><Mice><Mice Mammals><Modern Man><Murine><Mus><Mutation><Non-Trunk><Operative Procedures><Operative Surgical Procedures><Organ><Osteoblasts><Osteocytes><Osteogenesis><Osteogenesis Imperfect><Osteogenesis Imperfecta><Osteotomy><Pathology><Patients><Population><Procedures><Production><Progenitor Cell Engraftment><Progenitor Cell Transplantation><Progenitor Cells><Research Personnel><Researchers><Rod><Second Cancer><Second Primary Cancers><Secondary Malignancy><Secondary Malignant Neoplasm><Site><Source><Stem Cell Transplantation><Stem cell transplant><Stromal Cells><Surgical><Surgical Interventions><Surgical Procedure><Testing><Therapeutic><Therapeutic Studies><Therapy Research><Tissue Growth><Total Body Irradiation><Transgenic Organisms><Transplantation><Type 1 Collagen><Vascularization><Whole-Body Irradiation><Whole-Body Radiation><Work><adipose><assess effectiveness><bone><bone fracture><bone fragility><bone marrow derived progenitor><bone marrow derived stem cells><bone marrow stromal cell><bone marrow stromal stem cell><bone mass><bone tissue formation><bone transplant><bone turnover><brittle bone disease><cell based intervention><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular lineage mapping><cellular lineage tracking><cellular targeting><cellular therapeutic><cellular therapy><clinical relevance><clinically relevant><compact bone><cortical bone><determine effectiveness><developmental><effective therapy><effective treatment><effectiveness assessment><effectiveness evaluation><evaluate effectiveness><examine effectiveness><gene repair therapy><gene therapeutics><gene therapy><gene-based therapeutic><gene-based therapeutics><gene-based therapy><genes therapeutic><genes therapeutics><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><hemopoietic><improved><injuries><irradiation><kids><limb transplantation><mechanical properties><mesenchymal stromal cell><mesenchymal stromal progenitor cells><mesenchymal-derived stem cells><mouse model><murine model><myeloablation><novel><ontogeny><osteogenic><pharmacologic><pre-clinical study><preclinical study><preconditioning><progenitor><progenitor cell delivery><progenitor cell differentiation><progenitor delivery><progenitor differentiation><progenitor transplantation><secondary cancer><skeletal progenitor><skeletal progenitor cell><skeletal stem cell><stem and progenitor cell transplantations><stem and progenitor differentiation><stem cell delivery><stem cell differentiation><stem cell engraftment><stem cells><substantia spongiosa><substantia trabecularis><success><surgery><surgery outcome><surgical outcome><therapeutic gene><tibia><trabecular bone><transgenic><translation strategy><translational approach><translational goal><translational mission><translational strategy><translational study><transplant><white adipose tissue><yellow adipose tissue><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Colin Goding

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$285,994

FY 2026

Project Title

The integrated stress response and the microenvironment in melanoma progression

Grant Number:

5R01CA268597-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Despite the emergence novel therapeutic modalities, including BRAF inhibitors and immunotherapies, over 7,100 people are expected to die each year from malignant melanoma, primarily from metastatic dissemination and therapy resistance. The proposed studies leverage the expertise of the two c...

Research Terms

<22-kD Gene Caveolae Protein><22kD Gene Caveolin 1 Caveolae Protein><3-D><3-Dimensional><3D><Ablation><Adipocytes><Adipose Cell><Allografting><Alpha Isoform Gene Caveolin 1><Anoikis><Antioxidants><Apoptosis><Apoptosis Pathway><Apoptotic><Autophagocytosis><B-raf-1><BRAF><BRAF gene><Basal Transcription Factor><Basal transcription factor genes><Beta Isoform Gene Caveolin 1><Binding><Blood Vessels><CAV Gene><CAV1><CAV1 gene><Cancer Genes><Cancer-Promoting Gene><Caveolin-1 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Extracellular Matrix><Cells><Co-culture><Cocultivation><Coculture><Coculture Techniques><Collagen><Complex><DNA mutation><ECM><ER stress><Endothelial Cells><Endothelium><Equilibrium><Experimental Neoplasms><Experimental Tumor><Exposure to><Extracellular Matrix><Fat Cells><Fatty Acid Desaturases><Fatty Acid Desaturating Enzymes><Fatty Acids><Fibroblasts><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Growth><Heterogeneity><Heterograft><Heterologous Transplantation><Human><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Impairment><Inflammation><Integrins><Integrins Extracellular Matrix><Intracellular Communication and Signaling><Invaded><KO mice><Knock-out Mice><Knockout Mice><Link><Lipocytes><Lymph><MITF protein><Malignant Melanoma><Mature Lipocyte><Mature fat cell><Mediating><Mediator><Melanoma><Melanoma Cell><Melanoma Tumor><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Microphthalmic-associated transcription factor><Modality><Modeling><Modern Man><Molecular Interaction><Monounsaturated Fatty Acids><Murine><Mus><Mutation><Neoplasm Metastasis><Non-Malignant><Nuclear><Null Mouse><O element><O2 element><Oncogenes><Oncogenic><Output><Oxygen><Pathway interactions><Patients><Persons><Phenotype><Primary Neoplasm><Primary Tumor><Programmed Cell Death><Proliferating><Publishing><RAFB1><RNA Expression><Recovery><Refractory><Reporting><Repression><Resistance><Role><Secondary Neoplasm><Secondary Tumor><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Stress><Testing><Therapeutic><Therapeutic Intervention><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Translational Inhibition><Translational Repression><Tumor Cell><Tumor Suppressor Proteins><Tumor growth in melanoma><Tumor-infiltrating immune cells><VIP21 Gene><Xenograft><Xenograft procedure><Xenotransplantation><angiogenesis><autophagy><balance><balance function><biological adaptation to stress><biological signal transduction><cancer metastasis><cancer microenvironment><check point blockade><checkpoint blockade><endoplasmic reticulum stress><gain of function><genome mutation><immune cell infiltrate><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><infiltration of tumors by immune cells><inhibitor><intervention therapy><intratumoral immune cell><intratumoral immune infiltrate><lung metastasis><lymphatic fluid><metastasize to the lung><microphthalmia-associated transcription factor><mouse model><murine model><neoplastic cell><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><nonmalignant><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><nutrient deprivation><nutritional deprivation><ontogeny><pathway><pharmacologic><programs><pulmonary metastasis><reactioncrisis><resistant><response><social role><stress response><stressreaction><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><three dimensional><transcription factor><transcription factor Microphthalmia><tumor><tumor cell metastasis><tumor growth><tumor immune cell><tumor immune infiltrate><tumor infiltration of immune cells><tumor microenvironment><tumor suppressor><tumorigenic><uptake><v-raf Murine Sarcoma Viral Oncogene Homolog B1><vascular><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Constantinos Koumenis

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 58/100

Likely hiring

Solid budget

Recent

Active award

$285,994

FY 2026

Project Title

The integrated stress response and the microenvironment in melanoma progression

Grant Number:

5R01CA268597-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Despite the emergence novel therapeutic modalities, including BRAF inhibitors and immunotherapies, over 7,100 people are expected to die each year from malignant melanoma, primarily from metastatic dissemination and therapy resistance. The proposed studies leverage the expertise of the two c...

Research Terms

<22-kD Gene Caveolae Protein><22kD Gene Caveolin 1 Caveolae Protein><3-D><3-Dimensional><3D><Ablation><Adipocytes><Adipose Cell><Allografting><Alpha Isoform Gene Caveolin 1><Anoikis><Antioxidants><Apoptosis><Apoptosis Pathway><Apoptotic><Autophagocytosis><B-raf-1><BRAF><BRAF gene><Basal Transcription Factor><Basal transcription factor genes><Beta Isoform Gene Caveolin 1><Binding><Blood Vessels><CAV Gene><CAV1><CAV1 gene><Cancer Genes><Cancer-Promoting Gene><Caveolin-1 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Extracellular Matrix><Cells><Co-culture><Cocultivation><Coculture><Coculture Techniques><Collagen><Complex><DNA mutation><ECM><ER stress><Endothelial Cells><Endothelium><Equilibrium><Experimental Neoplasms><Experimental Tumor><Exposure to><Extracellular Matrix><Fat Cells><Fatty Acid Desaturases><Fatty Acid Desaturating Enzymes><Fatty Acids><Fibroblasts><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Growth><Heterogeneity><Heterograft><Heterologous Transplantation><Human><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Impairment><Inflammation><Integrins><Integrins Extracellular Matrix><Intracellular Communication and Signaling><Invaded><KO mice><Knock-out Mice><Knockout Mice><Link><Lipocytes><Lymph><MITF protein><Malignant Melanoma><Mature Lipocyte><Mature fat cell><Mediating><Mediator><Melanoma><Melanoma Cell><Melanoma Tumor><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Microphthalmic-associated transcription factor><Modality><Modeling><Modern Man><Molecular Interaction><Monounsaturated Fatty Acids><Murine><Mus><Mutation><Neoplasm Metastasis><Non-Malignant><Nuclear><Null Mouse><O element><O2 element><Oncogenes><Oncogenic><Output><Oxygen><Pathway interactions><Patients><Persons><Phenotype><Primary Neoplasm><Primary Tumor><Programmed Cell Death><Proliferating><Publishing><RAFB1><RNA Expression><Recovery><Refractory><Reporting><Repression><Resistance><Role><Secondary Neoplasm><Secondary Tumor><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Stress><Testing><Therapeutic><Therapeutic Intervention><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Translational Inhibition><Translational Repression><Tumor Cell><Tumor Suppressor Proteins><Tumor growth in melanoma><Tumor-infiltrating immune cells><VIP21 Gene><Xenograft><Xenograft procedure><Xenotransplantation><angiogenesis><autophagy><balance><balance function><biological adaptation to stress><biological signal transduction><cancer metastasis><cancer microenvironment><check point blockade><checkpoint blockade><endoplasmic reticulum stress><gain of function><genome mutation><immune cell infiltrate><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><infiltration of tumors by immune cells><inhibitor><intervention therapy><intratumoral immune cell><intratumoral immune infiltrate><lung metastasis><lymphatic fluid><metastasize to the lung><microphthalmia-associated transcription factor><mouse model><murine model><neoplastic cell><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><nonmalignant><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><nutrient deprivation><nutritional deprivation><ontogeny><pathway><pharmacologic><programs><pulmonary metastasis><reactioncrisis><resistant><response><social role><stress response><stressreaction><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><three dimensional><transcription factor><transcription factor Microphthalmia><tumor><tumor cell metastasis><tumor growth><tumor immune cell><tumor immune infiltrate><tumor infiltration of immune cells><tumor microenvironment><tumor suppressor><tumorigenic><uptake><v-raf Murine Sarcoma Viral Oncogene Homolog B1><vascular><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Anna M. Krichevsky

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Good lead · 56/100

Above-average budget

Very recent

Active award

Team-scale grant

$790,474

FY 2026

Project Title

miR-10b Gene Editing Therapy for Glioblastoma

Grant Number:

1UG3NS143075-01A1

Activity Code:

UG3

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT Malignant glioma, particularly glioblastoma (GBM), remains among the most lethal forms of cancer and represents a significant unmet need in current medicine. The median survival of GBM patients is approximately 15-20 months with highly aggressive standard care, and the five-year survival ra...

Research Terms

<21+ years old><ASO therapeutics><ASO therapy><ASO treatment><Abscission><Adult><Adult Human><Allografting><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Inhibitors><Angiostatic Agents><Animal Model><Animal Models and Related Studies><Animals><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Anti-VEGF><Anti-VEGF Humanized Monoclonal Antibody><Anti-VEGF RhuMAb><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><Antisense Agent><Antisense Oligonucleotide Therapy><Antisense Oligonucleotides><Apoptosis><Apoptosis Pathway><BCL2L11><BCL2L11 gene><BIM><BIMEL><BIML><BimMEL><Biodistribution><Brain><Brain Neoplasia><Brain Neoplasms><Brain Nervous System><Brain Tumors><CDK-Interacting Protein 1><CDK4I><CDKN1><CDKN1A><CDKN1A gene><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CIP1><CMM2><COVID-19><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CV-19><Cancers><Cas nuclease technology><Cell Body><Cell Cycle><Cell Differentiation><Cell Differentiation process><Cell Division Cycle><Cell Protection><Cell model><Cells><Cellular model><Clinical Paths><Clinical Pathways><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Coronavirus Infectious Disease 2019><Cyclin-Dependent Kinase Inhibitor 1A><Cyclin-Dependent Kinase Inhibitor 2A Gene><Cytoprotection><DNA Therapy><DNA mutation><Development><Diagnosis><Disease><Disorder><Dose><Drug Formulations><Drugs><EGF Receptor><EGFR><EGFRvIII Peptide><ERBB Protein><Encephalon><Epidermal Growth Factor Receptor><Epidermal Growth Factor Receptor Kinase><Epidermal Growth Factor Receptor Protein-Tyrosine Kinase><Epidermal Growth Factor-Urogastrone Receptors><Excision><Exhibits><Extirpation><FDA approved><FDA licensed drugs><FDA-approved agents><FDA-approved drug><FDA-approved medications><FDA-approved pharmaceuticals><FDA-approved therapeutic agent><Food and Drug Administration approved drug><Food and Drug Administration approved medications><Food and Drug Administration approved pharmaceuticals><Formulation><Gene Expression><Gene Transfer Clinical><Generalized Growth><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glia><Gliadel><Glial Cell Tumors><Glial Cells><Glial Neoplasm><Glial Tumor><Glioblastoma><Glioma><Gliomagenesis><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Growth><Guidelines><HER1><Heterograft><Heterologous Transplantation><Human><IND Filing><IND application><IND package><IND submission><INK4><INK4A><Immune mediated therapy><Immunocompetent><Immunologically Directed Therapy><Immunotherapy><Invaded><Investigational New Drug Application><Kolliker's reticulum><Lead><MTS1><MTS1 Genes><Malignant Glial Neoplasm><Malignant Glial Tumor><Malignant Glioma><Malignant Neoplasms><Malignant Neuroglial Neoplasm><Malignant Neuroglial Tumor><Malignant Tumor><Mediating><Medication><Medicine><Messenger RNA><Mice><Mice Mammals><MicroRNAs><MoAb VEGF><Modeling><Modern Man><Molecular Target><Monoclonal Antibody Anti-VEGF><Murine><Mus><Mutation><Neovascularization Inhibitors><Nerve Cells><Nerve Unit><Neural Cell><Neural Stem Cell><Neurocyte><Neuroglia><Neuroglial Cells><Neuroglial Neoplasm><Neuroglial Tumor><Neurons><Newly Diagnosed><Non-neuronal cell><Nonneuronal cell><Organoids><PK/PD><Patients><Pb element><Peptide Vaccines><Pharmaceutical Preparations><Phase><Play><Programmed Cell Death><RNA Splicing><RNA delivery><RNA vaccine><RNA-based vaccine><Recombinant Humanized Anti-VEGF Monoclonal Antibody><Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor><Recurrence><Recurrent><Regimen><Removal><Research Contracts><Resistance><RhuMAb VEGF><Rodent><Rodentia><Rodents Mammals><Role><Safety><Schedule><Signal Pathway><Splicing><Surgical Removal><Survival Rate><System><TGF-alpha Receptor><TP16><TSG9A><Temodal><Temodar><Testing><Therapeutic><Therapeutic Gene Editing><Tissue Growth><Toxic effect><Toxicities><Toxicology><Transcription Activation><Transcriptional Activation><Transforming Growth Factor alpha Receptor><Tumor Cell Nuclei><Tumor Subtype><U6 RNA><U6 small nuclear RNA><U6 snRNA><Urogastrone Receptor><WAF1><Wildtype p53-Activated Fragment 1><Work><Writing><Xenograft><Xenograft procedure><Xenotransplantation><addiction><addictive disorder><adulthood><anti-sense oligonucleotide drug><anti-sense oligonucleotide therapy><anti-sense oligonucleotide treatment><anti-sense therapy><antiangiogenic><antisense drug><antisense oligo><antisense oligonucleotide therapeutic><antisense therapeutics><antisense therapy><bevacizumab><c-erbB-1><c-erbB-1 Protein><cellular differentiation><check point inhibition><checkpoint inhibition><chemo-/radio-therapy><chemo-radiotherapy><chemoradiation><chemoradiation therapy><chemoradiation treatment><chemoradiotherapy><chemotherapy><clinical lot><coronavirus disease 2019><coronavirus disease-19><coronavirus infectious disease-19><cytoprotective><developmental><disease heterogeneity><drug development><drug/agent><effective therapy><effective treatment><erbB-1><erbB-1 Proto-Oncogene Protein><erbBl><first in man><first-in-human><gene repair therapy><gene therapy><gene-based therapy><gene-editing therapy><genetic therapy><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic therapy><glial-derived tumor><glioblastoma multiforme><glioma genesis><heavy metal Pb><heavy metal lead><immune check point inhibition><immune checkpoint inhibition><immune competent><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improve symptom><in vivo><inhibitor><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><malignancy><manufacture><methazolastone><miRNA><model of animal><mouse model><murine model><mutational status><neoplasm/cancer><nerve cement><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neuro-oncology><neurogenic progenitors><neurogenic stem cell><neuroglia neoplasm><neuroglia tumor><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neurooncology><neuroprogenitor><neurosurgery><oligonucleotide drug><oligonucleotide therapeutics><oligonucleotide therapies><oligonucleotide treatment><ontogeny><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><p21 gene><p21 protein><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><pharmacokinetics and pharmacodynamics><pre-clinical><precision medicine><precision-based medicine><preclinical><pro-apoptotic protein><progenitor and neural stem cells><proto-oncogene protein c-erbB-1><radio-chemo-therapy><radio-chemotherapy><radiochemotherapy><resection><resistant><rhuMabVEGF><social role><spongioblastoma multiforme><standard care><standard of care><standard treatment><success><symptom improvement><symptomatic improvement><targeted drug therapy><targeted drug treatments><targeted drug trials><targeted pharmaceutical trials><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted therapy trials><targeted treatment><targeted treatment trials><technology platform><technology system><temozolomide><therapeutic editing><therapeutic genome editing><therapeutic target><tumor><tumor growth><tumors in the brain><uncontrolled cell growth><uptake><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Stephan Frangakis

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Good lead · 56/100

Training-friendly

Very recent

Active award

Career award

$173,690

FY 2026

Project Title

Genetic Markers of Chronic Postsurgical Pain

Grant Number:

5K08AR082454-04

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/17/2023

End Date:

3/31/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY / ABSTRACT Over 100 million surgical procedures are performed in the United States each year, with up to 80% of patients experiencing postoperative pain. Higher levels of pain after surgery are associated with the development chronic post-surgical pain (CPSP) and chronic opioid use, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sai Gourisankar

STANFORD UNIVERSITY, STANFORD, CA

Good lead · 56/100

Training-friendly

Very recent

Active award

Career award

$135,594

FY 2026

Project Title

Rewiring fusion oncogenes to activate apoptosis

Grant Number:

5K99CA296700-02

Activity Code:

K99

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The proliferation, survival, invasion, and metastasis of human cancers are driven by oncogenic gene expression networks specific to a malignant cell. Exploiting cancer-specific vulnerabilities in gene expression offers an attractive opportunity for precision medicine. I propose to develop ...

Research Terms

<0-11 years old><ALL1><ALL1 gene><Acute Lymphoblastic Leukemia><Acute Lymphoblastic Leukemia Protein 1><Acute Lymphocytic Leukemia><Acute Lymphoid Leukemia><Acute leukemia><Apoptosis><Apoptosis Pathway><Apoptotic><Assay><Automobile Driving><B-Cell CLL/Lymphoma-6 Gene><BCL5><BCL6><BCL6 gene><Basal Transcription Factor><Basal transcription factor genes><Binding><Bioassay><Biochemical><Biological Assay><Biology><Biophysics><CXXC7><Cancer Genes><Cancer-Promoting Gene><Cancers><Cell Body><Cell Cycle><Cell Death><Cell Division Cycle><Cell Line><Cell model><CellLine><Cells><Cellular model><Cessation of life><Chemicals><Chemistry><Child><Child Youth><Children (0-21)><Chimera Protein><Chimeric Proteins><Chromatin><Clinical><Complex><Computer Models><Computerized Models><Crystallographies><Crystallography><Cys-His2 Zinc Finger Transcription Factor Gene><DNA mutation><DNA-Dependent RNA Polymerase II><Death><Drosophila Homolog of Trithorax><EC 2.1.1><Elongation Factor><Foundations><Fusion Oncogene Proteins><Fusion Protein><Gene Expression><Gene Transcription><GeneHomolog><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Genomics><Goals><Growth><HRX><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic Cancer><Hematopoietic Cellular Control Mechanisms><Homolog><Homologous Gene><Homologue><Human><Hyperactivity><In Vitro><Infant Leukemia><Invaded><Investigators><KMT2A><LAZ-3 Gene><LAZ3><Lead><Leukemic Cell><Libraries><Ligands><Link><Lysine-Specific Methyltransferase 2A><MLL fusion leukemia><MLL gene><MLL leukemia><MLL1><Malignant><Malignant - descriptor><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Measurement><Mediating><Medicinal Chemistry><Mentorship><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Methyltransferase><Mixed Lineage Leukemia Gene><Mixed-Lineage Leukemia><Mixed-Lineage Leukemia Protein><Modeling><Modern Man><Molecular><Molecular Interaction><Multiple lineage leukemia 1><Mutation><Myeloid-Lymphoid Leukemia Gene><Myeloid-Lymphoid Leukemia Protein><Myeloid/Lymphoid Leukemia Gene><Myeloid/Lymphoid Or Mixed Lineage Leukemia Protein><Myeloid/Lymphoid or Mixed Lineage Leukemia Gene><Neoplasm Metastasis><Oncogene Products><Oncogene Proteins><Oncogenes><Oncogenic><Oncoproteins><Organic Synthesis><Outcome><Patients><Pb element><Personalized medical approach><Pharmaceutic Chemistry><Pharmaceutical Chemistry><Pharmacology><Phenotype><Precision cancer therapy><Precision cancer treatment><Precursor Cell Lymphoblastic Leukemia><Precursor Lymphoblastic Leukemia><Programmed Cell Death><Proliferating><Property><Protein Biochemistry><Protein/Amino Acid Biochemistry><Proteins><Proto Oncogene Proteins MLL><RNA Expression><RNA Polymerase B><RNA Polymerase II><Regulation><Repression><Research><Research Personnel><Researchers><Rh (2,2'-biquinoline) complex><Role><Secondary Neoplasm><Secondary Tumor><Side><Stem Cell like><Strains Cell Lines><Structure><Surface><Survival Rate><Tissue Growth><Training><Transcription><Transcription Elongation><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Tumor Tissue><Work><ZNF51><ZNF51 Gene><Zinc Finger Protein 51 Gene><Zinc Finger Protein HRX><acute lymphatic leukemia><acute lymphogenous leukemia><acute lymphomatic leukemia><biophysical analysis><biophysical characteristics><biophysical characterization><biophysical foundation><biophysical measurement><biophysical parameters><biophysical principles><biophysical properties><biophysical sciences><biophysical studies><blood cell formation><cancer cell><cancer metastasis><cancer pharmacology><cancer progression><career><cell killing><cis-(Rh(biq)2Cl2)Cl><complex R><computational modeling><computational models><computer based models><computerized modeling><cultured cell line><cytotoxic><defined contribution><design><designing><developmental toxicity><driving><fusion gene><fusion oncoprotein><gene translocation><genome mutation><heavy metal Pb><heavy metal lead><individualized approach><infant acute leukemia><innovate><innovation><innovative><insight><kids><leukemia><loss of function><malignancy><member><methylase><mixed lineage leukemia 1><necrocytosis><neoplasm progression><neoplasm/cancer><neoplastic progression><new approaches><novel><novel approaches><novel strategies><novel strategy><ontogeny><overexpress><overexpression><personalized approach><pharmacologic><pre-clinical study><precision anticancer therapy><precision approach><precision cancer therapeutic><precision medicine><precision-based medicine><preclinical study><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><progenitor capacity><progenitor cell like><progenitor-like><programs><rational design><self-renew><self-renewal><skill acquisition><skill development><skills><social role><stem cell characteristics><stem-like><stemness><structural biology><success><synergism><tailored approach><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><transcription factor><transcriptomics><transmethylase><tumor><tumor cell metastasis><tumor progression><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jef D BOEKE

NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NEW YORK, NY

Good lead · 54/100

Large award

Very recent

Active award

$2,450,000

FY 2026

Project Title

CEGS: Center for Synthetic Regulatory Genomics - Renewal

Grant Number:

5RM1HG009491-09

Activity Code:

RM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

6/12/2018

End Date:

2/29/2028

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Title: Center for Synthetic Regulatory Genomics Abstract The Center for Synthetic Regulatory Genomics (SyRGe) is tasked with development and application of revolutionary technology for making dramatic, coordinated changes to extensive gene loci, which will enable broad investigation of the function ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

TIMOTHY P CRIPE

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

Good lead · 52/100

Likely hiring

Solid budget

Active award

$490,840

FY 2026

Project Title

A New Paradigm to Prevent and Treat Micrometastases

Grant Number:

5R01CA278995-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2024

End Date:

1/31/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Metastsis is the direct cause of the majority of deaths in patients with solid tumors, thus representing a major unmet medical need. In some cancer types, microscopic metastases may have already occurred at the time of diagnosis. Because an established tumor microenvironment mediates therap...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Guangping Gao

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$477,390

FY 2026

Project Title

Oligodendrocyte-focused rAAV gene therapy strategies for Canavan disease and Leukodystrophies

Grant Number:

5R01NS076991-12

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/1/2012

End Date:

1/31/2030

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Zolgensma, an FDA-approved gene therapy, employs recombinant adeno-associated virus (rAAV) to treat spinal muscular atrophy (SMA). However, toxicity and even death have been reported in patients, potentially due to widespread transgene expression caused by a constitutively active and...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KHANDAN KEYOMARSI

UNIVERSITY OF TX MD ANDERSON CAN CTR, HOUSTON, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$475,734

FY 2026

Project Title

Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients

Grant Number:

5R01CA255960-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/9/2020

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Estrogen receptor-positive (ER+)/HER2-negative breast cancer represents 70% of all breast cancer cases. Surgery and adjuvant/neo-adjuvant endocrine therapy (ET) are mainstays of treatment in early stage disease. However, some patients receiving ET for early stage ER-positive breast cancer o...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jer-Tsong Hsieh

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$474,892

FY 2026

Project Title

Overcoming mechanisms of PTPN1 driving therapy- and castration- resistant prostate cancer with novel theranostics

Grant Number:

5R01CA295762-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Overwhelming data from clinical experience clearly indicate that the recurrent therapy- and castration-resistant prostate cancer (t-CRPC) is responsible for the majority of these deaths because these cells exhibit resistant phenotype to hormonal therapy as well as convention...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

XIANKAI SUN

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$474,892

FY 2026

Project Title

Overcoming mechanisms of PTPN1 driving therapy- and castration- resistant prostate cancer with novel theranostics

Grant Number:

5R01CA295762-02

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Overwhelming data from clinical experience clearly indicate that the recurrent therapy- and castration-resistant prostate cancer (t-CRPC) is responsible for the majority of these deaths because these cells exhibit resistant phenotype to hormonal therapy as well as convention...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ya-Chieh Hsu

HARVARD UNIVERSITY, CAMBRIDGE, MA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$468,469

FY 2026

Project Title

Rapid functional genetics to study stem cell-niche interactions in the skin

Grant Number:

5R01AR080110-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/24/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Skin stem cells are heavily influenced by signals from their niches including different fibroblasts populations. While our ability to isolate and molecularly profile diverse cell types has improved drastically in the past decade, a major roadblock in identifying key genes driving ste...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rita C. R. Perlingeiro

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Good lead · 52/100

Likely hiring

Solid budget

Active award

$464,450

FY 2026

Project Title

Targeting Dystroglycanopathies using Pluripotent-derived Myogenic Progenitors

Grant Number:

5R01AR081882-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/10/2023

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary The biochemical hallmark of FKRP-associated dystroglycanopathies is the hypoglycosylation of α-dystroglycan (α-DG), which leads to disruption in the interaction of α-DG with extracellular matrix proteins, ultimately leading to muscle wasting. Recessive mutations in FKRP are associated with a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

THOMAS JEFFREY MARTIN

WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$437,935

FY 2026

Project Title

Cell-directed gene therapy for pain recovery after surgery and inflammation

Grant Number:

5R01NS122153-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/15/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary We have recently discovered macrophage ED2/CD163 gene overexpression as a novel and safe pain therapeutic target in the local peripheral immune system in a major surgery rat model. We propose to develop a cell-directed gene therapy that would correct the underlying local immunological cause ...

Research Terms

<(TNF)-α><3-D><3-Dimensional><3D><Acute Pain><Acutely painful><Address><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Arthritis><Assay><Attention><Behavior><Behavior assessment><Behavioral><Beta Proprotein Interleukin 1><Bioassay><Bioinformatics><Biological Assay><Body Tissues><Cachectin><Cell Body><Cell Communication and Signaling><Cell Reprogramming><Cell Signaling><Cells><Chronic><Chronic inflammatory pain><Clinical><Common Rat Strains><Complementary DNA><Complex><Critical Paths><Critical Pathways><Data><Development><Dimensions><Disease Progression><Dose><Dose Limiting><Drug abuse><Drugs><Freund's Adjuvant><Freund's Complete Adjuvant><Gene Expression><Gene Transcription><Genes><Genetic Transcription><Human><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Immune response><Immune system><Immunobiology><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunophysiology><Infiltration><Inflammation><Inflammation Mediators><Inflammatory><Infumorph><Injury><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Intervention><Intracellular Communication and Signaling><Kadian><Knee><Light><Link><Load Bearing><MS Contin><MSir><Macrophage><Macrophage-Derived TNF><Measures><Mechanics><Mediator><Medication><Modeling><Modern Man><Molecular><Monocyte-Derived TNF><Morphia><Morphine><Muscle><Muscle Tissue><Mφ><Nanotechnology><Nucleic Acids><Operative Procedures><Operative Surgical Procedures><Opiates><Opioid><Oramorph><Oramorph SR><Otomy><Outcome><Pain><Pain Control><Pain Therapy><Pain management><Painful><Patients><Peripheral><Pharmaceutical Preparations><Phenotype><Photoradiation><Plasmids><Polyaziridine><Polyethyleneimine><Position><Positioning Attribute><Post-operative Pain><Postoperative Pain><Preinterleukin 1 Beta><Process><Production><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Rat><Rats Mammals><Rattus><Recovery><Recovery of Function><Research><Resolution><Roxanol><Short interfering RNA><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Skin Tissue><Speed><Statex SR><Surgical><Surgical Interventions><Surgical Models><Surgical Procedure><Surgical incisions><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Technology><Testing><Therapeutic><Tissues><Transcription><Trauma><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Weight Bearing><Weight-Bearing state><Wound Repair><abuse of drugs><abuses drugs><addiction><addictive disorder><arthritic><behavioral assessment><biological signal transduction><cDNA><cellular reprogramming><chronic and inflammatory pain><chronic pain><chronic pain control><chronic pain intervention><chronic pain management><chronic pain therapy><chronic pain treatment><clinical relevance><clinically relevant><cutaneous tissue><cytokine><design><designing><developmental><drug/agent><functional recovery><gain of function><gene induction><gene signatures><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic signature><genome scale><genome-wide><genomewide><high risk><homopolymer Aziridine><host response><human data><immune system response><immunoresponse><improved><incision><induction of genes><inflammatory mediator><inflammatory pain><injured><injuries><innovate><innovation><innovative><insight><knock-down><knockdown><loss of function><mechanic><mechanical><multidisciplinary><muscular><nano particle><nano tech><nano technology><nano-sized particle><nano-technological><nanoparticle><nanosized particle><nanotech><nanotechnological><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><opiate abuse><opiate crisis><opiate drug abuse><opioid abuse><opioid crisis><opioid drug abuse><opioid epidemic><opioid sparing><overexpress><overexpression><pain after surgery><pain behavior><pain intervention><pain model><pain reduction><pain treatment><post-surgical pain><postoperative recovery><postsurgical pain><prevent><preventing><programs><recovery after surgery><recovery following surgery><reduce pain><resolutions><response><scRNA sequencing><scRNA-seq><siRNA><side effect><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><surgery><surgery pain><surgical pain><therapeutic target><three dimensional><tissue repair><tissue wound><tool><transcriptome sequencing><transcriptomic sequencing><transcriptomics><translational opportunities><translational potential><treat chronic pain><wound><wound healing><wound recovery><wound resolution><wounding><wounds>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

E. Alfonso Romero-Sandoval

WAKE FOREST UNIVERSITY HEALTH SCIENCES, WINSTON-SALEM, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$437,935

FY 2026

Project Title

Cell-directed gene therapy for pain recovery after surgery and inflammation

Grant Number:

5R01NS122153-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/15/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Summary We have recently discovered macrophage ED2/CD163 gene overexpression as a novel and safe pain therapeutic target in the local peripheral immune system in a major surgery rat model. We propose to develop a cell-directed gene therapy that would correct the underlying local immunological cause ...

Research Terms

<(TNF)-α><3-D><3-Dimensional><3D><Acute Pain><Acutely painful><Address><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Arthritis><Assay><Attention><Behavior><Behavior assessment><Behavioral><Beta Proprotein Interleukin 1><Bioassay><Bioinformatics><Biological Assay><Body Tissues><Cachectin><Cell Body><Cell Communication and Signaling><Cell Reprogramming><Cell Signaling><Cells><Chronic><Chronic inflammatory pain><Clinical><Common Rat Strains><Complementary DNA><Complex><Critical Paths><Critical Pathways><Data><Development><Dimensions><Disease Progression><Dose><Dose Limiting><Drug abuse><Drugs><Freund's Adjuvant><Freund's Complete Adjuvant><Gene Expression><Gene Transcription><Genes><Genetic Transcription><Human><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Immune response><Immune system><Immunobiology><Immunochemical Immunologic><Immunologic><Immunological><Immunologically><Immunologics><Immunophysiology><Infiltration><Inflammation><Inflammation Mediators><Inflammatory><Infumorph><Injury><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Intervention><Intracellular Communication and Signaling><Kadian><Knee><Light><Link><Load Bearing><MS Contin><MSir><Macrophage><Macrophage-Derived TNF><Measures><Mechanics><Mediator><Medication><Modeling><Modern Man><Molecular><Monocyte-Derived TNF><Morphia><Morphine><Muscle><Muscle Tissue><Mφ><Nanotechnology><Nucleic Acids><Operative Procedures><Operative Surgical Procedures><Opiates><Opioid><Oramorph><Oramorph SR><Otomy><Outcome><Pain><Pain Control><Pain Therapy><Pain management><Painful><Patients><Peripheral><Pharmaceutical Preparations><Phenotype><Photoradiation><Plasmids><Polyaziridine><Polyethyleneimine><Position><Positioning Attribute><Post-operative Pain><Postoperative Pain><Preinterleukin 1 Beta><Process><Production><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Rat><Rats Mammals><Rattus><Recovery><Recovery of Function><Research><Resolution><Roxanol><Short interfering RNA><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Skin><Skin Tissue><Speed><Statex SR><Surgical><Surgical Interventions><Surgical Models><Surgical Procedure><Surgical incisions><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Technology><Testing><Therapeutic><Tissues><Transcription><Trauma><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Weight Bearing><Weight-Bearing state><Wound Repair><abuse of drugs><abuses drugs><addiction><addictive disorder><arthritic><behavioral assessment><biological signal transduction><cDNA><cellular reprogramming><chronic and inflammatory pain><chronic pain><chronic pain control><chronic pain intervention><chronic pain management><chronic pain therapy><chronic pain treatment><clinical relevance><clinically relevant><cutaneous tissue><cytokine><design><designing><developmental><drug/agent><functional recovery><gain of function><gene induction><gene signatures><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic signature><genome scale><genome-wide><genomewide><high risk><homopolymer Aziridine><host response><human data><immune system response><immunoresponse><improved><incision><induction of genes><inflammatory mediator><inflammatory pain><injured><injuries><innovate><innovation><innovative><insight><knock-down><knockdown><loss of function><mechanic><mechanical><multidisciplinary><muscular><nano particle><nano tech><nano technology><nano-sized particle><nano-technological><nanoparticle><nanosized particle><nanotech><nanotechnological><non-narcotic analgesic><non-opiate analgesic><non-opioid><non-opioid analgesic><non-opioid therapeutics><nonnarcotic analgesics><nonopiate analgesic><nonopioid><nonopioid analgesics><novel><opiate abuse><opiate crisis><opiate drug abuse><opioid abuse><opioid crisis><opioid drug abuse><opioid epidemic><opioid sparing><overexpress><overexpression><pain after surgery><pain behavior><pain intervention><pain model><pain reduction><pain treatment><post-surgical pain><postoperative recovery><postsurgical pain><prevent><preventing><programs><recovery after surgery><recovery following surgery><reduce pain><resolutions><response><scRNA sequencing><scRNA-seq><siRNA><side effect><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><surgery><surgery pain><surgical pain><therapeutic target><three dimensional><tissue repair><tissue wound><tool><transcriptome sequencing><transcriptomic sequencing><transcriptomics><translational opportunities><translational potential><treat chronic pain><wound><wound healing><wound recovery><wound resolution><wounding><wounds>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sylvain Simon

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$435,730

FY 2026

Project Title

Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy

Grant Number:

5R01CA114536-21

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2005

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Abstract Adoptive cell therapy using T cells modified by gene transfer to express T cell receptors or synthetic chimeric antigen receptors (CARs) that specify T cell recognition of tumor associated antigens can be effective in patients with refractory malignancies. Clinical data has shown that tumor...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Shawn Hingtgen

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$430,681

FY 2026

Project Title

Harnessing Continuous Liquid Interface 3D Printing to Improve Tumor-homing Stem Cell Therapy for Post-surgical Brain Cancer

Grant Number:

5R01CA269974-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Glioblastoma is the most common primary brain tumor and one of the deadliest forms of cancer. Recently, we found that biocompatible matrices significantly improve the transplant of tumor-homing neural stem cells into the post-surgical GBM cavity allowing them to deliver anti...

Research Terms

<3-D><3-D print><3-D printer><3-Dimensional><3D><3D Print><3D printer><3D printing><APO2 Ligand><Abscission><Advanced Development><Allografting><Animals><Apo-2 Ligand><Architecture><Assay><Bioassay><Biological Assay><Biophysics><Blood - brain barrier anatomy><Blood-Brain Barrier><Body Tissues><Brain Cancer><Cancer Treatment><Cancers><Cell Survival><Cell Viability><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Clinical><Clinical Research><Clinical Study><Co-culture><Cocultivation><Coculture><Coculture Techniques><Combination Chemotherapy Regimen><Complex><Custom><Data><Deposit><Deposition><Detectable Residual Disease><Drugs><ELISA><Engineering / Architecture><Enzyme-Linked Immunosorbent Assay><Excision><Extirpation><Gelatin><Generalized Growth><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Growth><Hemato-Encephalic Barrier><Heterograft><Heterologous Transplantation><Homing><Human><Human Engineering><Image><Immune><Immune system><Immunes><Immunocompetent><Implant><In Vitro><Injections><Intrasurgical Resection Cavity><Kinetics><Liquid substance><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Brain><Malignant neoplasm of brain><Mechanics><Medication><Methods><Mice><Mice Mammals><Microscopic><Minimal Residual Disease><Modeling><Modern Man><Modulus><Murine><Mus><Neoplasm Transplantation><Neural Stem Cell><Operative Procedures><Operative Surgical Procedures><Patients><Penetration><Performance><Pharmaceutical Preparations><Postoperative><Postoperative Period><Primary Brain Neoplasms><Primary Brain Tumors><Printing><Production><Progenitor Cell Transplantation><Progenitor Cells><Proliferating><Property><Quimioterapia><Recombinant DNA Technology><Recurrence><Recurrent><Recurrent Neoplasm><Recurrent tumor><Removal><Resection Cavity><Residual><Residual Neoplasm><Residual Tumors><Residual state><Resolution><Safety><Shapes><Solid><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Stem Cell Transplantation><Stem cell transplant><Surgical><Surgical Interventions><Surgical Procedure><Surgical Removal><Surgically-Created Cystic Resection Cavity><Surgically-Created Resection Cavity><TNF-Related Apoptosis Inducing Ligand TRAIL><TNF-related apoptosis-inducing ligand><TNFSF10 Protein><TRAIL Protein><Testing><Therapeutic><Tissue Growth><Tissues><Translating><Transplantation><Tumor Necrosis Factor Ligand Superfamily Member 10><Variant><Variation><Xenograft><Xenograft procedure><Xenotransplantation><anti-cancer><anti-cancer therapy><biocompatibility><bioluminescence imaging><bioluminescent imaging><biomaterial compatibility><biophysical foundation><biophysical principles><biophysical sciences><bloodbrain barrier><brain tissue><cancer cell><cancer chemotherapy><cancer invasiveness><cancer progenitor><cancer progenitor cells><cancer stem cell><cancer stem like cell><cancer therapy><cancer-directed therapy><clinical relevance><clinically relevant><copolymer><customs><design><designing><drug/agent><enzyme linked immunoassay><fabrication><fabrication technology><first in man><first-in-human><fluid><gene product><genetically engineered><glioblastoma multiforme><hydrogel scaffold><imaging><immune competent><immunocytochemistry><improved><in vivo><liquid><malignancy><malignant progenitor><malignant stem cell><manufacture><manufacturing technology><mechanic><mechanical><migration><mouse model><murine model><neoplasm recurrence><neoplasm/cancer><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuroprogenitor><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncogenic progenitor><oncogenic stem cells><ontogeny><permissiveness><porous hydrogel><pre-clinical study><preclinical study><progenitor and neural stem cells><progenitor cell based therapy><progenitor cell therapy><progenitor cell treatment><progenitor like cancer cell><progenitor therapy><progenitor transplantation><progenitor treatment><rational design><resection><residual disease><resolutions><response><scaffold><scaffolding><spongioblastoma multiforme><statistical analysis><stem and progenitor cell therapy><stem and progenitor cell transplantations><stem cell based therapy><stem cell mediated therapy><stem cell therapeutics><stem cell therapy><stem cell treatment><stem cell-based therapeutic><stem cell-based treatment><stem cells><stem like cancer cell><surgery><three dimensional><three dimensional printing><transplant><tumor><tumor transplant><tumor transplantation><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jillian Perry

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$430,681

FY 2026

Project Title

Harnessing Continuous Liquid Interface 3D Printing to Improve Tumor-homing Stem Cell Therapy for Post-surgical Brain Cancer

Grant Number:

5R01CA269974-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract Glioblastoma is the most common primary brain tumor and one of the deadliest forms of cancer. Recently, we found that biocompatible matrices significantly improve the transplant of tumor-homing neural stem cells into the post-surgical GBM cavity allowing them to deliver anti...

Research Terms

<3-D><3-D print><3-D printer><3-Dimensional><3D><3D Print><3D printer><3D printing><APO2 Ligand><Abscission><Advanced Development><Allografting><Animals><Apo-2 Ligand><Architecture><Assay><Bioassay><Biological Assay><Biophysics><Blood - brain barrier anatomy><Blood-Brain Barrier><Body Tissues><Brain Cancer><Cancer Treatment><Cancers><Cell Survival><Cell Viability><Chemotherapy Protocol><Chemotherapy Regimen><Chemotherapy-Oncologic Procedure><Clinical><Clinical Research><Clinical Study><Co-culture><Cocultivation><Coculture><Coculture Techniques><Combination Chemotherapy Regimen><Complex><Custom><Data><Deposit><Deposition><Detectable Residual Disease><Drugs><ELISA><Engineering / Architecture><Enzyme-Linked Immunosorbent Assay><Excision><Extirpation><Gelatin><Generalized Growth><Genetic Engineering><Genetic Engineering Biotechnology><Genetic Engineering Molecular Biology><Glioblastoma><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Growth><Hemato-Encephalic Barrier><Heterograft><Heterologous Transplantation><Homing><Human><Human Engineering><Image><Immune><Immune system><Immunes><Immunocompetent><Implant><In Vitro><Injections><Intrasurgical Resection Cavity><Kinetics><Liquid substance><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Brain><Malignant neoplasm of brain><Mechanics><Medication><Methods><Mice><Mice Mammals><Microscopic><Minimal Residual Disease><Modeling><Modern Man><Modulus><Murine><Mus><Neoplasm Transplantation><Neural Stem Cell><Operative Procedures><Operative Surgical Procedures><Patients><Penetration><Performance><Pharmaceutical Preparations><Postoperative><Postoperative Period><Primary Brain Neoplasms><Primary Brain Tumors><Printing><Production><Progenitor Cell Transplantation><Progenitor Cells><Proliferating><Property><Quimioterapia><Recombinant DNA Technology><Recurrence><Recurrent><Recurrent Neoplasm><Recurrent tumor><Removal><Resection Cavity><Residual><Residual Neoplasm><Residual Tumors><Residual state><Resolution><Safety><Shapes><Solid><Statistical Data Analyses><Statistical Data Analysis><Statistical Data Interpretation><Stem Cell Transplantation><Stem cell transplant><Surgical><Surgical Interventions><Surgical Procedure><Surgical Removal><Surgically-Created Cystic Resection Cavity><Surgically-Created Resection Cavity><TNF-Related Apoptosis Inducing Ligand TRAIL><TNF-related apoptosis-inducing ligand><TNFSF10 Protein><TRAIL Protein><Testing><Therapeutic><Tissue Growth><Tissues><Translating><Transplantation><Tumor Necrosis Factor Ligand Superfamily Member 10><Variant><Variation><Xenograft><Xenograft procedure><Xenotransplantation><anti-cancer><anti-cancer therapy><biocompatibility><bioluminescence imaging><bioluminescent imaging><biomaterial compatibility><biophysical foundation><biophysical principles><biophysical sciences><bloodbrain barrier><brain tissue><cancer cell><cancer chemotherapy><cancer invasiveness><cancer progenitor><cancer progenitor cells><cancer stem cell><cancer stem like cell><cancer therapy><cancer-directed therapy><clinical relevance><clinically relevant><copolymer><customs><design><designing><drug/agent><enzyme linked immunoassay><fabrication><fabrication technology><first in man><first-in-human><fluid><gene product><genetically engineered><glioblastoma multiforme><hydrogel scaffold><imaging><immune competent><immunocytochemistry><improved><in vivo><liquid><malignancy><malignant progenitor><malignant stem cell><manufacture><manufacturing technology><mechanic><mechanical><migration><mouse model><murine model><neoplasm recurrence><neoplasm/cancer><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuroprogenitor><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncogenic progenitor><oncogenic stem cells><ontogeny><permissiveness><porous hydrogel><pre-clinical study><preclinical study><progenitor and neural stem cells><progenitor cell based therapy><progenitor cell therapy><progenitor cell treatment><progenitor like cancer cell><progenitor therapy><progenitor transplantation><progenitor treatment><rational design><resection><residual disease><resolutions><response><scaffold><scaffolding><spongioblastoma multiforme><statistical analysis><stem and progenitor cell therapy><stem and progenitor cell transplantations><stem cell based therapy><stem cell mediated therapy><stem cell therapeutics><stem cell therapy><stem cell treatment><stem cell-based therapeutic><stem cell-based treatment><stem cells><stem like cancer cell><surgery><three dimensional><three dimensional printing><transplant><tumor><tumor transplant><tumor transplantation><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew Shtrahman

UNIVERSITY OF CALIFORNIA, SAN DIEGO, LA JOLLA, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$430,041

FY 2026

Project Title

Developing a Synthetic Adeno-Associated Virus (AAV) for Engineering Safer Gene Therapies

Grant Number:

5R01NS131151-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2023

End Date:

1/31/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY Medicine is currently undergoing a revolution, where viable gene therapies are being developed for multiple disorders, including diseases of the central nervous system (CNS). One of the obstacles that limits the use of gene therapy is the availability of safe and effective vectors f...

Research Terms

<0-11 years old><Ablation><Acute Kidney Failure><Acute Kidney Insufficiency><Acute Renal Failure><Acute Renal Insufficiency><Adeno-Associated Viruses><Adverse effects><Ammon Horn><Attenuated><Base Pairing><Brain><Brain Nervous System><C9ALS/FTD><CNS Diseases><CNS disorder><Capsid><Cardiopulmonary><Cell Body><Cell Death><Cells><Central Nervous System Diseases><Central Nervous System Disorders><Cerebroatrophic Hyperammonemia><Cessation of life><Child><Child Youth><Children (0-21)><Clinical Trials><Cornu Ammonis><DNA><DNA Damage><DNA Injury><DNA Sequence><DNA Therapy><DNA mutation><Death><Deoxyribonucleic Acid><Dependoparvovirus><Dependovirus><Disease><Disorder><Dysfunction><Electroporation><Embryo><Embryonic><Encephalon><Engineering><FDA approved><Flanking Repeat Sequences><Functional disorder><Gene Delivery><Gene Transfer Clinical><Genes><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Genome><HS-mucopolysaccharidosis><Hippocampus><Histology><Human><Immune reaction><Injections><Inverted Terminal Repeat><Learning><Learning Disabilities><Learning disability><MPS III><MPS III A-D><MPS type III><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><MeCP-2 protein><MeCP2><MeCP2 protein><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medicine><Memory><Methods><Methyl CpG binding protein MeCP2><Methyl-CpG-Binding Protein 2><Methyl-DNA binding protein MECP2><Mice><Mice Mammals><MoMuSV 124 variant R7><Modern Man><Mucopolysaccharidosis 3><Mucopolysaccharidosis III><Mucopolysaccharidosis type 3><Murine><Mus><Mutation><NMR Imaging><NMR Tomography><Names><Nerve Cells><Nerve Unit><Neural Cell><Neural Stem Cell><Neurocyte><Neurons><Neurosciences><Non-Polyadenylated RNA><Nuclear Magnetic Resonance Imaging><Nucleotides><Pathologic><Patients><Physiopathology><Polydystrophic Oligophrenia><Production><Proteins><Publishing><R7 Virus><RNA><RNA Gene Products><Recombinant 7><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Recombinants><Reporting><Research><Rett Disorder><Rett Syndrome><Ribonucleic Acid><Risk><San Filippo's Syndrome><Sanfilippo disease><Sanfilippo syndrome (A, B, C, D)><Sanfilippos Syndrome><Single-Stranded DNA><Site><Source><Structure><Symptoms><Terminal Repeat><Terminal Repeat Sequences><Testing><Therapeutic><Thrombocytopenia><Thrombopenia><Toxic effect><Toxicities><Transgenes><Tropism><Viral><Viral Genome><Viral Vector><Virus><Work><Zeugmatography><acute kidney injury><adeno associated virus group><adult neurogenesis><adverse consequence><adverse outcome><attenuate><attenuates><c9FTD/ALS><c9als/frontotemporal dementia><c9ftd/amyotrophic lateral sclerosis><ddPCR><droplet digital PCR><droplet digital Polymerase Chain Reaction><droplet-based digital PCR><electroporative delivery><experiment><experimental research><experimental study><experiments><gene electrotransfer><gene product><gene repair therapy><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><heparitinuria><hippocampal><immunogenicity><immunoreaction><in utero><in vivo><kids><loss of function><mouse model><mucopolysaccharide storage disease III><mucopolysaccharidosis (MPS) III (A, B, C, D)><mucopolysaccharidosis type III><murine model><mutant><name><named><naming><necrocytosis><nerve stem cell><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuroprogenitor><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathophysiology><progenitor and neural stem cells><progenitor biology><progenitor cell biology><progenitor cell proliferation><progenitor proliferation><rAAV><recombinant AAV><response><ssDNA><stem and progenitor biology><stem and progenitor cell proliferation><stem cell biology><stem cell proliferation><transgene><transgene expression><vector><virus genome><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JOYCE MARIE SLINGERLAND

GEORGETOWN UNIVERSITY, WASHINGTON, DC

Good lead · 52/100

Likely hiring

Solid budget

Active award

$417,705

FY 2026

Project Title

Mechanistic Links Between Changing Estrogen Profiles, Inflammation and the Increased Risk and Metastasis of Breast Cancer in Obese Women

Grant Number:

5R01CA210440-10

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/7/2017

End Date:

11/30/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Obesity prevalence is >39% in the USA. Obesity increases estrone synthesis in fat; and both obesity and estrone correlate with increased postmenopausal ER+ breast cancer risk and mortality. We aim to elucidate how estrone links obesity, inflammation and breast cancer. Obese fat is chronically inflam...

Research Terms

<3-D><3-Dimensional><3D><Adipocytes><Adipose Cell><American><Aquadiol><B-Cell Differentiation Factor Gene><B-Cell Stimulatory Factor 2 Gene><BSF-2 Gene><BSF2 Gene><Basal Transcription Factor><Basal transcription factor genes><Beta-2 Gene Interferon><Binding><Body Tissues><Breast><Breast Cancer><Breast Cancer Cell><Breast Cancer Risk Factor><Breast Cancer cell line><Breast Cancer therapy><Breast Metastasis><Breast Neoplasms><Breast Tumors><Breast tumor cell line><CCL2><CCL2 gene><Cancer Genes><Cancer-Promoting Gene><Cancers><Cell Body><Cells><ChIP Sequencing><ChIP-seq><ChIPseq><Chemokine, CC Motif, Ligand 2><Chromatin><Chronic><Cytokine Gene><DNA mutation><Data><Development><Dimenformon><Diogyn><Diogynets><Drug resistance><ER Positive><ER+><ERalpha><ERα><ESR1><ESR1 gene><Endocrine Gland Secretion><Endocrine Therapy><Estrace><Estradiol><Estradiol Receptor alpha><Estradiol Receptor α><Estradiol-17 beta><Estradiol-17beta><Estraldine><Estrogen Receptor 1><Estrogen Receptor alpha><Estrogen Receptor α><Estrogen receptor positive><Estrogens><Estrone><Euchromatin><Expression Profiling><Expression Signature><Fat Cells><Fats><Fatty acid glycerol esters><Gene Action Regulation><Gene Activation><Gene Down-Regulation><Gene Expression><Gene Expression Profile><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Grant><Growth><HSF Gene><Hepatocyte Stimulatory Factor Gene><Heterochromatin><Heterograft><Heterologous Transplantation><Hormonal Therapy><Hormones><Human><Hybridoma Growth Factor Gene><IFNB2 Gene><IL-6 Gene><IL6><IL6 gene><In Vitro><Inflammation><Inflammatory><Interleukin 6 (Interferon, Beta 2) Gene><Interleukin-6 Gene><Leanness><Ligands><Link><Lipocytes><MCAF><MCF-7><MCF-7 Cell><MCF-7DR><MCF-7WT><MCF7><MCF7 cell><MCP-1><MCP1><Malignant Breast Neoplasm><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Mammary Cancer><Mammary Neoplasms><Mature Lipocyte><Mature fat cell><Mediating><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Modern Man><Molecular Configuration><Molecular Conformation><Molecular Interaction><Molecular Stereochemistry><Monocyte Chemoattractant Protein-1><Monocyte Chemotactic Protein-1><Monocyte Chemotactic and Activating Factor><Monocyte Chemotactic and Activating Protein><Monocyte Chemotactive and Activating Factor><Monocyte Secretory Protein JE><Mutation><NR3A1><Neoplasm Metastasis><Nuclear><Obesity><Obesity Epidemic><Oncogenes><Oncogenesis><Oncogenic><Organoids><Ovarian><Ovocyclin><Ovocylin><Post-Menopause><Post-menopausal Period><Postmenopausal Period><Postmenopause><Pre-Menopause><Pre-menopausal Period><Premenopausal><Premenopausal Period><Premenopause><Prevalence><Preventative strategy><Prevention strategy><Preventive strategy><Prognosis><Progynon><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Regulation><Repression><Repressor Proteins><Response Elements><Risk><SCYA2><Sampling><Secondary Neoplasm><Secondary Tumor><Site><Testing><Therapeutic Estradiol><Therapeutic Estrogen><Therapeutic Estrone><Therapeutic Hormone><Thinness><Tissue Growth><Tissues><Trans-Acting Factors><Trans-Activators><Transactivators><Transcription><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription factor genes><Transforming Genes><Tumor Promotion><Woman><Work><Xenograft><Xenograft procedure><Xenotransplantation><adiposity><after menopause><breast cancer metastasis><breast cancer risk><breast tumor cell><cancer cell><cancer metastasis><cancer prevention><cancer progenitor><cancer progenitor cells><cancer progression><cancer stem cell><cancer stem like cell><cell type><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><co-repressor><conformation><conformational><conformational state><conformationally><conformations><corepressor><corpulence><cytokine><developmental><drug resistant><epithelial to mesenchymal transition><falls><following menopause><gene co-repressor><gene corepressor><gene expression pattern><gene expression signature><gene induction><gene repression><genetic co-repressor><genetic corepressor><genome mutation><global gene expression><global transcription profile><hormone therapy><in vivo><induction of genes><malignancy><malignant breast tumor><malignant progenitor><malignant stem cell><mammary><mammary tumor><matrigel><mortality><mutant><neoplasm progression><neoplasm/cancer><neoplastic progression><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><oncogenic progenitor><oncogenic stem cells><ontogeny><p65><past menopause><post-menopausal><postmenopausal><postmenopausal status><pre-menopausal><premenopausal status><progenitor cell expansion><progenitor expansion><progenitor like cancer cell><programs><receptor binding><receptor bound><recruit><repressor complex><resistance to Drug><resistant to Drug><response><stem and progenitor cell expansion><stem cell expansion><stem like cancer cell><three dimensional><transcription factor><transcriptional profile><transcriptional signature><transcriptome><transcriptome sequencing><transcriptomic sequencing><tumor><tumor cell metastasis><tumor growth><tumor initiation><tumor progression><tumorigenesis><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ZHENG-RONG LU

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 52/100

Likely hiring

Solid budget

Active award

$405,116

FY 2026

Project Title

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy

Grant Number:

5R01CA235152-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/12/2018

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The goal of this project is to develop smart targeted lipid ECO/siRNA nanoparticles (ELNP) to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat triple-negative breast cancer (TNBC). Metastasis and drug resistance are the main causes for the high mortality rates of women dia...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

William Schiemann

CASE WESTERN RESERVE UNIVERSITY, CLEVELAND, OH

Good lead · 52/100

Likely hiring

Solid budget

Active award

$405,116

FY 2026

Project Title

Smart nanoparticles regulating oncogenic IncRNA for breast cancer therapy

Grant Number:

5R01CA235152-08

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/12/2018

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

The goal of this project is to develop smart targeted lipid ECO/siRNA nanoparticles (ELNP) to target oncogenic long non-coding RNAs (lncRNAs) as a novel therapy to treat triple-negative breast cancer (TNBC). Metastasis and drug resistance are the main causes for the high mortality rates of women dia...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Muna I. Naash

UNIVERSITY OF HOUSTON, HOUSTON, TX

Good lead · 52/100

Likely hiring

Solid budget

Active award

$400,787

FY 2026

Project Title

Non-viral gene delivery platforms for the treatment of Usher Syndrome Type 2A.

Grant Number:

5R01EY034671-04

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2023

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary/Abstract: Our goal is to advance our current intravitreal gene therapy platform consisting of DNA nanoparticles (DNA- NPs)/hyaluronic acid nanospheres (HA-NSs) to deliver large genes in order to develop safe/effective therapies for visual loss in Usher Syndrome type 2A (USH2A). Curre...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel Kerschensteiner

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Good lead · 52/100

Likely hiring

Solid budget

Active award

$387,881

FY 2026

Project Title

Synapse rescue and neuroprotection in the retina

Grant Number:

5R01EY027411-09

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2017

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary Nervous system functions, including vision, arises from precise patterns of synaptic communication. In neurodegenerative diseases, synapse loss can long precede cell death and predict functional impairments. We recently discovered that the cell adhesion molecule (CAM) Netrin-G ligand...

Research Terms

<21+ years old><Acceleration><Adhesion Molecule><Adult><Adult Human><Affect><Anatomic Sites><Anatomic structures><Anatomy><Assay><Award><Behavioral Assay><Bioassay><Biochemistry><Biological Assay><Biological Chemistry><Blindness><Cell Adhesion Molecule Gene><Cell Adhesion Molecules><Cell Communication and Signaling><Cell Death><Cell Signaling><Cessation of life><Code><Coding System><Communication><Complex><Cone><DNA Therapy><DNA mutation><Data><Death><Degenerative Neurologic Disorders><Development><Diminished Vision><Disease><Disease Progression><Disorder><Electrophysiology><Electrophysiology (science)><Functional impairment><Gene Transfer Clinical><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genome engineering><Grant><Human><Image><Intracellular Communication and Signaling><KO mice><Knock-out><Knock-out Mice><Knockout><Knockout Mice><Life><Ligands><Low Vision><Maintenance><Mediating><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><Mutation><Natural History><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System><Nervous System Degenerative Diseases><Nervous System Physiology><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Body System><Neurologic Degenerative Conditions><Neurologic Organ System><Neurologic function><Neurological function><Neuron Degeneration><Neurons><Neurophysiology - biologic function><Neurophysiology / Electrophysiology><Null Mouse><Operative Procedures><Operative Surgical Procedures><Organ Donor><Partial Sight><Pathogenesis><Pathway interactions><Patients><Pattern><Peptide Domain><Photoreceptor Cell><Photoreceptors><Photosensitive Cell><Preparation><Protein Domains><Proteomics><Reduced Vision><Resolution><Retina><Rod><Rod Photoreceptors><Shapes><Sight><Signal Transduction><Signal Transduction Systems><Signaling><Specific qualifier value><Specified><Subnormal Vision><Surgical><Surgical Interventions><Surgical Procedure><Synapses><Synaptic><System><Tertiary Protein Structure><Testing><Therapeutic><Time><Translations><Viral><Virus><Vision><Visual Receptor><Visual impairment><Wild Type Mouse><adulthood><biological signal transduction><cell adhesion protein><combinatorial><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><developmental><electrophysiological><functional restoration><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><global gene expression><global transcription profile><horizontal cell><imaging><inherited retinal degeneration><necrocytosis><nervous system function><neural circuit><neural circuitry><neural degeneration><neural function><neurocircuitry><neurodegeneration><neurodegenerative><neurodegenerative illness><neurological degeneration><neuronal><neuronal degeneration><neuroprotection><neuroprotective><overexpress><overexpression><pathway><photoreceptor degeneration><preparations><preservation><prevent><preventing><protein complex><resolutions><restore function><restore functionality><restore lost function><retinal neuron><retinal rods><rod cell><surgery><synapse><synapse formation><synapse function><synaptic circuit><synaptic circuitry><synaptic function><synaptogenesis><transcriptome><translation><translation to humans><vision impairment><vision loss><visual function><visual loss><visually impaired><wildtype mouse>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Hongwu Chen

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$368,288

FY 2026

Project Title

Targeting aberrant circadian regulator in advanced prostate cancer

Grant Number:

5R01CA259081-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/15/2021

End Date:

11/30/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

ABSTRACT Metastatic prostate cancer (PCa) remains to be one of the leading causes of cancer-related death. Patients with metastatic castration-resistant PCa or mCRPC often develop resistance to the 2nd generation therapeutics including enzalutamide and the disease becomes deadly. Like many other can...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HOSHANG JEHANGIR UNWALLA

FLORIDA INTERNATIONAL UNIVERSITY, MIAMI, FL

Good lead · 52/100

Likely hiring

Solid budget

Active award

$368,034

FY 2026

Project Title

A CRISP(e)R way to silence HIV

Grant Number:

5R01AI174269-03

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/14/2023

End Date:

11/30/2028

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

PROJECT SUMMARY: In aging HIV-infected populations comorbid diseases are important determinants of morbidity and mortality. HIV patients die of non-AIDS comorbidities almost a decade earlier that their non-HIV counterparts. cART is unable to eradicate HIV due to established HIV reservoirs. Mounting...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ALLAN M GOLDSTEIN

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$356,230

FY 2026

Project Title

Characterizing neurogenic progenitors in the adult intestine

Grant Number:

5R01DK119210-07

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2020

End Date:

12/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Project Summary The enteric nervous system (ENS) is of fundamental importance to human health through its regulation of all aspects of gastrointestinal (GI) function, most notably gut motility. Congenital or acquired abnormalities of the ENS consequently can lead to serious functional GI disorders, ...

Research Terms

<21+ years old><Acquired Abnormalities><Acquired Abnormality><Acute><Adult><Adult Human><Affect><Aganglionic Megacolon><Alimentary Canal><American><Basal Transcription Factor><Basal transcription factor genes><Bioinformatics><Birth Defects><CUT&RUN><Cardiospasm><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Therapy><Cell Transplantation><Cell-Extracellular Matrix><Cells><Chromatin><Chronic><Cleavage Targets and Release Using Nuclease><Cleavage Under Targets and Release Using Nuclease><Clinical><Colitis><Congenital Abnormality><Congenital Anatomical Abnormality><Congenital Defects><Congenital Deformity><Congenital Malformation><Congenital Megacolon><Constipation><DSS colitis><DSS model><DSS mouse model><DSS-induced acute colitis><DSS-induced colitis><Data><Development><Digestive Tract><Disease><Disorder><ECM><Enteral><Enteric><Enteric Nervous System><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Esophageal achalasia><Expression Signature><Extracellular Matrix><Family><Functional Gastrointestinal Disorders><GI Tract><Ganglia><Gastric Stasis><Gastrointestinal Diseases><Gastrointestinal Tract><Gastrointestinal tract structure><Gastroparesis><Gene Down-Regulation><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profile><Gene Expression Profiling><Gene Inactivation><Gene Silencing><General Transcription Factor Gene><General Transcription Factors><Genes><Genetic><Glia><Glial Cells><Glial Differentiation><Health><Health Care Costs><Health Costs><Hirschsprung Disease><Human><Idiopathic Intestinal Pseudo-Obstruction><Immunity><Immunologic Tests><Immunological Tests><In Vitro><Inflammation><Inflammation Mediators><Inflammatory><Inflammatory Bowel Diseases><Inflammatory Bowel Disorder><Intestinal><Intestinal Pseudo-Obstruction><Intestinal Pseudoobstruction><Intestines><Intracellular Communication and Signaling><Irritable Bowel Syndrome><Irritable Colon><Knowledge><Kolliker's reticulum><Lead><Macrophage><Mediating><Methods><Mice><Mice Mammals><Modern Man><Molecular><Morbidity><Motility><Mucous Colitis><Murine><Mus><Mφ><Nerve Cells><Nerve Unit><Neural Cell><Neural Ganglion><Neural Stem Cell><Neurocyte><Neuroglia><Neuroglial Cells><Neuronal Differentiation><Neurons><Neuropathy><Neurosphere><Non-neuronal cell><Nonneuronal cell><Pathway interactions><Patients><Pb element><Phenotype><Population><Process><Production><QOL><Quality of life><Receptor Protein><Regulation><Regulatory Element><Repression><Role><Signal Transduction><Signal Transduction Systems><Signaling><Stimulus><Techniques><Testing><Transcript Expression Analyses><Transcript Expression Analysis><Transcription Factor Proto-Oncogene><Transcription Repression><Transcription factor genes><Transplantation><Upregulation><adulthood><aganglionosis><alimentary tract><analyze gene expression><barriers to implementation><biological signal transduction><bowel><bowel inflammation><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><cellular transplant><cholinergic><chromatin remodeling><colitis-induced dysbiosis><cytokine><delayed gastric emptying><developmental><dextran sulfate sodium colitis><dextran sulfate sodium induced colitis><dextran sulfate sodium model><dextran sulfate sodium mouse model><digestive canal><dysmotility><dysmotility syndrome><enteric neuropathy><epigenetically><epigenome profiling><epigenomic profiling><experiment><experimental research><experimental study><experiments><gastrointestinal><gastrointestinal disorder><gastrointestinal function><gene expression analysis><gene expression assay><gene expression pattern><gene expression signature><gene locus><gene repression><genetic locus><genomic location><genomic locus><gut homeostasis><gut inflammation><heavy metal Pb><heavy metal lead><implementation barriers><implementation challenges><improved><in vivo><inflamed bowel><inflamed gut><inflamed intestine><inflammatory disease of the intestine><inflammatory disorder of the intestine><inflammatory mediator><innervation><innovate><innovation><innovative><intestinal autoinflammation><intestinal inflammation><intestine pseudoobstruction><motility disorder><multiomics><multiple omics><nerve cement><nerve stem cell><nerve supply><nervous system development><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenesis><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuropathic><neuroprogenitor><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><panomics><pathway><pelvirectal achalasia><postnatal><prevent><preventing><progenitor and neural stem cells><progenitor biology><progenitor cell biology><programs><protein expression><receptor><regeneration potential><regenerative cell><regenerative potential><response><restraint><social role><spastic colon><stem and progenitor biology><stem cell biology><transcription factor><transcriptional profile><transcriptional profiling><transcriptional signature><transcriptional silencing><transplant><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jill Ann Dembowski

DUQUESNE UNIVERSITY, PITTSBURGH, PA

Good lead · 52/100

Likely hiring

Solid budget

Active award

$345,000

FY 2026

Project Title

ROLES OF HOST FACTORS IN VIRAL REPLICATION COUPLED PROCESSES

Grant Number:

5R01AI158361-05

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/7/2022

End Date:

1/31/2027

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

Herpes simplex virus is a prevalent pathogen that infects the majority of the human population. Viral DNA replication is an essential step in the virus life cycle and can be targeted by antiviral treatments. Herpesviral DNA replication is coupled to other viral processes including transcription, DNA...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher Austin Klebanoff

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Good lead · 48/100

Above-average budget

Very recent

Active award

$538,178

FY 2026

Project Title

Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.

Grant Number:

4R37CA259177-06

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT - There are no changes. Immunotherapy induces durable remissions in a subset of patients with highly mutated cancers. However, most cancers are modestly mutated and fail to respond to current immunotherapy treatments. This is especially true for malignancies caused by activa...

Research Terms

<1-Phosphatidylinositol 3-Kinase><Adoptive Cellular Immunotherapy><Adoptive Immunotherapy><Affinity><Alleles><Allelomorphs><Antibodies><Antibody Therapy><Antigens><Autoantigens><Autologous Antigens><Avidity><Binding><Bioinformatics><Biometrics><Biometry><Biophysics><Biostatistics><Blood Sample><Blood specimen><Breast Cancer><Cancer Cause><Cancer Etiology><Cancer Genes><Cancer Patient><Cancer-Promoting Gene><Cancers><Carcinoma><Catalytic Core><Catalytic Domain><Catalytic Region><Catalytic Site><Catalytic Subunit><Cessation of life><Clone Cells><Colon><Complement><Complement Proteins><Complex><DNA Alteration><DNA Sequence Alteration><DNA Therapy><DNA mutation><Data><Death><Disease remission><Disseminated Malignant Neoplasm><Endocrine Therapy><Endometrium><Epithelial cancer><Exhibits><Frequencies><Gene Transfer><Gene Transfer Clinical><Generalized Growth><Genetic Alteration><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genomic approach><Genotype><Growth><HL-A Antigens><HLA Antigens><Heterogeneity><Hormonal Therapy><Human><Human Leukocyte Antigens><Immune><Immune Monitoring><Immune mediated therapy><Immune response><Immunes><Immunochemical Immunologic><Immunogenomics><Immunologic><Immunologic Monitoring><Immunological><Immunological Monitoring><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomonitoring><Immunotherapy><Individual><Kinetics><Knowledge><Leukocyte Antigens><MHC Receptor><Major Histocompatibility Complex Receptor><Malignant Breast Neoplasm><Malignant Cell><Malignant Epithelial Neoplasms><Malignant Epithelial Tumors><Malignant Neoplasms><Malignant Tumor><Mass Photometry/Spectrum Analysis><Mass Spectrometry><Mass Spectroscopy><Mass Spectrum><Mass Spectrum Analyses><Mass Spectrum Analysis><Measures><Mediating><Memory><Metastasis><Metastasize><Metastatic Cancer><Metastatic Lesion><Metastatic Malignant Neoplasm><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Modern Man><Molecular><Molecular Interaction><Mutate><Mutation><Neoplasm Metastasis><Oncogenes><PD 1><PD-1><PD1><PI-3 Kinase><PI3-Kinase><PI3CG><PI3KGamma><PI3k><PIK3><PIK3CG><PIK3CG gene><Pathway interactions><Patients><Peptides><Phosphatidylinositol 3-Kinase><Phosphatidylinositol-3-OH Kinase><Phosphoinositide 3-Hydroxykinase><Population><Pre-Clinical Model><Preclinical Models><Privatization><Process><Property><Proteins><PtdIns 3-Kinase><Reagent><Remission><Resistance><Secondary Neoplasm><Secondary Tumor><Self-Antigens><Sequence Alteration><Single Crystal Diffraction><Somatic Mutation><Structure><T cell response><T-Cell Antigen Receptors><T-Cell Development><T-Cell Ontogeny><T-Cell Receptor><T-Cell Receptor Genes><T-Cells><T-Lymphocyte><T-Lymphocyte Development><TcR Genes><Testing><Time><Tissue Growth><Toxic effect><Toxicities><Transforming Genes><Tumor Antigens><Tumor-Associated Antigen><Type I Phosphatidylinositol Kinase><Type III Phosphoinositide 3-Kinase><Uterine lining><Viral><Viral Antigens><Work><X Ray Crystallographies><X-Ray Crystallography><X-Ray Diffraction Crystallography><X-Ray/Neutron Crystallography><Xray Crystallography><adoptive cell immunotherapy><antibody based therapies><antibody treatment><antibody-based therapeutics><antibody-based treatment><antigen-specific T cells><biophysical foundation><biophysical principles><biophysical sciences><cancer antigens><cancer cell><cancer immunology><cancer metastasis><chemotherapy><complementation><conventional therapy><conventional treatment><cost efficient><curative intervention><curative therapeutic><curative therapy><curative treatments><engineered T cells><epithelial carcinoma><exhaustion><fitness><gain of function mutation><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetically engineered T-cells><genome mutation><genome sequencing><genomic alteration><genomic effort><genomic strategy><genomic therapy><hormone therapy><host response><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immune-genomic treatment><immuno therapy><immuno-gene therapy><immunogen><immunogene therapy><immunogenic><immunogenicity><immunoresponse><individual patient><inhibitor><innovate><innovation><innovative><malignancy><malignant breast tumor><multidisciplinary><mutant><neo-antigen><neo-epitopes><neoantigens><neoepitopes><neoplasm immunology><neoplasm/cancer><new approaches><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel approaches><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><ontogeny><pathway><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><personalized immunotherapy><precision immunotherapy><programmed cell death 1><programmed cell death protein 1><programmed death 1><resistant><response><sle2><somatic variant><structural biology><systemic lupus erythematosus susceptibility 2><therapeutic target><thymus derived lymphocyte><transgenic T- cells><translation strategy><translational approach><translational strategy><tumor><tumor cell metastasis><tumor immunology><tumor-specific antigen><virus antigen>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Evan Ratzan

BOSTON CHILDREN'S HOSPITAL, BOSTON, MA

Good lead · 48/100

Training-friendly

Recent

Active award

Career award

$132,705

FY 2026

Project Title

Defining the role of MET components in vestibular hair cell maturation and gene therapy responsiveness

Grant Number:

5K99DC022343-02

Activity Code:

K99

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/17/2024

End Date:

11/30/2026

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Abstract Balance and equilibrioception depend on vestibular hair cells that encode motion through mechanoelectrical transduction channels (MET) during movements of the head. Mutations in mechanoelectrical transduction channel genes (Tmc, Cib, Tmie, Lhfpl5) result in issues with hearing and balance i...

Research Terms

<21+ years old><ARHGEF5><ARHGEF5 gene><Actins><Adult><Adult Human><Affect><Aminoglycoside Agents><Aminoglycoside Antibiotics><Aminoglycoside Drugs><Auditory><Autopsy><Brain><Brain Nervous System><CDDP><CIB2><Calcium><Calcium and Integrin Binding Protein 2><Calcium-Binding Proteins><Cell Body><Cell Communication and Signaling><Cell Death><Cell Function><Cell Maturation><Cell Physiology><Cell Process><Cell Signaling><Cell Survival><Cell Viability><Cell membrane><Cells><Cellular Function><Cellular Mechanotransduction><Cellular Physiology><Cellular Process><Cis-diammine-dichloroplatinum><Cis-diamminedichloridoplatinum><Cis-diamminedichloro Platinum (II)><Cis-dichloroammine Platinum (II)><Cis-platinous Diamine Dichloride><Cis-platinum II><Cis-platinum II Diamine Dichloride><Cisplatin><Cisplatina><Cisplatinum><Clinical><Cochlea><Cochlear Organ><Coloring Agents><Compensation><Complex><Corti Cell><Cysplatyna><Cytoplasmic Membrane><DNA Therapy><DNA mutation><Data><Development><Diagnosis><Dichlorodiammineplatinum><Dyes><Dysfunction><Encephalon><Equilibrium><Equilibrium Hair Cell><Event><Evoked Potentials><Exhibits><Experimental Designs><FISH Technic><FISH Technique><FISH analysis><FISH assay><Failure><Fiber><Fluorescence Agents><Fluorescence In Situ Hybridization><Fluorescent Agents><Fluorescent Dyes><Fluorescent in Situ Hybridization><Foundations><Functional disorder><Future><GEF5><Gene Alteration><Gene Mutation><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Goals><Hair Cells><Head Movements><Hearing><Human><Image><Injections><Injury><Internal Ear><Intracellular Communication and Signaling><K element><KO mice><Knock-out Mice><Knockout Mice><Labyrinth><Link><Mechanical Signal Transduction><Mechanics><Mechanosensory Transduction><Mediating><Mice><Mice Mammals><Modern Man><Motion><Murine><Mus><Mutation><Natural regeneration><Neonatal><Null Mouse><Organ><P60><Patients><Permeability><Persons><Peyrone's Chloride><Peyrone's Salt><Phenotype><Physiopathology><Plasma Membrane><Platinum Diamminodichloride><Play><Population><Potassium><Precision therapeutics><Proteins><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><Regeneration><Research Methodology><Research Methods><Rest><Role><Saccule and Utricle><Sensory><Signal Transduction><Signal Transduction Systems><Signaling><Source><Subcellular Process><TIM1><Testing><Therapeutic><Therapeutic Intervention><Utricle structure><Utricles><Vestibular><Vestibular Hair Cells><Vestibular System Function><Vestibular function><Viral><adulthood><aged mice><aged mouse><balance><balance disorder><balance function><balance impairment><biological signal transduction><calcium indicator><cis dichlorodiammineplatinum><cis platinum compound><cis-Diaminedichloroplatinum><cis-Diamminedichloroplatinum><cis-Diamminedichloroplatinum(II)><cis-Dichlorodiammineplatinum(II)><cis-Platinum><critical period><determine efficacy><developmental><disturbed balance><drug induced hearing impairment><drug induced hearing loss><ear hair cell><effective therapy><effective treatment><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><elderly mice><equilibration disorder><equilibrium disorder><evaluate efficacy><examine efficacy><fluorescent dye/probe><gene defect><gene repair therapy><gene replacement><gene replacement therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><imaging><in vivo><injuries><inner ear><interest><intervention therapy><mechanic><mechanical><mechanical force><mechanosensing><mechanotransduction><mouse model><murine model><mutant allele><necrocytosis><necropsy><neuronal circuit><neuronal circuitry><new diagnostics><next generation diagnostics><novel diagnostics><oculovestibular reflex><old mice><ototoxic><ototoxicity><pathophysiology><plasmalemma><postmortem><precision therapies><precision treatment><pup><qRTPCR><regenerate><regional difference><repair><repaired><research and methods><resilience><resilient><response><sensor><social role><timeline><transduction efficiency><uptake><vestibo-ocular reflexes><vestibular system><vestibulo-occular system><vestibulo-ocular reflex><vestibulo-oculomotor reflex><vestibuloocular reflexes>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Colin Goding

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 48/100

Likely hiring

Recent

Active award

$115,768

FY 2026

Project Title

The integrated stress response and the microenvironment in melanoma progression

Grant Number:

3R01CA268597-05S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Despite the emergence novel therapeutic modalities, including BRAF inhibitors and immunotherapies, over 7,100 people are expected to die each year from malignant melanoma, primarily from metastatic dissemination and therapy resistance. The proposed studies leverage the expertise of the two c...

Research Terms

<22-kD Gene Caveolae Protein><22kD Gene Caveolin 1 Caveolae Protein><3-D><3-Dimensional><3D><Ablation><Adipocytes><Adipose Cell><Allografting><Alpha Isoform Gene Caveolin 1><Anoikis><Antioxidants><Apoptosis><Apoptosis Pathway><Apoptotic><Autophagocytosis><B-raf-1><BRAF><BRAF gene><Basal Transcription Factor><Basal transcription factor genes><Beta Isoform Gene Caveolin 1><Binding><Blood Vessels><CAV Gene><CAV1><CAV1 gene><Cancer Genes><Cancer-Promoting Gene><Caveolin-1 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Extracellular Matrix><Cells><Co-culture><Cocultivation><Coculture><Coculture Techniques><Collagen><Complex><DNA mutation><ECM><ER stress><Endothelial Cells><Endothelium><Equilibrium><Experimental Neoplasms><Experimental Tumor><Exposure to><Extracellular Matrix><Fat Cells><Fatty Acid Desaturases><Fatty Acid Desaturating Enzymes><Fatty Acids><Fibroblasts><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Growth><Heterogeneity><Heterograft><Heterologous Transplantation><Human><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Impairment><Inflammation><Integrins><Integrins Extracellular Matrix><Intracellular Communication and Signaling><Invaded><KO mice><Knock-out Mice><Knockout Mice><Link><Lipocytes><Lymph><MITF protein><Malignant Melanoma><Mature Lipocyte><Mature fat cell><Mediating><Mediator><Melanoma><Melanoma Cell><Melanoma Tumor><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Microphthalmic-associated transcription factor><Modality><Modeling><Modern Man><Molecular Interaction><Monounsaturated Fatty Acids><Murine><Mus><Mutation><Neoplasm Metastasis><Non-Malignant><Nuclear><Null Mouse><O element><O2 element><Oncogenes><Oncogenic><Output><Oxygen><Pathway interactions><Patients><Persons><Phenotype><Primary Neoplasm><Primary Tumor><Programmed Cell Death><Proliferating><Publishing><RAFB1><RNA Expression><Recovery><Refractory><Reporting><Repression><Resistance><Role><Secondary Neoplasm><Secondary Tumor><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Stress><Testing><Therapeutic><Therapeutic Intervention><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Translational Inhibition><Translational Repression><Tumor Cell><Tumor Suppressor Proteins><Tumor growth in melanoma><Tumor-infiltrating immune cells><VIP21 Gene><Xenograft><Xenograft procedure><Xenotransplantation><angiogenesis><autophagy><balance><balance function><biological adaptation to stress><biological signal transduction><cancer metastasis><cancer microenvironment><check point blockade><checkpoint blockade><endoplasmic reticulum stress><gain of function><genome mutation><immune cell infiltrate><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><infiltration of tumors by immune cells><inhibitor><intervention therapy><intratumoral immune cell><intratumoral immune infiltrate><lung metastasis><lymphatic fluid><metastasize to the lung><microphthalmia-associated transcription factor><mouse model><murine model><neoplastic cell><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><nonmalignant><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><nutrient deprivation><nutritional deprivation><ontogeny><pathway><pharmacologic><programs><pulmonary metastasis><reactioncrisis><resistant><response><social role><stress response><stressreaction><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><three dimensional><transcription factor><transcription factor Microphthalmia><tumor><tumor cell metastasis><tumor growth><tumor immune cell><tumor immune infiltrate><tumor infiltration of immune cells><tumor microenvironment><tumor suppressor><tumorigenic><uptake><v-raf Murine Sarcoma Viral Oncogene Homolog B1><vascular><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Constantinos Koumenis

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Good lead · 48/100

Likely hiring

Recent

Active award

$115,768

FY 2026

Project Title

The integrated stress response and the microenvironment in melanoma progression

Grant Number:

3R01CA268597-05S1

Activity Code:

R01

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2022

End Date:

12/31/2026

Why this may be worth a closer look

• Mechanism often supports lab expansion or staff hiring.

Project Abstract

SUMMARY Despite the emergence novel therapeutic modalities, including BRAF inhibitors and immunotherapies, over 7,100 people are expected to die each year from malignant melanoma, primarily from metastatic dissemination and therapy resistance. The proposed studies leverage the expertise of the two c...

Research Terms

<22-kD Gene Caveolae Protein><22kD Gene Caveolin 1 Caveolae Protein><3-D><3-Dimensional><3D><Ablation><Adipocytes><Adipose Cell><Allografting><Alpha Isoform Gene Caveolin 1><Anoikis><Antioxidants><Apoptosis><Apoptosis Pathway><Apoptotic><Autophagocytosis><B-raf-1><BRAF><BRAF gene><Basal Transcription Factor><Basal transcription factor genes><Beta Isoform Gene Caveolin 1><Binding><Blood Vessels><CAV Gene><CAV1><CAV1 gene><Cancer Genes><Cancer-Promoting Gene><Caveolin-1 Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell-Extracellular Matrix><Cells><Co-culture><Cocultivation><Coculture><Coculture Techniques><Collagen><Complex><DNA mutation><ECM><ER stress><Endothelial Cells><Endothelium><Equilibrium><Experimental Neoplasms><Experimental Tumor><Exposure to><Extracellular Matrix><Fat Cells><Fatty Acid Desaturases><Fatty Acid Desaturating Enzymes><Fatty Acids><Fibroblasts><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Growth><Heterogeneity><Heterograft><Heterologous Transplantation><Human><Immune infiltrates><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Impairment><Inflammation><Integrins><Integrins Extracellular Matrix><Intracellular Communication and Signaling><Invaded><KO mice><Knock-out Mice><Knockout Mice><Link><Lipocytes><Lymph><MITF protein><Malignant Melanoma><Mature Lipocyte><Mature fat cell><Mediating><Mediator><Melanoma><Melanoma Cell><Melanoma Tumor><Metastasis><Metastasis to the Lung><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Neoplasm to the Lung><Metastatic Tumor><Metastatic Tumor to the Lung><Mice><Mice Mammals><Microphthalmic-associated transcription factor><Modality><Modeling><Modern Man><Molecular Interaction><Monounsaturated Fatty Acids><Murine><Mus><Mutation><Neoplasm Metastasis><Non-Malignant><Nuclear><Null Mouse><O element><O2 element><Oncogenes><Oncogenic><Output><Oxygen><Pathway interactions><Patients><Persons><Phenotype><Primary Neoplasm><Primary Tumor><Programmed Cell Death><Proliferating><Publishing><RAFB1><RNA Expression><Recovery><Refractory><Reporting><Repression><Resistance><Role><Secondary Neoplasm><Secondary Tumor><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Stress><Testing><Therapeutic><Therapeutic Intervention><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transforming Genes><Translational Inhibition><Translational Repression><Tumor Cell><Tumor Suppressor Proteins><Tumor growth in melanoma><Tumor-infiltrating immune cells><VIP21 Gene><Xenograft><Xenograft procedure><Xenotransplantation><angiogenesis><autophagy><balance><balance function><biological adaptation to stress><biological signal transduction><cancer metastasis><cancer microenvironment><check point blockade><checkpoint blockade><endoplasmic reticulum stress><gain of function><genome mutation><immune cell infiltrate><immune cell infiltration of tumors><immune cells infiltrating the tumor><immune cells that infiltrate the tumor><immune check point blockade><immune checkpoint blockade><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><improved><infiltration of tumors by immune cells><inhibitor><intervention therapy><intratumoral immune cell><intratumoral immune infiltrate><lung metastasis><lymphatic fluid><metastasize to the lung><microphthalmia-associated transcription factor><mouse model><murine model><neoplastic cell><new drug target><new drug treatments><new druggable target><new drugs><new pharmacological therapeutic><new pharmacotherapy target><new therapeutic target><new therapeutics><new therapy><new therapy target><next generation therapeutics><nonmalignant><novel><novel drug target><novel drug treatments><novel druggable target><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel pharmacotherapy target><novel therapeutic target><novel therapeutics><novel therapy><novel therapy target><nutrient deprivation><nutritional deprivation><ontogeny><pathway><pharmacologic><programs><pulmonary metastasis><reactioncrisis><resistant><response><social role><stress response><stressreaction><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><three dimensional><transcription factor><transcription factor Microphthalmia><tumor><tumor cell metastasis><tumor growth><tumor immune cell><tumor immune infiltrate><tumor infiltration of immune cells><tumor microenvironment><tumor suppressor><tumorigenic><uptake><v-raf Murine Sarcoma Viral Oncogene Homolog B1><vascular><xeno-transplant><xeno-transplantation>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Charles John Robbins

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 48/100

Training-friendly

Very recent

Active award

$55,114

FY 2026

Project Title

Next-generation diagnostic approaches for HER2-low breast cancer and trastuzumab deruxtecan therapy

Grant Number:

5F30CA287869-03

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

The current assays for assessing HER2 were “fit-for-purpose” (over 25 years ago) to identify HER2 overexpression/gene amplification and are not built to subclassify unamplified HER2 expression in cancer. Applying these legacy assays results in high inter-rater disagreement rates for HER2-negative vs...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Daniel Andrés Colon-Rios

YALE UNIVERSITY, NEW HAVEN, CT

Good lead · 48/100

Training-friendly

Very recent

Active award

$55,114

FY 2026

Project Title

Elucidating mechanisms of PARP inhibitor resistance in IDH-mutant cancers

Grant Number:

5F30CA291077-02

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Isocitrate dehydrogenase (IDH) mutations are found in many malignancies including gliomas, cholangiocarcinomas, and acute myeloid leukemia. Mutations in the IDH gene lead to the neomorphic production of 2-hydroxyglurate (2HG), a competitive inhibitor of -ketoglutarate. A series of clinical studies ...

Research Terms

<53BP1><AML - Acute Myeloid Leukemia><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Assay><BRCA1><BRCA1 Gene Product><BRCA1 Protein><BRCA1 gene><BRCA2><BRCA2 gene><Bioassay><Biological Assay><Breast Cancer><Breast Cancer 1 Gene><Breast Cancer 1 Gene Product><Breast Cancer 2 Gene><Breast Cancer Type 1 Susceptibility Gene><Breast Cancer Type 1 Susceptibility Protein><Breast Cancer Type 2 Susceptibility Gene><Breast-Ovarian Cancer Protein><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cancer Drug><Cancer Treatment><Cancers><Cas nuclease technology><Cell Body><Cell Line><Cell Survival><Cell Viability><CellLine><Cells><ChIP assay><Chemotherapy and Radiation><Chemotherapy and/or radiation><Cholangiocarcinoma><Cholangiocellular Carcinoma><Chromatin><Chromatin Structure><Citric Acid Cycle><Clinical Research><Clinical Study><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Comet Assay><Complement><Complement Proteins><DNA Damage><DNA Damage Repair><DNA Double Strand Break><DNA Injury><DNA Repair><DNA mutation><DNA replication fork><Data><Defect><Dioxygenases><Down-Regulation><Drug resistance><Early Onset Gene Breast Cancer 1><Early Onset Gene Breast Cancer 2><Early Onset Protein Breast Cancer 1><Enzyme Gene><Enzymes><Exhibits><FANCD1><Foundations><Genes><Genetic><Genetic Change><Genetic defect><Genetic mutation><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioma><Hereditary Breast Cancer 1><Hereditary Breast Cancer 2><Heterogeneity><Human><Human Genome><Immunofluorescence><Immunofluorescence Immunologic><Impairment><Individual><Isocitrate Dehydrogenase><Isoforms><Knock-out><Knockout><Krebs Cycle><Lead><Libraries><Link><Malignant Breast Neoplasm><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Ovarian Neoplasm><Malignant Ovarian Tumor><Malignant Tumor><Malignant Tumor of the Ovary><Malignant neoplasm of ovary><Mediating><Methodology><Methods><Methylation><Modeling><Modern Man><Mutation><NGS Method><NGS system><Neoplastic Disease Chemotherapeutic Agents><Neuroglial Neoplasm><Neuroglial Tumor><Output><Ovary Cancer><PARP Inhibitor><PARP Polymerase><PARP protein><PARP-1 inhibitor><PARPi><PARS><Parents><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Pb element><Physical condensation><Physicians><Poly(ADP-ribose) Polymerase Inhibitor><Poly(ADP-ribose) Polymerases><Poly(ADP-ribose) polymerase 1 inhibitor><Poly(ADPribose) Polymerase><Production><Protein Isoforms><Proteins><RNA Seq><RNA analysis><RNA sequencing><RNAseq><RNF53><Radiation therapy><Radiotherapeutics><Radiotherapy><Regulation><Research><Resistance><Scientist><Series><Single-Cell Gel Electrophoresis><Site><Strains Cell Lines><TCA cycle><TP53BP1><Techniques><Testing><Therapeutic><Training><Tricarboxylic Acid Cycle><Tumor-Specific Treatment Agents><Unscheduled DNA Synthesis><Visualization><Work><acute granulocytic leukemia><acute myeloid leukemia><anti-cancer drug><anti-cancer therapy><biliary cancer><brca 1 gene><brca 2 gene><cancer cell><cancer therapy><cancer-directed therapy><chemo/radiation therapy><chemotherapy and radiotherapy><cholangiosarcoma><chromatin immunoprecipitation><chromatin remodeling><combinatorial><complementation><condensation><cultured cell line><drug resistant><exome sequencing><exome-seq><genome mutation><genome scale><genome-wide><genomewide><glial-derived tumor><graduate student><heavy metal Pb><heavy metal lead><human whole genome><inhibitor><insight><interest><malignancy><malignant breast tumor><mutant><neoplasm/cancer><neuroglia neoplasm><neuroglia tumor><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ovarian cancer><p202><p53-binding protein 1><p53BP1><parent><pathway><patient oriented outcomes><poly ADP polymerase><poly ADP ribose synthetase><pre-clinical study><preclinical study><radiation or chemotherapy><radiation treatment><recruit><repair><repaired><replication fork><resistance mechanism><resistance to Drug><resistant><resistant mechanism><resistant to Drug><response><restoration><synergism><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><transcriptome sequencing><transcriptomic sequencing><transcriptomics><treatment with radiation><tumor><tumor xenograft>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bailey West

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Good lead · 48/100

Training-friendly

Very recent

Active award

$50,114

FY 2026

Project Title

Role of the chromatin regulator HMGA1 in KMT2A-rearranged leukemia

Grant Number:

5F31CA284842-03

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

4/3/2024

End Date:

4/2/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.
• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT The objective of this project is to elucidate mechanisms underlying HMGA1 proteins in leukemogenesis and therapy resistance in KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). KMT2A-r AML is an aggressive form of leukemia that is resistant to current therapies and th...

Research Terms

<1.beta.-D-Arabinofuranosylcytosine><11q23><A1 protein><ABD-B><ALL1><ALL1 gene><AML - Acute Myeloid Leukemia><ARA-cell><Acute Lymphoblastic Leukemia Protein 1><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Address><Alexan><Anti-Oncogenes><Antioncogenes><Arabine><Arabinofuranosylcytosine><Arabinosylcytosine><Aracytidine><Aracytin><Aracytine><Assay><Binding><Bioassay><Biological Assay><CDK Inhibitor Protein><CDK-Interacting Protein 1><CDKI Protein><CDKN1><CDKN1A><CDKN1A gene><CIP1><CRISPR><CRISPR/Cas system><CXXC7><Cancer Suppressor Genes><Cancers><Cell Body><Cell Cycle><Cell Cycle Progression><Cell Division Cycle><Cell Line><CellLine><Cells><ChIP assay><Chemoresistance><Chimera Protein><Chimeric Proteins><Chromatin><Chromosome 11q23><Clinical><Clinical Trials><Clustered Regularly Interspaced Short Palindromic Repeats><Complex><Cyclin Gene><Cyclin Kinase Inhibitor><Cyclin-Dependent Kinase Inhibitor><Cyclin-Dependent Kinase Inhibitor 1A><Cyclins><Cytarabine><Cytarabinum><Cytarbel><Cytosar><Cytosar-U><CytosarU><Cytosine Arabinoside><Cytosine-.beta.-arabinoside><Cytotoxic Chemotherapy><Cytotoxic Therapy><Data><Data Set><Development><Drosophila Homolog of Trithorax><EC 2.1.1><Emerogenes><Environment><Erpalfa><Fusion Protein><Gene Down-Regulation><Gene Expression><Gene Transcription><Genes><Genetic Transcription><HOX gene><HOX1.7><HOX1.8><HOX1G><HOX1H><HOXA10><HOXA10 gene><HOXA9><HOXA9 gene><HRX><Hematopoietic><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Histones><Homeo Box Genes><Homeobox 1H><Homeobox A10><Homeobox A9><Homeobox Family Gene><Homeobox Genes><Homeodoamin Gene><Homeotic Genes><Human><Human Cell Line><Implant><In Vitro><Investigators><KMT2A><Knowledge><L-Lysine><Lab Findings><Laboratory Finding><Learning><Leukemic Cell><Lysine><Lysine-Specific Methyltransferase 2A><MEIS1><MEIS1 gene><MGC12859><MGC1934><MLL gene><MLL rearranged><MLL rearrangement><MLL-rearranged leukemia><MLL1><Malignant Hematopoietic Neoplasm><Malignant Neoplasms><Malignant Tumor><Manuscripts><Mediating><Meis homeobox 1><Methyltransferase><Mixed Lineage Leukemia Gene><Mixed-Lineage Leukemia Protein><Modeling><Modern Man><Molecular><Molecular Interaction><Multiple lineage leukemia 1><Myeloid-Lymphoid Leukemia Gene><Myeloid-Lymphoid Leukemia Protein><Myeloid/Lymphoid Leukemia Gene><Myeloid/Lymphoid Or Mixed Lineage Leukemia Protein><Myeloid/Lymphoid or Mixed Lineage Leukemia Gene><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><PDX model><Pathway interactions><Patient derived xenograft><Patients><Phenotype><Proliferating><Promoter Regions><Promotor Regions><Proteins><Proto Oncogene Proteins MLL><Publications><Publishing><RF-C protein><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recessive Oncogenes><Recruitment Activity><Refractory><Regulation><Reporter><Repression><Research><Research Personnel><Researchers><Resistance><Role><Scientific Publication><Strains Cell Lines><Tarabine PFS><Techniques><Testing><Training><Transcription><Transcription Repression><Transgenic Model><Tumor Suppressing Genes><Tumor Suppressor Genes><Tumor Suppressor Proteins><Udicil><Upregulation><WAF1><Wildtype p53-Activated Fragment 1><Work><Zinc Finger Protein HRX><academic preparation><academic readiness><active recruitment><acute granulocytic leukemia><acute granulocytic leukemia cell><acute myeloblastic leukemia cell><acute myelocytic leukemia cell><acute myelogenous leukemia cell><acute myeloid leukemia><acute myeloid leukemia cell><acute nonlymphocytic leukemia cell><blood cancer><cancer of blood><cancer of the blood><career><career development><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><chromatin immunoprecipitation><cultured cell line><developmental><effective therapy><effective treatment><efficacy testing><flavopiridol><gene locus><gene repression><genetic locus><genetic promoter element><genetic promoter sequence><genomic location><genomic locus><global gene expression><global transcription profile><hemopoietic><in vivo><inhibitor><innovate><innovation><innovative><leukemia><leukemogenesis><malignancy><medical college><medical schools><methylase><mixed lineage leukemia 1><mouse model><murine model><neoplasm/cancer><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><oncosuppressor gene><overexpress><overexpression><p21 gene><p21 protein><pathway><patient derived xenograft model><promoter sequence><recruit><replication factor C><resistance to therapy><resistant><resistant to therapy><response><school of medicine><shRNA><short hairpin RNA><social role><therapeutic resistance><therapy resistant><transcriptome><transcriptome sequencing><transcriptomic sequencing><transgenic trait><transmethylase><treatment resistance><treatment strategy><tumor><tumor suppressor>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yang-Yang Ding

JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD

Exploratory lead · 42/100

Training-friendly

Active award

Career award

$184,541

FY 2026

Project Title

Elucidating Critical Dependencies Underlying Therapeutic Evasion in Philadelphia Chromosome-like Acute Lymphoblastic Leukemia

Grant Number:

5K08CA273531-04

Activity Code:

K08

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/5/2024

End Date:

12/31/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT This mentored career development award proposal will facilitate my career goal to become an independent translational researcher using advances in experimental genomics and bioinformatics to develop improved precision medicine therapies for children with difficult-to-cure c...

Research Terms

<0-11 years old><ATAC sequencing><ATAC-seq><ATACseq><Acute B-Lymphocytic Leukemia><Acute Lymphoblastic Leukemia><Acute Lymphocytic Leukemia><Acute Lymphoid Leukemia><Acute leukemia><Adolescent><Adolescent Youth><Adult Acute Lymphoblastic Leukemia><Adult Acute Lymphocytic Leukemia><Adult Acute Lymphogenous Leukemia><Adult Acute Lymphoid Leukemia><Advisory Committees><Apoptosis><Apoptosis Pathway><Apoptotic><Assay for Transposase-Accessible Chromatin using sequencing><Automobile Driving><B-ALL><B-Cell Acute Lymphocytic Leukemia><B-Cell Acute Lymphoblastic Leukemia><B-Cell CLL/Lymphoma 2 Gene><B-Cell Lymphoblastic Leukemia><B-cell ALL><B-cell lymphoma/leukemia-2><B-cell precursor acute lymphoblastic leukemia><BCL2><BCL2 gene><Basal Transcription Factor><Basal transcription factor genes><Bcl-2><Big Data><BigData><Bioinformatics><Biological><Biology><Cancer Cause><Cancer Etiology><Cancers><Career Development Awards><Career Development Awards and Programs><Career Development Programs K-Series><Cell Body><Cell Communication and Signaling><Cell Cycle><Cell Cycle Arrest><Cell Division Cycle><Cell Growth in Number><Cell Line><Cell Multiplication><Cell Proliferation><Cell Signaling><CellLine><Cells><Cellular Proliferation><Cellular biology><Cessation of life><ChIP Sequencing><ChIP-seq><ChIPseq><Chemoresistance><Child><Child Youth><Childhood ALL><Childhood Acute Lymphoblastic Leukemia><Childhood Acute Lymphocytic Leukemia><Childhood Acute Lymphogenous Leukemia><Childhood Acute Lymphoid Leukemia><Childhood Cancers><Children (0-21)><Chronic><Clinical><Clinical Trials><Clinical Trials Design><Combined Modality Therapy><Complex><Computational Biology><DNA><DNA mutation><Dasatinib><Data><Data Set><Death><Deoxyribonucleic Acid><Dependence><Diagnosis><Drug Targeting><Drug Therapy><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Evolution><Expression Signature><Future><Gene Expression Profile><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Genomics><Goals><Growth><Harvest><Heterogeneity><Human><In Vitro><International><Intracellular Communication and Signaling><Investigators><K-Awards><K-Series Research Career Programs><Kinases><Knock-out><Knockout><L1 Lymphocytic Leukemia><Lymphoblastic Leukemia, Acute, L1><Malignant Childhood Neoplasm><Malignant Childhood Tumor><Malignant Neoplasms><Malignant Pediatric Neoplasm><Malignant Pediatric Tumor><Malignant Tumor><Malignant childhood cancer><Mediating><Mentors><Mentorship><Methodology><Modeling><Modern Man><Multimodal Therapy><Multimodal Treatment><Mutation><Oncogenic><Outcome><PDX model><PTK Inhibitors><Pathway interactions><Patient derived xenograft><Patients><Pediatric ALL><Pediatric Acute Lymphoblastic Leukemia><Pediatric Acute Lymphocytic Leukemia><Pediatric Acute Lymphogenous Leukemia><Pediatric Acute Lymphoid Leukemia><Ph 1 Chromosome><Ph1 Chromosome><Pharmacological Treatment><Pharmacotherapy><Phenotype><Philadelphia Chromosome><Phosphotransferase Gene><Phosphotransferases><Population><Pre-B-Cell Leukemia><Precursor B Lymphoblastic Leukemia><Precursor Cell Lymphoblastic Leukemia><Precursor Lymphoblastic Leukemia><Programmed Cell Death><Proliferating><Protein Tyrosine Kinase Inhibitors><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Recurrence><Recurrent><Relapse><Research><Research Career Program><Research Personnel><Research Resources><Researchers><Resistance><Resources><Role><Scientist><Signal Transduction><Signal Transduction Systems><Signaling><Strains Cell Lines><System><Systems Biology><TK Inhibitors><Task Forces><Techniques><Therapeutic><Time><Tissue Growth><Training><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Transcriptional Control><Transcriptional Regulation><Translating><Transphosphorylases><Tyrosine Kinase Inhibitor><Validation><acute lymphatic leukemia><acute lymphoblastic leukemia cell><acute lymphocytic leukemia cell><acute lymphogenous leukemia><acute lymphoid leukemia cell><acute lymphomatic leukemia><adult ALL><advisory team><assay for transposase accessible chromatin followed by sequencing><assay for transposase accessible chromatin seq><assay for transposase accessible chromatin sequencing><assay for transposase-accessible chromatin with sequencing><bcl-2 Genes><biologic><biological signal transduction><c myc><c-myc Genes><cancer death in children><cancer in a child><cancer in children><cancer mortality in children><cancer related death in children><career><ced9 homolog><cell biology><chemoresistant><chemotherapy resistance><chemotherapy resistant><child with cancer><childhood cancer death><childhood cancer mortality><childhood malignancy><chromatin immunoprecipitation coupled with sequencing><chromatin immunoprecipitation followed by sequencing><chromatin immunoprecipitation with sequencing><chromatin immunoprecipitation-seq><chromatin immunoprecipitation-sequencing><clinical relevance><clinical translation><clinically relevant><clinically translatable><cmyc><combination therapy><combined modality treatment><combined treatment><computer biology><cultured cell line><design><designing><driving><drug intervention><drug treatment><early clinical trial><early phase clinical trial><epigenetically><experience><experiment><experimental research><experimental study><experiments><gene expression pattern><gene expression signature><gene regulatory network><gene signatures><genetic signature><genome mutation><global gene expression><global transcription profile><high risk><high-risk driving><improved><in vivo><in vivo Model><infant ALL><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><insight><juvenile><juvenile human><kids><knock-down><knockdown><leukemia><malignancy><molecular targeted therapeutics><molecular targeted therapies><molecular targeted treatment><multi-modal therapy><multi-modal treatment><multidisciplinary><multiomics><multiple omics><neoplasm/cancer><non-genetic><nongenetic><oncogene addiction><ontogeny><overexpress><overexpression><panomics><pathway><patient derived xenograft model><pediatric cancer><pediatric malignancy><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><precision medicine><precision medicine clinical trials><precision-based medicine><preclinical><resistance mechanism><resistance to therapy><resistant><resistant mechanism><resistant to therapy><response to therapy><response to treatment><risky driving><single cell analysis><skills><social role><synergism><targeted agent><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic resistance><therapeutic response><therapy resistant><therapy response><transcription factor><transcription regulatory network><transcriptional profile><transcriptional signature><transcriptome><transcriptome sequencing><transcriptomic sequencing><transcriptomics><translational clinician><translational investigator><translational physician><translational researcher><translational scientist><treatment resistance><treatment response><treatment responsiveness><v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog><validations><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kelly M Makielski

UNIVERSITY OF MINNESOTA, MINNEAPOLIS, MN

Exploratory lead · 42/100

Training-friendly

Active award

Career award

$124,239

FY 2026

Project Title

Molecular Signatures of Biologic Behavior in Pediatric Osteosarcoma

Grant Number:

5K01OD031810-04

Activity Code:

K01

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

2/1/2023

End Date:

11/30/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Osteosarcoma, the most common primary tumor of bone, primarily affects children, adolescents, and young adults. A diagnosis of osteosarcoma is devastating, as approximately half of pediatric osteosarcoma patients experience metastasis and ultimately succumb to the disease wi...

Research Terms

<0-11 years old><Address><Adolescent and Young Adult><Affect><Award><Behavior><Binding><Bioinformatics><Biological><Biological Markers><Biology><Blood><Blood Reticuloendothelial System><Blood Serum><Blood Tests><Bone Sarcoma><Bone Tumor><Bone neoplasms><Cancers><Categories><Child><Child Youth><Childhood Osteosarcoma><Children (0-21)><Clinical><Clinical Trials><Data><Dedications><Development><Diagnosis><Diagnostic tests><Disease><Disease Progression><Disease remission><Disorder><Funding><Future><Gene Cluster><Genes><Goals><Hematologic Tests><Hematological Tests><Hematology Testing><Heterograft><Heterologous Transplantation><Human><Immune response><Incidence><Knowledge><Leadership><Machine Learning><Malignant Neoplasms><Malignant Tumor><Membrane><Mentors><Messenger RNA><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Modern Man><Molecular Fingerprinting><Molecular Interaction><Molecular Profiling><Morbidity><NGS Method><NGS system><Neoplasm Metastasis><Noise><Normal Cell><Operative Procedures><Operative Surgical Procedures><Osseous Neoplasm><Osseous Sarcoma><Osseous Tumor><Osteogenic Sarcoma><Osteosarcoma><Outcome><Patients><Pattern><Pediatric Osteosarcoma><Pediatric cohort><Probability><Prognosis><Prognostic Marker><Progression-Free Survivals><RNA Seq><RNA sequencing><RNAseq><Remission><Research><Research Resources><Resources><Risk Marker><SYS-TX><Sampling><Scientist><Second Cancer><Second Primary Cancers><Secondary Malignancy><Secondary Malignant Neoplasm><Secondary Neoplasm><Secondary Tumor><Sensitivity and Specificity><Serum><Severities><Skeletal Sarcoma><Surgical><Surgical Interventions><Surgical Procedure><Survivors><Systemic Therapy><Testing><Time><Toxic effect><Toxicities><Treatment Failure><Tumor Biology><Work><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><adult youth><aggressive therapy><aggressive treatment><bio-informatics pipeline><bio-markers><bioinformatics pipeline><biologic><biologic marker><biomarker><biomarker discovery><biomarker identification><biomarker selection><biomarker signature><cancer metastasis><career><chemotherapy><clinical relevance><clinically relevant><developmental><differential expression><differentially expressed><exosome><experience><experiment><experimental research><experimental study><experiments><gene signatures><genetic signature><host response><identification of biomarkers><identification of new biomarkers><immune system response><immunoresponse><improved><kids><mRNA><machine based learning><machine learned algorithm><machine learning algorithm><machine learning based algorithm><malignancy><marker identification><membrane structure><microvesicles><minimally invasive><molecular profile><molecular signature><mouse model><multidisciplinary><murine model><neoplasm/cancer><next gen sequencing><next generation sequencing><nextgen sequencing><novel><osteochondrosarcoma><osteoid sarcoma><patient stratification><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><predictive assay><predictive biological marker><predictive biomarkers><predictive marker><predictive molecular biomarker><predictive signature><predictive test><primary bone cancer><primary bone tumor><prognostic biomarker><prognostic indicator><response to therapy><response to treatment><risk minimization><risk predictor><risk predictors><secondary cancer><skills><standard of care><stratified patient><surgery><therapeutic response><therapy failure><therapy response><transcriptional differences><transcriptome sequencing><transcriptomic sequencing><translational investigator><translational model><translational researcher><translational scientist><treatment response><treatment responsiveness><treatment risk><tumor><tumor behavior><tumor cell metastasis><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model><young adult><young adult age><young adulthood><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Prem P Chapagain

FLORIDA INTERNATIONAL UNIVERSITY, MIAMI, FL

Exploratory lead · 40/100

Large award

Active award

$1,319,674

FY 2026

Project Title

CRISPR/dCas9-Targeted Histone Demethylation Interplays with DNA Repair to Contract GAA Repeats in Friedreich's Ataxia

Grant Number:

1RM1NS143850-01

Activity Code:

RM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/26/2026

End Date:

12/31/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Friedreich’s ataxia (FRDA) is the most common autosomal recessive ataxia. It is caused by expanded GAA repeats at the first intron of the frataxin (FXN) gene. No effective treatments are available for the disease due to the inherited expanded GAA repeats in the patient’s genome. Thus, there is an ur...

Research Terms

<3-D><3-Dimensional><3D><AI Augmented><AI assisted><AI driven><AI enhanced><AI integrated><AI powered><AI system><Affect><Architecture><Artificial Intelligence><Artificial Intelligence enhanced><Ataxia><Ataxy><Augmented by AI><Augmented by the AI><Augmented with AI><Augmented with the AI><BBB function><Base Excision Repairs><Basic Research><Basic Science><Binding Proteins><Biochemistry><Biological Chemistry><Blood - brain barrier anatomy><Blood-Brain Barrier><Brain><Brain Nervous System><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cardiac><Cas nuclease technology><Cell Body><Cell Communication><Cell Differentiation><Cell Differentiation process><Cell Interaction><Cell-to-Cell Interaction><Cells><Cerebrum><Chemistry><Chromatin><Clinical Research><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Computer Reasoning><Contracting Opportunities><Contracts><Coordination Impairment><Country><DNA Base Excision Repair><DNA Damage Repair><DNA Repair><DNA Therapy><Dimensions><Disease><Disorder><Dyssynergia><Encapsulated><Encephalon><Engineering><Engineering / Architecture><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Florida><Freidreich's Ataxia><Friedreich Ataxia><Friedreich Disease><Friedreich Spinocerebellar Ataxia><Friedreich's Familial Ataxia><Friedreich's Hereditary Ataxia><Friedreich's Hereditary Spinal Ataxia><Friedreich's tabes><Gene Activation><Gene Targeting><Gene Transfer Clinical><Genes><Genetic Intervention><Genome><Goals><Health Care Systems><Hemato-Encephalic Barrier><Hereditary><Hereditary Spinal Sclerosis><Heterochromatin><Histone H3><Histones><Human><Inherited><International><Intervening Sequences><Introns><L-Lysine><Ligand Binding Protein><Ligand Binding Protein Gene><Lysine><Machine Intelligence><Machine Learning><Mediating><Methylation><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Mission><Modern Man><Molecular><Molecular Dynamics Simulation><NIH><National Institutes of Health><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neurocyte><Neurologic Disorders><Neurological Disorders><Neurons><Nucleosomes><Other Genetics><Oxidative Stress><Patients><Phenotype><Physics><Plasmids><Population><Production><Protein Binding><Proteins><Recombinants><Research><System><Testing><Tissue Engineering><Transfection><Transgenic Mice><Trinucleotide Repeats><Triplet Repeats><United States><United States National Institutes of Health><Universities><Unscheduled DNA Synthesis><Upregulation><Work><artificial intelligence assisted><artificial intelligence augmented><artificial intelligence driven><artificial intelligence integrated><artificial intelligence powered><autosome><bioengineered tissue><blood-brain barrier function><bloodbrain barrier><bloodbrain barrier function><bound protein><cellular differentiation><cerebral><codon reiteration><demethylation><design><designing><disability><effective therapy><effective treatment><engineered tissue><enhanced with AI><enhanced with Artificial Intelligence><epigenetically><fabrication><family ataxia><frataxin><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><histone demethylase><human disease><iPS><iPSC><iPSCs><improved><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><insight><machine based learning><microfluidic chip><molecular dynamics><nano particle><nano-sized particle><nanoparticle><nanosized particle><neural><neurological disease><neuronal><next generation><novel><public health relevance><simulation><single cell analysis><single cell technology><three dimensional><tool>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jin He

FLORIDA INTERNATIONAL UNIVERSITY, MIAMI, FL

Exploratory lead · 40/100

Large award

Active award

$1,319,674

FY 2026

Project Title

CRISPR/dCas9-Targeted Histone Demethylation Interplays with DNA Repair to Contract GAA Repeats in Friedreich's Ataxia

Grant Number:

1RM1NS143850-01

Activity Code:

RM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/26/2026

End Date:

12/31/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Friedreich’s ataxia (FRDA) is the most common autosomal recessive ataxia. It is caused by expanded GAA repeats at the first intron of the frataxin (FXN) gene. No effective treatments are available for the disease due to the inherited expanded GAA repeats in the patient’s genome. Thus, there is an ur...

Research Terms

<3-D><3-Dimensional><3D><AI Augmented><AI assisted><AI driven><AI enhanced><AI integrated><AI powered><AI system><Affect><Architecture><Artificial Intelligence><Artificial Intelligence enhanced><Ataxia><Ataxy><Augmented by AI><Augmented by the AI><Augmented with AI><Augmented with the AI><BBB function><Base Excision Repairs><Basic Research><Basic Science><Binding Proteins><Biochemistry><Biological Chemistry><Blood - brain barrier anatomy><Blood-Brain Barrier><Brain><Brain Nervous System><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cardiac><Cas nuclease technology><Cell Body><Cell Communication><Cell Differentiation><Cell Differentiation process><Cell Interaction><Cell-to-Cell Interaction><Cells><Cerebrum><Chemistry><Chromatin><Clinical Research><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Computer Reasoning><Contracting Opportunities><Contracts><Coordination Impairment><Country><DNA Base Excision Repair><DNA Damage Repair><DNA Repair><DNA Therapy><Dimensions><Disease><Disorder><Dyssynergia><Encapsulated><Encephalon><Engineering><Engineering / Architecture><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Florida><Freidreich's Ataxia><Friedreich Ataxia><Friedreich Disease><Friedreich Spinocerebellar Ataxia><Friedreich's Familial Ataxia><Friedreich's Hereditary Ataxia><Friedreich's Hereditary Spinal Ataxia><Friedreich's tabes><Gene Activation><Gene Targeting><Gene Transfer Clinical><Genes><Genetic Intervention><Genome><Goals><Health Care Systems><Hemato-Encephalic Barrier><Hereditary><Hereditary Spinal Sclerosis><Heterochromatin><Histone H3><Histones><Human><Inherited><International><Intervening Sequences><Introns><L-Lysine><Ligand Binding Protein><Ligand Binding Protein Gene><Lysine><Machine Intelligence><Machine Learning><Mediating><Methylation><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Mission><Modern Man><Molecular><Molecular Dynamics Simulation><NIH><National Institutes of Health><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neurocyte><Neurologic Disorders><Neurological Disorders><Neurons><Nucleosomes><Other Genetics><Oxidative Stress><Patients><Phenotype><Physics><Plasmids><Population><Production><Protein Binding><Proteins><Recombinants><Research><System><Testing><Tissue Engineering><Transfection><Transgenic Mice><Trinucleotide Repeats><Triplet Repeats><United States><United States National Institutes of Health><Universities><Unscheduled DNA Synthesis><Upregulation><Work><artificial intelligence assisted><artificial intelligence augmented><artificial intelligence driven><artificial intelligence integrated><artificial intelligence powered><autosome><bioengineered tissue><blood-brain barrier function><bloodbrain barrier><bloodbrain barrier function><bound protein><cellular differentiation><cerebral><codon reiteration><demethylation><design><designing><disability><effective therapy><effective treatment><engineered tissue><enhanced with AI><enhanced with Artificial Intelligence><epigenetically><fabrication><family ataxia><frataxin><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><histone demethylase><human disease><iPS><iPSC><iPSCs><improved><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><insight><machine based learning><microfluidic chip><molecular dynamics><nano particle><nano-sized particle><nanoparticle><nanosized particle><neural><neurological disease><neuronal><next generation><novel><public health relevance><simulation><single cell analysis><single cell technology><three dimensional><tool>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Cheng-Yu Lai

FLORIDA INTERNATIONAL UNIVERSITY, MIAMI, FL

Exploratory lead · 40/100

Large award

Active award

$1,319,674

FY 2026

Project Title

CRISPR/dCas9-Targeted Histone Demethylation Interplays with DNA Repair to Contract GAA Repeats in Friedreich's Ataxia

Grant Number:

1RM1NS143850-01

Activity Code:

RM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/26/2026

End Date:

12/31/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Friedreich’s ataxia (FRDA) is the most common autosomal recessive ataxia. It is caused by expanded GAA repeats at the first intron of the frataxin (FXN) gene. No effective treatments are available for the disease due to the inherited expanded GAA repeats in the patient’s genome. Thus, there is an ur...

Research Terms

<3-D><3-Dimensional><3D><AI Augmented><AI assisted><AI driven><AI enhanced><AI integrated><AI powered><AI system><Affect><Architecture><Artificial Intelligence><Artificial Intelligence enhanced><Ataxia><Ataxy><Augmented by AI><Augmented by the AI><Augmented with AI><Augmented with the AI><BBB function><Base Excision Repairs><Basic Research><Basic Science><Binding Proteins><Biochemistry><Biological Chemistry><Blood - brain barrier anatomy><Blood-Brain Barrier><Brain><Brain Nervous System><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cardiac><Cas nuclease technology><Cell Body><Cell Communication><Cell Differentiation><Cell Differentiation process><Cell Interaction><Cell-to-Cell Interaction><Cells><Cerebrum><Chemistry><Chromatin><Clinical Research><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Computer Reasoning><Contracting Opportunities><Contracts><Coordination Impairment><Country><DNA Base Excision Repair><DNA Damage Repair><DNA Repair><DNA Therapy><Dimensions><Disease><Disorder><Dyssynergia><Encapsulated><Encephalon><Engineering><Engineering / Architecture><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Florida><Freidreich's Ataxia><Friedreich Ataxia><Friedreich Disease><Friedreich Spinocerebellar Ataxia><Friedreich's Familial Ataxia><Friedreich's Hereditary Ataxia><Friedreich's Hereditary Spinal Ataxia><Friedreich's tabes><Gene Activation><Gene Targeting><Gene Transfer Clinical><Genes><Genetic Intervention><Genome><Goals><Health Care Systems><Hemato-Encephalic Barrier><Hereditary><Hereditary Spinal Sclerosis><Heterochromatin><Histone H3><Histones><Human><Inherited><International><Intervening Sequences><Introns><L-Lysine><Ligand Binding Protein><Ligand Binding Protein Gene><Lysine><Machine Intelligence><Machine Learning><Mediating><Methylation><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Mission><Modern Man><Molecular><Molecular Dynamics Simulation><NIH><National Institutes of Health><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neurocyte><Neurologic Disorders><Neurological Disorders><Neurons><Nucleosomes><Other Genetics><Oxidative Stress><Patients><Phenotype><Physics><Plasmids><Population><Production><Protein Binding><Proteins><Recombinants><Research><System><Testing><Tissue Engineering><Transfection><Transgenic Mice><Trinucleotide Repeats><Triplet Repeats><United States><United States National Institutes of Health><Universities><Unscheduled DNA Synthesis><Upregulation><Work><artificial intelligence assisted><artificial intelligence augmented><artificial intelligence driven><artificial intelligence integrated><artificial intelligence powered><autosome><bioengineered tissue><blood-brain barrier function><bloodbrain barrier><bloodbrain barrier function><bound protein><cellular differentiation><cerebral><codon reiteration><demethylation><design><designing><disability><effective therapy><effective treatment><engineered tissue><enhanced with AI><enhanced with Artificial Intelligence><epigenetically><fabrication><family ataxia><frataxin><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><histone demethylase><human disease><iPS><iPSC><iPSCs><improved><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><insight><machine based learning><microfluidic chip><molecular dynamics><nano particle><nano-sized particle><nanoparticle><nanosized particle><neural><neurological disease><neuronal><next generation><novel><public health relevance><simulation><single cell analysis><single cell technology><three dimensional><tool>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yuan Liu

FLORIDA INTERNATIONAL UNIVERSITY, MIAMI, FL

Exploratory lead · 40/100

Large award

Active award

$1,319,674

FY 2026

Project Title

CRISPR/dCas9-Targeted Histone Demethylation Interplays with DNA Repair to Contract GAA Repeats in Friedreich's Ataxia

Grant Number:

1RM1NS143850-01

Activity Code:

RM1

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/26/2026

End Date:

12/31/2030

Why this may be worth a closer look

• Large budget suggests more room for personnel or project growth.

Project Abstract

Friedreich’s ataxia (FRDA) is the most common autosomal recessive ataxia. It is caused by expanded GAA repeats at the first intron of the frataxin (FXN) gene. No effective treatments are available for the disease due to the inherited expanded GAA repeats in the patient’s genome. Thus, there is an ur...

Research Terms

<3-D><3-Dimensional><3D><AI Augmented><AI assisted><AI driven><AI enhanced><AI integrated><AI powered><AI system><Affect><Architecture><Artificial Intelligence><Artificial Intelligence enhanced><Ataxia><Ataxy><Augmented by AI><Augmented by the AI><Augmented with AI><Augmented with the AI><BBB function><Base Excision Repairs><Basic Research><Basic Science><Binding Proteins><Biochemistry><Biological Chemistry><Blood - brain barrier anatomy><Blood-Brain Barrier><Brain><Brain Nervous System><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cardiac><Cas nuclease technology><Cell Body><Cell Communication><Cell Differentiation><Cell Differentiation process><Cell Interaction><Cell-to-Cell Interaction><Cells><Cerebrum><Chemistry><Chromatin><Clinical Research><Clinical Study><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Computer Reasoning><Contracting Opportunities><Contracts><Coordination Impairment><Country><DNA Base Excision Repair><DNA Damage Repair><DNA Repair><DNA Therapy><Dimensions><Disease><Disorder><Dyssynergia><Encapsulated><Encephalon><Engineering><Engineering / Architecture><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Florida><Freidreich's Ataxia><Friedreich Ataxia><Friedreich Disease><Friedreich Spinocerebellar Ataxia><Friedreich's Familial Ataxia><Friedreich's Hereditary Ataxia><Friedreich's Hereditary Spinal Ataxia><Friedreich's tabes><Gene Activation><Gene Targeting><Gene Transfer Clinical><Genes><Genetic Intervention><Genome><Goals><Health Care Systems><Hemato-Encephalic Barrier><Hereditary><Hereditary Spinal Sclerosis><Heterochromatin><Histone H3><Histones><Human><Inherited><International><Intervening Sequences><Introns><L-Lysine><Ligand Binding Protein><Ligand Binding Protein Gene><Lysine><Machine Intelligence><Machine Learning><Mediating><Methylation><Microfluidic Device><Microfluidic Lab-On-A-Chip><Microfluidic Microchips><Mission><Modern Man><Molecular><Molecular Dynamics Simulation><NIH><National Institutes of Health><Nerve Cells><Nerve Unit><Nervous System Diseases><Nervous System Disorder><Neural Cell><Neurocyte><Neurologic Disorders><Neurological Disorders><Neurons><Nucleosomes><Other Genetics><Oxidative Stress><Patients><Phenotype><Physics><Plasmids><Population><Production><Protein Binding><Proteins><Recombinants><Research><System><Testing><Tissue Engineering><Transfection><Transgenic Mice><Trinucleotide Repeats><Triplet Repeats><United States><United States National Institutes of Health><Universities><Unscheduled DNA Synthesis><Upregulation><Work><artificial intelligence assisted><artificial intelligence augmented><artificial intelligence driven><artificial intelligence integrated><artificial intelligence powered><autosome><bioengineered tissue><blood-brain barrier function><bloodbrain barrier><bloodbrain barrier function><bound protein><cellular differentiation><cerebral><codon reiteration><demethylation><design><designing><disability><effective therapy><effective treatment><engineered tissue><enhanced with AI><enhanced with Artificial Intelligence><epigenetically><fabrication><family ataxia><frataxin><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><histone demethylase><human disease><iPS><iPSC><iPSCs><improved><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><insight><machine based learning><microfluidic chip><molecular dynamics><nano particle><nano-sized particle><nanoparticle><nanosized particle><neural><neurological disease><neuronal><next generation><novel><public health relevance><simulation><single cell analysis><single cell technology><three dimensional><tool>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Theodore Scott Nowicki

UNIVERSITY OF CALIFORNIA LOS ANGELES, LOS ANGELES, CA

Exploratory lead · 40/100

Above-average budget

Recent

Active award

$647,632

FY 2026

Project Title

TNF-alpha-"armed" TCR vectors to enhance adoptive cell therapy for solid tumors

Grant Number:

5R37CA289813-02

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/11/2025

End Date:

2/28/2030

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY/ABSTRACT Cancer immunotherapy with T-cells expressing a transgenic T-cell receptor (TCR) or chimeric antigen receptor (CAR) can generate dramatic clinical responses in a variety of solid tumors. However, a significant number of patients do not respond to therapy. We have previously s...

Research Terms

<(TNF)-α><Activities of Daily Living><Activities of everyday life><Adoptive Cell Transfers><Antigens><Assay><Bioassay><Biologic Factor><Biological Assay><Biological Factors><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CTAG><CTAG1><CTAG1 gene><CTAG1B><CTAG1B Gene><Cachectin><Cachectin Receptors><Cancer Treatment><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell Therapy><Cell secretion><Cells><Cellular Secretion><Cellular biology><Cellular immunotherapy><Chronic><Clinical><Cytometry><Data><ESO1><Expression Signature><Future Generations><Gene Expression><Gene Expression Profile><HPV 16><HPV-16><HPV16><Helper Cells><Helper T-Cells><Helper T-Lymphocytes><Helper-Inducer T-Cells><Helper-Inducer T-Lymphocyte><Heterograft><Heterologous Transplantation><Human papilloma virus type 16><Human papillomavirus 16><Human papillomavirus type 16><Immune infiltrates><Immune mediated therapy><Immunoglobulin Enhancer-Binding Protein><Immunologically Directed Therapy><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Immunotherapy><Impairment><In Vitro><Incidence><Inducer Cells><Inducer T-Lymphocytes><Inferior><Intracellular Communication and Signaling><Knock-out><Knockout><LAGE2B><Lentiviral Vector><Lentivirus Vector><MHC Receptor><Macrophage-Derived TNF><Major Histocompatibility Complex Receptor><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mediating><Mice><Mice Mammals><Monocyte-Derived TNF><Murine><Mus><NF-kB><NF-kappa B><NF-kappaB><NFKB><NY-ESO-1><Nature><Nuclear Factor kappa B><Nuclear Transcription Factor NF-kB><Patients><Phenotype><Proteomics><Recurrent disease><Relapsed Disease><Role><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><T cell based immune therapy><T cell based therapeutics><T cell based therapy><T cell differentiation><T cell directed therapies><T cell immune therapy><T cell immunotherapy><T cell infiltration><T cell receptor based immunotherapy><T cell receptor cellular immunotherapy><T cell receptor engineered therapy><T cell receptor immunotherapy><T cell targeted therapeutics><T cell therapy><T cell treatment><T cell-based immunotherapy><T cell-based treatment><T cells for CAR><T cellular immunotherapy><T cellular therapy><T lymphocyte based immunotherapy><T lymphocyte based therapy><T lymphocyte therapeutic><T lymphocyte treatment><T-Cell Antigen Receptors><T-Cell Receptor><T-Cell Receptor Therapy><T-Cell Receptor Treatment><T-Cell Receptor based Therapy><T-Cell Receptor based Treatment><T-Cells><T-Lymphocyte><T-cell therapeutics><T-cell transfer therapy><TCR T cell immunotherapy><TCR T cell therapy><TCR Therapy><TCR based T cell immunotherapy><TCR based Therapy><TCR based immune therapy><TCR based immunotherapy><TCR based treatment><TCR immunotherapy><TNF><TNF A><TNF Alpha><TNF Receptor Family Protein><TNF Receptor Superfamily><TNF Receptors><TNF gene><TNF-α><TNFA><TNFR><TNFα><Testing><Time><Toxic effect><Toxicities><Toxicology><Transcription Factor NF-kB><Transgenic Organisms><Translations><Treatment Failure><Tumor Antigens><Tumor Cell><Tumor Necrosis Factor><Tumor Necrosis Factor Receptor><Tumor Necrosis Factor Receptor Family><Tumor Necrosis Factor Receptor Superfamily><Tumor Necrosis Factor-alpha><Tumor Tissue><Tumor-Associated Antigen><Tumor-Infiltrating Lymphocytes><Xenograft><Xenograft Model><Xenograft procedure><Xenotransplantation><adoptive T cell transfer><adoptive T lymphocyte transfer><adoptive T-cell therapy><adoptive cell therapy><adoptive cellular therapy><anti-cancer immunotherapy><anti-cancer therapy><anticancer immunotherapy><biological signal transduction><cancer antigens><cancer immunotherapy><cancer infiltrating T cells><cancer microenvironment><cancer therapy><cancer type><cancer-directed therapy><cell based intervention><cell biology><cell killing><cell mediated intervention><cell mediated therapies><cell-based immunotherapy><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chimeric antigen T cell receptor><chimeric antigen receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><cytokine><daily living function><daily living functionality><design><designing><digital><engineered T cells><experiment><experimental research><experimental study><experiments><functional ability><functional capacity><gene expression pattern><gene expression signature><genetically engineered T-cells><human papilloma virus 16><humanized mice><humanized mouse><immune cell infiltrate><immune cell therapy><immune suppression><immune suppressive activity><immune suppressive function><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunosuppressive activity><immunosuppressive function><immunosuppressive response><immunotherapy for cancer><immunotherapy of cancer><improved><in vitro Assay><in vitro activity><in vivo><innovate><innovation><innovative><kappa B Enhancer Binding Protein><mouse model><murine model><neoplastic cell><next generation><novel><nuclear factor kappa beta><phospho-proteomics><phosphoproteomics><responders and non-responders><responders from non-responders><responders or non-responders><responders versus non-responders><responders vs non-responders><responders/nonresponders><response><response to therapy><response to treatment><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><systemic toxicity><therapeutic T-cell platform><therapeutic response><therapy failure><therapy response><thymus derived lymphocyte><transcriptional profile><transcriptional signature><transgenic><transgenic T- cells><translation><translational therapeutics><translational therapy><treatment response><treatment responsiveness><tumor><tumor growth><tumor infiltrating T cells><tumor microenvironment><tumor-specific antigen><type 16 Human papilloma virus><type 16 Human papillomavirus><vector><xeno-transplant><xeno-transplantation><xenograft transplant model><xenotransplant model>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Dawn E Bowles

DUKE UNIVERSITY, DURHAM, NC

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$444,125

FY 2026

Project Title

Speeding Immune Reconstitution after Thymus Transplantation

Grant Number:

1R21AI196275-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT: Speeding Immune Reconstitution after Thymus Transplantation Pivotal prior work by our team showed that cultured thymus tissue implantation (CTTI; also called thymus transplantation) into athymic humans generates a functional immune system where T cells protect against infection and are tol...

Research Terms

<(IFN) α><(IFN)-α><(IFN)α><0-11 years old><4 year old><4 years of age><AAV vector><AAV-based vector><Adolescent><Adolescent Youth><Affect><Alferon><Allogeneic Transplantation><Antigens><Architecture><Athymic Mice><Athymic Nude Mouse><Autoimmune Status><Autoimmunity><Autoregulation><BCL1><Biology><Bone Marrow><Bone Marrow Reticuloendothelial System><CCND1><CCND1 Protein><CCND1 gene><Cancer Treatment><Cancers><Capsid><Cardiac Transplantation><Cause of Death><Cell Count><Cell Number><Cell Protection><Cessation of life><Characteristics><Child><Child Youth><Children (0-21)><Clinical Treatment><Common Rat Strains><Cyclin D1><Cyclin D1 Gene><Cytoprotection><D11S287E><DNA Therapy><DNA cassette><Data><Death><Donor person><Drug Therapy><Engineering / Architecture><Exhibits><FDA approved><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><G1/S-Specific Cyclin D1><Gene Transfer Clinical><Generalized Growth><Genetic Intervention><Goals><Grafting Procedure><Growth><Heart><Heart Grafting><Heart Transplantation><Homeostasis><Homologous Transplantation><Human><IFN><IFN Alpha><IFN α><IFN-Gamma><IFN-g><IFN-α><IFN-γ><IFNG><IFNa><IFNα><IFNγ><Immune Interferon><Immune response><Immune system><Immunity><Immunocompetent><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Implant><Infant><Infection><Interferon Alfa-n3><Interferon Gamma><Interferon Type II><Interferon-α><Interferons><Intervention><JAK-2><JAK1><JAK1 gene><JAK1 protein><JAK1A><JAK2><JAK2 gene><JAK2 protein><Jak1 kinase><Janus kinase 1><Janus kinase 2><K5 keratin><Lead><Leukocyte Interferon><Life><Lymphoblast Interferon><Lymphoblastoid Interferon><MHC antigen><MLC test><MLR test><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measures><Methods><Mice><Mice Mammals><Mixed Leukocyte Culture Test><Mixed Leukocyte Reaction><Mixed Lymphocyte Culture><Mixed Lymphocyte Culture Test><Mixed Lymphocyte Reaction><Modern Man><Murine><Mus><Nude Mice><Organ Transplantation><Organ Transplants><PRAD1><PRAD1 Protein><Pathway interactions><Patients><Pb element><Perinatal><Peripartum><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiological Homeostasis><Process><Production><Progenitor Cells><Proliferating><Proto-Oncogene Proteins c-bcl-1><Qualifying><Rat><Rats Mammals><Rattus><Research><Self Tolerance><Signal Pathway><Speed><T cell reconstitution><T-Cell Development><T-Cell Ontogeny><T-Cells><T-Lymphocyte><T-Lymphocyte Development><Thymic Tissue><Thymic epithelial cell><Thymus><Thymus Gland><Thymus Proper><Thymus Reticuloendothelial System><Time><Tissue Growth><Transgenic Mice><Transgenic Organisms><Translating><Transplant Recipients><Transplantation><Tyrosine-Protein Kinase JAK1><Tyrosine-Protein Kinase JAK2><U21B31><Vaccination><Viral Vector><Weight><Work><adeno-associated viral vector><adeno-associated virus vector><age 4><age 4 years><age associated decline><age dependent decline><age related decline><anti-cancer therapy><athymia><bcl-1 Proto-Oncogene Products><bcl-1 Proto-Oncogene Proteins><bcl1 Proto-Oncogene Proteins><c-bcl-1 Proteins><cancer therapy><cancer-directed therapy><cardiac damage><cardiac graft><clinical intervention><clinical therapy><cyclin D><cytokine><cytoprotective><decline with age><develop therapy><drug intervention><drug treatment><enhancer cassette><experience><expression cassette><flow cytophotometry><four year old><four years of age><gene cassette><gene repair therapy><gene therapy><gene-based therapy><genetic cassette><genetic therapy><genomic therapy><heart damage><heart transplant><heavy metal Pb><heavy metal lead><host response><hypoimmunity><immune competent><immune deficiency><immune reconstitution><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immunodeficiency><immunogen><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><implantation><improved><inhibitor><integration cassette><intervention development><juvenile><juvenile human><keratin 5><kids><lFN-Gamma><malignancy><mixed lymphocyte reaction test><mouse model><murine model><neoplasm/cancer><novel><ontogeny><organ allograft><organ graft><organ transplant patient><organ transplant recipient><organ xenograft><overexpress><overexpression><pathway><perinatal period><perinatal phase><peripheral blood><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><prevent><preventing><programs><promoter><promoter cassette><promotor><rational design><reporter cassette><resistance cassette><scRNA sequencing><scRNA-seq><selectable cassette><selection cassette><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><stem cells><stop cassette><success><therapy development><thymocyte><thymus derived lymphocyte><thymus transplantation><transcription cassette><transcriptional cassette><transgene cassette><transgenic><transplant><transplant donor><transplant patient><treatment development><treatment effect><trial regimen><trial treatment><weights><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Laura P. Hale

DUKE UNIVERSITY, DURHAM, NC

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$444,125

FY 2026

Project Title

Speeding Immune Reconstitution after Thymus Transplantation

Grant Number:

1R21AI196275-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT: Speeding Immune Reconstitution after Thymus Transplantation Pivotal prior work by our team showed that cultured thymus tissue implantation (CTTI; also called thymus transplantation) into athymic humans generates a functional immune system where T cells protect against infection and are tol...

Research Terms

<(IFN) α><(IFN)-α><(IFN)α><0-11 years old><4 year old><4 years of age><AAV vector><AAV-based vector><Adolescent><Adolescent Youth><Affect><Alferon><Allogeneic Transplantation><Antigens><Architecture><Athymic Mice><Athymic Nude Mouse><Autoimmune Status><Autoimmunity><Autoregulation><BCL1><Biology><Bone Marrow><Bone Marrow Reticuloendothelial System><CCND1><CCND1 Protein><CCND1 gene><Cancer Treatment><Cancers><Capsid><Cardiac Transplantation><Cause of Death><Cell Count><Cell Number><Cell Protection><Cessation of life><Characteristics><Child><Child Youth><Children (0-21)><Clinical Treatment><Common Rat Strains><Cyclin D1><Cyclin D1 Gene><Cytoprotection><D11S287E><DNA Therapy><DNA cassette><Data><Death><Donor person><Drug Therapy><Engineering / Architecture><Exhibits><FDA approved><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><G1/S-Specific Cyclin D1><Gene Transfer Clinical><Generalized Growth><Genetic Intervention><Goals><Grafting Procedure><Growth><Heart><Heart Grafting><Heart Transplantation><Homeostasis><Homologous Transplantation><Human><IFN><IFN Alpha><IFN α><IFN-Gamma><IFN-g><IFN-α><IFN-γ><IFNG><IFNa><IFNα><IFNγ><Immune Interferon><Immune response><Immune system><Immunity><Immunocompetent><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Immunosuppression><Immunosuppression Effect><Immunosuppressive Effect><Implant><Infant><Infection><Interferon Alfa-n3><Interferon Gamma><Interferon Type II><Interferon-α><Interferons><Intervention><JAK-2><JAK1><JAK1 gene><JAK1 protein><JAK1A><JAK2><JAK2 gene><JAK2 protein><Jak1 kinase><Janus kinase 1><Janus kinase 2><K5 keratin><Lead><Leukocyte Interferon><Life><Lymphoblast Interferon><Lymphoblastoid Interferon><MHC antigen><MLC test><MLR test><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Measures><Methods><Mice><Mice Mammals><Mixed Leukocyte Culture Test><Mixed Leukocyte Reaction><Mixed Lymphocyte Culture><Mixed Lymphocyte Culture Test><Mixed Lymphocyte Reaction><Modern Man><Murine><Mus><Nude Mice><Organ Transplantation><Organ Transplants><PRAD1><PRAD1 Protein><Pathway interactions><Patients><Pb element><Perinatal><Peripartum><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiological Homeostasis><Process><Production><Progenitor Cells><Proliferating><Proto-Oncogene Proteins c-bcl-1><Qualifying><Rat><Rats Mammals><Rattus><Research><Self Tolerance><Signal Pathway><Speed><T cell reconstitution><T-Cell Development><T-Cell Ontogeny><T-Cells><T-Lymphocyte><T-Lymphocyte Development><Thymic Tissue><Thymic epithelial cell><Thymus><Thymus Gland><Thymus Proper><Thymus Reticuloendothelial System><Time><Tissue Growth><Transgenic Mice><Transgenic Organisms><Translating><Transplant Recipients><Transplantation><Tyrosine-Protein Kinase JAK1><Tyrosine-Protein Kinase JAK2><U21B31><Vaccination><Viral Vector><Weight><Work><adeno-associated viral vector><adeno-associated virus vector><age 4><age 4 years><age associated decline><age dependent decline><age related decline><anti-cancer therapy><athymia><bcl-1 Proto-Oncogene Products><bcl-1 Proto-Oncogene Proteins><bcl1 Proto-Oncogene Proteins><c-bcl-1 Proteins><cancer therapy><cancer-directed therapy><cardiac damage><cardiac graft><clinical intervention><clinical therapy><cyclin D><cytokine><cytoprotective><decline with age><develop therapy><drug intervention><drug treatment><enhancer cassette><experience><expression cassette><flow cytophotometry><four year old><four years of age><gene cassette><gene repair therapy><gene therapy><gene-based therapy><genetic cassette><genetic therapy><genomic therapy><heart damage><heart transplant><heavy metal Pb><heavy metal lead><host response><hypoimmunity><immune competent><immune deficiency><immune reconstitution><immune suppression><immune suppressive activity><immune suppressive function><immune system response><immunodeficiency><immunogen><immunoresponse><immunosuppressive activity><immunosuppressive function><immunosuppressive response><implantation><improved><inhibitor><integration cassette><intervention development><juvenile><juvenile human><keratin 5><kids><lFN-Gamma><malignancy><mixed lymphocyte reaction test><mouse model><murine model><neoplasm/cancer><novel><ontogeny><organ allograft><organ graft><organ transplant patient><organ transplant recipient><organ xenograft><overexpress><overexpression><pathway><perinatal period><perinatal phase><peripheral blood><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><prevent><preventing><programs><promoter><promoter cassette><promotor><rational design><reporter cassette><resistance cassette><scRNA sequencing><scRNA-seq><selectable cassette><selection cassette><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><stem cells><stop cassette><success><therapy development><thymocyte><thymus derived lymphocyte><thymus transplantation><transcription cassette><transcriptional cassette><transgene cassette><transgenic><transplant><transplant donor><transplant patient><treatment development><treatment effect><trial regimen><trial treatment><weights><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kyle Fink

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$442,750

FY 2026

Project Title

Optimization of AAV gene therapy through the unbiased, high-throughput screening of novel ITR domains in the mouse brain

Grant Number:

1R21NS142879-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Adeno-associated viral (AAV) vectors have become the gold standard for delivery of genetic cargo the central nervous system. Remarkable efficacy and strong safety profiles have led to FDA approval of multiple AAV gene therapies for genetic disorders validating this platform as a key leader ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Julian Halmai

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$442,750

FY 2026

Project Title

Optimization of AAV gene therapy through the unbiased, high-throughput screening of novel ITR domains in the mouse brain

Grant Number:

1R21NS142879-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Adeno-associated viral (AAV) vectors have become the gold standard for delivery of genetic cargo the central nervous system. Remarkable efficacy and strong safety profiles have led to FDA approval of multiple AAV gene therapies for genetic disorders validating this platform as a key leader ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Priyanka Sharma

UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS CITY, KS

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$398,544

FY 2026

Project Title

Pre-Clinical Evaluation of a Highly Selective SMARCA2 Degrader in Therapy-Resistant Triple-Negative Breast Cancer

Grant Number:

1R21CA307485-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/8/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY / ABSTRACT Patients who achieve a pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) have good outcomes, while patients with residual disease (RD) are at high risk of recurrence and death. Patients who achieve a pathologic complete response (pCR) to NAST have g...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Shane Richard Stecklein

UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS CITY, KS

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$398,544

FY 2026

Project Title

Pre-Clinical Evaluation of a Highly Selective SMARCA2 Degrader in Therapy-Resistant Triple-Negative Breast Cancer

Grant Number:

1R21CA307485-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/8/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY / ABSTRACT Patients who achieve a pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) have good outcomes, while patients with residual disease (RD) are at high risk of recurrence and death. Patients who achieve a pathologic complete response (pCR) to NAST have g...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Michael Benjamin Major

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$254,437

FY 2026

Project Title

Identifying the effects of NRF2 signaling on lung squamous cell carcinoma development

Grant Number:

5R21CA292297-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY: The NRF2 transcription factor is mutated and activated in more than 30% of lung and upper aerodigestive squamous cell carcinomas. NRF2 drives a gene expression program that mitigates oxidative and electrophilic stress, reprograms and enables cancer cell metabolism, and suppresses ly...

Research Terms

<10 year old><10 years of age><Adenocarcinoma of the Esophagus><Affect><Antioncogene Protein p53><Automobile Driving><Autoregulation><Basal Transcription Factor><Basal transcription factor genes><C-K-RAS><CDK4I><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CMM2><CMV><Cancers><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cellular Tumor Antigen P53><Checkpoint inhibitor><Custom><Cyclin-Dependent Kinase Inhibitor 2A Gene><Cytomegalovirus><DNA mutation><Data><Development><Dimensions><Epidermoid Cell Lung Carcinoma><Esophageal Adenocarcinoma><Evaluation><Event><Failure><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Future><GEM model><GEMM model><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Genotype><Goals><Grant><Growth><HCMV><HNSCC><Head and Neck Squamous Cell Carcinoma><Histologic><Histologically><Histology><Homeostasis><Hot Spot><Human><INK4><INK4A><IRES><Immune><Immune Regulators><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunomodulation><Immunomodulators><Immunoprevention><Immunotherapy><Incidence><Intermediary Metabolism><Internal Ribosome Entry Segment><Internal Ribosome Entry Site><Intracellular Communication and Signaling><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KRAS><KRAS2><KRAS2 gene><Keytruda><Ki-RAS><Knowledge><LKB1><LKB1/STK11 Gene><Laboratories><Lung><Lung Adenocarcinoma><Lung Respiratory System><Lymphocyte Suppression><Lymphocytic Infiltrate><MMAC1><MMAC1 protein><MTS1><MTS1 Genes><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Metabolic><Metabolic Processes><Metabolism><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Missense Mutation><Modeling><Modern Man><Molecular><Monitor><Murine><Mus><Mutate><Mutated in Multiple Advanced Cancers 1><Mutation><Neoplasm Metastasis><Nivolumab><Normal Cell><Oat cell carcinoma><Oncogene K-Ras><Oncogenesis><Oncogenic><Oncoprotein p53><Opdivo><Oral Cavity Squamous Cell Carcinoma><Oral squamous cell carcinoma><P53><PHTS gene><PHTS protein><PI3K-Alpha><PIK3-Alpha><PIK3CA><PIK3CA gene><PTEN><PTEN gene><PTEN protein><PTEN1><Pathology><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Phenotype><Phosphatase and Tensin Homolog><Phosphatase and Tensin Homolog Deleted on Chromosome 10><Phosphatidylinositol 3-Kinase, Catalytic, 110-kD, Alpha><Phosphatidylinositol 3-Kinase, Catalytic, Alpha><Phosphoprotein P53><Phosphoprotein pp53><Physiological Homeostasis><Play><Portraits><Position><Positioning Attribute><Preneoplastic Change><Process><Prognosis><Protein TP53><Proteomics><Publishing><Pulmonary Cancer><Pulmonary Pathology><Pulmonary malignant Neoplasm><RASK2><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Radiation therapy><Radiotherapeutics><Radiotherapy><Reporting><Research><Research Proposals><Resistance><Ribosome Entry Site><Role><SCCHN><STK11><STK11 gene><Salivary Gland Viruses><Secondary Neoplasm><Secondary Tumor><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Squamous Cell Lung Carcinoma><Squamous cell lung cancer><Strains Cell Lines><Stress><Study models><T cell infiltration><T-Stage><TP16><TP53><TP53 gene><TRP53><TSG9A><Testing><Time><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tumor Protein p53><Tumor Protein p53 Gene><Tumor stage><Validation><Work><aerodigestive squamous cell cancer><aerodigestive squamous cell carcinomas><age 10><age 10 years><biological adaptation to stress><biological signal transduction><cancer cell><cancer cell metabolism><cancer metabolism><cancer metastasis><cancer microenvironment><cancer progression><cell type><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemotherapy><cultured cell line><customs><cytomegalovirus group><determine efficacy><developmental><driving><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><flow cytophotometry><gain of function><genetically engineered mouse model><genetically engineered murine model><genome mutation><head and neck squamous carcinoma><head and neck squamous cell cancer><high dimensionality><human cancer mouse model><imaging mass spectrometry><immune cell infiltrate><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune microenvironment><immune modulation><immune modulators><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunomodulatory molecules><immunoregulation><immunoregulator><immunoregulatory><immunoregulatory molecules><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><in vitro Model><in vivo><inhibitor drug><inhibitor therapeutic><inhibitor therapy><liver kinase B1><loss of function mutation><lung cancer><lung oat cell carcinoma><lung pathology><lung small cell neuroendocrine carcinoma><lung squamous cancer><lung squamous carcinoma><lung squamous cell carcinoma><malignancy><mass spectrometric imaging><missense single nucleotide polymorphism><missense single nucleotide variant><missense variant><mouse model><mouth SCC><mouth squamous cell carcinoma><murine model><mutant><mutated in multiple advanced cancers 1 protein><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oat cell cancer><ontogeny><oral cavity SCC><oral squamous cancer><oral squamous carcinoma><p110-Alpha><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient oriented outcomes><pembrolizumab><pharmacologic><phosphatase and tensin homologue on chromosome ten><pre-clinical><pre-neoplastic change><preclinical><programs><protein p53><radiation treatment><reactioncrisis><resistant><response><response to therapy><response to treatment><social role><squamous cell carcinoma of the lung><stress response><stressreaction><suppress lymphocytes><ten year old><ten years of age><therapeutic response><therapeutic target><therapy response><transcription factor><transcriptome sequencing><transcriptomic sequencing><transcriptomics><treatment response><treatment responsiveness><treatment with radiation><tumor><tumor cell metabolism><tumor cell metastasis><tumor immune microenvironment><tumor initiation><tumor metabolism><tumor microenvironment><tumor progression><tumor-immune system interactions><tumorigenesis><tumorigenic><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Bernard E. Weissman

UNIV OF NORTH CAROLINA CHAPEL HILL, CHAPEL HILL, NC

Exploratory lead · 40/100

Solid budget

Very recent

Active award

$254,437

FY 2026

Project Title

Identifying the effects of NRF2 signaling on lung squamous cell carcinoma development

Grant Number:

5R21CA292297-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY: The NRF2 transcription factor is mutated and activated in more than 30% of lung and upper aerodigestive squamous cell carcinomas. NRF2 drives a gene expression program that mitigates oxidative and electrophilic stress, reprograms and enables cancer cell metabolism, and suppresses ly...

Research Terms

<10 year old><10 years of age><Adenocarcinoma of the Esophagus><Affect><Antioncogene Protein p53><Automobile Driving><Autoregulation><Basal Transcription Factor><Basal transcription factor genes><C-K-RAS><CDK4I><CDKN2><CDKN2 Genes><CDKN2A><CDKN2A gene><CMM2><CMV><Cancers><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cellular Tumor Antigen P53><Checkpoint inhibitor><Custom><Cyclin-Dependent Kinase Inhibitor 2A Gene><Cytomegalovirus><DNA mutation><Data><Development><Dimensions><Epidermoid Cell Lung Carcinoma><Esophageal Adenocarcinoma><Evaluation><Event><Failure><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Future><GEM model><GEMM model><Gene Expression><Gene Transcription><General Transcription Factor Gene><General Transcription Factors><Generalized Growth><Genetic Change><Genetic Transcription><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Genotype><Goals><Grant><Growth><HCMV><HNSCC><Head and Neck Squamous Cell Carcinoma><Histologic><Histologically><Histology><Homeostasis><Hot Spot><Human><INK4><INK4A><IRES><Immune><Immune Regulators><Immune checkpoint inhibitor><Immune infiltrates><Immune mediated therapy><Immunes><Immunologically Directed Therapy><Immunomodulation><Immunomodulators><Immunoprevention><Immunotherapy><Incidence><Intermediary Metabolism><Internal Ribosome Entry Segment><Internal Ribosome Entry Site><Intracellular Communication and Signaling><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KRAS><KRAS2><KRAS2 gene><Keytruda><Ki-RAS><Knowledge><LKB1><LKB1/STK11 Gene><Laboratories><Lung><Lung Adenocarcinoma><Lung Respiratory System><Lymphocyte Suppression><Lymphocytic Infiltrate><MMAC1><MMAC1 protein><MTS1><MTS1 Genes><Malignant Cell><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Mediating><Metabolic><Metabolic Processes><Metabolism><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Missense Mutation><Modeling><Modern Man><Molecular><Monitor><Murine><Mus><Mutate><Mutated in Multiple Advanced Cancers 1><Mutation><Neoplasm Metastasis><Nivolumab><Normal Cell><Oat cell carcinoma><Oncogene K-Ras><Oncogenesis><Oncogenic><Oncoprotein p53><Opdivo><Oral Cavity Squamous Cell Carcinoma><Oral squamous cell carcinoma><P53><PHTS gene><PHTS protein><PI3K-Alpha><PIK3-Alpha><PIK3CA><PIK3CA gene><PTEN><PTEN gene><PTEN protein><PTEN1><Pathology><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Phenotype><Phosphatase and Tensin Homolog><Phosphatase and Tensin Homolog Deleted on Chromosome 10><Phosphatidylinositol 3-Kinase, Catalytic, 110-kD, Alpha><Phosphatidylinositol 3-Kinase, Catalytic, Alpha><Phosphoprotein P53><Phosphoprotein pp53><Physiological Homeostasis><Play><Portraits><Position><Positioning Attribute><Preneoplastic Change><Process><Prognosis><Protein TP53><Proteomics><Publishing><Pulmonary Cancer><Pulmonary Pathology><Pulmonary malignant Neoplasm><RASK2><RNA Expression><RNA Seq><RNA sequencing><RNAseq><Radiation therapy><Radiotherapeutics><Radiotherapy><Reporting><Research><Research Proposals><Resistance><Ribosome Entry Site><Role><SCCHN><STK11><STK11 gene><Salivary Gland Viruses><Secondary Neoplasm><Secondary Tumor><Shapes><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Squamous Cell Lung Carcinoma><Squamous cell lung cancer><Strains Cell Lines><Stress><Study models><T cell infiltration><T-Stage><TP16><TP53><TP53 gene><TRP53><TSG9A><Testing><Time><Tissue Growth><Transcription><Transcription Factor Proto-Oncogene><Transcription factor genes><Tumor Cell><Tumor Protein p53><Tumor Protein p53 Gene><Tumor stage><Validation><Work><aerodigestive squamous cell cancer><aerodigestive squamous cell carcinomas><age 10><age 10 years><biological adaptation to stress><biological signal transduction><cancer cell><cancer cell metabolism><cancer metabolism><cancer metastasis><cancer microenvironment><cancer progression><cell type><check point immunotherapy><check point inhibitor therapy><check point inhibitory therapy><check point therapy><checkpoint immunotherapy><checkpoint inhibitor therapy><checkpoint inhibitory therapy><checkpoint therapy><chemotherapy><cultured cell line><customs><cytomegalovirus group><determine efficacy><developmental><driving><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><evaluate efficacy><examine efficacy><flow cytophotometry><gain of function><genetically engineered mouse model><genetically engineered murine model><genome mutation><head and neck squamous carcinoma><head and neck squamous cell cancer><high dimensionality><human cancer mouse model><imaging mass spectrometry><immune cell infiltrate><immune check point inhibitor><immune check point therapy><immune checkpoint therapy><immune microenvironment><immune modulation><immune modulators><immune regulation><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunologic reactivity control><immunomodulatory><immunomodulatory molecules><immunoregulation><immunoregulator><immunoregulatory><immunoregulatory molecules><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><in vitro Model><in vivo><inhibitor drug><inhibitor therapeutic><inhibitor therapy><liver kinase B1><loss of function mutation><lung cancer><lung oat cell carcinoma><lung pathology><lung small cell neuroendocrine carcinoma><lung squamous cancer><lung squamous carcinoma><lung squamous cell carcinoma><malignancy><mass spectrometric imaging><missense single nucleotide polymorphism><missense single nucleotide variant><missense variant><mouse model><mouth SCC><mouth squamous cell carcinoma><murine model><mutant><mutated in multiple advanced cancers 1 protein><neoplasm progression><neoplasm/cancer><neoplastic cell><neoplastic progression><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oat cell cancer><ontogeny><oral cavity SCC><oral squamous cancer><oral squamous carcinoma><p110-Alpha><p14ARF><p16 Genes><p16INK4 Genes><p16INK4A Genes><p16INK4a><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient oriented outcomes><pembrolizumab><pharmacologic><phosphatase and tensin homologue on chromosome ten><pre-clinical><pre-neoplastic change><preclinical><programs><protein p53><radiation treatment><reactioncrisis><resistant><response><response to therapy><response to treatment><social role><squamous cell carcinoma of the lung><stress response><stressreaction><suppress lymphocytes><ten year old><ten years of age><therapeutic response><therapeutic target><therapy response><transcription factor><transcriptome sequencing><transcriptomic sequencing><transcriptomics><treatment response><treatment responsiveness><treatment with radiation><tumor><tumor cell metabolism><tumor cell metastasis><tumor immune microenvironment><tumor initiation><tumor metabolism><tumor microenvironment><tumor progression><tumor-immune system interactions><tumorigenesis><tumorigenic><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Georgia Rae Atkins

MAGEE-WOMEN'S RES INST AND FOUNDATION, Pittsburgh, PA

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$50,114

FY 2026

Project Title

AAV gene therapy to restore fertility in mammalian Sertoli cell dysfunction models

Grant Number:

5F31HD114406-03

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/1/2024

End Date:

2/28/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

ABSTRACT: Infertility impacts 48 million couples worldwide and 50% of cases are due to a male factor. Non-obstructive azoospermia (NOA) is the absence of sperm due to spermatogenic failure. Some cases are due to known conditions (Klinefelter’s Syndrome, Y chromosome microdeletions, and hypogonadism)...

Research Terms

<0-11 years old><AAV vector><AAV-based vector><Abnormal Karyotype><Academia><Address><Adeno-Associated Viruses><Biological><Birth Defects><Blood-Testis Barrier><Breeding><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cannot achieve a pregnancy><Cas nuclease technology><Cell Body><Cell Function><Cell Physiology><Cell Process><Cells><Cellular Function><Cellular Physiology><Cellular Process><Chickens><Child><Child Youth><Children (0-21)><Clinic><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Congenital Abnormality><Congenital Anatomical Abnormality><Congenital Defects><Congenital Deformity><Congenital Malformation><Couples><DNA Therapy><DNA mutation><Data><Defect><Dependoparvovirus><Dependovirus><Development><Difficulty conceiving><Dysfunction><Ejaculation><Embryo><Embryonic><Ethics><Exhibits><Faculty><Failure><Fecundability><Fecundity><Fertility><Foundations><Functional disorder><Funding><Future><Gallus domesticus><Gallus gallus><Gallus gallus domesticus><Gametes><Gene Alteration><Gene Modified><Gene Mutation><Gene Transfer Clinical><Gene variant><Genes><Genetic><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Genome><Genotype><Germ Cells><Germ Lines><Germ-Line Cells><Grant><Histology><Human><Hypogonadism><ICSI><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Infection><Infertility><Intracytoplasmic Sperm Injections><Investigators><Japan><KITLG><KITLG gene><KL-1><Kit Ligand Gene><Kitl><Klinefelter><Klinefelter syndrome (KS)><Klinefelter's Syndrome><Klinefelter-Reifenstein syndrome><Klinefelter-Reifenstein-Albright syndrome><Knock-out><Knockout><Knowledge><Legal><Leydig Cells><Male Infertility><Mediating><Meiosis><Melanogenesis><Methods><Mice><Mice Mammals><Modeling><Modern Man><Modification><Murine><Mus><Mutation><NGS Method><NGS system><Natural regeneration><Organ Culture><Organ Culture Techniques><Patients><Phenotype><Physiopathology><Production><Regeneration><Reporter Genes><Reporting><Reproductive Cells><Research><Research Personnel><Researchers><Risk><Route><Safety><Seminiferous Tubules><Seminiferous tubule structure><Serotyping><Sex Cell><Somatic Cell><Somatic Gene Therapy><Specificity><Sperm><Spermatogenesis><Spermatozoa><Spermiogenesis><Subcellular Process><System><Techniques><Technology><Testicles><Testicular Interstitial Cells><Testicular Parenchyma><Testicular Tissue><Testing><Testis><Therapeutic><Toxic effect><Toxicities><Toxicity Testing><Toxicity Tests><Translations><Transmission><Tubular><Tubular formation><Variant><Variation><Work><XXY syndrome><XXY trisomy><Xq Klinefelter syndrome><Y chromosome deletion><Y chromosome microdeletions><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><allelic variant><bench bed side><bench bedside><bench to bed side><bench to bedside><bench to clinic><bench to clinical practice><beta Actin><biobank><biologic><biorepository><career><cell type><chromosome XXY syndrome><developmental><diagnostic development><diagnostic tool><entire genome><ethical><exome sequencing><exome-seq><feasibility testing><fertility cessation><fertility loss><full genome><gene defect><gene modification><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic variant><genetically modified><genome mutation><genomic therapy><genomic variant><human model><human tissue><in vitro Organ Culturing><in vitro vertebrate organ culturing><in vivo><infertile><infertile males><infertile men><infertility in men><initial cell><insight><kids><leydig interstitial cell><male><male factor infertility><meiotic><men><men facing infertility><men with infertility><model of human><mouse genome><mouse model><murine model><mutant allele><next gen sequencing><next generation sequencing><nextgen sequencing><novel><pathophysiology><polycarbonate><pup><regenerate><safety and feasibility><screening><screenings><self-renew><self-renewal><seminiferous tubule dysgenesis><sertoli cell><sexual cell><skills><somatic cell gene therapy><somatic gene transfer><species difference><sperm cell><testis interstitial cell><testis sustentacular cell><transduction efficiency><translation><translation to humans><transmission process><vector><whole genome><youngster><zoosperm><β-Actin><♂>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Mason T Myers

UNIVERSITY OF MICHIGAN AT ANN ARBOR, ANN ARBOR, MI

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$43,589

FY 2026

Project Title

Leveraging a 'sliding-window' Type I CRISPR base editing platform to correct CFTR null mutations

Grant Number:

5F31HL177911-02

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

Project Summary Cystic Fibrosis (CF) is an autosomal recessive genetic disorder affecting nearly 160,000 patients worldwide. It is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, which encodes a chloride ion channel crucial for salt and water homeostasis across epithel...

Research Terms

<1H-Purin-6-amine><Adenine><Adverse effects><Affect><Ailmentary System><Alimentary System><Alleles><Allelomorphs><Arginine><Assay><Autoregulation><Bioassay><Biological Assay><CF patients><CFTR><CFTR Protein><CRISPR><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><Cas nuclease technology><Cell Body><Cell Line><CellLine><Cells><Chloride Channels><Chloride Ion Channels><ClinVar><Clinical><Clone Cells><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Complex><Computer Analysis><Cystic Fibrosis><Cystic Fibrosis Transmembrane Conductance Regulator><DNA><DNA Double Strand Break><DNA Therapy><DNA mutation><Data Bases><Databases><Deaminase><Deoxyribonucleic Acid><Development><Digestive System><Disease><Disorder><Drug Modulation><Drug Therapy><Drugs><Dysfunction><Effectiveness><Electrophysiology><Electrophysiology (science)><Electroporation><Epithelial Cells><Epithelium><FDA approved><Face><Fluid Balance><Fluid Homeostasis><Functional disorder><Gastrointestinal Body System><Gastrointestinal Organ System><Gene Transfer Clinical><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Genome engineering><Genotype><Goals><Guanine><Guide RNA><Hb SS disease><HbSS disease><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Homeostasis><Human><Hydrogen Oxide><Impairment><Individual><Intestinal><Intestines><Ions><Ivacaftor><L-Arginine><Length><Life><Lung><Lung Respiratory System><Lung damage><Measures><Mediating><Medical><Medication><Membrane><Messenger RNA><Modeling><Modern Man><Monitor><Morbidity><Mucous body substance><Mucoviscidosis><Mucus><Mutation><Neurophysiology / Electrophysiology><Non-Polyadenylated RNA><Nonsense Codon><Organoids><Outcome Measure><Pancreas><Pancreatic><Pathogenicity><Patients><Persons><Pharmaceutical Agent><Pharmaceutical Preparations><Pharmaceuticals><Pharmacologic Substance><Pharmacological Substance><Pharmacological Treatment><Pharmacotherapy><Phenotype><Physiological Homeostasis><Physiology><Physiopathology><Premature Stop Codon><Property><Proteins><RNA><RNA Gene Products><Regulator Genes><Ribonucleic Acid><Safety><Sickle Cell Anemia><Site><Slide><Societies><Sodium Chloride><Strains Cell Lines><Swelling><System><Testing><Therapeutic><Therapeutic Gene Editing><Transcriptional Regulatory Elements><VX-770><Variant><Variation><Vitamin B4><Water><autosome><base><base editing><base editor><bases><bowel><bronchial epithelium><burden of disease><burden of illness><computational analyses><computational analysis><computer analyses><cost><cultured cell line><cystic fibrosis patients><cystic fibrosis transmembrane regulator><data base><deep sequencing><design><designing><developmental><disease burden><drug detection><drug development><drug intervention><drug testing><drug treatment><drug/agent><electrophysiological><electroporative delivery><faces><facial><flexibility><flexible><functional restoration><gRNA><gastrointestinal system><gene corrected><gene correction><gene editing method><gene editing methodology><gene editing platform><gene editing strategy><gene editing system><gene editing techniques><gene editing technology><gene editing tools><gene electrotransfer><gene locus><gene null><gene repair therapy><gene therapy><gene-based therapy><gene-editing approach><gene-editing therapy><gene-editing toolkit><genetic condition><genetic disorder><genetic locus><genetic recessive><genetic therapy><genetic trans acting element><genome editing based therapy><genome editing therapy><genome editing treatment><genome editing-based therapeutics><genome mutation><genomic correction><genomic location><genomic locus><genomic therapy><individuals with CF><individuals with cystic fibrosis><induced pluripotent stem cells derived from patients><induced pluripotent stem cells from patients><lung injury><mRNA><measurable outcome><membrane structure><mortality><mucous><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><nuclease><null mutation><off-target site><outcome measurement><pathophysiology><patient derived human iPS><patient derived human iPSC><patient derived human induced pluripotent stem cell><patient derived iPS><patient derived iPSC><patient derived induced pluripotent cells><patient derived induced pluripotent stem cells><patient-derived pluripotent stem cells><patients with CF><patients with cystic fibrosis><pharmaceutical><pharmaceutical intervention><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><pre-clinical><preclinical><protein function><pulmonary damage><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><recessive genetic trait><recessive trait><regulatory gene><restoration><restore function><restore functionality><restore lost function><salt><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><side effect><stoichiometry><success><synergism><theories><therapeutic editing><therapeutic genome editing><therapeutic outcome><therapy outcome><tool><trans acting element><unpublished works>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Steven Elias Valdez

UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH, SALT LAKE CITY, UT

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$37,609

FY 2026

Project Title

Myocarditis is necessary for the development of arrhythmogenic cardiomyopathy

Grant Number:

5F31HL178200-02

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

1/6/2025

End Date:

1/5/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Arrhythmogenic cardiomyopathy (ACM) is a devastating inherited disease that causes sudden cardiac death in young people, accounting for up to 22% of sudden cardiac deaths in adults under 35. Despite the identification of causative mutations, the mechanisms triggering ACM rem...

Research Terms

<(TNF)-α><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><21+ years old><2aR phosphoprotein I><2ar peptide><AAV vector><AAV-based vector><Acceleration><Accounting><Adult><Adult Human><Age><Anti-Inflammatories><Anti-Inflammatory Agents><Anti-inflammatory><Arrhythmia><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><B220><BCDF><BSF-2><BSF2><Benign><Birth><CCL2><CCL2 gene><CD45><CD68 antigen><CMV promoter><COVID-19 S protein><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><Cachectin><Cardiac Arrhythmia><Cardiac Muscle Cells><Cardiac Myocytes><Cardiac Transplantation><Cardiocyte><Cd68><Cell Body><Cell Communication and Signaling><Cell Signaling><Cells><Cessation of life><Chemokine, CC Motif, Ligand 2><Childhood><Cicatrix><Clinical><Clinical Management><Connexin 43><Connexin43><Coupling><Cx43><DNA Therapy><DNA mutation><Data><Death><Desmosomes><Development><Devices><Disease><Disorder><Dose><Dysfunction><ECG><EKG><Early Intervention><Electrocardiogram><Electrocardiography><Environmental Factor><Environmental Risk Factor><Eta-1 protein><Eta-1-Op protein><Event><Exercise><Extremities><Fibrosis><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Functional disorder><GP180><Gene Transfer Clinical><Gene variant><Genes><Genetic Carriers><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><HPGF><Heart><Heart Arrhythmias><Heart Grafting><Heart Muscle Cells><Heart Transplantation><Heart failure><Heart myocyte><Hepatocyte-Stimulating Factor><Hereditary Disease><Hybridoma Growth Factor><IFN-beta 2><IFNB2><IL-6><IL6 Protein><Immune><Immune Cell Activation><Immune infiltrates><Immunes><Immunoblotting><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Implant><Inborn Genetic Diseases><Individual><Infection><Infiltration><Inflammation><Inflammatory><Inherited disorder><Injections><Interleukin-6><Intervention><Intracellular Communication and Signaling><Isoforms><LY5><Limb structure><Limbs><MCAF><MCP-1><MCP1><MGI-2><Macrophage><Macrophage-Derived TNF><Macula Adherens><Measures><Mechanics><Mediating><Mice><Mice Mammals><Monocyte Chemoattractant Protein-1><Monocyte Chemotactic Protein-1><Monocyte Chemotactic and Activating Factor><Monocyte Chemotactic and Activating Protein><Monocyte Chemotactive and Activating Factor><Monocyte Secretory Protein JE><Monocyte-Derived TNF><Murine><Mus><Mutant Strains Mice><Mutation><Myeloid Differentiation-Inducing Protein><Myocardial><Myocardial depression><Myocardial dysfunction><Myocarditis><Myocardium><Mφ><Neonatal><Node of Bizzozero><Non-Trunk><Onset of illness><Other Genetics><Outcome><Outcome Study><PTPRC><PTPRC gene><Parturition><Pathway interactions><Patients><Persons><Phase><Phenotype><Physiopathology><Plasmacytoma Growth Factor><Population><Predisposition><Preventative therapy><Preventative treatment><Preventive therapy><Preventive treatment><Protein Isoforms><Proteins><Reporting><Research><Role><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SCYA2><Saline><Saline Solution><Scars><Serotyping><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severities><Signal Transduction><Signal Transduction Systems><Signaling><Spot Desmosome><Structure><Sudden Death><Susceptibility><T200><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Telemetries><Telemetry><Testing><Transgenic Mice><Translating><Trichrome stain><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Ventricular Arrhythmia><Viral Vector><Western Blotting><Western Immunoblotting><Work><adeno-associated viral vector><adeno-associated virus vector><adulthood><ages><allele carriers><allelic variant><arrhythmogenic cardiomyopathy><biological signal transduction><bone sialoprotein 1><bone sialoprotein I><cardiac dysfunction><cardiac failure><cardiac graft><cardiac inflammation><cardiac muscle><cardiomyocyte><causal allele><causal gene><causal mutation><causal variant><causative mutation><causative variant><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><curative intervention><curative therapeutic><curative therapy><curative treatments><cytokine><desmoglein 2><desmoglein II><desmosomal glycoprotein 2><developmental><disease causing variant><disease onset><disease phenotype><disease-causing allele><disease-causing mutation><disorder onset><early T-lympocyte activation-1 protein><early adulthood><emerging adult><environmental risk><familial cardiomyopathy><flow cytophotometry><gene repair therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic cardiomyopathy><genetic therapy><genetic variant><genome mutation><genomic therapy><genomic variant><heart dysfunction><heart muscle><heart transplant><hereditary cardiomyopathy><hereditary disorder><heritable disorder><immune activation><immune cell infiltrate><inborn error><inherited cardiomyopathy><inherited diseases><inherited genetic disease><inherited genetic disorder><innovate><innovation><innovative><interferon beta 2><mechanic><mechanical><mortality><mouse model><mouse mutant><murine model><mutant mouse model><mutation carrier><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><osteopontin><pathogenic allele><pathogenic variant><pathophysiology><pathway><pediatric><prevent><preventing><protein blotting><recruit><secreted phosphoprotein 1><sialoprotein 1><social role><spike proteins on SARS-CoV-2><sudden cardiac death><telemetric><treatment strategy>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jane-Valeriane Kimberly Boua

WASHINGTON UNIVERSITY, SAINT LOUIS, MO

Exploratory lead · 40/100

Training-friendly

Recent

Active award

$36,673

FY 2026

Project Title

Investigating the Feasibility of Gene Therapy for the Treatment of TBRS

Grant Number:

1F30MH143481-01

Activity Code:

F30

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

3/1/2026

End Date:

2/28/2028

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY Neurodevelopmental disorders (NDDs) often result from mutations in genes essential for brain development and function. Recent advances in gene replacement therapy have shown promise for rescuing molecular and behavioral deficits in mouse models, even when gene restoration occurs post...

Research Terms

<21+ years old><AAV delivered><AAV delivery><AAV vector><AAV-based delivery><AAV-based vector><AAV-based viral delivery><AAV-mediated delivery><ASD><Address><Adeno-Associated Viruses><Adeno-associated-virus-based delivery><Adult><Adult Human><Affect><Allelic Loss><Animals><Autism><Autistic Disorder><Behavior><Behavioral><Body Tissues><Brain><Brain Nervous System><CRE Recombinase><Candidate Disease Gene><Candidate Gene><Cell Body><Cell Differentiation><Cell Differentiation process><Cells><Cerebral cortex><Collaborations><Computational Biology><Cytosine><DNA Methylation><DNA Methyltransferase><DNA Modification Methylases><DNA Modification Methyltransferases><DNA Therapy><DNA mutation><DNA-Methyltransferases><Decreased Muscle Tone><Dependoparvovirus><Dependovirus><Deposit><Deposition><Development><Dinucleoside Phosphates><Disease><Disorder><Dnmt><Dose><Early Infantile Autism><Encephalon><Ensure><Enterobacteria phage P1 Cre recombinase><Environment><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Face><Family><Fostering><Foundations><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Gene Targeting><Gene Transfer Clinical><Generalized Growth><Genes><Genetic><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Genome><Genomics><Goals><Growth><Head circumference><Health><Height><Human><Hypomyotonia><Hypotonia><Industry Standard><Infantile Autism><Intellectual disability><Intellectual functioning disability><Intellectual limitation><Investigators><Joint Hypermobility><Joint Laxity><Kanner's Syndrome><Learning Disabilities><Learning disability><Life><Life Expectancy><Link><Location><Loss of Heterozygosity><Mediating><Mentorship><Methods><Methylation><Mice><Mice Mammals><Modern Man><Modification Methylases><Molecular><Murine><Mus><Muscle Hypotony><Muscle Tone Poor><Muscle hypotonia><Muscular Hypotonia><Mutate><Mutation><Nerve Cells><Nerve Unit><Neural Cell><Neurocyte><Neurodevelopmental Disorder><Neurological Development Disorder><Neuronal Differentiation><Neurons><Obesity><Organism><Outcome><Patients><Persons><Phenotype><Play><Protein Methylases><Protein Methyltransferases><QOL><Quality of life><RNA Seq><RNA sequencing><RNAseq><Rahman Syndrome><Research><Research Personnel><Research Resources><Researchers><Resolution><Resources><Role><Scientific Inquiry><Seizures><Single-Nucleus Sequencing><Site-Specific DNA-methyltransferase><Specific qualifier value><Specified><Symptoms><Tamoxifen><Technology><Testing><Therapeutic><Time><Tissue Growth><Tissues><Transcript Expression Analyses><Transcript Expression Analysis><Universities><Washington><Work><adeno associated virus group><adeno-associated viral vector><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adeno-associated virus vector><adenovirus mediated delivery><adiposity><adulthood><analyze gene expression><autism spectral disorder><autism spectrum disorder><autistic spectrum disorder><bacteriophage P1 recombinase Cre><cell type><cellular differentiation><computer biology><corpulence><delivered with AAV><delivery with AAV><developmental><dinucleotide><disease model><disorder model><dosage><epigenetically><experiment><experimental research><experimental study><experiments><faces><facial><feasibility testing><functional outcomes><functional restoration><gene expression analysis><gene expression assay><gene repair therapy><gene replacement><gene replacement therapy><gene therapy><gene-based therapy><gene-based treatment><gene-directed therapy><gene-targeted therapy><gene-targeted treatment><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><imaging platform><improved><improved outcome><in vivo><in vivo Model><induced Cre><inducible Cre><innovate><innovation><innovative><insight><intellectual and developmental disability><limited intellectual functioning><living system><methylation pattern><methylomics><mouse model><murine model><neural><neurodevelopmental disease><neuron development><neuronal><neuronal development><ontogeny><overexpress><overexpression><post-natal period><postnatal><postnatal period><protein expression><resolutions><restoration><restore function><restore functionality><restore lost function><sNuc-Seq><single nucleus RNA-sequencing><single nucleus seq><single-nucleus RNA-seq><snRNA sequencing><snRNA-seq><social role><spatial RNA sequencing><spatial gene expression analysis><spatial gene expression profiling><spatial resolved transcriptome sequencing><spatial transcriptome analysis><spatial transcriptome profiling><spatial transcriptome sequencing><spatial transcriptomics><spatially resolved transcriptomics><spatio transcriptomics><synapse formation><synapse function><synaptic function><synaptic pruning><synaptogenesis><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><tool><trait><transcriptional profiling><transcriptome sequencing><transcriptomic sequencing><transcriptomics><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yingbin Fu

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Exploratory lead · 38/100

Very recent

Active award

Team-scale grant

$1

FY 2026

Project Title

A two-pronged approach to generating novel models of photoreceptor degeneration for regenerative cell therapy

Grant Number:

5U24EY033272-05

Activity Code:

U24

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

9/30/2021

End Date:

7/31/2026

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Inherited retinal diseases (IRD), such as retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), are a common cause of visual impairment worldwide. Recent studies show that cell replacement therapy is a promising therapeutic option for IRD patients with severe retinal degenera...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Alice F Tarantal

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Exploratory lead · 34/100

Above-average budget

Active award

$787,215

FY 2026

Project Title

Translational Nonhuman Primate Regenerative Medicine and Gene Therapy/Genome Editing Resource Program

Grant Number:

5R24OD034056-04

Activity Code:

R24

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2026

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY / ABSTRACT There is a critical need for investigators to have ready access to a dedicated resource to evaluate new regenerative medicine and gene therapy/somatic cell genome editing applications with nonhuman primates for the treatment of human diseases. This application is focused o...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christopher Seet

UNIVERSITY OF CALIFORNIA LOS ANGELES, LOS ANGELES, CA

Exploratory lead · 34/100

Above-average budget

Active award

$569,863

FY 2026

Project Title

Death receptor signaling as an immune checkpoint in tumor-specific iPSC-T cell function

Grant Number:

5R37CA290185-02

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/5/2024

End Date:

11/30/2029

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

PROJECT SUMMARY Realizing the potential of cell therapies for cancer requires advances in manufacturing, cell potency, and in vivo durability of anti-tumor responses. In vitro generation of T cells from induced pluripotent stem cells (iPSCs) can advance these goals by enabling complex gene editing i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Eugene Pietzak

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 34/100

Above-average budget

Active award

$514,185

FY 2026

Project Title

Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer

Grant Number:

5R37CA276946-04

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2022

End Date:

11/30/2027

Why this may be worth a closer look

• Award size is strong enough to merit immediate review.

Project Abstract

Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer PI: Eugene Pietzak, MD SUMMARY Our overall goal is to develop therapies that selectively target molecular alterations responsible for progression of bladder cancers from non-invasive to the often-lethal muscle-i...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brooke Horist

BAYLOR COLLEGE OF MEDICINE, HOUSTON, TX

Exploratory lead · 34/100

Training-friendly

Active award

$50,114

FY 2026

Project Title

Disease mechanism and genetic therapy for a pathogenic STXBP1 variant

Grant Number:

5F31NS141322-02

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/16/2024

End Date:

12/15/2026

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY STXBP1 encodes syntaxin-binding protein 1, an essential protein for presynaptic neurotransmitter release. Patients with heterozygous pathogenic variants in STXBP1 are characterized by intellectual disability, epilepsy, movement, and psychiatric disorders, which are collectively terme...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sham Rampersaud

UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, SAN FRANCISCO, CA

Exploratory lead · 34/100

Training-friendly

Active award

$42,520

FY 2026

Project Title

Engineering best in class Acute Myeloid Leukemia (AML) CAR-T therapies by enhancing persistence and defining the immune landscape of AML

Grant Number:

5F31CA294978-02

Activity Code:

F31

Mechanism:

Training, Individual

Agency:

NIH

Start Date:

12/17/2024

End Date:

12/16/2027

Why this may be worth a closer look

• Activity code is useful for trainees, fellows, or mentored roles.

Project Abstract

PROJECT SUMMARY/ABSTRACT Acute Myeloid Leukemia (AML) is a devastating disease with <30% 5-year survival on current treatment regimens. This cancer, diagnosed in >20,000 Americans per year, has an urgent need for new therapeutic strategies. One of the most exciting new treatment strategies for blood...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Tuomas Tammela

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 32/100

Solid budget

Recent

Active award

$490,849

FY 2026

Project Title

Targeting stem-like cells and their niche in pancreatic cancer

Grant Number:

5R37CA244911-07

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2026

Project Abstract

PROJECT SUMMARY Less than 8% of pancreatic ductal adenocarcinoma (PDAC) patients are alive 5 years after diagnosis. PDAC is typically diagnosed at an advanced stage, limiting treatment options. Chemotherapies are the mainstay for advanced PDAC, though they produce incomplete responses. Thus, develop...

Research Terms

<21+ years old><Ablation><Acyltransferase><Adult><Adult Human><Alleles><Allelomorphs><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Basal Cell><Biology><C-K-RAS><Cancer Drug><Cancer Treatment><Cell Body><Cell Communication and Signaling><Cell Compartmentation><Cell Compartmentations><Cell Signaling><Cells><Characteristics><Colorectal Adenocarcinoma><Complex><Cycloamylose><Cyclodextrins><Cyclomaltooligosaccharides><DNA mutation><Data><Desmoplastic><Desmoplastic Reaction><Development><Diagnosis><Drug Delivery><Drug Delivery Systems><EC 2.3><Enzyme Gene><Enzymes><Failure><GEM model><GEMM model><Gene Expression><Gene Expression Monitoring><Gene Expression Pattern Analysis><Gene Expression Profiling><Genetic><Genetic Change><Genetic defect><Genetic mutation><Genetically Engineered Mouse><Growth Agents><Growth Factor><Growth Substances><HG38><HSP-90><HSP90><Heat-Shock Proteins 90><Heterogeneity><Human><Immune><Immunes><In Vitro><Intracellular Communication and Signaling><Investments><K-RAS2A><K-RAS2B><K-Ras><K-Ras 2A><K-Ras-2 Oncogene><KRAS><KRAS2><KRAS2 gene><Ki-RAS><LGR5><LGR5 gene><Large Bowel Adenocarcinoma><Large Intestine Adenocarcinoma><Ligands><Lineage Tracing><Lung Adenocarcinoma><MEKs><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Pancreatic Neoplasm><Malignant neoplasm of pancreas><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Murine><Mus><Mutation><Neoplasm Metastasis><Neoplastic Disease Chemotherapeutic Agents><Normal Tissue><Normal tissue morphology><Oncogene K-Ras><PDA model><PDAC Model><PDAC cancer cell><PDAC cell><PDX model><Pancreas><Pancreas Cancer><Pancreas Ductal Adenocarcinoma><Pancreas Neoplasms><Pancreas Tumor><Pancreatic><Pancreatic Cancer><Pancreatic Ductal Adenocarcinoma><Pancreatic Tumor><Patient derived xenograft><Patients><Phenotype><Population><Porcupines><Post-Translational Modification Protein/Amino Acid Biochemistry><Post-Translational Modifications><Post-Translational Protein Modification><Post-Translational Protein Processing><Posttranslational Modifications><Posttranslational Protein Processing><Primary Neoplasm><Primary Tumor><Progenitor Cells><Proliferating><Property><Protein Modification><Proteins Growth Factors><Proteomics><RASK2><Reporter><Reporting><Resistance><Role><SOX11><SOX11 gene><SRY-Box 11><SRY-Related HMG-Box Gene 11><Secondary Neoplasm><Secondary Tumor><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Solid Neoplasm><Solid Tumor><Stem Cell like><Testing><Therapeutic><Toxic effect><Toxicities><Transcript Expression Analyses><Transcript Expression Analysis><Translating><Tumor-Specific Treatment Agents><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><WNT Signaling Pathway><WNT signaling><addiction><addictive disorder><adulthood><analyze gene expression><anti-cancer drug><anti-cancer therapy><biological signal transduction><cancer cell><cancer metastasis><cancer progenitor><cancer progenitor cells><cancer progression><cancer stem cell><cancer stem like cell><cancer therapy><cancer-directed therapy><cell lineage analysis><cell lineage mapping><cell lineage tracing><cell lineage tracking><cellular lineage mapping><cellular lineage tracking><chemotherapy><conventional therapy><conventional treatment><developmental><gene expression analysis><gene expression assay><genetically engineered mouse model><genetically engineered murine model><genome mutation><hsp90 Family><improved><in vivo><inhibitor><inhibitor drug><inhibitor therapeutic><inhibitor therapy><insight><malignant progenitor><malignant stem cell><mutant><neoplasm progression><neoplastic progression><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><oncogenic progenitor><oncogenic stem cells><palmitoylation><pancreatic cancer cells><pancreatic ductal adenocarcinoma cell><pancreatic ductal adenocarcinoma model><pancreatic malignancy><pancreatic neoplasia><pancreatic neoplasm><pancreatic tumor cells><patient derived xenograft model><progenitor capacity><progenitor cell like><progenitor like cancer cell><progenitor-like><progenitor-like cell><proliferation capability><proliferation capacity><proliferation potential><proliferative capability><proliferative capacity><proliferative potential><resistance to therapy><resistant><resistant to therapy><response><social role><stem cell characteristics><stem cells><stem like cancer cell><stem-like><stem-like cell><stemness><subcutaneous><subdermal><therapeutic evaluation><therapeutic resistance><therapeutic target><therapeutic testing><therapy resistant><transcriptional profiling><treatment resistance><tumor><tumor cell metastasis><tumor progression><ubiquitin ligase><v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

John Matthew Higgins

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Exploratory lead · 32/100

Solid budget

Recent

Active award

$467,102

FY 2026

Project Title

Development of platform technology to measure kinetics and equilibrium concentration of sickle hemoglobin polymerization in single RBCs for drug potency assessment and patient risk stratification

Grant Number:

5R33HL173898-02

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/18/2025

End Date:

2/28/2027

Project Abstract

Sickle cell disease is caused by the pathologic polymerization of variant sickle hemoglobin (HbS) when deoxygenated. Polymerization of HbS inside red blood cells (RBCs) immediately compromises RBC morphology and blood flow properties, and it also triggers exacerbation of inflammation and cellular ad...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Selene Ingusci

UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PITTSBURGH, PA

Exploratory lead · 32/100

Solid budget

Recent

Active award

$433,710

FY 2026

Project Title

Epigenetically optimized replication-defective Herpes Simplex Virus vectors for multigenic gene therapy in Alzheimer’s disease.

Grant Number:

1R21AG098360-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

1/31/2028

Project Abstract

Abstract. Alzheimer's disease (AD) is the most common neurodegenerative disorder, significantly impacting older adults and placing a substantial economic burden on healthcare systems. Despite extensive research, including numerous clinical trials and drug development efforts, current treatments for ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joshua Leitch Bonkowsky

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

Exploratory lead · 32/100

Solid budget

Recent

Active award

$381,127

FY 2026

Project Title

Evaluation of Gene Replacement Therapy in In Vivo and Patient-Derived In Vitro Models of Vanishing White Matter Disease

Grant Number:

1R61NS140718-01A1

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2027

Project Abstract

Project Summary/Abstract Leukodystrophy with vanishing white matter (VWM) is a severe, progressive neurodegenerative disease that most commonly afflicts infants and children. There are no disease modifying treatments. VWM is caused by autosomal recessive mutations in the five subunit genes of the E...

Research Terms

<0-11 years old><AAV vector><AAV-based vector><Acute><Adeno-Associated Viruses><Aran-Duchenne disease><Architecture><Astrocytes><Astrocytus><Astroglia><Astroprotein><Ataxia><Ataxy><Attenuated><Automobile Driving><Autopsy><Biochemical><Biodistribution><Body Tissues><Brain><Brain Nervous System><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cerebrum><Cessation of life><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Complex><Coordination Impairment><Cruveilhier disease><DNA Therapy><DNA mutation><Data><Death><Degenerative Neurologic Disorders><Dependoparvovirus><Dependovirus><Deterioration><Disease><Disease Marker><Disorder><Dose><Dysfunction><Dyssynergia><EEG><EIF2B><EIF2B2><EIF2B2 gene><EIF2B5><EIF2B5 gene><EIF2BB><EIF2BE><Electroencephalogram><Electroencephalography><Encephalon><Engineering / Architecture><Ensure><Eukaryotic Initiation Factors><Eukaryotic Peptide Initiation Factors><Eukaryotic Translation Initiation Factors><Evaluation><Functional disorder><GFA-Protein><GFAP><Gait Analysis><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glia><Glial Cells><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Goals><Histologic><Histologically><Human><Impairment><In Vitro><Individual><Infant><Infection><Intracellular Communication and Signaling><Investigators><Kolliker's reticulum><LVWM><Lead><Leukoencephalopathy><MR Imaging><MR Tomography><MRI><MRI/EEG><MRI/electroencephalography><MRIs><Magnetic Resonance Imaging><Measures><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medulla Spinalis><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Motor><Murine><Mus><Mutant Strains Mice><Mutation><Myelin><NMR Imaging><NMR Tomography><Nature><Nerve Degeneration><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neuroglia><Neuroglial Cells><Neurologic><Neurologic Degenerative Conditions><Neurological><Neuron Degeneration><Non-neuronal cell><Nonneuronal cell><Nuclear Magnetic Resonance Imaging><Oligodendrocytes><Oligodendrocytus><Oligodendroglia><Oligodendroglia Cell><Onset of illness><Organoids><Outcome Measure><Pathogenesis><Pathology><Patients><Pb element><Pediatric Hospitals><Peripheral><Phase><Phenotype><Physiopathology><Post-Transcriptional Gene Silencing><Production><Proteins><Publishing><RNA Interference><RNA Silencing><RNAi><Regulation><Regulatory approval><Research Personnel><Research Resources><Researchers><Resources><Seizures><Sequence-Specific Posttranscriptional Gene Silencing><Serotyping><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spinal Cord><Spinal Muscular Atrophy><Strains Cell Lines><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Transgenes><Translating><Translations><Transplantation><Trauma><Variant><Variation><Viral><Viral Diseases><Viral Packaging><Virus Diseases><Virus Packagings><Weight><Weight Gain><Weight Increase><White Matter Disease><Wild Type Mouse><Work><Zeugmatography><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><astrocytic glia><attenuate><attenuates><attenuation><autosome><biological adaptation to stress><biological signal transduction><body weight gain><body weight increase><cerebral><clinical relevance><clinically relevant><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><disease onset><disorder onset><driving><gait examination><gene repair therapy><gene replacement therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><glial neural stem cell><glial progenitor><glial stem cell><heavy metal Pb><heavy metal lead><human model><improved><in vitro Model><in vivo><inhibitor><insight><kids><lead candidate><leukodystrophy><life span><lifespan><loss of function><mRNA Expression><magnetic resonance imaging/electroencephalography><measurable outcome><model of human><mouse model><mouse mutant><murine model><mutant mouse model><necropsy><nerve cement><neural degeneration><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroglial progenitor><neuroglial stem cells><neurological degeneration><neuronal degeneration><novel><oligodendrocyte precursor><oligodendrocyte precursor cell><oligodendrocyte progenitor><oligodendrocyte stem cell><outcome measurement><pathophysiology><postmortem><pre-clinical><preclinical><premature><prematurity><prevent><preventing><progenitor cell differentiation><progenitor differentiation><promoter><promotor><protein expression><reactioncrisis><regulatory authorization><regulatory certification><regulatory clearance><spasticity><stem><stem and progenitor differentiation><stem cell differentiation><stress response><stressreaction><stressor><substantia alba><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><transgene><translation><transplant><viral infection><virus infection><virus-induced disease><weights><white matter><wildtype mouse><wt gain><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Allison M Bradbury

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

Exploratory lead · 32/100

Solid budget

Recent

Active award

$381,127

FY 2026

Project Title

Evaluation of Gene Replacement Therapy in In Vivo and Patient-Derived In Vitro Models of Vanishing White Matter Disease

Grant Number:

1R61NS140718-01A1

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2027

Project Abstract

Project Summary/Abstract Leukodystrophy with vanishing white matter (VWM) is a severe, progressive neurodegenerative disease that most commonly afflicts infants and children. There are no disease modifying treatments. VWM is caused by autosomal recessive mutations in the five subunit genes of the E...

Research Terms

<0-11 years old><AAV vector><AAV-based vector><Acute><Adeno-Associated Viruses><Aran-Duchenne disease><Architecture><Astrocytes><Astrocytus><Astroglia><Astroprotein><Ataxia><Ataxy><Attenuated><Automobile Driving><Autopsy><Biochemical><Biodistribution><Body Tissues><Brain><Brain Nervous System><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cerebrum><Cessation of life><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Complex><Coordination Impairment><Cruveilhier disease><DNA Therapy><DNA mutation><Data><Death><Degenerative Neurologic Disorders><Dependoparvovirus><Dependovirus><Deterioration><Disease><Disease Marker><Disorder><Dose><Dysfunction><Dyssynergia><EEG><EIF2B><EIF2B2><EIF2B2 gene><EIF2B5><EIF2B5 gene><EIF2BB><EIF2BE><Electroencephalogram><Electroencephalography><Encephalon><Engineering / Architecture><Ensure><Eukaryotic Initiation Factors><Eukaryotic Peptide Initiation Factors><Eukaryotic Translation Initiation Factors><Evaluation><Functional disorder><GFA-Protein><GFAP><Gait Analysis><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glia><Glial Cells><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Goals><Histologic><Histologically><Human><Impairment><In Vitro><Individual><Infant><Infection><Intracellular Communication and Signaling><Investigators><Kolliker's reticulum><LVWM><Lead><Leukoencephalopathy><MR Imaging><MR Tomography><MRI><MRI/EEG><MRI/electroencephalography><MRIs><Magnetic Resonance Imaging><Measures><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medulla Spinalis><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Motor><Murine><Mus><Mutant Strains Mice><Mutation><Myelin><NMR Imaging><NMR Tomography><Nature><Nerve Degeneration><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neuroglia><Neuroglial Cells><Neurologic><Neurologic Degenerative Conditions><Neurological><Neuron Degeneration><Non-neuronal cell><Nonneuronal cell><Nuclear Magnetic Resonance Imaging><Oligodendrocytes><Oligodendrocytus><Oligodendroglia><Oligodendroglia Cell><Onset of illness><Organoids><Outcome Measure><Pathogenesis><Pathology><Patients><Pb element><Pediatric Hospitals><Peripheral><Phase><Phenotype><Physiopathology><Post-Transcriptional Gene Silencing><Production><Proteins><Publishing><RNA Interference><RNA Silencing><RNAi><Regulation><Regulatory approval><Research Personnel><Research Resources><Researchers><Resources><Seizures><Sequence-Specific Posttranscriptional Gene Silencing><Serotyping><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spinal Cord><Spinal Muscular Atrophy><Strains Cell Lines><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Transgenes><Translating><Translations><Transplantation><Trauma><Variant><Variation><Viral><Viral Diseases><Viral Packaging><Virus Diseases><Virus Packagings><Weight><Weight Gain><Weight Increase><White Matter Disease><Wild Type Mouse><Work><Zeugmatography><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><astrocytic glia><attenuate><attenuates><attenuation><autosome><biological adaptation to stress><biological signal transduction><body weight gain><body weight increase><cerebral><clinical relevance><clinically relevant><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><disease onset><disorder onset><driving><gait examination><gene repair therapy><gene replacement therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><glial neural stem cell><glial progenitor><glial stem cell><heavy metal Pb><heavy metal lead><human model><improved><in vitro Model><in vivo><inhibitor><insight><kids><lead candidate><leukodystrophy><life span><lifespan><loss of function><mRNA Expression><magnetic resonance imaging/electroencephalography><measurable outcome><model of human><mouse model><mouse mutant><murine model><mutant mouse model><necropsy><nerve cement><neural degeneration><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroglial progenitor><neuroglial stem cells><neurological degeneration><neuronal degeneration><novel><oligodendrocyte precursor><oligodendrocyte precursor cell><oligodendrocyte progenitor><oligodendrocyte stem cell><outcome measurement><pathophysiology><postmortem><pre-clinical><preclinical><premature><prematurity><prevent><preventing><progenitor cell differentiation><progenitor differentiation><promoter><promotor><protein expression><reactioncrisis><regulatory authorization><regulatory certification><regulatory clearance><spasticity><stem><stem and progenitor differentiation><stem cell differentiation><stress response><stressreaction><stressor><substantia alba><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><transgene><translation><transplant><viral infection><virus infection><virus-induced disease><weights><white matter><wildtype mouse><wt gain><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Paul Joseph Tesar

RESEARCH INST NATIONWIDE CHILDREN'S HOSP, COLUMBUS, OH

Exploratory lead · 32/100

Solid budget

Recent

Active award

$381,127

FY 2026

Project Title

Evaluation of Gene Replacement Therapy in In Vivo and Patient-Derived In Vitro Models of Vanishing White Matter Disease

Grant Number:

1R61NS140718-01A1

Activity Code:

R61

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/15/2026

End Date:

2/28/2027

Project Abstract

Project Summary/Abstract Leukodystrophy with vanishing white matter (VWM) is a severe, progressive neurodegenerative disease that most commonly afflicts infants and children. There are no disease modifying treatments. VWM is caused by autosomal recessive mutations in the five subunit genes of the E...

Research Terms

<0-11 years old><AAV vector><AAV-based vector><Acute><Adeno-Associated Viruses><Aran-Duchenne disease><Architecture><Astrocytes><Astrocytus><Astroglia><Astroprotein><Ataxia><Ataxy><Attenuated><Automobile Driving><Autopsy><Biochemical><Biodistribution><Body Tissues><Brain><Brain Nervous System><Cell Body><Cell Communication and Signaling><Cell Line><Cell Signaling><CellLine><Cells><Cerebrum><Cessation of life><Child><Child Youth><Children (0-21)><Children's Hospital><Clinical><Complex><Coordination Impairment><Cruveilhier disease><DNA Therapy><DNA mutation><Data><Death><Degenerative Neurologic Disorders><Dependoparvovirus><Dependovirus><Deterioration><Disease><Disease Marker><Disorder><Dose><Dysfunction><Dyssynergia><EEG><EIF2B><EIF2B2><EIF2B2 gene><EIF2B5><EIF2B5 gene><EIF2BB><EIF2BE><Electroencephalogram><Electroencephalography><Encephalon><Engineering / Architecture><Ensure><Eukaryotic Initiation Factors><Eukaryotic Peptide Initiation Factors><Eukaryotic Translation Initiation Factors><Evaluation><Functional disorder><GFA-Protein><GFAP><Gait Analysis><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glia><Glial Cells><Glial Fibrillary Acid Protein><Glial Fibrillary Acidic Protein><Glial Intermediate Filament Protein><Goals><Histologic><Histologically><Human><Impairment><In Vitro><Individual><Infant><Infection><Intracellular Communication and Signaling><Investigators><Kolliker's reticulum><LVWM><Lead><Leukoencephalopathy><MR Imaging><MR Tomography><MRI><MRI/EEG><MRI/electroencephalography><MRIs><Magnetic Resonance Imaging><Measures><Mediating><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Medulla Spinalis><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Motor><Murine><Mus><Mutant Strains Mice><Mutation><Myelin><NMR Imaging><NMR Tomography><Nature><Nerve Degeneration><Nervous System Degenerative Diseases><Neural Degenerative Diseases><Neural degenerative Disorders><Neurodegenerative Diseases><Neurodegenerative Disorders><Neuroglia><Neuroglial Cells><Neurologic><Neurologic Degenerative Conditions><Neurological><Neuron Degeneration><Non-neuronal cell><Nonneuronal cell><Nuclear Magnetic Resonance Imaging><Oligodendrocytes><Oligodendrocytus><Oligodendroglia><Oligodendroglia Cell><Onset of illness><Organoids><Outcome Measure><Pathogenesis><Pathology><Patients><Pb element><Pediatric Hospitals><Peripheral><Phase><Phenotype><Physiopathology><Post-Transcriptional Gene Silencing><Production><Proteins><Publishing><RNA Interference><RNA Silencing><RNAi><Regulation><Regulatory approval><Research Personnel><Research Resources><Researchers><Resources><Seizures><Sequence-Specific Posttranscriptional Gene Silencing><Serotyping><Signal Transduction><Signal Transduction Systems><Signaling><Specificity><Spinal Cord><Spinal Muscular Atrophy><Strains Cell Lines><Testing><Therapeutic><Tissues><Toxic effect><Toxicities><Transgenes><Translating><Translations><Transplantation><Trauma><Variant><Variation><Viral><Viral Diseases><Viral Packaging><Virus Diseases><Virus Packagings><Weight><Weight Gain><Weight Increase><White Matter Disease><Wild Type Mouse><Work><Zeugmatography><adeno associated virus group><adeno-associated viral vector><adeno-associated virus vector><astrocytic glia><attenuate><attenuates><attenuation><autosome><biological adaptation to stress><biological signal transduction><body weight gain><body weight increase><cerebral><clinical relevance><clinically relevant><cultured cell line><curative intervention><curative therapeutic><curative therapy><curative treatments><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><disease onset><disorder onset><driving><gait examination><gene repair therapy><gene replacement therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><glial neural stem cell><glial progenitor><glial stem cell><heavy metal Pb><heavy metal lead><human model><improved><in vitro Model><in vivo><inhibitor><insight><kids><lead candidate><leukodystrophy><life span><lifespan><loss of function><mRNA Expression><magnetic resonance imaging/electroencephalography><measurable outcome><model of human><mouse model><mouse mutant><murine model><mutant mouse model><necropsy><nerve cement><neural degeneration><neurodegeneration><neurodegenerative><neurodegenerative illness><neuroglial progenitor><neuroglial stem cells><neurological degeneration><neuronal degeneration><novel><oligodendrocyte precursor><oligodendrocyte precursor cell><oligodendrocyte progenitor><oligodendrocyte stem cell><outcome measurement><pathophysiology><postmortem><pre-clinical><preclinical><premature><prematurity><prevent><preventing><progenitor cell differentiation><progenitor differentiation><promoter><promotor><protein expression><reactioncrisis><regulatory authorization><regulatory certification><regulatory clearance><spasticity><stem><stem and progenitor differentiation><stem cell differentiation><stress response><stressreaction><stressor><substantia alba><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic target><transgene><translation><transplant><viral infection><virus infection><virus-induced disease><weights><white matter><wildtype mouse><wt gain><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jonathan L. Coloff

UNIVERSITY OF ILLINOIS AT CHICAGO, Chicago, IL

Exploratory lead · 32/100

Solid budget

Recent

Active award

$359,689

FY 2026

Project Title

Targeting Serine Auxotrophy in Luminal Breast Cancer

Grant Number:

4R37CA251216-06

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2021

End Date:

2/29/2028

Project Abstract

PROJECT SUMMARY/ABSTRACT A major challenge of targeting metabolism for cancer therapy is pathway redundancy, where multiple sources of critical nutrients can diminish the effects of metabolic therapies. An example of this can be found in recent attempts to target the serine synthesis pathway for ca...

Research Terms

<3-phosphoserine aminotransferase><3-phosphoserine oxoglutarate transaminase><ASP-1><Acute T Cell Leukemia><Acute T-Cell Lymphoblastic Leukemia><Acute T-Cell Lymphocytic Leukemia><Acute T-Lymphocytic Leukemia><Address><Amino Acids><Anabolism><Area><Asparaginase II><Asparagine><Asparagine Deaminase><Biological Markers><Breast Cancer><Breast Cancer Cell><Breast Cancer Patient><Breast Neoplasms><Breast Tumor Patient><Breast Tumors><Cancer Patient><Cancer Treatment><Cell Body><Cells><Circulation><Clinical><Colaspase><Data><Diet><Disease Resistance><Disparities><Disparity><Elspar><Endocrine Therapy><Environment><Enzyme Gene><Enzymes><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Gene Expression><Gene Transcription><Generalized Growth><Genes><Genetic Transcription><Goals><Growth><Hormonal Therapy><Human><In Vitro><Intermediary Metabolism><Kidrolase><Knowledge><L asparagine amidohydrolase><L-ASP><L-Asparaginase><L-Asparagine><L-Serine><Lcf-ASP><Malignant Breast Neoplasm><Malignant Cell><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Mammary Cancer><Mammary Neoplasms><Mediating><Metabolic><Metabolic Pathway><Metabolic Processes><Metabolism><Methylation><Mice><Mice Mammals><Modern Man><Murine><Mus><Non-Essential Amino Acid><Nonessential Amino Acid><Normal Tissue><Normal tissue morphology><Nutrient><Outcome><Pathway interactions><Patients><Phenotype><Phosphoserine aminotransferase><Position><Positioning Attribute><Precursor T Lymphoblastic Leukemia><Prognosis><Proliferating><RNA Expression><Relapse><Research><Research Resources><Resistance development><Resistant development><Resources><Serasa><Serine><Source><Starvation><T-Cell Type Acute Leukemia><T-lineage acute lymphoblastic leukemia><Testing><Therapeutic><Tissue Growth><Transcription><Translating><Tumor Tissue><amino acid metabolism><aminoacid><anti-cancer therapy><asparaginase><auxotrophy><bio-markers><biologic marker><biomarker><biosynthesis><breast tumor cell><cancer cell><cancer cell metabolism><cancer metabolism><cancer therapy><cancer-directed therapy><candidate identification><developing resistance><dietary><diets><epigenetic gene silencing><epigenetic silencing><epigenetically><experience><experiment><experimental research><experimental study><experiments><extracellular><hormone therapy><hydroxypyruvate-P glutamate transaminase><in vivo><individuals with breast cancer><inhibitor><malignant breast tumor><mammary tumor><metabolic phenotype><metabotype><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><ontogeny><pathway><patients with breast cancer><person with breast cancer><pharmacologic><prevent><preventing><prospective><resistance to disease><resistance to therapy><resistant disease><resistant to disease><resistant to therapy><side effect><standard of care><success><targeted cancer therapy><therapeutic resistance><therapeutic target><therapy resistant><treatment resistance><tumor><tumor cell metabolism><tumor metabolism><tumor xenograft><uptake>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Joshua D Brody

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, NY

Exploratory lead · 32/100

Solid budget

Recent

Active award

$351,924

FY 2026

Project Title

Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination

Grant Number:

5R37CA246239-07

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2026

Project Abstract

PROJECT SUMMARY Checkpoint blockade therapy of cancer has had tremendous impact, but still only a subset of patients respond. One possible explanation is that some tumor types do not have a sufficient number of somatic mutations to produce tumor-associated-antigens (TAA) that can be targeted by the...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Angela L. Roger

DUKE UNIVERSITY, DURHAM, NC

Exploratory lead · 30/100

Very recent

Active award

$249,000

FY 2026

Project Title

Novel Adjunctive Therapies for Pompe Disease

Grant Number:

5R00HL161420-05

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/19/2024

End Date:

1/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Candidate & Environment: The short and long-term goals of the candidate are to gain skills, knowledge, and experience necessary to become a successful independent investigator in gene therapy for neuromuscular diseases (NMDs) with respiratory pathology, such as Pompe disease. Duke Un...

Research Terms

<1,4-alpha-D-Glucan glucohydrolase><AAV vector><AAV-based vector><Acid Maltase><Acid Maltase Deficiency Disease><Acute><Address><Affect><Airway failure><Amyloglucosidase><Architecture><Automobile Driving><Autophagocytosis><Autophagosome><BBB crossing><Blood><Blood Reticuloendothelial System><Brain><Brain Nervous System><Breathing><CNS plasticity><Cardiac><Cell Therapy><Childhood><Clinical><Clinical Treatment><Clinical Trials><Collaborations><Complex><DNA Therapy><DNA mutation><Disease><Disorder><Distress><Dysfunction><Encephalon><Engineering / Architecture><Environment><Enzyme Gene><Enzymes><Exo-1,4-alpha-Glucosidase><FDA approved><FK506 Binding Protein 12-Rapamycin Associated Protein 1><FKBP12 Rapamycin Complex Associated Protein 1><FRAP1><FRAP1 gene><FRAP2><Foundations><Functional disorder><Future><GaAs><Gene Delivery><Gene Transfer Clinical><Generalized Glycogenosis><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><Glucan 1,4-alpha-Glucosidase><Glucan 1,4-α-Glucosidase><Glucoamylase><Glycogen><Glycogen Storage Disease><Glycogen storage disease type II><Glycogenosis><Glycogenosis 2><Glycogenosis Type II><Goals><Health><Heart><Heart Hypertrophy><Human><Hypoxia><Hypoxic><Immune response><Immunohistochemistry><Immunohistochemistry Cell/Tissue><Immunohistochemistry Staining Method><Immunosuppressants><Immunosuppressive Agents><Immunosuppressive drug><Immunosuppressive treatment><Infant><Intervention><Investigators><Knowledge><Lead><Location><Lysosomal alpha-1,4-Glucosidase Deficiency Disease><Lysosomal alpha-Glucosidase><Lysosomal α-Glucosidase><Lysosomes><Mechanistic Target of Rapamycin><Mentors><Metabolic><Methods><Mice><Mice Mammals><Modern Man><Molecular><Motor><Motor Cell><Motor Neurons><Murine><Mus><Muscle><Muscle Tissue><Muscle Weakness><Muscle function><Muscular Weakness><Mutation><Myocardium><Nerve><Neurobiology><Neuromuscular Diseases><Neuronal Plasticity><Nutrient><Organelles><Output><Oxygen Deficiency><Pathology><Pathway interactions><Patient Care><Patient Care Delivery><Patients><Pb element><Phase><Physiopathology><Pompe Disease><Process><Protein Replacement Therapy><Proteins><Proteomics><RAFT1><Rapamune><Rapamycin><Recombinant adeno-associated virus><Recombinant adeno-associated virus (rAAV)><Recombinants><Recycling><Research><Research Personnel><Researchers><Respiration><Respiratory Aspiration><Respiratory Failure><Respiratory Inspiration><Respiratory Muscles><Respiratory Therapy><Respiratory distress><Respiratory physiology><Scientist><Secondary to><Sirolimus><Skeletal Muscle><Testing><Therapeutic><Translating><Universities><Ventilatory Muscles><Viral Genes><Voluntary Muscle><Whole Body Plethysmography><Work><acid alpha glucosidase><acid maltase deficiency><acid α-glucosidase><adeno-associated viral vector><adeno-associated virus vector><alpha 1,4 glucosidase deficiency><autophagy><blood-brain barrier crossing><bloodbrain barrier crossing><cardiac hypertrophy><cardiac muscle><care for patients><care of patients><career><caring for patients><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><central nervous system plasticity><clinical care><clinical intervention><clinical therapy><driving><enzyme deficiency><enzyme replacement therapy><enzyme replacement treatment><experience><experiment><experimental research><experimental study><experiments><gallium arsenide><gamma-Amylase><gene repair therapy><gene replacement><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><heart muscle><heavy metal Pb><heavy metal lead><host response><immune suppressive agent><immune suppressor><immune system response><immunoresponse><immunosuppressive substance><immunosuppressor><improved><infancy><infantile><innovate><innovation><innovative><inspiration><lysosomal acid alpha glucosidase><lysosomal acid α glucosidase><mTOR><mammalian target of rapamycin><motoneuron><motor recovery><mouse model><murine model><muscular><myoneural disorder><neural><neural plasticity><neurobiological><neuromuscular degenerative disorder><neuromuscular disorder><neurophysiological><neurophysiology><neuroplastic><neuroplasticity><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathophysiology><pathway><pediatric><preservation><prevent><preventing><rAAV><recombinant AAV><repair><repaired><respiratory><respiratory disease therapy><respiratory disease/disorder therapy><respiratory disorder therapy><respiratory function><respiratory mechanism><skeletal><skills><standard of care><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><trial regimen><trial treatment>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Nicole D. Marino

UNIVERSITY OF PENNSYLVANIA, PHILADELPHIA, PA

Exploratory lead · 30/100

Very recent

Active award

$249,000

FY 2026

Project Title

Discovery of novel phage-bacterial interactions

Grant Number:

5R00GM143476-05

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

9/7/2021

End Date:

12/31/2026

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY Interactions between bacteria and their viruses (phages) are among the most ubiquitous in nature and have yielded transformative tools for genetic engineering, such as restriction enzymes and CRISPR-Cas. More than three dozen new bacterial immune systems have recently been discovered...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Shan Lin

SEATTLE CHILDREN'S HOSPITAL, SEATTLE, WA

Exploratory lead · 30/100

Very recent

Active award

$248,977

FY 2026

Project Title

Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia

Grant Number:

5R00CA263161-05

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project Summary Acute myeloid leukemia (AML) remains a devastating illness, with a clear need for the development of novel anti-leukemic therapy. Inhibition of anti-apoptotic BCL2 family proteins to directly stimulate apoptosis provides a feasible therapeutic strategy for treating AML. Venetoclax, a...

Research Terms

<20S Catalytic Proteasome><20S Core Proteasome><20S Proteasome><20S Proteosome><AML - Acute Myeloid Leukemia><APF-1><ATP-Dependent Proteolysis Factor 1><Acute Myeloblastic Leukemia><Acute Myelocytic Leukemia><Acute Myelogenous Leukemia><Acute leukemia><Advisory Committees><Apoptosis><Apoptosis Pathway><Apoptosis Regulation Gene><Apoptosis Regulator><Apoptotic><Award><B-Cell CLL/Lymphoma 2 Gene><B-cell lymphoma-extra large><B-cell lymphoma/leukemia-2><BCL-XL><BCL2><BCL2 gene><BCL2-Like 1><BCL2-Related Gene><BCL2-Related Protein, Long Isoform><BCL2-Related Protein, Short Isoform><BCL2L1><BCL2L1 gene><BCLX><BCLXL><BCLXS><Bcl-2><Biochemical><Biological><Business-Friendly Atmosphere><CRISPR><CRISPR approach><CRISPR based approach><CRISPR editing screen><CRISPR method><CRISPR methodology><CRISPR screen><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based screen><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas system><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 screen><CRISPR/Cas9 technology><Cancers><Cas nuclease technology><Cell Death><Cell Function><Cell Physiology><Cell Process><Cellular Expansion><Cellular Function><Cellular Growth><Cellular Physiology><Cellular Process><Clinic><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Collaborations><Communities><Complex thinking><Critical Thinking><DF/HCC><Dana-Farber Cancer Institute><Data><Dependence><Development><Dropout><Drug Therapy><Drugs><E3 Ligase><E3 Ubiquitin Ligase><Enzyme Gene><Enzymes><Essential Genes><Evaluative Thinking><Exhibits><Family member><Generalized Growth><Genetic><Goals><Growth><HDM2><HMG-20><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><High Mobility Protein 20><In Vitro><Knock-out><Knockout><Knowledge><Laboratories><MCL-1><MCL1><MCL1 gene><MDM2><MDM2 gene><MDMX protein><Macropain><Macroxyproteinase><Maintenance><Malignant Cell><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Mdm-2 protein><Mediating><Medication><Mentorship><Mitochondria><Molecular><Multicatalytic Proteinase><Oncogenic><Oncoprotein MDM2><Patients><Pediatric Oncology><Pharmaceutical Preparations><Pharmacological Treatment><Pharmacotherapy><Postdoc><Postdoctoral Fellow><Pre-Clinical Model><Preclinical Models><Prognosis><Programmed Cell Death><Prosome><Proteasome><Proteasome Endopeptidase Complex><Protein Family><Proteins><Proteosome><Regulation><Regulatory Protein><Research><Research Associate><Research Resources><Resistance><Resistance development><Resistant development><Resources><Role><Sight><Solid><Specificity><Stress><Subcellular Process><Substrate Interaction><System><Task Forces><Technical Expertise><Therapeutic><Tissue Growth><Training><Translating><Ubiquitilation><Ubiquitin><Ubiquitin Protein Ligase><Ubiquitin-Activating Enzyme E1><Ubiquitin-Activating Enzymes><Ubiquitin-Conjugating Enzyme E2><Ubiquitin-Conjugating Enzymes><Ubiquitin-Protein Ligase Complexes><Ubiquitin-Protein Ligase E3><Ubiquitination><Ubiquitination Activating Enzyme E1><Ubiquitinoylation><Vision><Xenograft Model><acute granulocytic leukemia><acute granulocytic leukemia cell><acute myeloblastic leukemia cell><acute myelocytic leukemia cell><acute myelogenous leukemia cell><acute myeloid leukemia><acute myeloid leukemia cell><acute nonlymphocytic leukemia cell><advisory team><bcl-2 Genes><biologic><business-friendly environment><cancer cell><cancer survival><career><ced9 homolog><cell growth><clinical applicability><clinical application><clustered regularly interspaced short palindromic repeats screen><collaborative atmosphere><collaborative environment><developing resistance><developmental><drug intervention><drug treatment><drug/agent><frontier><functional genomics><genetic regulatory protein><human model><improved><in vivo><inhibitor><insight><interactive atmosphere><interactive environment><interdisciplinary atmosphere><interdisciplinary environment><leukemia><leukemia treatment><leukemic therapy><leukemogenesis><malignancy><mdm-2 oncogene protein><mdm2 protein><mitochondrial><model of human><multicatalytic endopeptidase complex><myeloid cell leukemia 1><myeloid cell leukemia sequence 1><myeloid leukemia cell differentiation protein><necrocytosis><neoplasm/cancer><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><older adult><older adulthood><ontogeny><p53-Binding Protein MDM2><patient subclass><patient subcluster><patient subgroups><patient subpopulations><patient subsets><patient subtypes><pediatric department><peer-group atmosphere><peer-group environment><pharmaceutical intervention><pharmacologic><pharmacological intervention><pharmacological therapy><pharmacology intervention><pharmacology treatment><pharmacotherapeutics><post-doc><post-doctoral><post-doctoral trainee><prevent><preventing><programs><regulatory gene product><research associates><resistant><skills><social role><targeted cancer therapy><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><technical skills><therapeutic agent development><therapeutic development><therapeutic target><translational opportunities><translational potential><tumor><ubiquination><ubiquitin conjugation><ubiquitin-protein ligase><visual function><xenograft transplant model><xenotransplant model>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

KEITH R JEROME

FRED HUTCHINSON CANCER CENTER, SEATTLE, WA

Exploratory lead · 30/100

Very recent

Active award

$232,558

FY 2026

Project Title

AAV-delivered meganucleases for durable control of genital HSV disease

Grant Number:

1R21AI195413-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/13/2026

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Project summary Herpes simplex virus (HSV) establishes latency in ganglionic neurons of the peripheral nervous system. Latent HSV can later reactivate, causing recurrent disease and possible transmission to new hosts. Current anti-HSV therapy is inadequate, in that it does not eliminate latent HSV, ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

HEATHER C. MEFFORD

ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TN

Exploratory lead · 30/100

Very recent

Active award

$231,250

FY 2026

Project Title

Investigating the role of RHOBTB2 in DEE to develop novel therapies

Grant Number:

5R21NS142525-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

ABSTRACT The past decade has seen an explosion of gene discovery in the developmental and epileptic encephalopathies (DEEs) due to rapid advances in sequencing technologies. CurrenUy, nearly 50% of patients will receive a precise genetic diagnosis, yet few diagnoses have an effective, targeted treat...

Research Terms

<3-D><3-Dimensional><3D><Accounting><Adaptor Protein><Adaptor Protein Gene><Adaptor Signaling Protein><Adaptor Signaling Protein Gene><Affect><Alleles><Allelic Loss><Allelomorphs><Anti-Oncogenes><Antimorphic mutation><Antioncogenes><Antisense Agent><Antisense Oligonucleotides><Apoptosis><Apoptosis Pathway><BTB Domain><BTB/POZ Domain><Brain><Brain Nervous System><Cancer Suppressor Genes><Cell Body><Cell Cycle Control><Cell Cycle Regulation><Cell model><Cells><Cellular Matrix><Cellular model><Complex><Cullin Homolog 3><Cytoskeletal System><Cytoskeleton><Decreased Muscle Tone><Defect><Development><Diagnosis><Disease><Disorder><Dominant Negative><Dominant-Negative Mutant><Dominant-Negative Mutation><Down-Regulation><Dyskinesia Syndromes><Emerogenes><Encephalon><Epilepsy><Epileptic Seizures><Epileptics><Exhibits><Explosion><Gene Alteration><Gene Mutation><Genes><Genetic Diseases><Heterozygote><Human><Hypomyotonia><Hypotonia><Impairment><Individual><Intractable Epilepsy><Loss of Heterozygosity><Malignant Cell><Membrane><Metabolic Protein Degradation><Microcephaly><Modeling><Modern Man><Molecular><Molecular Tumor Suppression><Movement Disorder Syndromes><Movement Disorders><Muscle Hypotony><Muscle Tone Poor><Muscle hypotonia><Muscular Hypotonia><Nerve Cells><Nerve Unit><Neural Cell><Neural Development><Neurocyte><Neurons><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Organoids><Other Genetics><POZ Domain><Parents><Pathogenicity><Patients><Phenotype><Precision therapeutics><Programmed Cell Death><Protein Turnover><Proteins><Recessive Oncogenes><Recurrence><Recurrent><Refractory epilepsy><Regulation><Regulatory Protein Degradation><Role><Seizure Disorder><Technology><Testing><Therapeutic Intervention><Tumor Suppressing Genes><Tumor Suppression><Tumor Suppressor Genes><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><Variant><Variation><adapter protein><antisense oligo><cancer cell><cell engineering><cellular engineering><cullin-3><developmental><developmental disease><developmental disorder><discover genes><disease phenotype><drug-resistant epilepsy><effective therapy><effective treatment><epilepsia><epileptic encephalopathies><epileptogenic><experience><experiment><experimental research><experimental study><experiments><gene defect><gene discovery><gene product><genetic condition><genetic diagnosis><genetic disorder><genetic disorder diagnosis><heterozygosity><iPS><iPSC><iPSCs><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><intervention therapy><intracellular skeleton><knock-down><knockdown><loss of function><membrane structure><micrencephaly><microencephaly><mutant><mutant allele><neurodevelopment><neuronal><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next generation therapeutics><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><oncosuppressor gene><overexpress><overexpression><parent><postnatal><precision therapies><precision treatment><protein degradation><recruit><rho><social role><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><three dimensional><trafficking><ubiquitin ligase>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

ELISABETH D MARTINEZ

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Exploratory lead · 30/100

Very recent

Active award

$230,010

FY 2026

Project Title

Jumonji KDM4A drives targetable oncogenic programs in small cell lung cancer

Grant Number:

5R21CA280319-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Abstract Small cell lung cancer (SCLC) is a recalcitrant disease that rapidly acquires drug resistance and for which no mechanistically novel drug therapies have been developed over the last several decades. SCLC responds poorly to second line therapy or immunotherapy. There is therefore a challengi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

JINXING Li

MICHIGAN STATE UNIVERSITY, EAST LANSING, MI

Exploratory lead · 30/100

Very recent

Active award

$211,400

FY 2026

Project Title

Magnetic Microrobots Assist AAV4 for CFTR Gene Delivery Through Mucus Barrier

Grant Number:

5R21EB037346-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

5/10/2025

End Date:

3/31/2028

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Scientific Abstract Cystic fibrosis (CF) is caused by mutations in the gene that encodes the CF transmembrane conductance regulator (CFTR) anion channel. In CF patients, the loss of CFTR impairs airway host defense mechanisms, leading to chronic airway infections and inflammation, which are the pri...

Research Terms

<2-photon><3-D print><3-D printer><3D Print><3D printer><3D printing><4-dimensional><Adeno-Associated Viruses><Affect><Airway infections><Animal Model><Animal Models and Related Studies><Animals><Anions><Associated Viruses><Beta Proprotein Interleukin 1><Bicarbonates><Binding><Biological><Biology><Blood><Blood Reticuloendothelial System><Body Tissues><CF airway><CF airway epithelia><CF lung disease><CF mice><CF mouse model><CF mucus><CF patients><CFTR><CFTR Protein><Cause of Death><Chronic><Clinical><Complementary DNA><Coupling><Cystic Fibrosis><Cystic Fibrosis Transmembrane Conductance Regulator><DNA Therapy><DNA mutation><Defect><Dependoparvovirus><Dependovirus><Diffusion><Engineering><Epithelial Cells><Family suidae><Four-dimensional><Gene Alteration><Gene Delivery><Gene Mutation><Gene Transfer Clinical><Genes><Genetic Change><Genetic Diseases><Genetic Intervention><Genetic defect><Genetic mutation><Goals><Goblet Cells><HCO3><Host Defense><Host Defense Mechanism><Human><Hydrogels><Hydrogen Carbonates><Hydrolysis><IL-1 beta><IL-1 β><IL-1-b><IL-1β><IL1-Beta><IL1-β><IL1B Protein><IL1F2><IL1β><Image><Immune><Immunes><In Vitro><Inhalation><Inhaling><Injections><Interleukin 1beta><Interleukin-1 beta><Interleukin-1β><Liquid substance><Lung><Lung Diseases><Lung Parenchyma><Lung Respiratory System><Lung Tissue><Lung infections><Lymphatic cell><Lymphocyte><Lymphocytic><Magnetic Nanoparticle imaging><Magnetic Particle Imaging><Magnetic nanoparticles><Magnetism><Mediating><Medicine><Membrane><Metaplasia><Metaplastic Change><Methods><Mice><Mice Mammals><Modern Man><Molecular Interaction><Morbidity><Mucous body substance><Mucoviscidosis><Mucus><Murine><Mus><Mutation><Obstruction><Organ><PEG-DA><Pancreas><Pancreatic><Pathogenesis><Patients><Penetration><Pigs><Pore Proteins><Position><Positioning Attribute><Pre-Clinical Model><Preclinical Models><Preinterleukin 1 Beta><Printing><Property><Pulmonary Cystic Fibrosis><Pulmonary Diseases><Pulmonary Disorder><Research><Respiratory Epithelium><Respiratory Infections><Respiratory Tract Infections><Robot><Rotation><Satellite Viruses><Serotyping><Structure of parenchyma of lung><Structure of respiratory epithelium><Suidae><Swine><System><Techniques><Testing><The Jackson Laboratory><Therapeutic><Tissues><Transfection><Translating><Treatment Efficacy><Tropism><Viral Vector><Viscosity><Work><active method><active technique><active treatment><adeno associated virus group><airflow limitation><airflow obstruction><airway epithelium><airway epithelium inflammation><airway inflammation><airway injury><airway limitation><airway obstruction><airway surface liquid><biologic><cDNA><cystic fibrosis airway><cystic fibrosis airway epithelia><cystic fibrosis lung><cystic fibrosis lung disease><cystic fibrosis mouse><cystic fibrosis mouse model><cystic fibrosis mucus><cystic fibrosis patients><cystic fibrosis transmembrane regulator><diffused><diffuses><diffusing><diffusions><disease of the lung><disorder of the lung><fluid><gene defect><gene repair therapy><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic therapy><genome mutation><genomic therapy><image guidance><image guided><imaging><imaging in vivo><impaired airway><improved><in vivo><in vivo imaging><individuals with CF><individuals with cystic fibrosis><injured airway><innovate><innovation><innovative><intervention efficacy><liquid><lung disorder><lymph cell><magnetic><magnetic field><membrane structure><microrobot><microrobotics><model of animal><mortality><mouse model><mucous><murine model><mutant allele><nano meter scale><nano meter sized><nano robotics><nanometer scale><nanometer sized><nanorobotics><nanoscale><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapy approaches><new treatment approach><new treatment strategy><novel><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapy approach><obstructed airflow><obstructed airway><patients with CF><patients with cystic fibrosis><poly(ethylene glycol)diacrylate><poly(ethyleneglycol) diacrylate><polyethyleneglycol diacrylate><porcine><prevent><preventing><pulmonary infections><quantum><respiratory airway obstruction><respiratory inflammation><respiratory injury><respiratory tract epithelium><respiratory tract inflammation><respiratory tract injury><restoration><robot assistance><robot assisted><robotic assistance><site targeted delivery><suid><targeted delivery><therapeutic efficacy><therapy efficacy><three dimensional printing><transduction efficiency><two-photon><vector><viscoelasticity>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Jialiang Liang

UNIVERSITY OF CINCINNATI, CINCINNATI, OH

Exploratory lead · 30/100

Very recent

Active award

$202,500

FY 2026

Project Title

Engineering RNA biodevices for precise modulation of fibroblasts to boost cardiac reprogramming

Grant Number:

5R21HL177541-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2026

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

SUMMARY: Myocardial infarction (MI)-induced cardiovascular diseases remain a major global cause of death. Post-MI excessive fibrosis can lead to adverse remodeling and eventual heart failure. Unfortunately, there are limited therapies to prevent fibrosis and hinder heart failure progression. In vivo...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Punam Malik

CINCINNATI CHILDRENS HOSP MED CTR, CINCINNATI, OH

Exploratory lead · 30/100

Very recent

Active award

$187,584

FY 2026

Project Title

Mechanisms underlying increased risk of hematological malignancy in sickle cell disease.

Grant Number:

5R21CA299166-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2025

End Date:

3/31/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

PROJECT SUMMARY/ABSTRACT Sickle cell disease (SCD) affects millions globally and results in recurrent vascular occlusions, chronic organ damage and early death. While childhood mortality is reduced and patients are surviving to adulthood with current therapies, an increased risk of hematological mal...

Research Terms

<2'-deoxy-guanosine><21+ years old><Acceleration><Active Oxygen><Address><Adult><Adult Human><Affect><Age><Age Years><Allogenic><Anemia><Antioxidants><Autologous><Blood><Blood Precursor Cell><Blood Reticuloendothelial System><Blood Vessels><Blood erythrocyte><Bone Marrow><Bone Marrow Reticuloendothelial System><Bone Marrow Stem Cell Transplantation><Breeding><COCA1><Cancer Genes><Cancer-Promoting Gene><Cardiovascular Diseases><Cell Communication and Signaling><Cell Signaling><Cessation of life><Childhood><Chronic><Chronic stress><Clonal expansion of hematopoietic cells><Clonal expansion of hematopoietic stem cells><Clonal hematopoietic expansion><Clone Cells><Custom><DNA><DNA Damage><DNA Injury><DNA Therapy><DNA lesion><DNA mutation><Death><Deoxyguanosine><Deoxyribonucleic Acid><Development><Disease><Disorder><Engraftment><Erythrocytes><Erythrocytic><Event><Experimental Models><FCC1><FDA approved><Frequencies><Gene Frequency><Gene Modified><Gene Transfer Clinical><Gene variant><General Population><General Public><Genes><Genetic Change><Genetic Intervention><Genetic defect><Genetic mutation><HSC regeneration><HSC self-renewal><HSC transplantation><Hb SS disease><HbSS disease><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Cellular Control Mechanisms><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Progenitor Cells><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hematopoietic stem cells><Hemoglobin S Disease><Hemoglobin sickle cell disease><Hemoglobin sickle cell disorder><Hereditary><Heterozygote><Human><Incidence><Inflammation><Inflammatory><Inherited><Intracellular Communication and Signaling><Knock-out><Knockout><Lesion><Licensing><MSH2><MSH2 gene><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Marrow erythrocyte><Mediating><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Molecular><Murine><Mus><Mutation><NGS Method><NGS system><Natural regeneration><Oncogenes><Oral><Organ><Oxidative Stress><Oxidative Stress Induction><Oxygen Radicals><Pain><Painful><Patients><Persons><Predisposition><Prevalence><Pro-Oxidants><Quercetin><Reactive Oxygen Species><Recurrence><Recurrent><Red Blood Cells><Red Cell><Regeneration><Risk><Shapes><Sickle Cell Anemia><Signal Transduction><Signal Transduction Systems><Signaling><Somatic Mutation><Stress><Susceptibility><Transforming Genes><Transplantation><adulthood><age associated><age correlated><age dependent><age linked><age related><age specific><ages><allelic frequency><allelic variant><biological signal transduction><blood cancer><blood cell formation><blood cell progenitor><blood corpuscles><blood progenitor><blood stem cell><blood stem cell regeneration><blood stem cell self-renewal><blood stem cell transplantation><blood vessel occlusion><blood-forming stem cell><cancer of blood><cancer of the blood><cardiovascular disorder><clonal expansions in the blood><clonal hematopoiesis><clones in hematopoietic cells><conditioning><curative intervention><curative therapeutic><curative therapy><curative treatments><customs><deep sequencing><developmental><early onset><experiment><experimental research><experimental study><experiments><gain of function><gene modification><gene repair><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genetic variant><genetically modified><genome mutation><genomic therapy><genomic variant><genotoxicity><hematopoietic cell clones><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor><hematopoietic progenitor cell self-renewal><hematopoietic progenitor cell transplantation><hematopoietic stem cell clonality><hematopoietic stem cell regeneration><hematopoietic stem cell self-renewal><hematopoietic stem progenitor cell><hemopoietic><hemopoietic progenitor><hemopoietic stem cell><heterozygosity><high risk><leukemia><life span><lifespan><loss of function><mitochondrial><mortality><mutant><next gen sequencing><next generation sequencing><nextgen sequencing><pediatric><polyphenol><reconstitute><reconstitution><regenerate><regeneration of blood stem cells><regenerative><regenerative cell><risk mitigation><self - renewal in hematopoietic stem cells><sickle cell disease><sickle cell disorder><sickle disease><sicklemia><sickling><somatic variant><stem cell bone marrow transplantation><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><trait><transition mutation><transplant><transversion mutation><vascular><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew H Porteus

STANFORD UNIVERSITY, STANFORD, CA

Exploratory lead · 30/100

Very recent

Active award

$30,000

FY 2026

Project Title

Center for Definitive and Curative Medicine Annual Symposium

Grant Number:

1R13TR006103-01

Activity Code:

R13

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

3/23/2026

End Date:

2/28/2027

Why this may be worth a closer look

• Award timing is recent enough to matter for outreach and opportunity scanning.

Project Abstract

Summary The transformative advancements in cell and gene therapy have significantly enhanced our understanding and treatment of congenital diseases and regenerative medicine. As we approach the 10th annual Center for Definitive and Curative Medicine (CDCM) symposium, scheduled for March 30-31, 2026,...

Research Terms

<0-11 years old><AI system><Academia><Acceleration><Achievement><Achievement Attainment><Address><Area><Artificial Intelligence><Automobile Driving><CAR T cells><CAR modified T cells><CAR-T><CAR-Ts><Case Study><Case-Base Studies><Cell Body><Cell Components><Cell Structure><Cell Therapy><Cells><Cellular Structures><Child><Child Youth><Children (0-21)><Clinic><Clinical Research><Clinical Study><Clinical Trials><Collaborations><Communities><Complex><Computer Reasoning><DNA Therapy><Development><Disease><Disorder><Educational workshop><Ensure><Event><Exposure to><Family><Federal Government><Feedback><Financial Support><Fostering><Friends><Funding><Future><Gene Transfer Clinical><Genes><Genetic><Genetic Intervention><Goals><Government><HSC transplantation><Health Care><Health Sciences><Hematopoietic Stem Cell Transplant><Hematopoietic Stem Cell Transplantation><Hour><Industry><Interdisciplinary Research><Interdisciplinary Study><Investigators><Knowledge><Lab Findings><Laboratories><Laboratory Finding><Learning><Life><Machine Intelligence><Medical><Medicine><Molecular><Multicellular Process><Multidisciplinary Collaboration><Multidisciplinary Research><National Government><Participant><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Postdoc><Postdoctoral Fellow><Process><Regenerative Medicine><Regulatory Affairs><Regulatory Pathway><Research><Research Associate><Research Personnel><Researchers><Role><Schedule><T cells for CAR><Translating><Universities><Vocation><Work><Workshop><bench bed side><bench bedside><bench to bed side><bench to bedside><bench to clinic><bench to clinical practice><blood stem cell transplantation><career><case report><catalyst><cell based intervention><cell mediated intervention><cell mediated therapies><cell-based therapeutic><cell-based therapy><cellular therapeutic><cellular therapy><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cells><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clinical applicability><clinical application><clinical relevance><clinical translation><clinically relevant><clinically translatable><community engagement><conference><convention><developmental><driving><engagement with communities><financial aid><financial assistance><fundamental research><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><graduate student><hematopoietic cell transplantation><hematopoietic cellular transplantation><hematopoietic progenitor cell transplantation><human disease><improved><innovate><innovation><innovative><insight><interest><kids><manufacture><meeting><meetings><member><new approaches><novel approaches><novel strategies><novel strategy><operation><operations><patient oriented outcomes><post-doc><post-doctoral><post-doctoral trainee><posters><pre-clinical development><preclinical development><programs><research associates><social role><success><summit><symposia><symposium><translational investigator><translational researcher><translational scientist><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Brian Jason Wainger

MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA

Exploratory lead · 26/100

Solid budget

Active award

$484,178

FY 2026

Project Title

Toward Precision Gene Therapy for Treatment of Severe Pain in Older Individuals

Grant Number:

5R33AG075419-05

Activity Code:

R33

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/1/2022

End Date:

2/28/2027

Project Abstract

Project Summary: The primary goal of this R21/R33 Translational Aging Research Identification award is develop, optimize, and validate a novel gene therapy-based treatment approach for refractory pain in older individuals. Pain is a major socioeconomic problem, affecting more than 25% of adults in t...

Research Terms

<21+ years old><AAV delivered><AAV delivery><AAV-based delivery><AAV-based viral delivery><AAV-mediated delivery><Adeno-associated-virus-based delivery><Adult><Adult Human><Adverse effects><Affect><Aging><Animal Model><Animal Models and Related Studies><Arthritis><Award><Behavioral><Bioinformatics><Biology><Candidate Disease Gene><Candidate Gene><Cell Body><Cell Communication and Signaling><Cell Signaling><Cell model><Cells><Cellular model><Clinical Trials><Congenital Analgesia><Congenital Pain Indifference><Congenital Pain Insensitivity><Contralateral><DNA Therapy><Data><Development><Dorsal Root Ganglia><Dose><Drug usage><Elderly><Electrophysiology><Electrophysiology (science)><Gene Therapy Vectors><Gene Transcription><Gene Transduction Agent><Gene Transduction Vectors><Gene Transfer Clinical><Genes><Genetic Intervention><Genetic Models><Genetic Transcription><Goals><Hereditary><Human><Human Genetics><Impairment><Individual><Inflammatory><Inherited><Injections><Intra-Articular Injections><Intraarticular Injections><Intracellular Communication and Signaling><Intractable Pain><Intramuscular><Ipsilateral><K channel><Knock-out><Knockout><Label><Measures><Medical><Medulla Spinalis><Mice><Mice Mammals><Modern Man><Molecular><Motor Cell><Motor Neurons><Murine><Mus><Neural Stem Cell><Neuropathy><Neurophysiology / Electrophysiology><Nociceptors><Older Population><Pain><Pain Control><Pain Therapy><Pain management><Painful><Pathologic><Phase><Phenotype><Physiologic><Physiological><Polypharmacy><Post-operative Pain><Postoperative Pain><Potassium Channel><Potassium Ion Channels><Prevalence><Promoter Regions><Promotor Regions><Quantitative RTPCR><Quantitative Reverse Transcriptase PCR><RNA Expression><Refractory Pain><Research><Risk><Route><Safety><Serotyping><Signal Transduction><Signal Transduction Systems><Signaling><Sodium Channel><Sodium Ion Channels><Specificity><Spinal Cord><Spinal Ganglia><Testing><Toxic effect><Toxicities><Transcript><Transcription><Translations><Validation><Voltage-Gated K+ Channels><Voltage-Gated Potassium Channel><adeno-associated viral vector delivery><adeno-associated virus delivery><adeno-associated virus mediated delivery><adenovirus mediated delivery><adulthood><advanced age><aged animal><aged animals><aged mice><aged mouse><aggressive therapy><aggressive treatment><animal old age><arthritic><biological signal transduction><cell type><chronic pain><co-morbid><co-morbidity><comorbidity><congenital hyposensitivity to pain><congenital insensitivity to pain><cost><delivered with AAV><delivery with AAV><dermatome><design><designing><developmental><dorsal root ganglion><drug use><effective therapy><effective treatment><elderly animal><elderly mice><elderly patient><electrophysiological><experience><familial hyposensitivity to pain><familial insensitivity to pain><gain of function mutation><gene repair therapy><gene therapy><gene-based therapy><genetic promoter element><genetic promoter sequence><genetic therapy><genomic therapy><geriatric><hiPSC><human iPS><human iPSC><human induced pluripotent cell><human induced pluripotent stem cells><human inducible pluripotent stem cells><human inducible stem cells><iPS><iPSC><iPSCs><in vivo><induced human pluripotent stem cells><induced pluripotent cell><induced pluripotent stem cell><inducible pluripotent cell><inducible pluripotent stem cell><intractable pain syndrome><knock-down><knockdown><model of animal><motoneuron><mouse model><murine model><nerve stem cell><neural cell body><neural precursor><neural precursor cell><neural progenitor><neural progenitor cells><neural stem and progenitor cells><neurogenic progenitors><neurogenic stem cell><neuron progenitors><neuronal cell body><neuronal progenitor><neuronal progenitor cells><neuronal stem cells><neuropathic><neuroprogenitor><new approaches><nociceptive neurons><novel><novel approaches><novel strategies><novel strategy><old animals><old mice><older groups><older individuals><older patient><older person><opiate crisis><opioid crisis><opioid epidemic><overexpress><overexpression><pain after surgery><pain intervention><pain model><pain signal><pain treatment><pain-sensing neurons><pain-sensing sensory neurons><pain-sensing somatosensory neurons><patch clamp><patch sequencing><patch-seq><patchseq><post-surgical pain><postsurgical pain><pre-clinical development><preclinical development><prevent><preventing><progenitor and neural stem cells><progenitor cell model><progenitor model><promoter><promoter sequence><promotor><qRTPCR><senior citizen><side effect><socio-economic><socio-economically><socioeconomically><socioeconomics><soma><stem and progenitor cell model><stem cell based model><stem cell derived model><stem cell model><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapy optimization><translation><treatment optimization><treatment strategy><validations><voltage>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Matthew Witkowski

UNIVERSITY OF COLORADO DENVER, Aurora, CO

Exploratory lead · 26/100

Solid budget

Active award

$464,293

FY 2026

Project Title

Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia

Grant Number:

5R37CA295527-02

Activity Code:

R37

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/20/2025

End Date:

12/31/2029

Project Abstract

Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-cell Acute Lymphoblastic Leukemia Abstract Chemotherapy-resistant B-cell acute lymphoblastic leukemia (B-ALL) remains a leading cause of cancer-related death for children and young adults. While CD19-directed chimeric a...

Research Terms

<0-11 years old><2-ketoglutarate><2-oxoglutarate><Ablation><Acute B-Lymphocytic Leukemia><Address><Affect><Anti-Oncogenes><Antioncogene Protein p53><Antioncogenes><B-ALL><B-ALL cell><B-Cell Acute Lymphocytic Leukemia><B-Cell Acute Lymphoblastic Leukemia><B-Cell Childhood ALL><B-Cell Childhood Acute Lymphoblastic Leukemia><B-Cell Childhood Acute Lymphogenous Leukemia><B-Cell Childhood Acute Lymphoid Leukemia><B-Cell Lymphoblastic Leukemia><B-Cell Lymphomas><B-Cell Pediatric ALL><B-Cell Pediatric Acute Lymphoblastic Leukemia><B-Cell Pediatric Acute Lymphogenous Leukemia><B-Cell Pediatric Acute Lymphoid Leukemia><B-Cell Subsets><B-Lymphocyte Subsets><B-cell ALL><B-cell acute lymphoblastic leukemia cell><B-cell acute lymphocytic leukemia cell><B-cell precursor acute lymphoblastic leukemia><B-cell precursor acute lymphoblastic leukemia cell><B-cell precursor acute lymphocytic leukemia cell><Bioinformatics><Biology><Biometrics><Biometry><Biostatistics><CAR T cell therapy><CAR T cells><CAR T therapy><CAR modified T cells><CAR-T><CAR-Ts><CD19><CD19 gene><CRISPR editing screen><CRISPR screen><CRISPR-based screen><CRISPR/Cas9 screen><Cancer Cause><Cancer Etiology><Cancer Suppressor Genes><Cancers><Cell Body><Cell Line><Cell Survival><Cell Viability><CellLine><Cells><Cellular Tumor Antigen P53><Cessation of life><Chemoresistance><Child><Child Youth><Childhood Precursor B Lymphoblastic Leukemia><Children (0-21)><Clinical><Clinical Data><Cohort Analyses><Cohort Analysis><DNA mutation><Data><Death><Dependence><Diagnosis><Disease Resistance><Dissection><Emerogenes><Ensure><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Exhibits><Exposure to><Failure><Fatty Acids><Free Fatty Acids><Gene Expression><Genes><Genetic><Genetic Change><Genetic Risk><Genetic defect><Genetic mutation><Human><In Vitro><Interdisciplinary Research><Interdisciplinary Study><Intermediary Metabolism><Investigation><Link><Linoleic Acids><Malignant Neoplasms><Malignant Tumor><Mediating><Metabolic><Metabolic Pathway><Metabolic Processes><Metabolism><Methodology><Modern Man><Multidisciplinary Collaboration><Multidisciplinary Research><Mutate><Mutation><Nonesterified Fatty Acids><Onco-Suppressor Genes><Oncogenes-Tumor Suppressors><Oncoprotein p53><Outcome><P53><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><Phosphoprotein P53><Phosphoprotein pp53><Position><Positioning Attribute><Pre-B-Cell Leukemia><Precursor B Lymphoblastic Leukemia><Protein Family><Protein TP53><RNA Seq><RNA sequencing><RNAseq><Recessive Oncogenes><Refractory><Refractory Disease><Relapse><Research><Resistance><Role><Stable Isotope Labeling><Strains Cell Lines><Succinates><T cells for CAR><TP53><TP53 gene><TRP53><Testing><Therapeutic><Tumor Cell><Tumor Protein p53><Tumor Protein p53 Gene><Tumor Suppressing Genes><Tumor Suppressor Genes><adult youth><alpha ketoglutarate><cancer death in children><cancer mortality in children><cancer related death in children><cell killing><chemoresistant><chemotherapy><chemotherapy resistance><chemotherapy resistant><childhood cancer death><childhood cancer mortality><chimeric antigen T cell receptor><chimeric antigen receptor (CAR) T cell therapy><chimeric antigen receptor (CAR) T cells><chimeric antigen receptor T><chimeric antigen receptor T cell therapy><chimeric antigen receptor T cells><chimeric antigen receptor T therapy><chimeric antigen receptor fusion protein T-cells><chimeric antigen receptor modified T cells><clustered regularly interspaced short palindromic repeats screen><cohort><cultured cell line><demethylation><effectiveness testing><epigenetically><fatty acid transport><genome mutation><genome scale><genome-wide><genomewide><high risk><histone demethylase><improved><in vivo><kids><leukemia><leukemia relapse><loss of function mutation><mRNA Expression><malignancy><metabolism measurement><metabolomics><metabonomics><neoplasm/cancer><neoplastic cell><novel><oncosuppressor gene><p53 Antigen><p53 Genes><p53 Tumor Suppressor><pathway><patient oriented outcomes><pharmacologic><pre-B acute lymphoblastic leukemia cell><pre-clinical><preclinical><protein p53><public health relevance><recurrent leukemia><resistance mechanism><resistance to disease><resistant><resistant disease><resistant mechanism><resistant to disease><response><social role><stable isotope><synergism><therapeutic target><transcriptome sequencing><transcriptomic sequencing><uptake><validation studies><young adult><young adult age><young adulthood><youngster><α-ketoglutarate><α-oxoglutarate><αKG>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Christian Gabriel FIGUEROA-ESPADA

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 24/100

Active award

Career award

$104,765

FY 2026

Project Title

Engineering Biomaterials to Modulate the Tumor Immune Microenvironment

Grant Number:

5K00CA284294-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

1/1/2025

End Date:

12/31/2028

Project Abstract

Cancer remains a significant global health challenge, with an anticipated 611,240 deaths in 2024. Substantial strides in cancer research have enhanced our understanding of the mechanisms underlying its development, progression, and spread. While current treatments such as surgery, radiation, chemoth...

Research Terms

<3-D><3-Dimensional><3D><Acceleration><Address><Assay><Automobile Driving><Bioassay><Biocompatible Materials><Bioinformatics><Biological Assay><Biomaterials><Breast><Breast Cancer><CD34><CD34 gene><Cancer Biology><Cancer Treatment><Cancers><Cause of Death><Cell Body><Cell Communication><Cell Growth in Number><Cell Interaction><Cell Line><Cell Multiplication><Cell Proliferation><Cell-to-Cell Interaction><CellLine><Cells><Cellular Proliferation><Cessation of life><Co-culture><Cocultivation><Coculture><Coculture Techniques><Complement><Complement Proteins><DNA mutation><Data><Death><Development><Differential Gene Expression><Drug Delivery><Drug Delivery Systems><Drug resistance><Drugs><Dysfunction><Effectiveness><Engineering><Event><Expression Signature><Functional disorder><Funding><Future><Gene Expression><Gene Expression Profile><Generalized Growth><Genetic Change><Genetic defect><Genetic mutation><Germinoblastic Sarcoma><Germinoblastoma><Goals><Grips><Growth><HPCA1><Heterogeneity><Human><Immune><Immune infiltrates><Immune mediated therapy><Immune system><Immunes><Immunologically Directed Therapy><Immunotherapy><In Vitro><Laboratory Research><Ligands><Liquid substance><Literature><Lung><Lung Respiratory System><Lymphoma><MSKCC><Malignant Breast Neoplasm><Malignant Cell><Malignant Lymphoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Lung><Malignant neoplasm of lung><Malignant neoplasm of prostate><Malignant prostatic tumor><Medication><Memorial Sloan-Kettering Cancer Center><Methods><Mice><Mice Mammals><Modality><Modeling><Modern Man><Molecular><Molecular Fingerprinting><Molecular Profiling><Multiple Myeloma><Murine><Mus><Mutation><NIH><National Institutes of Health><Natural regeneration><Non-Polyadenylated RNA><Operative Procedures><Operative Surgical Procedures><Outcome><Patients><Pennsylvania><Pharmaceutical Preparations><Physiopathology><Plasma-Cell Myeloma><Process><Prostate><Prostate CA><Prostate Cancer><Prostate Gland><Prostate malignancy><Prostatic Gland><Pulmonary Cancer><Pulmonary malignant Neoplasm><RNA><RNA Gene Products><Radiation><Receptor Protein><Regeneration><Relapse><Reporting><Research><Resistance><Resistance development><Resistant development><Rest><Reticulolymphosarcoma><Ribonucleic Acid><Solid><Strains Cell Lines><Surgical><Surgical Interventions><Surgical Procedure><System><Therapeutic Effect><Therapeutic Uses><Time><Tissue Engineering><Tissue Growth><Tissue-Specific Differential Gene Expression><Tissue-Specific Gene Expression><Training><Treatment Efficacy><Treatment outcome><United States National Institutes of Health><Universities><Validation><analytical tool><anti-cancer><anti-cancer research><anti-cancer therapy><anti-cancer treatment><bioengineered tissue><biological material><cancer cell><cancer heterogeneity><cancer microenvironment><cancer progression><cancer research><cancer therapy><cancer type><cancer-directed therapy><cell regeneration><cell type><cellular regeneration><chemotherapy><clinical relevance><clinically relevant><complementation><cultured cell line><determine efficacy><developing resistance><developmental><dosage><driving><drug discovery><drug efficacy><drug resistant><drug sensitivity><drug/agent><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><engineered tissue><evaluate efficacy><examine efficacy><fluid><gene expression pattern><gene expression signature><genome mutation><global gene expression><global health><global transcription profile><grasp><high dimensionality><high-throughput drug screening><immune cell infiltrate><immune microenvironment><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><individualized cancer therapy><ineffective therapies><ineffective treatment><insight><intervention efficacy><liquid><lung cancer><malignancy><malignant breast tumor><molecular profile><molecular signature><mortality><myeloma><myelomatosis><nanosystems><neoplasm progression><neoplasm/cancer><neoplastic progression><new drug target><new druggable target><new pharmacotherapy target><new therapeutic target><new therapy target><novel drug target><novel druggable target><novel pharmacotherapy target><novel therapeutic target><novel therapy target><ontogeny><pathophysiology><personalization of treatment><personalized cancer therapy><personalized cancer treatment><personalized medicine><personalized therapy><personalized treatment><physical model><programs><receptor><regenerate><regeneration potential><regenerative potential><resistance to Drug><resistance to therapy><resistant><resistant to Drug><resistant to therapy><response><scATAC sequencing><scATAC-seq><single cell ATAC-seq><single cell ATAC-sequencing><single cell Assay for Transposase Accessible Chromatin sequencing><single cell sequencing assay for transposase accessible chromatin><single cell technology><single-cell Assay for Transposase-Accessible Chromatin with sequencing><single-cell assay for transposase-accessible chromatin using sequencing><single-cell assay for transposase-accessible chromatin-seq><surgery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic resistance><therapeutic target><therapy efficacy><therapy resistant><three dimensional><transcriptional profile><transcriptional signature><transcriptome><treatment resistance><treatment strategy><tumor><tumor growth><tumor immune microenvironment><tumor microenvironment><tumor progression><tumor-immune system interactions><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Wen-Hao Hsu

STANFORD UNIVERSITY, STANFORD, CA

Exploratory lead · 24/100

Active award

Career award

$103,162

FY 2026

Project Title

Oncogenic Kras drives stromal adipogenesis to promote colorectal cancer (CRC) progression

Grant Number:

5K00CA274661-05

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

8/1/2022

End Date:

11/30/2027

Project Abstract

Genomic instability is a characteristic hallmark of cancer, leading to an increased propensity for mutations in tumor suppressor genes, activation of oncogenes, and chromosomal alterations. These genomic changes not only contribute to tumor initiation but also play a critical role in tumor progressi...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Ivan Susin Pires

BRIGHAM AND WOMEN'S HOSPITAL, BOSTON, MA

Exploratory lead · 24/100

Active award

Career award

$89,145

FY 2026

Project Title

Development of Lipid Nanoparticles for B-cell Mediated Immunotherapies

Grant Number:

5K00CA274651-04

Activity Code:

K00

Mechanism:

Other Research-Related

Agency:

NIH

Start Date:

12/1/2024

End Date:

11/30/2028

Project Abstract

Gene therapy has had an exciting last decade with many novel FDA approved therapies reaching the clinic. These treatments have not only been fruitful in cancer treatment, but also for genetic diseases and, more recently, in COVID-19 vaccines. Unlike macromolecules or small molecules, nucleic acids (...

Research Terms

<2019-nCoV vaccine><4T1><ASO therapeutics><ASO therapy><ASO treatment><Address><Antigen-Presenting Cells><Antisense Oligonucleotide Therapy><B-Cell Activation><B-Cells><B-Lymphocytes><B-cell><B16F10><Blood Serum><Body Tissues><Breast><COVID-19 vaccine><CT-26><CT26><Cancer Model><Cancer Treatment><Cancer cell line><CancerModel><Cancers><Cell Body><Cell Line><CellLine><Cells><Characteristics><Charge><Circulation><Clinic><Clinical><Colon><DNA><DNA Therapy><Data Set><Dendritic Cells><Deoxyribonucleic Acid><Dependence><Development><Engineering><Enzyme Gene><Enzymes><Evaluation><FDA approved><FRET><Face><Fluorescence Resonance Energy Transfer><Formulation><Foundations><Förster Resonance Energy Transfer><Gene Delivery><Gene Inactivation><Gene Silencing><Gene Transcription><Gene Transfer Clinical><Genes><Genetic Diseases><Genetic Intervention><Genetic Transcription><Goals><Human><Immune><Immune Modulation Therapy><Immune Targeting><Immune mediated therapy><Immune response><Immune system><Immunes><Immunity><Immunochemical Immunologic><Immunologic><Immunologic Subtyping><Immunological><Immunologically><Immunologically Directed Therapy><Immunologics><Immunomodulation><Immunophenotyping><Immunotherapeutic agent><Immunotherapy><In Vitro><In vivo analysis><Libraries><Lipids><Lung><Lung Respiratory System><Macrophage><Malignant Melanoma><Malignant Neoplasm Therapy><Malignant Neoplasm Treatment><Malignant Neoplasms><Malignant Tumor><Mediating><Melanoma><Messenger RNA><Mice><Mice Mammals><Modern Man><Murine><Mus><Myeloid Cells><Mφ><Nanotechnology><Non-Polyadenylated RNA><Nucleic Acids><Pathway interactions><Patients><Play><Post-Transcriptional Gene Silencing><Production><Proteins><RNA><RNA Expression><RNA Gene Products><RNA Interference><RNA Silencing><RNAi><Ribonucleic Acid><Role><SARS-CoV-2 vaccine><SARS-coronavirus-2 vaccine><Sampling><Sequence-Specific Posttranscriptional Gene Silencing><Serum><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vaccine><Short interfering RNA><Solid><Strains Cell Lines><T-Cells><T-Lymphocyte><TCGA><The Cancer Genome Atlas><Therapeutic><Therapeutic Agents><Tissues><Transcription><Transfection><Translating><Translations><Treatment Efficacy><Tumor Immunity><Validation><Veiled Cells><accessory cell><activated B cells><anti-cancer immunotherapy><anti-cancer therapy><anti-sense oligonucleotide drug><anti-sense oligonucleotide therapy><anti-sense oligonucleotide treatment><anti-sense therapy><anti-tumor effect><anti-tumor immune response><anti-tumor immunity><anticancer immunotherapy><antisense drug><antisense oligonucleotide therapeutic><antisense therapeutics><antisense therapy><antitumor effect><antitumor immunity><biophysical characteristics><biophysical characterization><biophysical measurement><biophysical parameters><biophysical properties><cancer immunity><cancer immunotherapy><cancer therapy><cancer-directed therapy><coronavirus disease 2019 vaccine><coronavirus disease-19 vaccine><cultured cell line><cytokine><cytokine based immunotherapy><cytokine based therapy><cytokine immunotherapy><cytokine therapy><cytokine treatment><delivery vector><delivery vehicle><design><designing><developmental><effective therapy><effective treatment><experiment><experimental research><experimental study><experiments><faces><facial><gene repair therapy><gene therapy><gene-based therapy><genetic condition><genetic disorder><genetic therapy><genomic therapy><host response><immune drugs><immune microenvironment><immune modulation><immune modulatory therapies><immune modulatory treatment><immune regulation><immune regulation therapy><immune regulation treatment><immune regulatory therapy><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immune-modulation treatment><immuno therapy><immunologic reactivity control><immunologic therapeutics><immunomodulation therapy><immunomodulation treatment><immunomodulator therapies><immunomodulator treatment><immunomodulator-based therapies><immunomodulatory><immunomodulatory biologics><immunomodulatory therapies><immunomodulatory treatment><immunoregulation><immunoregulatory><immunoregulatory therapy><immunoregulatory treatment><immunoresponse><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><in vivo><in vivo evaluation><in vivo testing><insight><intervention efficacy><lipid based nanoparticle><lipid nanoparticle><mRNA><macromolecule><malignancy><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nano particle><nano tech><nano technology><nano-sized particle><nano-technological><nanoparticle><nanosized particle><nanotech><nanotechnological><neoplasm/cancer><new approaches><novel><novel approaches><novel strategies><novel strategy><nucleic acid delivery><pathway><programs><rational design><response><siRNA><social role><subcutaneous><subdermal><success><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic immunomodulation><therapeutic immunoregulation><therapy efficacy><thymus derived lymphocyte><transcriptional silencing><translation><tumor><tumor growth><tumor immune microenvironment><tumor-immune system interactions><uptake><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine strategy><vaccines preventing COVID><vaccines to prevent COVID><validations>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Xin Chen

UT SOUTHWESTERN MEDICAL CENTER, DALLAS, TX

Exploratory lead · 22/100

Recent

Active award

$249,000

FY 2026

Project Title

CMT4A and CMT2K Gene Replacement Therapy with AAV9/GDAP1 in Rats

Grant Number:

1R21NS146806-01

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/15/2026

End Date:

1/31/2028

Project Abstract

PROJECT SUMMARY/ABSTRACT Charcot–Marie–Tooth (CMT) neuropathies are a genetically and phenotypically heterogeneous group of disorders caused by pathogenic variants in over 100 different genes. Ganglioside-induced differentiation- associated protein 1 (GDAP1) gene mutations cause various forms of CMT...

Research Terms

<Adeno-Associated Viruses><Affect><Age Months><Alleles><Allelomorphs><Animal Model><Animal Models and Related Studies><Antimorphic mutation><Autopsy><Behavioral><CLN1><CLN1 gene><CLN1 protein><CLN5><CLN5 gene><CLN5 protein><Cell Body><Cells><Cerebroatrophic Hyperammonemia><Cerebrospinal Fluid><Charcot Marie Disorder><Charcot Marie Muscular Atrophy><Charcot Marie Tooth Disorder><Charcot Marie Tooth muscular atrophy><Charcot-Marie Disease><Charcot-Marie-Tooth><Charcot-Marie-Tooth Disease><Charcot-Marie-Tooth neuropathy><Clinical><Clinical Trials><Collaborations><Common Rat Strains><DNA Therapy><Data><Dependoparvovirus><Dependovirus><Development><Diffuse Globoid Body Sclerosis><Disease><Disorder><Dominant Negative><Dominant-Negative Mutant><Dominant-Negative Mutation><Dose><Electrophysiology><Electrophysiology (science)><Equilibrium><Euthanasia><Feedback><Future><GDAP protein><Galactosylceramidase Deficiency Disease><Gene Alteration><Gene Mutation><Gene Transfer Clinical><Genes><Genetic Intervention><Globoid Leukodystrophy><Globoid cell leukodystrophy><Goals><Hand functions><Heterozygote><Histologic><Histologically><Human><IND Filing><IND application><IND package><IND submission><Injections><Intervention><Intrathecal Injections><Investigational Drugs><Investigational New Drug Application><Investigational New Drugs><KO mice><Knock-out Mice><Knockout Mice><Krabbe Disease><Krabbe leukodystrophy><Laboratories><Leg><Life><Longitudinal Studies><Longitudinal Surveys><Mediating><Medulla Spinalis><Mercy Killing><Mice><Mice Mammals><Modeling><Modern Man><Monitor><Murine><Mus><Muscle Atrophy><Muscle Weakness><Muscular Atrophy><Muscular Weakness><Nature><Nerve Cells><Nerve Conduction><Nerve Unit><Neural Cell><Neural Conduction><Neurilemma Cell><Neurilemmal Cell><Neurocyte><Neuromuscular Diseases><Neurons><Neuropathy><Neurophysiology / Electrophysiology><Null Mouse><Pathogenicity><Patients><Peripheral Nerves><Peripheral Nervous System><Peroneal Muscular Atrophy><Persons><Phenotype><Randomized><Rat><Rats Mammals><Rattus><Rett Disorder><Rett Syndrome><Safety><Schwann Cells><Sensory><Spinal Cord><Testing><Therapeutic><Therapy Clinical Trials><Toxic effect><Toxicities><Translating><Translations><Using hands><Variant><Variation><Walking><Work><adeno associated virus group><arm><autosomal dominant mutation><autosome><balance><balance function><behavior phenotype><behavioral phenotyping><beta galactocerebrosidase deficiency><cerebral spinal fluid><clinical translation><clinically translatable><design><designing><determine efficacy><developmental><diffuse globoid cell cerebral sclerosis><disease phenotype><early onset><efficacy analysis><efficacy assessment><efficacy determination><efficacy evaluation><efficacy examination><electrophysiological><evaluate efficacy><examine efficacy><experience><first in man><first-in-human><gain of function mutation><galactocerebrosidase (GALC) deficiency><galactocerebrosidase deficiency><galactosylceramide beta-galactosidase deficiency><galactosylceramide deficiency><galactosylceramide lipidosis><galactosylsphingosine lipidosis><ganglioside-induced differentiation-associated protein><gene defect><gene repair therapy><gene replacement therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><giant axonal neuropathy><globoid cell cerebral sclerosis><globoid cell sclerosis><heterozygosity><long-term study><longitudinal outcome studies><longitudinal research study><loss of function mutation><model of animal><mouse model><murine model><muscle breakdown><muscle degradation><muscle deterioration><muscle loss><muscle wasting><mutant allele><myoneural disorder><necropsy><neuromuscular degenerative disorder><neuromuscular disorder><neuronal><neuronal 5 ceroid-lipofuscinosis><neuropathic><postmortem><pre-clinical><preclinical><protein function><psychosine lipidosis><randomisation><randomization><randomly assigned><spinal fluid><success><transgene expression><translation><treatment group><vector>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Senthil Velan Bhoopalan

ST. JUDE CHILDREN'S RESEARCH HOSPITAL, MEMPHIS, TN

Exploratory lead · 22/100

Recent

Active award

$248,999

FY 2026

Project Title

Hematopoietic stem cell defects in Diamond-Blackfan Anemia

Grant Number:

4R00DK134844-03

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

4/1/2024

End Date:

2/28/2029

Project Abstract

(PLEASE KEEP IN WORD, DO NOT PDF) Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure disorder caused mainly by heterozygous loss-of-function mutations in 24 out of 83 ribosomal protein genes, with RPS19 being the most commonly affected gene. DBA usually presents with isolated eryt...

Research Terms

<0-11 years old><Acceleration><Address><Affect><Allelic Loss><Allo BMT><Allogeneic BMT><Allogeneic Bone Marrow Transplantation><Anemia><Animal Model><Animal Models and Related Studies><Antioncogene Protein p53><Assay><Bioassay><Biological Assay><Biology><Blood><Blood Diseases><Blood Precursor Cell><Blood Reticuloendothelial System><Bone Marrow><Bone Marrow Grafting><Bone Marrow Reticuloendothelial System><Bone Marrow Transplant><Bone Marrow Transplantation><Bone marrow failure><CD34><CD34 gene><CITE sequencing><CITE-seq><CITEseq><CRISPR approach><CRISPR based approach><CRISPR method><CRISPR methodology><CRISPR technique><CRISPR technology><CRISPR tools><CRISPR-CAS-9><CRISPR-based method><CRISPR-based technique><CRISPR-based technology><CRISPR-based tool><CRISPR/CAS approach><CRISPR/Cas method><CRISPR/Cas technology><CRISPR/Cas9><CRISPR/Cas9 technology><CUT&RUN><Cas nuclease technology><Cell Body><Cells><Cellular Indexing of Transcriptomes and Epitopes by Sequencing><Cellular Tumor Antigen P53><Child><Child Youth><Children (0-21)><Chronic><Cleavage Targets and Release Using Nuclease><Cleavage Under Targets and Release Using Nuclease><Clinical><Clustered Regularly Interspaced Short Palindromic Repeats approach><Clustered Regularly Interspaced Short Palindromic Repeats method><Clustered Regularly Interspaced Short Palindromic Repeats methodology><Clustered Regularly Interspaced Short Palindromic Repeats technique><Clustered Regularly Interspaced Short Palindromic Repeats technology><Complex><DNA Therapy><DNA mutation><Data><Defect><Development><Diamond-Blackfan anemia><Disease><Disorder><Dysfunction><Epigenetic><Epigenetic Change><Epigenetic Mechanism><Epigenetic Process><Erythrocyte Transfusion><Erythroid><Erythropoiesis><Exhibits><Experimental Models><Failure><Foundations><Functional disorder><Funding><Future><Gene Expression><Gene Proteins><Gene Transcription><Gene Transfer Clinical><Genes><Genetic Change><Genetic Intervention><Genetic Transcription><Genetic defect><Genetic mutation><Glucocorticoids><Goals><HDM2><HPCA1><Hematologic Diseases><Hematological Disease><Hematological Disorder><Hematopoiesis><Hematopoietic Cellular Control Mechanisms><Hematopoietic Progenitor Cells><Hematopoietic stem cells><Heterograft><Heterologous Transplantation><Heterozygote><Human><Immune Precipitation><Immunoblotting><Immunodeficient Mouse><Immunoprecipitation><Impairment><In Vitro><Inherited bone marrow failure><Investigation><Loss of Heterozygosity><MDM2><MDM2 gene><MDMX protein><Maintenance><Maps><Marrow Transplantation><Mdm-2 protein><Mediating><Modern Man><Molecular><Mutation><Myelopoiesis><NIH><National Institutes of Health><Oncoprotein MDM2><Oncoprotein p53><P53><Pathway interactions><Patients><Phenotype><Phosphoprotein P53><Phosphoprotein pp53><Physicians><Physiology><Physiopathology><Polycomb><Population><Population Heterogeneity><Process><Production><Protein Deficiency><Protein Gene Products><Protein Subunits><Protein TP53><RNA Expression><RNA Seq><RNA sequencing><RNAseq><RPS19><RPS19 gene><Red Blood Cell Transfusion><Repression><Repressor Proteins><Research><Ribo-seq><Ribonucleoproteins><Ribosomal Proteins><Ribosomal RNA><Ribosomes><Scientist><Spectroscopy><Spectrum Analyses><Spectrum Analysis><Structure><TP53><TP53 gene><TRP53><Testing><Therapeutic><Training><Transcription><Translations><Transplantation><Tumor Protein p53><Tumor Protein p53 Gene><Ubiquitin Ligase Component Gene><Ubiquitin Ligase Gene><United States National Institutes of Health><Western Blotting><Western Immunoblotting><Xenograft><Xenograft procedure><Xenotransplantation><allogeneic bone marrow transplant><allogenic bone marrow transplant><blood cell formation><blood cell progenitor><blood disorder><blood formation><blood progenitor><blood stem cell><blood-forming stem cell><bone marrow allograft><bone marrow failure syndrome><career><cellular indexing of transcriptomes and epitopes by single cell sequencing><cofactor><cytopenia><deficiency of protein><developmental><diverse populations><effective therapy><effective treatment><elderly patient><epigenetically><erythroid development><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genome mutation><genomic therapy><global gene expression><global transcription profile><hematopoietic differentiation><hematopoietic hierarchy><hematopoietic progenitor><hematopoietic stem progenitor cell><hemopoietic progenitor><hemopoietic stem cell><heterogeneous population><heterozygosity><human derived model><human derived platform><human derived system><human like model><human like platform><human like system><human model><human specific alternative><human specific model><human specific platform><human specific system><human-based alternative><human-based biological models><human-based model><human-based nonanimal models><human-based platform><human-based research><human-based system><human-based tools><human-centered model><human-centered platform><human-centered research><human-centered system><human-focused research><human-relevant alternative><human-relevant model><human-relevant platform><human-relevant system><improved><in vivo><infancy><infantile><inherited disease of bone marrow failure><insight><kids><loss of function mutation><mdm-2 oncogene protein><mdm2 protein><model of animal><model of human><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><older patient><p53 Antigen><p53 Genes><p53 Tumor Suppressor><p53-Binding Protein MDM2><pathophysiology><pathway><population diversity><progenitor><progenitor biology><progenitor cell biology><progenitor cell function><progenitor cell maintenance><progenitor function><progenitor maintenance><programs><protein blotting><protein p53><rRNA><repressor complex><ribosome footprint profiling><ribosome profiling><ribosomopathy><scRNA sequencing><scRNA-seq><self-renew><self-renewal><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><stem and progenitor biology><stem and progenitor cell function><stem and progenitor function><stem cell biology><stem cell function><stem cell maintenance><transcriptome><transcriptome sequencing><transcriptomic sequencing><transcriptomics><translation><translatome><transplant><transplant therapy><transplant treatment><transplantation therapy><transplantation treatment><ubiquitin ligase><xeno-transplant><xeno-transplantation><youngster>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Rona Yaeger

SLOAN-KETTERING INST CAN RESEARCH, NEW YORK, NY

Exploratory lead · 22/100

Recent

Active award

$246,840

FY 2026

Project Title

Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response

Grant Number:

5R21CA292178-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/1/2025

End Date:

2/28/2027

Project Abstract

PROJECT SUMMARY Therapies targeting oncogenic drivers have revolutionized the treatment of metastatic colorectal cancer (CRC) with new agents holding the potential to target most CRCs in the not-too-distant future. However, the impact of these new therapies has been limited by the short duration of ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Micah T. McClain

DUKE UNIVERSITY, DURHAM, NC

Exploratory lead · 22/100

Recent

Active award

$242,250

FY 2026

Project Title

Prognostic Biomarkers in Invasive Candidiasis

Grant Number:

1R21AI190741-01A1

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

2/13/2026

End Date:

1/31/2028

Project Abstract

Abstract There remains an urgent need for expanded understanding of the pathophysiology of invasive fungal infections (IFI), and improved tools for diagnosis and management of these devastating diseases. Invasive candidiasis alone causes significant morbidity and mortality, especially in solid organ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Yoshihiro Izumiya

UNIVERSITY OF CALIFORNIA AT DAVIS, DAVIS, CA

Exploratory lead · 22/100

Recent

Active award

$225,803

FY 2026

Project Title

Characterization of KSHV-Associated Disease Specific Gene Therapy

Grant Number:

5R21CA299587-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

3/10/2025

End Date:

2/28/2027

Project Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) was discovered in 1994 and is one of the eight human herpesviruses. KSHV is the causative agent of Kaposi's sarcoma, two human lymphoproliferative diseases, primary effusion lymphoma, AIDS-related multicentric Castleman's disease, and a more recently de...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Robert L Mauck

PHILADELPHIA VA MEDICAL CENTER, PHILADELPHIA, PA

Exploratory lead · 22/100

Recent

Active award

$0

FY 2026

Project Title

Bioactive Injectable Implants for Functional Intervertebral Disc Regeneration

Grant Number:

2I01RX001321-11A2

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

1/1/2026

End Date:

12/31/2029

Project Abstract

Intervertebral disc degeneration is strongly implicated as a cause of low back pain. Over a 10 year period, more than 130,000 active service members received diagnoses of disc degeneration, with annual incidence rates more than doubling during this time. Current treatment approaches are mostly conse...

Research Terms

<3D cell culture><3D culture><Ablation><Address><Animal Model><Animal Models and Related Studies><Armed Forces Personnel><Back Ache><Back Pain><Backache><Biodistribution><Body Tissues><Caprine Species><Cell Body><Cell Communication and Signaling><Cell Culture Techniques><Cell Signaling><Cell-Extracellular Matrix><Cells><Characteristics><Chronic low back pain><Clinical Trials><DNA Therapy><Diagnosis><ECM><Early Intervention><Extracellular Matrix><Failure><Fibrosis><Formulation><Gene Transfer Clinical><Genetic Intervention><Glycolates><Goals><Goat><Goats Mammals><Health><Human><Hydration><Hydration status><Implant><In Vitro><Incidence><Injectable><Intervertebral Disc Degenerative Disease><Intervertebral Disc Degenerative Disorder><Intervertebral Disk><Intervertebral disc structure><Intracellular Communication and Signaling><Joints><Lipids><Low Back Ache><Low Back Pain><Low Backache><Lumbago><Mechanics><Mediating><Messenger RNA><Military><Military Personnel><Modeling><Modern Man><Natural regeneration><Non-Polyadenylated RNA><Operative Procedures><Operative Surgical Procedures><Opiate Addiction><Opiate Dependence><Organ Culture><Organ Culture Techniques><Pathologic><Pathway interactions><Patients><Phenotype><Porosity><Position><Positioning Attribute><Production><Property><Proteoglycan><RNA><RNA Gene Products><RNA based therapeutics><RNA based therapy><RNA therapy><Regeneration><Rejuvenation><Ribonucleic Acid><Safety><Severities><Short interfering RNA><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Spinal Fusion><Spondylosyndeses><Structure><Surgical><Surgical Interventions><Surgical Procedure><Symptoms><System><Therapeutic Uses><Time><Tissues><Toxic effect><Toxicities><Transcription Activation><Transcriptional Activation><Transcriptional Control><Transcriptional Regulation><Transfection><Veterans><Viral Vector><active duty><active service><biological signal transduction><cell culture><cell cultures><clinical relevance><clinically relevant><degenerated intervertebral disc><degenerative disc disease><design><designing><disc degeneration><disc regeneration><effective therapy><effective treatment><functional outcomes><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><glycolic acid><improved><in vitro Organ Culturing><in vitro vertebrate organ culturing><in vivo><intervertebral disk degeneration><lipid based nanoparticle><lipid nanoparticle><mRNA><mechanic><mechanical><military member><military population><military veteran><model of animal><new approaches><novel><novel approaches><novel strategies><novel strategy><nucleic acid delivery><nucleus pulposus><opioid addiction><opioid dependence><opioid dependent><pathway><pre-clinical><preclinical><regenerate><regenerate disc tissue><regeneration based therapy><regeneration therapy><regenerative therapeutics><regenerative therapy><response><scRNA sequencing><scRNA-seq><service member><siRNA><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><surgery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic RNA><therapy optimization><three dimensional cell culture><treatment optimization><treatment strategy><veteran population>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Lachlan James Smith

PHILADELPHIA VA MEDICAL CENTER, PHILADELPHIA, PA

Exploratory lead · 22/100

Recent

Active award

$0

FY 2026

Project Title

Bioactive Injectable Implants for Functional Intervertebral Disc Regeneration

Grant Number:

2I01RX001321-11A2

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

1/1/2026

End Date:

12/31/2029

Project Abstract

Intervertebral disc degeneration is strongly implicated as a cause of low back pain. Over a 10 year period, more than 130,000 active service members received diagnoses of disc degeneration, with annual incidence rates more than doubling during this time. Current treatment approaches are mostly conse...

Research Terms

<3D cell culture><3D culture><Ablation><Address><Animal Model><Animal Models and Related Studies><Armed Forces Personnel><Back Ache><Back Pain><Backache><Biodistribution><Body Tissues><Caprine Species><Cell Body><Cell Communication and Signaling><Cell Culture Techniques><Cell Signaling><Cell-Extracellular Matrix><Cells><Characteristics><Chronic low back pain><Clinical Trials><DNA Therapy><Diagnosis><ECM><Early Intervention><Extracellular Matrix><Failure><Fibrosis><Formulation><Gene Transfer Clinical><Genetic Intervention><Glycolates><Goals><Goat><Goats Mammals><Health><Human><Hydration><Hydration status><Implant><In Vitro><Incidence><Injectable><Intervertebral Disc Degenerative Disease><Intervertebral Disc Degenerative Disorder><Intervertebral Disk><Intervertebral disc structure><Intracellular Communication and Signaling><Joints><Lipids><Low Back Ache><Low Back Pain><Low Backache><Lumbago><Mechanics><Mediating><Messenger RNA><Military><Military Personnel><Modeling><Modern Man><Natural regeneration><Non-Polyadenylated RNA><Operative Procedures><Operative Surgical Procedures><Opiate Addiction><Opiate Dependence><Organ Culture><Organ Culture Techniques><Pathologic><Pathway interactions><Patients><Phenotype><Porosity><Position><Positioning Attribute><Production><Property><Proteoglycan><RNA><RNA Gene Products><RNA based therapeutics><RNA based therapy><RNA therapy><Regeneration><Rejuvenation><Ribonucleic Acid><Safety><Severities><Short interfering RNA><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Spinal Fusion><Spondylosyndeses><Structure><Surgical><Surgical Interventions><Surgical Procedure><Symptoms><System><Therapeutic Uses><Time><Tissues><Toxic effect><Toxicities><Transcription Activation><Transcriptional Activation><Transcriptional Control><Transcriptional Regulation><Transfection><Veterans><Viral Vector><active duty><active service><biological signal transduction><cell culture><cell cultures><clinical relevance><clinically relevant><degenerated intervertebral disc><degenerative disc disease><design><designing><disc degeneration><disc regeneration><effective therapy><effective treatment><functional outcomes><gene repair therapy><gene therapy><gene-based therapy><genetic therapy><genomic therapy><glycolic acid><improved><in vitro Organ Culturing><in vitro vertebrate organ culturing><in vivo><intervertebral disk degeneration><lipid based nanoparticle><lipid nanoparticle><mRNA><mechanic><mechanical><military member><military population><military veteran><model of animal><new approaches><novel><novel approaches><novel strategies><novel strategy><nucleic acid delivery><nucleus pulposus><opioid addiction><opioid dependence><opioid dependent><pathway><pre-clinical><preclinical><regenerate><regenerate disc tissue><regeneration based therapy><regeneration therapy><regenerative therapeutics><regenerative therapy><response><scRNA sequencing><scRNA-seq><service member><siRNA><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><surgery><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic RNA><therapy optimization><three dimensional cell culture><treatment optimization><treatment strategy><veteran population>

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

SANDRA ORSULIC

VA GREATER LOS ANGELES HEALTHCARE SYSTEM, LOS ANGELES, CA

Exploratory lead · 22/100

Recent

Active award

$0

FY 2026

Project Title

BCCMA: Overcoming chemoresistance in ovarian cancer: Identification and validation of biomarkers and targetable drivers of platinum resistance

Grant Number:

5I01BX006020-03

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

4/1/2023

End Date:

3/31/2027

Project Abstract

This Collaborative Merit Award application (CMA), consisting of three projects (CMA1-3), addresses a critical challenge in the clinical management of ovarian cancer (OC). The most common and lethal subtype of OC is high-grade serous ovarian carcinoma (HGSOC). Standard treatment for HGSOC combines su...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Kevin Ron Nash

UNIVERSITY OF SOUTH FLORIDA, TAMPA, FL

Exploratory lead · 16/100

Active award

$225,000

FY 2026

Project Title

Reelin and Fragile X Syndrome

Grant Number:

5R21NS141304-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

1/3/2025

End Date:

12/31/2026

Project Abstract

This grant initiative undertakes an exploration of Reelin, an extracellular signaling protein, and its role in Fragile X syndrome (FXS). FXS is the most prevalent inherited form of intellectual disability, that manifests with a spectrum of clinical symptoms including impaired cognition, anxiety, hyp...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Zeribe Chike Nwosu

CORNELL UNIVERSITY, ITHACA, NY

Exploratory lead · 16/100

Active award

$224,100

FY 2026

Project Title

Disrupting glutathione dependency in pancreatic cancer

Grant Number:

5R00CA267176-05

Activity Code:

R00

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

7/7/2022

End Date:

12/31/2026

Project Abstract

PROJECT SUMMARY/ABSTRACT Pancreatic ductal carcinoma (PDAC) is the most common form of pancreatic cancer and is highly lethal and resistant to therapy. There is a need to explore new, effective, strategies to treat PDAC, given that only ~10% of the patients survive beyond five years. PDAC overutiliz...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Phillip Tai

UNIV OF MASSACHUSETTS MED SCH WORCESTER, WORCESTER, MA

Exploratory lead · 16/100

Active award

$167,500

FY 2026

Project Title

In vitro and in vivo modeling of gene therapy vector stability when challenged by natural virus infection in human hepatocytes

Grant Number:

5R21AI183080-02

Activity Code:

R21

Mechanism:

Non-SBIR/STTR

Agency:

NIH

Start Date:

11/13/2024

End Date:

10/31/2026

Project Abstract

PROJECT SUMMARY Gene therapies based on adeno-associated virus (AAV) vectors have been a revolutionary medical advancement in treating human genetic diseases. With a single dose, AAV-mediated gene therapies can confer long-term correction or abatement of disease for the lifetime of the patient. Rec...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Sumati Gupta

VA SALT LAKE CITY HEALTHCARE SYSTEM, SALT LAKE CITY, UT

Exploratory lead · 10/100

Active award

$0

FY 2026

Project Title

Targeting ARID1A mutated Urothelial Carcinoma

Grant Number:

5I01BX005765-03

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2023

End Date:

9/30/2027

Project Abstract

Bladder cancer is the most common urinary tract cancer in men. The cumulative effects of smoking and deployment-related carcinogens in the aging Veteran population play a major role in the pathogenesis of bladder cancer. The recurring and progressive nature of bladder cancer poses a significant heal...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Richard Thomas O'Neil

RALPH H JOHNSON VA MEDICAL CENTER, CHARLESTON, SC

Exploratory lead · 10/100

Active award

$0

FY 2026

Project Title

Immune modulating T cell therapy for lung cancer

Grant Number:

5I01BX006455-02

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

11/1/2024

End Date:

10/31/2028

Project Abstract

Background and Innovation: The studies proposed here aim to develop a novel T cell- based platform for delivering the cytokine Interleukin 12 directly to lung cancer tumors. We have developed novel CAR-T cell engineering constructs targeting two tumor associated targets, mesothelin and C3d. We also ...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

CANDACE L. FLOYD

VETERANS HEALTH ADMINISTRATION, Decatur, GA

Exploratory lead · 10/100

Active award

$0

FY 2026

Project Title

Evaluation of 6SHG/EM1 as a treatment for spinal cord injury-induced neuropathic pain in a pig model

Grant Number:

5I01BX005203-06

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2021

End Date:

9/30/2026

Project Abstract

Project Summary: The goal of this research is to validate a novel treatment for neuropathic pain after spinal cord injury (SCI-NP) using a novel and highly clinically-relevant pig model. This research is innovative as we will validate exciting new findings from research in rodents which discovered a...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

VERONICA SHUBAYEV

VA SAN DIEGO HEALTHCARE SYSTEM, SAN DIEGO, CA

Exploratory lead · 10/100

Active award

$0

FY 2026

Project Title

Pathogenesis of Nerve Injury: Role of Tissue Inhibitor of Metalloproteinases-1

Grant Number:

5I01BX000638-14

Activity Code:

I01

Mechanism:

Non-SBIR/STTR

Agency:

VA

Start Date:

10/1/2009

End Date:

9/30/2028

Project Abstract

Extremity (e.g., leg) trauma accounts for the majority of combat wounds and causes peripheral nerve injury. Despite the high regenerative capacity of the peripheral nervous system (PNS), patients develop severe sensorimotor abnormalities and neuropathic pain (NP) sustaining for years after injury. I...

Research Terms

View Full Project Details on NIH Reporter

Public NIH records usually do not include a direct email address. For outreach, verify the investigator through their institution profile, lab website, recent publications, or official NIH project page.

Principal Investigator Finder

Search Principal Investigators

Search Results

Opportunity Digest

Neil Alan Shneider

Project Title

Project Abstract

Research Terms

Roland W. Herzog

Project Title

Project Abstract

Research Terms

YONG-HUI JIANG

Project Title

Project Abstract

Research Terms

STEPHEN M STRITTMATTER

Project Title

Project Abstract

Research Terms

Kevin Navin Sheth

Project Title

Project Abstract

Research Terms

Jiangbing Zhou

Project Title

Project Abstract

Research Terms

Tippi Mackenzie

Project Title

Project Abstract

Research Terms

Venigalla B. Rao

Project Title

Project Abstract

Research Terms

Patrick Hogan

Project Title

Project Abstract

Research Terms

Anjana Rao

Project Title

Project Abstract

Research Terms

Douglas Gould

Project Title

Project Abstract

Research Terms

Patricia L Musolino

Project Title

Project Abstract

Research Terms

David Andrew Brown

Project Title

Project Abstract

Research Terms

KENNETH D POSS

Project Title

Project Abstract

Research Terms

J Kevin Donahue

Project Title

Project Abstract

Research Terms

HANS-PETER KIEM

Project Title

Project Abstract

Research Terms

Wenhui Hu

Project Title

Project Abstract

Research Terms

Binhua Julie Ling

Project Title

Project Abstract

Research Terms

Alexander Bick

Project Title

Project Abstract

Research Terms